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Healthcare budgets are limited, and decisions must be made about which 
healthcare technologies should be funded from these limited budgets.  Decision 
makers rely on clinical and cost-effectiveness evidence on which to base their 
decisions, the gold standard vehicle for this evidence is a clinical trial. Guidance 
exists for conducting economic evaluations alongside clinical trials using 
standard treatment arm-based comparisons to assess cost-effectiveness, 
however because of differences in the purposes of the clinical effectiveness and 
cost-effectiveness analyses this conventional treatment arm-based economic 
evaluation is often uncertain. Furthermore, economic evaluations focus on the 
final cost-effectiveness summary measure without consideration of what is 
driving this measure.  There is scope for providing a more detailed 
understanding of the conventional cost-effectiveness results. 
Conceptual models are simplified versions of real-life systems in a visual format, 
illustrating how key components of the system are linked and interact within it. 
In the field of economic evaluation conceptual models are recommended for and 
used as a guide to establish the structure of decision analytic models, in other 
fields they are also used as a communication tool, to aid understanding of the 
system and to give direction to research.  
The aim of this thesis was to expand the role of conceptual models in economic 
evaluation.  This thesis proposed a new role for conceptual models to provide 
additional understanding to decision makers, extending the conventional 
economic evaluation analysis beyond a treatment arm-based analysis. This role 
was demonstrated using two case studies as illustrative examples, aiming to 
show how the role could be applied. 
This thesis demonstrates the value of an additional conceptual model driven 
analysis to supplement the conventional treatment arm-based analysis, adding 
further insight into the trial mechanism and what is driving the economic 
evaluation results.  The contribution of this thesis to the field of economic 
evaluation is twofold; a new role for conceptual models in economic evaluation 
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Definitions and abbreviations 
Conceptual model  
A visual representation of the causal relationships linking key components in a 
real-life system using simplifying assumptions. A conceptual model provides a 
framework for hanging information on about the interactions and connections 
between these key components. 
Methodological framework 
A structured practical tool for guiding the user through a stepwise process, 
enabling/facilitating a standardised approach to the given task. 
Mathematical model  
A simulation-based model commonly described as a decision analytic model in 
the field of economic evaluation. It is an umbrella term for all models based on 
mathematical links. 
Treatment/intervention and comparator 
Treatment is any therapy, pharmaceutical or other care, given to the 
participants in the clinical trial and compared with other therapies, 
pharmaceuticals or other care to answer the research question of the clinical 
trial.  An intervention is the new treatment which is being compared to an 
existing treatment.  The comparator is the existing current treatment that the 







BNF  British National Formulary 
BODE  Body mass index, airflow Obstruction, Dyspnea, and Exercise 
C  Cost (in equations) 
CBT  Cognitive behavioural therapy 
CEA  Cost-effectiveness analysis 
CEAC  Cost-effectiveness acceptability curve 
CHEERS Consolidated Health Economic Evaluation Reporting Standards 
CI  Confidence interval 
COPD  Chronic obstructive pulmonary disease 
CSRI  Client service receipt inventory 
E  Effects (in equations) 
EQ-5D  Euroqol-5 Dimension 
EQ-5D-Y Euroqol-5 Dimension Youth  
EQ-5D-3L Euroqol-5 Dimension 3-Levels 
EVPI  Expected value of perfect information 
EVPPI  Expected value of perfect parameter information 
GDS-LD Glasgow Depression Scale for Learning Disabilities 
GOLD  Global initiative for chronic Obstructive Lung Disease 
HIS  Health Improvement Scotland 
HTA  Health technology assessment 
ICER  Incremental cost-effectiveness ratio 
ICS  Inhaled corticosteroids 
ISD  Information Services Division 
ISPOR The Professional Society for Health Economics and Outcomes 
Research 
IRR Incidence rate ratio 
LABA  Long-acting β2 agonists 
mg Milligram 
NMB Net monetary benefit 
NHS  National Health Service 
NICE  National Institute for Health and Care Excellence] 
NIHR  National Institute for Health Research 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-
Analyses 
PSSRU Personal Social Services Research Unit 
QALY Quality adjusted life-year 
RCT Randomised controlled trial 
SD Standard deviation 
SHTG  Scottish Health Technologies Group 
SMC Scottish Medicines Consortium  
SSM Soft systems methodology 
TWICS          Theophylline With Corticosteroids  
UK United Kingdom 
US United States 
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Chapter 1 Introduction 
1.1 Chapter overview 
The aim of this chapter is to provide an introduction and orientation to the 
thesis. In Section 1.2 the rationale of the thesis is explained, in Section 1.3 the 
research question, aim and objectives are presented, and in Section 1.4 an 
overview of the thesis structure is provided. 
1.2 Rationale  
Health care resources in most countries are scarce and limited, therefore not all 
technologies and treatments can be funded and made available for patients, and 
decisions need to be made about which technologies and treatments to fund.  
These decisions are based on clinical efficacy, clinical effectiveness and 
availability, and cost-effectiveness evidence.  To establish the clinical benefits 
of a technology for informing decision makers, a clinical trial is needed and is 
considered the gold standard vehicle for this evidence, the cost-effectiveness of 
the technology is frequently evaluated alongside the clinical trial (1).   
The cost-effectiveness of a new technology is assessed using economic 
evaluation techniques, the purpose of which are to identify the healthcare 
technologies which deliver the maximum additional health benefits per 
additional unit of resource, this information is used to inform decision makers 
and help them to make the best use of the limited healthcare resources (2).  An 
economic evaluation compares both the costs and the health benefits for one or 
more healthcare technologies to assess which of those technologies is worth 
funding compared to other technologies which could be funded with the same 
resources (1, 3).  Economic evaluations alongside trials are specifically designed 
to answer cost-effectiveness questions and can influence the trial design, with 
input from a health economist.  The clinical effectiveness of an intervention is 
typically the primary outcome of a clinical trial, with the cost-effectiveness 
typically a secondary outcome. 
Guidance for conducting an economic evaluation alongside a clinical trial is well 
established and provides health economists with best practice (4-6), this 
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guidance focusses on a treatment arm-based approach where the costs and 
outcomes of all relevant technologies are compared to assess cost-effectiveness.  
However, the objectives and audience for a clinical analysis and a cost-
effectiveness analysis differ, these conflicting objectives can result in uncertain 
economic evaluation results (where there is no difference between cost or 
health benefits).  Recent research found that conflicting objectives can lead to 
conflicting conclusions being drawn in clinical trials; almost a third of trials 
identified in this research reported at least one ‘doubly null’ result (where there 
was no statistical difference between arms in the primary outcome or the cost 
per participant), but reported a favourable cost-effectiveness result (7). The 
extend of uncertain cost-effectiveness results is reported by Hollingworth et al. 
in research which found conclusions on primary outcomes were more likely than 
conclusions on economic outcomes (42.1% v 15.8%)(8). This research also found 
that only 1/38 trials considered a sample size based on economic outcomes; 
powering a trial on economic outcomes requires a larger sample size and longer 
follow-up to detect statistically significant differences and avoid uncertain 
results (9). Furthermore, economic evaluations have been described as 
producing a ‘black box’ analysis which focusses entirely on the final summary 
measure, with little or no consideration of what is driving this measure (10).  
These drawbacks of economic evaluation provide scope to develop an approach 
which gives additional interpretation to uncertain results and goes beyond the 
conventional outcomes focussed economic evaluation to provide an 
understanding of the trial mechanism driving the results.  In this thesis I consider 
capturing the causal relationships inherent in conceptual models to further 
investigate valuable clinical trial data, providing additional evidence to decision 
makers for allocating scarce healthcare resources. Proposing and demonstrating 
this supplementary conceptual model driven analysis is the first objective in this 
thesis.   
Although an early description of a conceptual model from 1976 exists; ‘a 
simplification of reality’ (11), today there is no widely accepted definition of a 
conceptual model, and any definitions are unclear and interpreted in different 
ways (12). However, despite there being no widely accepted definition there are 
commonalities in existing definitions of a conceptual model: a top level visual 
representation of a real-world system in a simplified form (13); it illustrates 
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causal relationships (14) using simplifying assumptions (15); linking the key 
constituents in a process or system, and explaining how these interconnect and 
interact (16); an abstraction of the real world (13, 17, 18), simplifying the 
decision problem (19); it provides a rack or framework on which to hang 
information from the system (20); a compass (13), which formalises 
understanding of the dynamics, and links in the process or system (20). 
In disciplines other than economic evaluation, the primary purpose of a 
conceptual model is an effective communication tool due to its visual and 
simplified nature, making understanding of the causal relationships 
straightforward (14).  They can also help gain an understanding of the system, 
objectives, rationale and assumptions used (14), and give shape and direction to 
the research (16). They can define the study context, research objectives and 
assumptions (13). While a conceptual model should always precede a 
mathematical model to inform the development of the mathematical model, not 
all conceptual models will lead to a mathematical model, it can be an end in 
itself, helping the user to understand a problem and allowing decisions to be 
made (15).  A conceptual model can also enable the understanding of the 
relationships between key components (principal characteristics) of a system 
(15).  When conceptual models are part of a mathematical model process they 
are crucial for a successful mathematical model (21), often developing the 
conceptual model is more important than developing the mathematical one (19, 
20), and should be independent of the software used for a mathematical model 
(17, 18).  
Definitions of conceptual models in the field of economic evaluation include the 
abstraction, simplification, and depiction of components of reality that are 
related to the decision problem, allowing understanding of the decision problem 
to be shared and agreed between interested parties and a mathematical model 
to be implemented (22, 23).   
In the economic evaluation discipline conceptual modelling has emerged 
relatively recently, an early mention of conceptual modelling was in 2000, this 
briefly described the usefulness of using conceptual models in determining the 
structure of mathematical models (commonly known as ‘decision analytic 
models’ in economic evaluation, and from now on in this thesis described as 
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decision analytic models), but it did not go into detail on how to operationalise 
this (24). In 2010 Chilcott et al. conducted research into how modellers develop 
decision analytic models and a conceptual modelling stage was identified by nine 
out of 12 modellers interviewed (25). In 2012 two sets of guidance were 
published for developing conceptual models in economic evaluation (23, 26), a 
further set of guidance was published in 2016 (22). However, all mentions of 
conceptual modelling in economic evaluation relate to developing the structure 
of decision analytic models, and almost none relate to a trial-based evaluation. 
In economic evaluation the main purpose of a conceptual model is the first step 
in developing a decision analytic model (22); all decision analytic models should 
be based on a conceptual model (23). A decision analytic model is used to 
compare costs and health outcomes between treatment arms to estimate cost-
effectiveness, particularly when there is scarce evidence. There are many 
benefits of using a conceptual model in this way in an economic evaluation, all 
linked to improving the quality of the decision analytic model: ensuring it 
answers the correct question and meets the needs of the stakeholders; making 
sure that there is a common understanding and agreement of the problem; 
helping stakeholders to understand the impact of the intervention on economic 
outputs (costs and outcomes), ensuring that the decision analytic model is 
clinically correct and that all relevant components (events, resources, 
outcomes) are included; it provides a reference point; it highlights any 
differences in clinical practice; it enables validity and credibility of the decision 
analytic model; it verifies any structural uncertainty analysis, identifying areas 
for future research; enabling transparency, and leading to efficient model 
development (22, 23). 
Current guidance for developing conceptual models for use in economic 
evaluations focusses solely on the purpose of a conceptual model to determine 
the structure of a decision analytic model.  This existing guidance was 
mentioned above and is described in more detail below. 
In 2010 Chilcott et al. conducted research to establish how modellers develop 
decision analytic models; modellers were interviewed to determine their 
methods and strategies for developing these models (25).  In synthesising the 
research Chilcott et al. identified five steps that modellers used to develop a 
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decision analytic model, the second step was conceptual modelling. Nine out of 
12 modellers implicitly or explicitly acknowledged ‘conceptualisation and 
abstraction’ of the problem prior to developing the decision analytic model. The 
main purpose of this was to come to an agreement on the problem and proposed 
decision analytic model, as well as sense-checking, and developing ideas. 
Overall, the abstraction of the decision problem into a conceptual model served 
as a communication tool between the research team, decision maker and client. 
The authors acknowledged that without specific conceptual modelling the 
overall validity of a decision analytic model is compromised and recommended 
the publication of definitions for conceptual model validation.   
Following Chilcott’s research three sets of guidelines for conceptual modelling in 
health economic evaluations have been published.  These guidelines are 
summarised below.  
The first guidance was published in 2012; Tappenden published generalised 
guidance on developing conceptual models for health economic model 
development, a process for determining a decision analytic model structure (23). 
Tappenden’s definition of a conceptual model is the ‘abstraction and 
representation’ of the decision problem which is used to discuss and agree 
stakeholder understanding of the decision system and its representation in the 
decision analytic model.  Two types of conceptual model are considered: 
problem-oriented and design-oriented. Problem-oriented conceptual models are 
developed to understand the decision problem and the system relevant to the 
decision problem, analogous to asking, ‘what is relevant’? This stage is 
particularly helpful for communication with stakeholders and agreeing on the 
description of the decision system for a clinical understanding of the disease and 
treatment pathways. A design-oriented conceptual model focusses on designing, 
specifying and justifying the decision analytic model and structure, analogous to 
asking, ‘what is feasible’?  It sets a boundary around the scope of the decision 
analytic model. Tappenden echoes Chilcott’s view that conceptual modelling is 
directly linked to the credibility and validation of the decision analytic model.  
Tappenden’s paper sets out a ‘practical framework’ for deciding on a decision 
analytic model’s structure, with ‘practical approaches’ and includes case studies 
to illustrate the practical guidance.  The guidance consists of a list of suggested 
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questions the modeller could ask to help develop the conceptual models as well 
as high-level ‘recommendations for practice’ for each type of conceptual model 
and potential sources of evidence to inform the models.  Tappenden’s guidance 
was summarised in the National Institute for Health and Care Excellence (NICE) 
Interim Methods Guide for Developing Service Guidance 2014 (27). 
Also published in 2012 was the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) ‘consensus based best practice’ guidance for 
conceptualising a decision analytic model authored by Roberts et al. (26).  This 
best practice was developed by experts in the modelling field from different 
types of organisations and countries and defines the decision analytic model as 
one which will ‘inform medical decisions and health-related resource allocation 
questions’.  Similar to Tappenden’s guidance it focusses on developing the 
structure of decision analytic models in two steps: conceptualising the problem 
and conceptualising the model.  The first step focusses on understanding the 
decision problem, perspective of the study, model population, outcomes and 
valuing them, comparators, time horizon and uncertainties requiring additional 
sensitivity analysis.  The conceptualising the model section focusses on the most 
suitable model structure for the problem, with key considerations of whether 
the model represents individuals or groups, and whether there is any interaction 
between these individuals or groups. Examples of model structure include 
decision trees and state transition models. Each ‘best practice’ is accompanied 
by recommendations. The Roberts et al. best practice is presented as guidance 
not as a methodological framework and has been described as giving guidance on 
‘what to do’ but not ‘how to do it’(22).  
The third set of guidance was published more recently in 2016; Squires et al. 
published a methodological framework specifically for developing public health 
conceptual models (22), providing the first public health specific standardised 
approach to developing a decision analytic model structure using conceptual 
models.  The authors argue that due to the complex nature of public health 
interventions more thought should be applied to developing a public health 
conceptual model compared to a more straightforward conceptual model, for 
example the comparison of drug treatments. Squires et al. define conceptual 
modelling as an ‘abstraction of elements of reality at an appropriate level of 
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simplification for the problem’.  Squires et al. developed a draft conceptual 
modelling framework using information from a literature review and qualitative 
work, which was then tested with a case study, and revised to produce a final 
framework.  The framework comprises four sections, steps within the last two 
sections guide the modeller through the process of developing a conceptual 
model to inform the decision analytic model structure. 
Conceptual models are recommended for, and conventionally used in economic 
evaluation to develop decision analytic model structures. This thesis considers a 
new role for conceptual models; using their visual nature and the identification 
of relationships between components within them, to illustrate and determine 
the links between key components of an economic evaluation alongside a clinical 
trial to further explore clinical trial data.  As previously discussed, current 
guidance for developing conceptual models in economic evaluation is restricted 
to developing conceptual models with the sole purpose of informing the 
structure design of a decision analytic model, therefore new guidance for 
developing conceptual models to use in the new role is required; this is the 
second objective in the thesis.  
An appropriate format for this new guidance is a methodological framework. 
Although there is no formal definition of a methodological framework there is 
unspoken agreement that a methodological framework provides structured 
practical guidance, or a tool, to guide the user through a process, using phases, 
stages or a step-by-step approach (22, 28-35). Specific descriptions of a 
methodological framework have included: an ‘algorithm’ (36), ‘practical 
guidance’ (37), a ‘practice based tool’ (38),`a body of methods, rules and 
postulates employed by a particular procedure or set of procedures’ (39), a ‘set 
of structured principles’, an approach for ‘structuring how a given task is 
performed’ (40), and a ‘sequence of methods’ (41). There are many benefits of 
using methodological frameworks: the standardised approach provided by a step-
by-step guide can improve the consistency, robustness and reporting of the 
activity (42), enhancing the quality of the research (22), and maximising the 
trustworthiness of findings (38). 
Methodological frameworks for conceptual modelling provide structure and 
direction for developing conceptual models (43), recommending methods and 
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good practices (44).  They provide guidance for inexperienced modellers, whilst 
acting as an ‘aide memoire’ to more experienced modellers (15), and the 
documents created during the development of a conceptual model can form a 
helpful audit trail (15, 21).  
Using a methodological framework as a format for the new guidance for 
developing conceptual models would direct the user through a series of 
standardised steps, providing structure for the user and improving the quality, 
consistency, robustness and validity of the conceptual model. 
At the outset of this thesis there was no consensus on approaches which could be 
used for guiding the development of methodological frameworks (39).  Due to 
this lack of guidance an extra work strand was added to the thesis with the aim 
of compiling practical suggestions for developing a methodological framework.  
This work strand is part of the second objective of this thesis; to propose a 
methodological framework for developing conceptual models. 
In summary, the new role for conceptual models included in this thesis provides 
additional information beyond the conventional treatment arm-based economic 
evaluation for decision makers, particularly when evidence is uncertain, 
providing an understanding of the mechanism driving the economic evaluation 
results.  In this thesis the new role for conceptual models is described and 
illustrated, and to support this proposed new role for conceptual models new 
guidance is proposed for their development.   
1.3 Research question and aims 
The research question posed and answered in this thesis is:  
‘How can conceptual modelling enhance health economic evaluation?’ 
The aim of the thesis is to expand the role of conceptual modelling in health 
economic evaluation. 
To answer the research question two objectives were set, these were introduced 
in the rationale in Section 1.2: 
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• Propose and demonstrate (with illustrative case studies) a new role for 
conceptual models in health economic evaluations.  
• Propose and demonstrate a methodological framework for developing 
conceptual models in this new role. 
1.4 Thesis layout  
An overview of layout of the thesis is provided below which is made up of seven 
further chapters. 
Chapter 2 
This chapter introduces the role of economic evaluation in decision making and 
describes the existing guidance for conducting economic evaluations alongside 
clinical trials. The practice of conducting economic evaluations alongside clinical 
trials is critiqued, and drawbacks are highlighted, in particular the uncertainty 
inherent in economic evaluation results which can lead to scant evidence for 
decision makers.  An explanation of the ‘black box’ nature of economic 
evaluations is made. Finally, the concept of the new role for conceptual models 
in economic evaluation is explained, addressing both uncertainty in results and 
the lack of consideration to the mechanism driving the economic evaluation 
results. 
Chapter 3 
This chapter introduces the two cases studies used for illustration purposes 
throughout this thesis, both case studies are from clinical trials reporting 
uncertain results in the economic evaluation. The background and rationale of 
each clinical trial and clinical results are summarised in turn, then the methods 
used in the economic evaluation are explained, particularly in relation to the 
existing guidance described in Chapter 2, and finally the results of the economic 




Chapter 4  
To comprehensively present the new role for conceptual models in economic 
evaluation advice is needed to create the guidance for developing conceptual 
models in this new role.  At the outset of this thesis there was no available 
guidance for developing a methodological framework, and this chapter takes a 
step towards filling this gap in the form of practical suggestions. A scoping 
review identified reported approaches used in developing methodological 
frameworks; these approaches were then amalgamated and grouped into 
suggestions for developing methodological frameworks.  This chapter partly 
fulfils the second objective of the thesis and has been published as a peer 
reviewed article (45). 
Chapter 5  
The suggestions from Chapter 4 for developing methodological frameworks are 
applied in this chapter to guide the development of the methodological 
framework for conceptual models.  After identifying evidence from a scoping 
review a draft methodological framework was developed, which was evaluated 
by comparing it to the existing guidance for creating conceptual models in 
economic evaluation, then revised to produce the final methodological 
framework. This final methodological framework comprises seven discrete stages 
which are divided into three phases: I) Context, II) Development and III) 
Finalising.  The methodological framework includes a diagram and a written 
document explaining the seven stages. This chapter fulfils the second objective 
of the thesis and has been prepared as a manuscript which will be submitted for 
publication. 
Chapter 6 
Chapter 6 demonstrates the application of the methodological framework 
presented in Chapter 5 using the case studies introduced in Chapter 3.  These 
case studies are illustrative in nature with the aim of demonstrating how a 
conceptual model might be developed. Each case study shows the progression of 
the conceptual model development, concluding with the final conceptual model 




This chapter uses the two conceptual models developed in Chapter 6, from the 
two case studies, to demonstrate how the new role for conceptual models could 
be implemented. A recap of the original treatment arm-based results is 
presented for each case study, followed by an illustrative application of the 
novel approach proposed in the new role in Chapter 2.  This chapter fulfils the 
first objective of the thesis and a draft manuscript was presented and discussed 
at the Health Economists’ Study Group in January 2021, with a view to 
submitting for publication.   
Chapter 8  
The final chapter of the thesis provides a discussion of the work and gives a 
conclusion to the thesis. First, each chapter is summarised in an overview, then 
the strengths and limitations of the work in the thesis are discussed, the policy 
and practice implications are considered and recommendations made, 
suggestions for future work are described, and finally an overall conclusion is 
presented. 
In summary, the work in this thesis has led to three outputs, which are 
presented in the thesis in the following order: 
1. Practical suggestions for developing a methodological framework  
2. A methodological framework for developing conceptual models for health 
economic evaluations, with illustrative case studies  
3. A new approach for the use of conceptual models in health economic 
evaluations, with illustrative case studies  
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Chapter 2 The role and practices of economic 
evaluation alongside clinical trials 
2.1 Chapter overview 
The aim of this chapter is to give the reader an overview of the role of economic 
evaluations in the decision-making process, present approaches recommended to 
conduct them alongside clinical trials and to discuss the strengths and 
limitations of using clinical trial data to inform economic evaluations, providing 
an overview of the current position of economic evaluation.  The chapter aims to 
show why there is scope for a supplementary analysis in economic evaluation 
and presents a proposed new approach for this supplementary analysis.  
The current role of health economic evaluations and how clinical trials are used 
to inform decisions in healthcare are discussed in Section 2.2.  Existing guidance 
on conducting health economic evaluations alongside clinical trials is presented 
in Sections 2.3 to 2.7, and a critique of conducting economic evaluations 
alongside clinical trials highlights the strengths (Section 2.8), and limitations 
(Section 2.9) of this process.  The consequences of these limitations underline 
the scope for an additional new approach to provide further evidence to decision 
makers and the new approach proposed in this thesis is presented in Section 
2.10. The chapter is summarised in Section 2.11.  
2.2 The current role of health economic evaluations 
alongside clinical trials 
Healthcare resources such as medication, staff time, blood supply, donated 
organs or hospital facilities are limited, and as a consequence of these limited 
resources the demand for health resources outstrips supply (46). In healthcare 
systems around the world decisions have to be made on how best to allocate 
scarce resources when there is increasing demand and limits on budget, to meet 
the needs of populations and to achieve the efficient use of scarce healthcare 
resources (47). The reasons for this increasing demand include advances in 
technology, aging populations and higher chronic disease prevalence (48).   
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To make decisions on how to best allocate these scarce resources, options are 
ranked to allow the costs and benefits to society of alternative technologies to 
be assessed(49). This ranking is typically achieved by using either a welfarism or 
extra-welfarism framework. Both frameworks allow ranking of two or more 
options but differ in how they measure the benefits received from the changes 
in healthcare resulting from the technologies.  Welfarism assumes that 
individuals want to maximise their utility (welfare) and are best placed to assess 
this utility and show this by making choices(50).  In standard economics, 
inferences about the benefits received from these choices is achieved by 
observing individual choices made, this is termed ‘revealed preference’. 
However, in healthcare, which is often publicly funded, choices cannot be 
studied, so ‘stated preferences’ are used; stated preferences assess hypothetical 
choices made by a sample of the public to obtain willingness-to-pay monetary 
amounts(49). However, some researchers are not comfortable with valuing 
health in monetary terms, leading to the extra-welfarism approach.  Culyer 
introduced the concept of extra-welfarism in 1989, this measures benefits from 
changes in healthcare using a health state utility: the quality adjusted life-year 
(QALY)(49, 51). The QALY is a generic measure combining length and quality of 
life, it has the benefit of enabling comparison of different technologies and 
different disease areas. 
However, evidence shows that society is not only concerned about maximising 
health; capabilities are important too (50).  Capability relates to an individual’s 
potential functioning based on choice and opportunity; the more choices and 
opportunities an individual has the more improved wellbeing, whether or not the 
individual chooses to make use of those opportunities (50, 52).  Furthermore, 
when a technology is complex, or the system the technology is situated in is 
complex, restricting the measurement of benefits to health has the potential to 
underestimate the benefits of the health technology.  In these complex 
interventions a broader approach is needed to assess the wider impacts of the 
technology, including benefits such as friendships, dignity, self-respect, spillover 
effects to family and community and multisectoral benefits, for example to the 
education and criminal sectors (50, 53).  
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The extra-welfarist approach of measuring benefits as QALYs has been widely 
adopted in health economics and this is the approach considered in this thesis.   
The purpose of the research discipline ‘Health Technology Assessment’ is to 
provide evidence to inform decision makers about whether to adopt new 
technologies. In many countries Health Technology Assessment (HTA) 
organisations oversee evaluations, specifically for their jurisdiction, on clinical 
and cost-effectiveness for informing local decisions about adopting new 
technologies (54). For example, in Scotland the umbrella organisation Health 
Improvement Scotland (HIS) includes the Scottish Medicines Consortium (SMC) to 
oversee pharmaceutical decisions and the Scottish Health Technologies Group 
(SHTG) which oversees non-pharmaceutical decisions, and in England and Wales 
NICE has topic specific committees to oversee decisions on funding.   
Clinical effectiveness evaluations compare the health outcomes of a new 
technology to the health outcomes of one or more existing technologies, or a 
placebo, to assess the size of the treatment effect.   Cost-effectiveness 
evaluations investigate whether the health improvements resulting from the new 
technology represent value for money compared to the existing technology, or a 
placebo, by calculating the additional benefits per additional resources used (2). 
The cost-effectiveness component of a Health Technology Assessment is referred 
to as an ‘economic evaluation’ (1). 
An economic evaluation comprises of two measurements: the difference in costs 
and the difference in health benefits of a new technology compared to an 
existing alternative (or placebo). The total costs and total health benefits 
accumulated by each participant in a clinical trial are estimated and averaged 
across all participants in the new technology group (t) and the existing 
technology group (or placebo) (c), resulting in a mean cost (C) and health 
benefit (E) per participant in each group. A summary measure for the cost-
effectiveness of the new technology compared to the existing technology is 
calculated by applying the following equation (Equation 1), dividing the 













Equation 1: Incremental cost-effectiveness ratio 
 
The product of this equation is referred to as an ‘incremental cost-effectiveness 
ratio’, typically shortened to the acronym ‘ICER’.  To evaluate whether the 
resultant ICER is cost-effective it is assessed against the local willingness-to-pay 
threshold, which is currently £20,000 to £30,000 in the United Kingdom (UK) 
(55); if the ICER is below the willingness-to-pay threshold it is considered cost-
effective. 
However, using the ICER to assess cost-effectiveness by simply comparing it to 
the threshold is not always straightforward; it can cause problems when the ICER 
is not a simple product of higher costs and improved health benefits, to give the 
ICER full interpretation it should be plotted onto a cost-effectiveness plane 
(Figure 1); the quadrant where the ICER sits explains the interpretation of cost-
effectiveness. The vertical axis of the cost-effectiveness plane represents 
incremental costs, above the horizontal axis (incremental costs are positive) the 
new technology is more costly than the existing technology, below the horizontal 
axis (incremental costs are negative) the new technology is less costly than the 
existing technology. The horizontal axis of the cost-effectiveness plane 
represents incremental health benefits, to the right of the vertical axis 
(incremental health benefits are positive) the new technology has more health 
benefits than the existing technology, and to the left of the vertical axis 
(incremental health benefits are negative) the new technology has less health 
benefits than the existing technology.  If the ICER is in the southeast quadrant 
the new technology is less costly and has more health benefits than the existing 
health technology, in this scenario the new technology is described as 
‘dominant’ and should be adopted.  If the ICER is in the northwest quadrant the 
new technology is more costly and has less health benefits that the existing 
technology, in this scenario the new technology is described as ‘dominated’ and 
should be rejected.  If the ICER is in the southwest quadrant the decision on 
whether to accept or reject the new technology will depend on the decision-
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making body’s willingness to accept; there will be cost savings, but this comes at 
the price of losing health benefits and the willingness to accept decision is the 
amount of decrease in health benefits for a cost saving that decision makers are 
willing to accept.  If the ICER is in the northeast quadrant the decision will 
depend on the willingness to pay threshold; the willingness to pay extra for a 
defined amount of additional health benefits. As previously discussed, if the 
ICER is below this threshold in the northeast quadrant the new technology should 
be adopted.  As previously mentioned, relying on only the ICER is problematic; if 
the ICER is positive it can be in either the northeast or southwest quadrants 
where the decision is based either on willingness to pay to willingness to accept, 
if it is negative it could be in either the northwest or southeast quadrants where 
the decisions is to adopt or reject.  If the ICER is plotted on the cost-
effectiveness plane the decision is clear. 
 
Figure 1: Cost-effectiveness plane interpretation 
 
Evidence used to inform HTA policy decisions typically comes from clinical trials 
(4, 5), however it can also come from decision analytic models and routinely 
collected data (56).  The focus of this thesis is economic evaluations alongside 
clinical trials and the evidence discussed in it will be clinical trial data; this data 
provides evidence on the safety, efficacy and clinical effectiveness of medicine, 
medical devices and procedures, and a rising number of clinical trials are also 
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collecting data for economic evaluations. The aforementioned growth in demand 
for healthcare has resulted in an increase in the number of economic evaluations 
(5), and over the past 30 years economic evaluation alongside clinical trials have 
become more popular, with increasing numbers being published (4).  In a clinical 
trial two or more treatments (intervention and comparator) are compared to 
assess one or more outcomes agreed in advance and participants in each 
treatment arm are followed for a specified length of time to test the safety, 
efficacy and effectiveness of the intervention(s) (57).  There are typically four 
phases in clinical trials: Phase 1 studies assesses the safe dose range and 
potential side effects of the intervention in a small number of patients; Phase 2 
studies assess potential adverse events of the intervention in a larger group of 
people; Phase 3 studies assess the effectiveness of the intervention compared to 
a similar treatment or placebo in a large group of people, across different sites 
and countries, this Phase is typically the last step in assessing the intervention 
before it is either approved or not approved by different jurisdictions (although 
recently some decisions are being based on Phase 2 evidence (58)), and Phase 4 
trials only take place after a new technology is approved and if required for 
further testing.  For the clinical effectiveness and cost-effectiveness discussed in 
this thesis the clinical trial referred to is a Phase 3 study. 
Clinical trials are considered the ‘gold standard’ for providing evidence on the 
efficacy and clinical effectiveness of a new health technology, assessing the 
causal relationship and association between the intervention and outcome of 
interest.  The ability to examine causal relationships is possible because of the 
practice of randomisation of participants in the trials, this removes much of the 
bias seen in other study designs.  Randomisation ensures that there is a balance 
in participant characteristics between the arms, this allows any difference in 
outcomes to be accredited to the effects of the intervention only, these effects 
are known as ‘treatment effects’.  Clinical trials are closely monitored to ensure 
that they are managed correctly, the management of clinical trials includes: 
participants recruited according to strict inclusion and exclusion criteria; the 
concealment of randomisation to trial arms; randomisation and blinding of 
allocation to trial arm where either the researcher, participant or both are not 
aware of the treatment they are randomised to; calculating an appropriate 
sample size to ensure the trial has enough power to determine reliable 
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treatment effect results; an intention-to-treat analysis is conducted, and all 
information regarding the clinical trial management should be pre-specified in a 
protocol. Whilst clinical trials have disadvantages such as expense, 
generalisability and dropouts, they provide the best available evidence on 
causality without the inherent bias of other study designs, for example 
observational studies (59). 
Although clinical trials are considered the ‘gold standard’ vehicle for providing 
evidence on the efficacy and clinical effectiveness of a new health technology, 
and despite the increase in their use for economic evaluations, there have been 
doubts raised about their sole use in assessing the cost-effectiveness of a new 
health technology, resulting in a restricted analysis (60).  The specific 
limitations of using a clinical trial as evidence for an economic evaluation are 
discussed in detail in Section 2.9. 
The increase in the number of economic evaluations alongside clinical trials has 
led to a need for guidance for conducting robust economic evaluations, this need 
has been met by published recommendations for economic evaluation methods 
(4-6). This guidance is summarised and described in Section 2.3. 
2.3 Current guidance for conducting economic 
evaluations alongside clinical trials 
The guidance described in this section has been mainly taken from three 
sources: two journal papers – the ISPOR 2015 Good Research Practices Report 
(Ramsey et al.) (5) and Petrou et al. guidance (6), and the Glick et al. book on 
the subject (4).  An earlier version of the ISPOR good research practices report 
was published in 2005 in response to a growing number of clinical trials which 
included health economic endpoints (61), this was updated in 2015. 
The economic evaluation guidance is presented in four sections: Section 2.4 
describes the initial step of designing economic evaluations alongside clinical 
trials; Section 2.5 describes methods of data collection, Section 2.6 describes 
analysis of the data once it has been collected and Section 2.7 describes the 
recommended layout for reporting an economic evaluation. 
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2.4 Current guidance - design of trial based economic 
evaluations 
The intrinsic features of a clinical trial design will feed directly into the quality 
of the economic data collected in the trial, so it is important that the health 
economist is involved in the design of the study and collaborates closely with the 
clinical trialist to ensure that the best quality economic data is collected (5, 6).  
Details of this collaboration should be recorded in the standard operating 
procedures of the clinical trials unit (6).  
The health economist should assess whether the clinical trial design is a suitable 
vehicle for conducting an economic evaluation, it may be the case that the 
clinical trial design is an exploratory non-comparative Phase 1 or 2 trial, or 
otherwise inappropriate (5). To assess the suitability of the clinical trial data the 
underlying principles of economic evaluations should also be considered, these 
include: 
• The sample size should be large enough to reliably detect differences in 
economic outcomes (62). 
• All relevant evidence should be included in the economic evaluation, this 
includes clinical effectiveness of the intervention, relevant resource use 
and health benefits (3). 
• Comparators should reflect all available treatments routinely used in the 
National Health Service (NHS) and those considered best practice (3, 63). 
• The economic resource use should be representative of usual clinical 
practice (5, 6).  
• The preferred outcome measure to assess health benefit is one that is 
estimated using a preference-based measure (63), if this is not available 
or not considered sensitive enough for the disease in question then the 
outcome should reflect an episode of care which then triggers a cost (for 
example a stroke) (4). However, in clinical trials surrogate endpoints are 
often used, these allow a reduced sample size and/or trial duration, 
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reducing costs and speeding up the decision-making progress (64, 65). The 
surrogate endpoint should be associated with the final endpoint such that 
all treatment effect on the final endpoint is captured by the surrogate 
endpoint (65). NICE has made decisions based on economic evaluations 
using surrogate endpoints, however it has been shown that the final 
endpoint may show no clinical or cost-effectiveness once more evidence is 
collected (64). To avoid subsequent evidence on final endpoints reversing 
treatment effect sizes and direction based on surrogate endpoints, robust 
validation of the surrogate endpoint should be conducted.  This comprises 
assessing the level of evidence and strength of association between the 
surrogate and final endpoints, and quantifying the relationship between 
them, preferably in terms of QALYs (64). 
• A sufficient follow-up period is required to capture all costs and health 
benefits relating to the comparators to estimate cost-effectiveness, 
preferably over a lifetime (3, 5, 63).  If there are strong links between an 
intermediate end point in the clinical trial and a long-term disease 
episode of care, then more reliance can be given to these intermediate 
end points.  The length of time between data collection time points is 
also important, care should be taken not to leave too long between data 
collection time points; this enables the participant to remember exactly 
what resources were used in the previous period.   
• Finally, uncertainty in the results should be characterised, in particular 
decision uncertainty which explores the probability that the decision 
based on the available evidence is the correct one (3).  
2.5 Current guidance - data collection  
As discussed previously in this chapter, the two main components of an 
economic evaluation are costs and health benefits.  Costs are a combination of 
the resources used by participants during and prior to the clinical trial (for 
example nurse visits or inpatient hospital stays) and the relevant unit cost for 
each resource used.  For health benefits this should be a preference-based 
outcome, but may be restricted to disease specific clinical outcomes, or a 
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mixture of both. Careful consideration should go into the collection of economic 
data (5).  
2.5.1 Resource use and costs - identification 
Typically calculating costs requires two steps; the first ascertains relevant 
resource use categories and collects these identified resources used by trial 
participants, and the second applies unit costs to these resources to estimate 
total costs.  It is possible but less common to have access to routine resource 
data collection that has costs already included in the economic data.  The 
typical categories of resource use collected in a clinical trial include: the 
treatments; healthcare use related to the disease or treatment; treatment of 
side effects related to the intervention, and other resource use deemed 
important (6).  The economic evaluation guidance recommends several 
techniques which can be used to identify relevant resource use, these are 
discussed below. 
The perspective of the economic evaluation will help to determine the resource 
use categories that should be included; a healthcare perspective (also known as 
payer perspective) will include use of health and social services as already 
described, this is the basic perspective required in UK by NICE (63).  A more 
broad societal perspective also includes resource use incurred outside of health 
and social care services and includes personal costs, informal care by friends and 
family and productivity losses from being unable to work (6).  Another method 
for ascertaining relevant resource use is to conduct an assessment of the typical 
resource use categories in a care pathway to identify key resource categories (4, 
5), in addition to administrative data and patient logs. 
Generally, the economic evaluation guidance recommends the collection of data 
use categories that should affect the results of the economic evaluation (5).  In 
particular, recommending the identification of two types of resource uses: those 
most likely to differ between arms (cost drivers), but not necessarily linked to 
the disease or intervention, and high value resources.  The first type (resource 
use that may differ between arms) estimates the intervention’s effect on costs, 
and the second estimates overall variability on costs (4, 5).  Other resource use 
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categories recommended for collection are those which are used by many 
participants (62).  
Suggestions for reducing the burden of resource use collection include restricting 
the resource use categories to those related to the disease or intervention, 
those provided by the study site(s), and reducing the number of participants who 
provide resource use data, however a balance should be struck between 
minimising the burden and undermining the results from the economic 
evaluation (4). The general view is that including a restricted range of resource 
use categories should be avoided as there may be unexpected consequences of 
the intervention (4, 5).   
Ideally the unit costs attached to the resource use should represent the 
opportunity cost of that resource; the value of the next best alternative. 
However for practical reasons, site- or nation-specific unit costs are more 
frequently used, the most appropriate unit cost to use will depend on the 
research question (4, 6).  Tariffs are one alternative to using opportunity costs, 
these are set by governments and either relate to a diagnosis related group or 
health resource group payments, the benefits of using these costs are that they 
represent the true cost of what is spent by governments (4, 6), however the 
costs for different procedures or stays are often put in wide categories that do 
not accurately reflect the actual costs. Another alternative to opportunity costs 
are site-specific unit costs, micro-costing techniques are needed to calculate 
these, and the benefit of using site-specific unit costs is that an accurate cost 
for each site can be calculated and applied to resource use (4). Micro-costing 
also has the benefit of reflecting the actual resources used and therefore 
displaced similar to the concept of opportunity cost, and could arguably more 
accurately measure differences between treatment arms (66). Whatever type of 
unit cost is used to value resource use, it should always be for the same price 
year, inflated using healthcare price indices if necessary. In multinational trials 




2.5.2 Resource use and costs - data collection options 
Conventional collection of participant data during clinical trials is through the 
case report form which is completed by all trial participants at their follow-up 
visits (67), it is common for economic resource use data to be collected using 
the same case report form that is used to collect other relevant (non-economic 
evaluation) data during the clinical trial.  However, other instruments which 
have been designed to collect data directly from participants (or via a carer or 
proxy) during a clinical trial may be used, these including patient questionnaires 
and diaries.  It is also possible to include resource use which is not collected 
directly from participants during the clinical trial, this is known as routinely 
collected data, for example patient medical records (ie GP or hospital) (5, 6).  
Case report forms are often adapted specifically for each trial which can lead to 
variability in the data collected, therefore best practice is to use validated 
resource collection instruments (5, 68, 69) and instruments for calculating 
productivity costs (70-72).  If it is not possible to use validated resource 
collection instruments then any new versions of forms or instruments used to 
collect economic data should be tested and evaluated for suitability of use (6).  
Recall bias can affect the completeness and accuracy of resource use collected 
directly from participants, this occurs when the participant is unable to 
accurately remember the healthcare resources that they have used since the last 
follow-up (6).  It is often the case that, for practicality, the collection of 
economic data coincides with the clinical trial follow-up visits, and if the timing 
is unlikely to result in recall bias this is deemed suitable for the economic 
evaluation.  However, if there is likely to be a lot of resources used by trial 
participants during the follow-up period, then using a case report form which is 
completed at set trial follow-up points may not be suitable, in this case a diary 
may be more practical in helping the participant to record resource use more 
frequently, and results in resource use data collection not subject to recall bias 
(5).  Another way of minimising recall bias is to verify the resource use directly 
reported by participants using secondary sources (5). 
Using electronic databases for collecting clinical trial data is becoming 
increasingly popular, this enables a simplified method of clinical and economic 
data collection for sites; data is input into an electronic case report form which 
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is uploaded to the trial database. The advantages of these databases are that 
data can be checked for accuracy and completeness throughout the time period 
of the trial and any data issues spotted by trial staff monitoring the database 
can be highlighted before the end of the trial and queries can sent to trial site 
staff (5).  More recent additions to the electronic trial database are the ability 
to use electronic health care records data to partially populate the trial 
database, and using the internet, smartphones and mobile health applications to 
upload data (5).  The main benefit of these electronic methods is an 
improvement in efficiency, however further research is needed to understand 
the quality and completeness of the resulting trial databases (5). Whatever 
process is chosen to collect economic data it should be piloted prior to use (6). 
2.5.3 Outcomes measures 
When conducting an economic evaluation it is best practice for the health 
benefit measure included to allow for comparisons across diseases and 
interventions, and not be limited to the disease and intervention of the specific 
clinical trial (4). As discussed previously, the favoured outcome measures for 
assessing health benefits in an economic evaluation are preference-based quality 
of life measures, however the health benefit may also be measured in disease 
specific clinical outcomes such as blood pressure, cholesterol or strokes avoided, 
if possible alongside the preference-based measure or, if it is not possible to 
include a preference-based measure, as the sole measure of health benefit (4).   
Preference-based quality of life measures combine a health utility score (quality 
of life) with a measure of length of life to calculate a QALY. The QALY is the 
preferred health benefit outcome in many jurisdictions as it can be used to 
compare cost-effectiveness across different disease areas, as recommended in 
the guidance.  The value of the health utility is on a scale from 0 to 1, where 0 
represents death and 1 represents full health.  For example, in combining health 
utility and length of life, a QALY of 0.6 signifies that the health state the 
participant is in is worth 0.6 years at full health or one year at less than full 
health (4).  However using the QALY may not pick up differences in health 
related quality of life in an economic evaluation due to its restrictive and 
insensitive nature, it has been reported that QALYs are not responsive to 
changes in disease states (4, 6).  
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There are two main preference-based techniques for calculating QALYs, the first 
uses a ‘pre-scored’ questionnaire asking participants about their health state. 
Each participant completes a questionnaire (for example EuroQol-5 Dimension 
(EQ-5D), Health Utilities Index or SF-6D) (73-76) at pre-determined time points 
during the clinical trial follow-up. The responses to these questionnaires are 
valued using existing population-based value sets using population preferences, 
the value sets can be country specific. There are quality of life questionnaires 
specifically for children (for example EQ-5D-Y and HUI2) (75, 77, 78), and for 
seriously ill participants or those with cognitive impairment proxies can be used 
(79). The second technique for assessing quality of life is using preferences 
obtained directly from participants using techniques such as time trade-off or 
standard gamble (79, 80), these ask each participant about their health status 
and then to value it, however these latter techniques can be time consuming 
and expensive and therefore not suitable for use in many trial based economic 
evaluations which are constrained by time and costs.   
Where preference based quality of life measures are not collected from 
participants in the trial, there is the option to map non-preference based 
responses from the trial to preference-based measures (81), however this 
technique has limitations due to few mapping algorithms being validated and 
issues with the reliability of results (5). 
To calculate QALYs over the trial period the utility scores at each follow-up time 
point are combined with the length of time between follow-ups using area-
under-the-curve techniques (4). 
The frequency of quality of life data collection will depend on disease severity, 
disease progression and the perceived burden on participants, if relevant and for 
convenience the trial follow-up points used for collecting clinical outcomes and 
resource use data, can also be used to collect the quality of life data (6).   
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2.6 Current guidance - analysis  
2.6.1 Analysis plan  
Each economic evaluation should be planned in advance and a written analysis 
plan should be produced and agreed before the trial data is unblinded (5, 82).  
Key approaches common to all economic evaluations include: 1) the analysis 
should use an intention-to-treat population where the analysis is based on the 
treatment arms that participants were randomised to regardless of which 
treatment they received; 2) the within trial analysis should use the same time 
horizon for costs and outcomes; 3) uncertainty around each result should be 
included; 4) if a trial follow-up is longer than a year then a discount rate should 
be applied to costs and outcomes for all years after the first year, this adjusts 
for time preference, (for England and Wales the recommended discount rate is 
3.5%), and 5) if there is missing data, techniques should be employed to deal 
with this (4-6, 63).  
2.6.2 Costs 
The appropriate cost measure for economic evaluations is the arithmetic mean – 
an average cost per person, this allows decision makers to estimate total 
population costs for the intervention.  Costs are often right skewed; most 
participants incur low or no costs while a small number will incur high costs. To 
estimate the difference in mean costs between arms, if there is a large sample it 
can be assumed that the costs are normally distributed and parametric 
techniques can be used, however generally best practice is to use a generalised 
linear model to analyse skewed data, using a gamma family and log link (4-6).  
2.6.3 Outcomes 
For health benefits best practice is to replicate the primary clinical analysis 
methods for any clinical outcomes included in the economic evaluation, however 
the primary clinical trial outcome may be presented as a time to event while the 
economic evaluation will include all clinical outcome events.  Recommended 
methods for analysing QALYs include adjusting for baseline characteristics of 
participants and baseline EQ-5D (83), and, as with the cost analysis, a 
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generalised linear model is a suitable method to estimate the differences in 
QALY, using a Gauss family and log link (5, 6, 83).  
2.6.4 Missing data 
There is an inherent problem with missing data in economic evaluations 
alongside clinical trials (6), there are two main types of missing data and the 
techniques for dealing with these types of missing data are explained next. 
The first type of missing data occurs when participants do not report or record 
all the data that they are asked for.  The trial team can help reduce the amount 
of missing data by auditing the trial database, and health economists can help by 
reminding trial researchers the importance of minimising missing data.  Naive 
methods of dealing with missing data are presenting complete case and full 
sample (available case) analyses, although these methods are not generally 
recommended.  However if the amount of missing data is less than 5% of the 
observations, and the quantity and pattern of missing data do not differ between 
treatment arms, a complete case analysis is permissible (5).  A more suitable 
approach for dealing with missing data is the use of multiple imputation 
techniques, the exact multiple imputation technique used will depend on the 
type of missing data, if the data is missing at random the multiple imputation 
using chained equations is recommended (84).   
The second type of missing data is censored data, which is when a participant 
drops out of the trial and the data on them is restricted to their time in the 
clinical trial, suitable methods for dealing with censored data in an economic 
evaluation are available for use (5, 6). The health economists should work with 
the trial team to minimise the amount of censored data, and similar to missing 
data, if around 5-10% of the total data is censored it is not believed that it will 
have an impact on the results so not further methods are required. Again 
complete case or full sample analyses are naïve methods often applied, however 
more suitable methods are available, these include: Lin 1997 method, Lin 2000 




2.6.5 Summary measures 
The difference in costs and health benefits between arms should be summarised 
in a measure, this summary measure provides cost-effectiveness evidence to the 
decision maker.  There are three measures commonly used to demonstrate the 
value of the interventions (5): 
1. The ICER described in Section 2.2 where the cost of gaining or losing one 
QALY, or other health benefit, is presented, and is often the main 
summary measure reported in an economic evaluation.  However, the 
nature of ratios can prove challenging; the difference in health benefit 
(either QALY or alternative clinical outcome) may be near to zero which 
results in a large ICER, and negative ICERs points (represented in the 
northwest and/or southeast quadrants of the cost-effectiveness plane) 
can be the result of higher costs and outcomes lower outcomes, or lower 
costs and higher outcomes in the new technology arm compared to the 
existing technology arm.  Furthermore, negative ICERs make confidence 
intervals difficult to calculate and interpret (6), the net benefit measure 
overcomes these issues and is discussed next. 
2. The net monetary benefit (NMB) measure incorporates the healthcare 
payer’s willingness-to-pay threshold (λ) with incremental costs (∆𝐶) and 
incremental QALYs (∆𝐸) (Equation 2): 
𝑁𝑒𝑡 𝑚𝑜𝑛𝑒𝑡𝑎𝑟𝑦 𝑏𝑒𝑛𝑒𝑓𝑖𝑡 =  𝜆. ∆𝐸 − ∆𝐶 > 0 
Equation 2: Net monetary benefit 
 
If the net monetary benefit measure is positive it should be interpreted as 
the new technology being cost-effective and it should be adopted, if the 
net monetary benefit it is negative then the new technology is not cost-
effective and should be rejected; the costs outweigh the value assigned to 
the health benefits (6).  
3. The third summary measure is a measure of probability, the method for 
estimating this summary measure is to present net monetary benefit 
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results on a cost-effectiveness acceptability curve using different levels of 
willingness-to-pay thresholds (2, 6).  This shows the probability of the new 
technology being cost-effective at different levels of willingness-to-pay 
thresholds (5). 
2.6.6 Uncertainty 
When there is uncertainty around the economic evaluation results this should be 
characterised and presented to decision makers as evidence for basing their 
funding decision on.  There are four key types of uncertainty that can occur in 
the results: sampling, parameter, imputation and heterogeneity uncertainty. 
Sampling uncertainty occurs when a sample of people is extracted from the 
population of interest and an analysis is based on this limited pool of people who 
may not be representative of the entire population (5).  Guidance includes four 
recommendations for characterising this uncertainty: 1) Measures of variability 
should be reported for mean costs and mean health benefits for each arm of the 
trial, as well as for the differences between arms for mean costs and health 
benefits, and summary measures such as the ICER and net benefit (5).  The 
measure of variability most useful when estimating differences is the 95% 
confidence interval. 2) Results can also be shown on a cost-effectiveness plane 
using non-parametric bootstrapped samples, this has the benefit of avoiding 
complications from using a ratio, and uncertainty can be represented on the 
plane by including confidence ellipses (4). 3) Sampling uncertainty can also be 
presented on a cost-effectiveness acceptability curve using the bootstrapped 
samples and varying the levels of the willingness-to-pay threshold, this was 
discussed above in relation to summary measures (2, 5).  4) Using the value of 
information measure; the expected value of perfect information (EVPI) can be 
calculated to inform decision makers on the value of removing uncertainty from 
the data ; the EVPI represents difference between the value of a decision based 
on current information and the value of a decision based on perfect information 
(85). The cost of acquiring perfect information is based on the probability of 
making the wrong decision when deciding whether to adopt or reject the 
intervention, and the cost of making the wrong decision (4, 5).  If the population 
EVPI is greater than the cost of further investigation in a future trial or other 
research, this this is a necessary, but not sufficient, condition to conduct further 
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research; it is potentially worthwhile. To establish whether future research is 
worthwhile the expected value of sample information (EVSI) should be 
calculated (85).  The EVSI measures how much the uncertainty, and related 
consequences of this uncertainty, are diminished by evidence from additional 
research.  This is a result of the design of the future research, for example 
sample size, follow-up and endpoints, all these factors affect the cost of the 
research (86).  The difference between the population EVSI and the expected 
cost of the research is termed the expected net benefit of sampling (ENBS) and 
should be calculated for a range of study designs.  If the ENBS is positive this 
suggests that further research is worthwhile, this is a sufficient condition, if the 
ENBS is negative further research is not worthwhile (86).  EBNS is useful for 
determining the study design of future research; the design with the highest 
ENBS should be chosen (87). 
Parameter uncertainty is the uncertainty in the parameter estimates due to 
uncertainties in the economic data (5). There are two recommendations for 
dealing with parameter uncertainty in economic evaluations: 1) Sensitivity 
analysis, where uncertain parameters are assessed for their impact on the 
results by varying these parameters within probable ranges. 2) Another 
technique is to use a value of information approach similar to EVPI to calculate 
the expected value of perfect parameter information (EVPPI); this approach 
focusses on calculating the value of gaining perfect information on specific 
parameters. 
Imputation uncertainty occurs when imputing missing values artificially shrinks 
sampling uncertainty estimates, a suggestion for tackling this type of uncertainty 
is to bootstrap the results, the results of this technique can be used to create a 
cost-effectiveness plane and a cost-effectiveness acceptability curve (5).  
Heterogeneity uncertainty is driven by differences (heterogeneity) between the 
trial participants, this can be investigated using regression techniques applied to 
the results, using characteristics of participants as covariates, and by sub-group 
analyses (6).  
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2.6.7 Extending the analysis beyond the trial time horizon 
The economic evaluation should capture all costs and health benefits related to 
the intervention, this is often not possible within the timescale of a clinical trial, 
in these circumstances an extrapolation of trial results is needed. Life 
expectancy can be estimated using survival analysis techniques such as Cox 
proportional hazards or Weibull models to extrapolate survival data (6), and if 
the trial period is long enough to capture sufficient data for modelling then 
direct modelling can be used, if this is not feasible the trial data can be 
combined with longer-term observational data for conducting decision analytic 
modelling (5).  
2.7 Current guidance - reporting 
This section briefly describes the recommendations for reporting economic 
evaluation results, this is included for completeness only as the main focus of 
this chapter is the analysis of the economic evaluation. 
Guidance is available for reporting economic evaluations alongside clinical trials 
(88-91). The audience for economic evaluation is often varied so detailed 
reporting of the analysis is required (5). 
2.7.1 Trial information 
The economic evaluation report should begin with clinical trial related 
information, such as a description of the clinical trial, the setting and location, 
the inclusion and exclusion criteria for participants, a description of the 
treatments, details of the protocol driven treatments, the clinical trial time 
horizon, participants’ baseline characteristics and a link to the registry of the 
trial.  Following this overview, a summary of the clinical results should be 
included (5).  
2.7.2 Economic data 
An overall description of the economic data used in the economic evaluation 
should be reported, including the economic data collected (costs and outcomes), 
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a timetable of what data was collected when, unit cost sources and how much 
missing and censored data there is (5). 
2.7.3 Methods 
The methods section should describe the component parts of the costs and 
outcomes and how they were calculated, if the outcome is the clinical endpoint 
and differs to the clinical analysis results an explanation of how this difference 
occurred should be included.  Planned methods for dealing with missing and 
censored data should be included as well as planned statistical methods for the 
comparison of resource use, costs and outcomes.  If the time horizon is to be 
extended beyond the follow-up period of the clinical trial the methods and 
assumptions planned to do this should be reported. Finally, any deviations from 
the analysis plan should be reported and justified (5). 
2.7.4 Results 
The point estimates and corresponding measures of uncertainty should be 
reported for resource use, costs and outcomes.  Results for the within trial time 
horizon and any longer time horizons (if appropriate) should be presented, and 
any results not suited to table presentation should be presented as graphs and 
other suitable formats (5). 
2.8 Strengths of conducting economic evaluations 
alongside clinical trials 
As discussed in Section 2.2 clinical trials are considered to be the gold standard 
vehicle for assessing safety, efficacy and effectiveness of an intervention, and 
necessary to gain a licence for a new pharmaceutical product, or an existing 
pharmaceutical product used for a new indication (1).  One of the main 
strengths of a clinical trial is that any confounding issues experienced in an 
observational study are removed by applying the system of randomisation, this 
gives an unbiased estimate of the size of benefit or risk from using the new 
technology compared to the existing technology, thus clinical trials are deemed 
to be the best vehicle for estimating the relative treatment effect between the 
intervention and comparator (55, 92).   
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Many funders are calling for economic evaluations to be included in the design of 
clinical trials to add cost-effectiveness evidence as well clinical evidence for 
decision makers (6).  Economic evaluations conducted alongside clinical trials 
benefit from the robust clinical trial design, unbiased estimates of effectiveness 
and from the trial systems for collecting data, giving a unique chance to 
collected individual resource use data (62, 93).  Having this individual level data 
gives the opportunity for robust statistical analysis (1, 62) and provides valuable 
information on resource use, health related quality of life and the disease being 
researched (92).  They also provide additional information on the cost-
effectiveness of an intervention with high internal validity, and with external 
validity if the clinical trial is designed and conducted correctly (1, 5, 62).  
There are also potential financial benefits from conducting an economic 
evaluation alongside a clinical trial, as it gives a practical opportunity to conduct 
a cost-effectiveness analysis, which provides reliable evidence with little extra 
cost on top the existing large, fixed cost of the trial.  Conducting clinical trials is 
expensive and using the trial data to conduct an economic evaluation adds small 
marginal costs for arguably a large analytical gain (1, 6, 62).   
2.9 Limitations of conducting economic evaluations 
alongside clinical trials 
Despite these strengths of using a clinical trial as a vehicle to conduct an 
economic evaluation there are inherent weaknesses too, which despite the 
robust guidance set out in 2.3 to 2.7 can undermine the results of the economic 
evaluation.  Whilst it is agreed that a clinical trial is the gold standard vehicle 
for providing clinical effectiveness evidence, it is also agreed that clinical trials 
are not gold standard for providing cost-effectiveness evidence as discussed by 
Sculpher at al. in 2006 (60).  
The objectives of a clinical trial (an unbiased protocol driven assessment of 
treatment safety, efficacy and effectiveness) are inconsistent with the 
objectives of an economic evaluation (estimation of the costs and health 
benefits of a intervention provided in real clinical practice to all, not carefully 
selected patients, compared to current best practice, over a suitable follow up 
period) (62, 63, 94).  The audience for these two analyses is also different; the 
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clinical evaluation from a clinical trial informs regulatory licensing and clinical 
decision makers, whereas economic evaluations inform healthcare policy makers 
and payers (94).  
These contrasting objectives and audiences lead to inherent shortcomings when 
conducting economic evaluations alongside clinical trials, which challenge the 
underlying principles of conducting an economic evaluation (set out in Section 
2.4) as a result of the necessary features of a clinical trial (5, 6).  The main 
conflicts between the economic principles and features of a clinical trial are 
described in detail in the following sub-sections. 
2.9.1 Protocol driven care 
The care provided to participants in clinical trials is driven by the trial protocol 
not clinical practice, so is not always representative of resource use in ‘real-
life’. Blinding of participants and/or researchers exacerbates this additional 
resource use with participants in the control arm potentially being given tests 
and other procedures that are only needed in the intervention arm, which can 
potentially underestimate any true difference in costs.  More frequent 
monitoring can lead to ‘case findings’; which is when an undiagnosed condition 
is discovered during a protocol driven visit or test, and, as it is almost impossible 
to know whether this condition would have been diagnosed in the absence of the 
protocol driven visit or test, it is unclear whether resources used in diagnosing or 
treating should be included in the economic evaluation (5, 62). In protocol-
driven care participants are encouraged to attend visits and comply with 
medication, in a real-life setting compliance is often lower, leading to an 
artificially high resource use in the economic evaluation (62), this can lead to 
problems with external validity.  There are three recommended approaches for 
mitigating these issues; 1) the economic evaluation can omit resource use 
resulting solely from the influence of the trial protocol; 2) the trial team could 
run a pragmatic trial where the care is based on clinical practice; and 3) the 
trial team could include a usual care arm, either as part of the trial or run 
parallel to the trial (62). 
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2.9.2 Single comparator arm, which may not be current best 
practice 
The comparator chosen in a clinical trial is often a placebo, therefore the 
estimated treatment effect from the clinical trial is the maximum possible 
treatment effect and may overestimate the effectiveness of the new technology.  
A key principle of health economic evaluations is to compare the new technology 
to all treatments currently being routinely used, especially those considered to 
be current best practice, so a clinical trial comparing the new technology to 
usual care is considered more appropriate than one comparing the new 
technology to a placebo (62, 92). The recommended approach for mitigating this 
limitation is to conduct an analysis using a decision analytic model which 
includes all possible and existing comparators used in current practice (3). 
2.9.3 Unrepresentative study sites 
Study sites included in the clinical trial may not be representative of the sites 
that would provide the intervention if it is adopted; study sites are often chosen 
on their ability to recruit participants only. This misrepresentation can lead to a 
variation in clinical practice between study sites, and the participants from the 
study sites may differ to those at other sites too, for example severe morbidity 
compared to mild. This can result in resource use at study sites not representing 
overall clinical practice and undermining external validity, this problem can be 
overcome by including several study sites with different characteristics (62). 
2.9.4 Strict inclusion and exclusion criteria 
Strict inclusion and exclusion criteria are necessary in exploratory trials to 
minimise variation between participants and, as accurately as possible estimate 
the treatment effect, this can lead to the trial participants not being 
representative of the target population, undermining external validity (5, 6, 62).  
One recommendation for dealing with this weakness is to use a pragmatic trial 
design; pragmatic trials enrol participants who are representative of all patients, 
the new technology is compared to current practice, and follow-up is carried out 
under typical clinical practice routines, however internal validity for pragmatic 
trials can be low (62, 94). 
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2.9.5 Clinical endpoints do not match economic evaluation 
endpoints 
The clinical end points used in a clinical trial are often not suited to economic 
evaluations, which use an episode of care as an endpoint which then triggers a 
cost (4). There are typically three types of clinical endpoints used, each of 
which are discussed in terms of their suitability as an economic endpoint next: 
1) composite endpoints are when several endpoints are combined to give greater 
statistical power to the results, for example all-cause mortality, recurrent 
myocardial infarction and new congestive heart failure (3). The cost per 
composite endpoint is not suitable for an economic evaluation, mainly because 
the endpoints do not have the same importance, so when composite endpoints 
are used in a clinical trial it is recommended that they are presented separately 
and are common across different diseases and treatments for comparison (5).  2) 
Intermediate or surrogate endpoints are used primarily when the expense of a 
longer follow-up in the clinical trial is prohibitive.  An intermediate or surrogate 
endpoint is not usually an episode of care, an example a percentage decrease in 
blood pressure. The time horizon of the clinical trial is usually based on assessing 
the clinical effectiveness of the intervention, which when the endpoint is an 
intermediate one is not always long enough to capture all important health 
economic resources and outcomes related to the disease for all comparators, a 
key principle for conducting economic evaluations (92).  In these cases, the 
intermediate clinical endpoint should be linked to long-term costs and 
outcomes, and if a link is not available the health economist should push for 
longer follow-up to allow for the collection of a suitable economic outcome. 
When deciding on a suitable length of follow-up for economic endpoints this may 
be longer than the clinical endpoint, for example a clinical endpoint may be a 
blood pressure reading whereas the related economic endpoint will be an 
episode of care triggering a cost, for example number of strokes linked to an 
increase or decrease in blood pressure. 3)  The third type of clinical endpoint is 
aimed at assessing how a participant feels, functions, or survives, these are the 
preferred endpoints for economic evaluations.  Preference-based quality of life 
scores can be combined with survival data to produce a QALY, the preferred 
economic evaluation outcome in many jurisdictions (5).  
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A suggested approach to deal with this limitation is to use a decision analytic 
model and epidemiologic data to predict final outcomes from intermediate 
outcomes (1, 62). 
2.9.6 Censored data 
Censored data reduces the economic evidence, either as a result of the 
participants being lost to follow up or due to data collection stopping at a pre-
determined point.  Approaches recommended to mitigate this issue are to use 
modelling techniques to extrapolate trial results, to predict final economic 
outcomes using clinical intermediate outcomes, and to analyse censored data 
using techniques suggested in sub-section 2.6.4. (62).   
2.9.7 Insufficient follow-up  
A key principle in economic evaluation is using an appropriate length of follow-
up to capture all costs and health benefits to estimate cost-effectiveness, 
preferably over a lifetime, however often this is limited to a much shorter 
period (5).  If there are strong links between an intermediate end point and a 
long-term disease episode of care more reliance can be given to these 
intermediate end points.  Another approach for dealing with insufficient follow-
up is to extrapolate the clinical trial results using modelling techniques. 
2.9.8 All relevant evidence not collected 
Another key principle is based on the requirement to include all relevant 
evidence in the economic evaluation, however using a clinical trial as a vehicle 
for economic evaluation invariably narrows the range of evidence available on 
health related quality of life and resource use (92).  A suggested approach to 
mitigate this limitation is the use of systematic reviews and evidence to inform a 
decision analytic model (92). 
2.9.9 Insufficient sample size 
One of the key issues of using clinical trials for economic evaluations is sample 
size; a sample size (power) calculation informs the investigators on how many 
participants are needed to reach a significant conclusion on the size of 
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treatment effect from the intervention in the clinical trial (62, 95). If too few 
participants are recruited the clinical trial will not be able to evaluate 
effectiveness reliably, and if too many participants are recruited the clinical 
trial becomes too expensive and hard to run. The power calculation ensures the 
correct number of participants are recruited to the trial to answer the research 
question (95). To determine the power calculation the null hypothesis, the type I 
error, and the type II error should be defined.  The null hypothesis is ‘there is no 
difference between treatment A and treatment B’, a type I error is the 
probability of rejecting the null hypothesis when it is true and is typically set at 
two sided 0.05, and a type II error is the probability of not rejecting the null 
hypothesis when it is false which is typically set high at 0.80, the higher this is 
set the larger the sample size.  The clinically acceptable margin of difference 
(treatment effect size) should also be estimated, either from a pilot study or 
extracted from the literature (96).  The type of clinical trial design is also 
needed to calculate the sample size; designs comprise superiority, equivalence, 
and non-inferiority.  Superiority trials assess whether one treatment is more 
effective than the other either in statistical or clinical terms, equivalence trials 
assess whether the treatments are equally effective, and a non-inferiority trial 
assesses whether one treatment is as effective as the other within a previously 
set margin.  Finally, the effectiveness outcome is defined as either dichotomous 
or continuous (95). 
When an economic evaluation is conducted alongside a clinical trial this often 
results in the underpowering of the economic evaluation (62).  The clinical 
outcome often requires a smaller sample size than the economic outcomes due 
to a large variability in resource use and costs relating to the economic 
evaluation, leaving clinical trials underpowered to detect economic differences 
(5, 6).  Even if it was possible (financially and ethically) to recruit additional 
participants so that the economic evaluation is not underpowered, there is no 
agreed definition of an economically meaningful difference for an economic 
outcome sample size calculation, and estimating the joint distribution of the 
difference in costs and health benefits between treatment arms is a complex 
issue (6, 62).  Economic evaluations are not powered to test a hypothesis and 
instead focus on estimating the differences in costs and health benefits, and the 
likelihood that an intervention is cost-effective (6, 97). Several approaches have 
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been proposed to address the limitations of an inadequate sample size, these 
relate to the statistical analysis of the economic evaluation: estimating 
uncertainty around the ICER, presenting a cost-effectiveness plane and using the 
net monetary benefit summary measure (62). 
2.10 An introduction to the new role for conceptual 
models 
This section introduces the new role for conceptual models in economic 
evaluation.  It begins with an overview of the role and explanation of why it is 
needed, then presents suggestions for how the new role will work, including the 
contents of the conceptual model, how the expected relationships within the 
conceptual model can be assessed for accuracy, and how the conceptual model 
could be used for an additional analysis.  The section finishes with a discussion 
of the new role. 
2.10.1 Overview  
In conventional health economic evaluations alongside clinical trials, study data 
are analysed by comparing the costs and outcomes of each treatment arm to 
assess the cost-effectiveness of a new technology, or for the new use of an 
existing technology.  However, while clinical trials are essential for evaluating 
the clinical safety, efficacy and effectiveness of an intervention they do not 
always provide economic data that matches the key principles of economic 
evaluation. Due to not always achieving these key principles it is common for the 
results of treatment-arm based analyses to be uncertain (reporting no significant 
difference in costs or outcomes between arms), particularly as a result of 
underpowering of the economic evaluation, the suboptimal collection of 
economic data and protocol-driven costs (98).  Because of this inherent 
uncertainty in economic evaluation results it is recommended that the focus in 
the results should be estimation and not hypothesis testing (99). The role of 
economic evaluations is to provide cost-effectiveness evidence to decision 
makers for allocating healthcare resources, when this evidence is uncertain the 
decision makers’ role is made harder, but a decision must still be made.  
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Methods have been developed to represent this uncertainty in results (62, 94) 
and are reported in sub-section 2.6.6, they comprise presenting confidence 
intervals around the results, producing a cost-effectiveness plane, providing a 
cost-effectiveness acceptability curve, and presenting value of information 
estimates.  When uncertain results are plotted on a cost-effectiveness plane, the 
plots will straddle the axis’ and crowd around the origin, this is described as 
‘Scenario 9’ (Figure 2) as depicted by Briggs and O’Brien (100), where there are 
no differences between arms in either costs or health benefits. 
 
Figure 2: Cost-effectiveness plane from Briggs et al. (100) 
 
Despite this uncertainty in economic evaluation results the treatment costs in a 
clinical trial are often known and precise; a greater cost in the intervention arm 
compared to comparator arm, resulting in a highly statistically significant 
difference between treatment arms.  Conversely, non-treatment costs often 
have a statistically non-significant difference.  It is when the uncertain non-
treatment incremental costs are combined with known and precise incremental 
treatment costs the resultant plots on the cost-effectiveness plane fall into 
Scenario 9. Despite treatment costs often being known and precise and non-
treatment costs less precise, it is rare to see a discussion in the literature about 
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the certainty of treatment costs being overshadowed by the uncertainty of non-
treatment costs; of the 72 UK National Institute for Health Research (NIHR) HTA 
reports published in 2020, 32 included a within trial economic evaluation, 17 of 
these discussed the costs of different resource categories, only 5 of these 
mentioned increased treatment costs being offset by cost savings in other 
categories, and none of the reports confirmed that treatment costs were known 
and certain (Appendix 1: NIHR HTA reports published in 2020 (Volume 24) 
(Chapter 2).  
In the absence of alternative guidance, the established recommendations for 
conducting economic evaluations alongside clinical trials described in this 
chapter should be followed. However, when there is uncertainty in results 
decision makers are often left contemplating a cloud of dots on the cost-
effectiveness plane, with the only certainty being that the new intervention cost 
is greater than the comparator.   
As well as the uncertainty in economic evaluation results, economic evaluations 
have been described as ‘intervention-focussed’ and ‘outcomes -driven’ (10); the 
analysis is driven by a direct comparison of costs and outcomes between 
treatment arms, so the results are defined only by the treatment arm the 
participants are randomised to.  This is also known as a ‘black box’ evaluation 
where there is little interest in how the outcomes occur (10) and no 
understanding of the causal mechanism linking the intervention to the outcomes 
(101).   This intervention focussed approach results in the analyst concentrating 
only on the ICER and not considering the mechanism driving the ICER.  By 
focussing on a treatment arm-based analysis no attention is given to the causal 
mechanism that is believed to drive the economic outcomes of costs and health 
benefit (10).  This misses an opportunity to provide additional insight into the 
trial data, identifying the mechanism linking invention to outcomes and what is 
driving the outcomes, and giving further understanding of the treatment arm-
based results.  
Despite the limitations highlighted in Section 2.9 the patient-level data from 
clinical trials is the preferred choice of many and conducting economic 
evaluations alongside clinical trials provides an appropriate vehicle to collect 
this patient-level data.  There will continue to be demand for economic 
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evaluations alongside clinical trials, and there are approaches recommended to 
address the limitations (62), which were presented in Section 2.9.   
Decision makers consider two questions when allocating scarce healthcare 
resources; 1) should the new technology be adopted, based on the results of the 
economic evaluation and measures of uncertainty and 2) is any additional 
information needed to help make the adoption decision (3)? There are four 
distinct conditions required of economic evaluation methods; defining the 
objective and limitations of the ‘health care provision’, defining the decision 
problem, portraying uncertainty, and providing a method for interpreting the 
results (3).  The conventional guidance for economic evaluation described earlier 
meets the first three conditions, however the latter consideration still is not 
completely filled.  Furthermore, when there are uncertain results and limited 
understanding of how the economic outputs occur and are driven, the answer to 
question 2 above (‘is any additional information needed to help make the 
adoption decision?’) is ‘yes’.  Clinical trials are expensive and time consuming; 
in England alone clinical research is worth £2.7 billion annually, supporting over 
47,000 jobs, and delivering over £28.6 million savings to the NHS (102).  As there 
will always be demand for economic evaluations alongside clinical trials there is 
scope for proposing a new approach to analysing valuable clinical trial data, 
which addresses the limitations (uncertainty and ‘black box’ analysis) of 
economic evaluations and provides a supplementary analysis to the conventional 
treatment arm-based analysis to give additional information to decision makers. 
This thesis proposes a conceptual model driven analysis of the clinical trial data 
to provide additional interpretation and understanding of the economic 
evaluation results based on the expected causal mechanism in the clinical trial, 
linking the intervention to outcomes. This proposed new approach would act as a 
supplement to the conventional treatment arm-based approach of analysing 
clinical trial data for economic evaluations, giving additional evidence to 
decision makers.   
While the use of conceptual models is recommended and frequently adopted for 
developing decision analytic models in economic evaluation, they are rarely used 
in the context of trial-based analyses.  The proposed new role for conceptual 
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models is to further investigate, interpret and understand trial data, extending 
the analysis beyond the conventional treatment-arm based comparison.  
Conceptual models visually illustrate the casual relationships between key 
components in a real-life system or process (13-16).  The aim of the new 
approach is to use the causal relationships inherent in conceptual models to 
further analyse clinical trial results; the conceptual model will illustrate a 
simplification of the relationships (causal or otherwise) in the trial mechanism, 
linking the key economic evaluation components, from treatment (inputs) to 
health benefit outcomes (outputs).  There are a variety of possible types of trial 
mechanism, including biological, behavioural or a policy change.   
To omit bias in this new role the conceptual model should be developed prior to 
the analysis, however any unexpected outcomes can be explored with additional 
conceptual model analyses as sensitivity analyses; these could potentially use 
either a different trial mechanism or different components.  Having a 
conceptual model depicting the anticipated consequences of the intervention 
can also help to limit data mining and post hoc analysis, although care should be 
taken not to ignore genuine unexpected consequences of the intervention. 
This thesis suggests three aspects of the conceptual model driven analysis:1) As 
a communication tool, illustrating the contents of the model, depicting expected 
associations (causal or otherwise) between key components in the trial 
mechanism, linking inputs to economic outputs; 2) Assessing the expected 
associations in the conceptual model to confirm (or otherwise) the validity and 
accuracy of the conceptual model in terms of the expected mechanisms driving 
the study results, and 3) conducting additional analysis on the clinical trial data 
to provide additional and more detailed interpretation of the treatment arm-
based results.  
2.10.2 Conceptual model 
The conceptual model should show how the economic inputs (ie patients, 
facilities and treatment) are linked through the trial mechanism (and mediators) 
to the economic outputs (ie costs, QALYs or other health benefits). 
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The key components included in the conceptual model will relate to the 
assumed trial mechanism and economic inputs and outputs, these should be 
identified when the conceptual model is developed (a methodological framework 
for guiding the development of the conceptual model is presented in Chapter 5).  
These key components are expected to include the disaggregated components of 
economic resource use and health benefits, and the clinical components of the 
trial mechanism.  
A suggestion of the typical disaggregated economic resource use collected in a 
clinical trial was discussed previously in sub-section 2.5.1, as reported by Petrou 
et al., these include: the treatments; healthcare use related to the disease or 
intervention; treatment of side effects related to the intervention, and other 
resource use deemed important (6). 
Further guidance to help determine relevant disaggregated economic 
components can be taken from the equations presented by Weinstein and Stason 
in 1977, these equations illustrate the individual components making up the 
cost-effectiveness calculus; one relating to incremental costs and one to 
incremental QALYs (41).  The equations give an overview of the individual 
components expected in an economic evaluation; however they should be 
applied with relevance to each situation individually as all economic evaluations 
differ, and therefore so will conceptual models.  It is anticipated that each 
economic evaluation comprises a different set of costs and outcomes, but the 
equations presented by Weinstein and Stason provide a helpful guide to typical 
components of an economic evaluation. 
In the equation for total incremental costs, the cost categories are broken down 
into four components (Equation 3): medical and healthcare costs (∆CRx); costs 
resulting from treatment side effects (∆CSE); cost savings resulting from the 
intervention alleviating and preventing disease (∆CMorb), and costs from 
treating diseases resulting from living longer (∆CRx∆LE).   
                                   ∆C= ∆CRx + ∆CSE - ∆CMorb + ∆CRx∆LE 




The effectiveness equation representing QALYs is broken down into three 
components: number of life years (∆Y); improvement in quality of life as a result 
of the intervention alleviating or preventing disease (∆YMorb), and a decrease in 
quality of life from side effects of the treatment (∆YSE) (Equation 4).   
∆E= ∆Y + ∆YMorb - ∆YSE 
Equation 4: Weinstein and Stason's incremental effectiveness equation 
 
The number of life years represents the quantity-of-life element of a QALY and 
the results of the intervention alleviating or preventing disease and detrimental 
effect of treatment side effects represent the quality of life aspects of the 
QALY.  
From identifying these cost and outcome categories, the analyst specifies the 
relevant cost components that make up the total net-incremental costs and total 
net-incremental QALYs.  The two components from Weinstein and Stason’s 
disaggregated calculus; costs and health benefits, are combined in a simple 
template in Figure 3, this template can be used as a guide on which to base the 
conceptual model. The hypothetical mechanism in this template is based on 
disease progression, and the intervention is assumed to have an association with 
survival, acute events linked to the disease, disease severity and side effects 
from the treatment.  The total incremental costs (∆C) would comprise: 
incremental treatment costs (∆CTX); incremental healthcare costs resulting from 
living longer because of an increase in survival (∆CLE); incremental cost savings 
from a decrease in disease severity/number of acute health events (∆CDS/E), and 
incremental costs resulting from treatment side effects (∆CSE).  The total 
incremental effects (∆E) components comprise: an incremental improvement in 
the effects measure from an increase in survival (∆ELE); an incremental 
improvement in the effects measure as a result of a decrease in disease 
severity/number of acute health events (∆EDS/E), and finally an incremental 





TX - treatment, LE - life expectancy, DS/E - disease severity/acute health events, SE - side 
effects 
Figure 3: Adaptation of Weinstein and Stason calculus into a cost-effectiveness template which 
demonstrates combining a disease process with disaggregated costs and effects 
 
In the adaption of the Weinstein and Stason equations in Figure 3, it is clear that 
survival, disease severity/acute health events and treatment side effects are 
mirrored in both the incremental total costs and incremental total effects, 
however this is not the case with the treatment component of the diagram.  The 
treatment component relates solely to incremental total costs, however it could 
be argued that process utility is the equivalent to treatment costs in the effects 
side of the equation. As previously mentioned, in the UK, the concept behind 
economic evaluation is typically extra-welfarism, where the focus is on the 
QALY. However, the effects of a patient actually receiving the treatment could 
also be considered, this is called ‘process utility’. Process utility includes 
elements such as dignity, reassurance and treatment type such as surgery v. 
drugs or oral v. intravenous drugs (103). Research shows that EQ-5D based QALYs 
do not capture all factors relating to healthcare, and that process utility 
outcomes can be successfully captured by ‘bolting on’ a process utility element 
to the SF-6D questionnaire (104).     
Because treatment costs  are often known and precise, if we remove these from 
the equation, we are left to establish whether there is evidence of cost savings 
in the remaining cost components.  As discussed by Petrou et al. other types of 
resource use may also be important (6), therefore the template is a guide rather 
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than a prescriptive measure. This template is referred to as the ‘disaggregated 
cost-effectiveness template’ throughout the rest of the thesis.  
The disaggregation of a mechanism into constituent parts is an approach also 
used in realist evaluations, where the mechanism behind how an intervention 
works, focussing on context, mechanisms and outcomes, is broken down into 
constituent parts (101, 105).  It could be argued that the proposed conceptual 
model approach also focusses on context, mechanisms and outcomes: the 
context of the clinical trial, the mechanism of the trial and the outcomes driven 
by the trial mechanism.  Realist evaluations are typically conducted in social 
science, however there is a growing interest in using this approach for complex 
interventions in economic evaluations (10).   
The suggested format of the conceptual model is based on a simple path analysis 
diagram.  Path analysis is a method developed by Sewall Wright in the early 
twentieth century to test whether a hypothesised model structure is consistent 
with observed data(106). The path analysis method is based on a set of 
hypothesised nested causal relationships within a system represented by linear 
regressions. The structure is derived from the causal path hypothesis and 
variables (inputs) at the start of the model do not always directly link to the 
variables at the end (outputs).  The links may be mediated through the pathway, 
some variables are causes, some are effects(107).  The path diagram describes 
the relationships between variables, linking them with directional arrows.  This 
format is similar to directed acyclic graphs (DAGs), the difference being that in 
path analysis the models predetermine linear causal effects, whereas in DAGs 
the models may be linear or non-linear (108). It should be noted that path 
analysis is used in this instance as a basis for the visual aspect of the conceptual 
model, not for methods of analysis. 
The components of the conceptual model should all be represented by a shape 
(rectangle or square etc.) and the relationships between the components are 
represented by arrows, the relationships may be direct or mediated through 
further components.  The arrows will either be solid or dashed; solid lines 
represent assumed relationships and dashed lines represent possible 
relationships.  Components with arrow heads entering them are dependant 
variables (for example all model outputs).  Components with arrows leaving 
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them are independent (explanatory) variables (for example all model inputs); 
the component to which their arrow enters (dependent variable) is predicted by 
them.  Mediating entities are both explanatory and dependant; they have arrows 
entering and leaving. Each dependant variable should be allocated a consecutive 
number which is used to identify regressions in the conceptual model, these 
regressions are used to test the assumed and possible associations linked to each 
numbered entity, this is explained in sub-section 2.10.3.  The suggestion of using 
regressions is only one way to demonstrate how the conceptual analysis could 
work and is included as an illustrative example to test the associations depicted 
in the conceptual model in a simple and straightforward way. 
The purpose of suggesting a format for the visual representation of the 
conceptual model is to ensure consistency and clarity of presentation in terms of 
design and structure.   
2.10.3 Testing the accuracy of the conceptual model 
The variables from the clinical trial data used in the regressions should be 
presented and described for clarity and to provide understanding of how each of 
the conceptual model components are represented in the regressions and which 
variables they are sourced from.   
The numbered regressions identified in the conceptual model should be 
conducted, the results will confirm, or otherwise, the accuracy and validity of 
the relationships presented in the conceptual model.  Testing the accuracy of 
the conceptual model helps to identify how the intervention is working; how the 
key components in the economic evaluation are related to each other and which 
components are driven by the expected trial mechanism. Any regression model 
could be used for this purpose, however, as costs and count data are typically 
skewed the analyst may choose a regression technique that takes account of this 





Regression results that provide confirmation of the conceptual model structure 
can be taken forward and utilised to conduct an additional analysis on the 
clinical trial data to provide additional interpretation of the treatment arm-
based results.  One suggested illustrative method for this additional analysis is to 
use bootstrapped samples.  Bootstrapped samples can be produced to calculate 
point estimates for differences in costs and outcomes (ie QALYs), uncertainty 
around these point estimates, and to calculate an ICER.  Bootstrapped results 
can also be used to produce cost-effectiveness planes, cost-effectiveness 
acceptability curves (CEAC), net monetary benefit calculations, and value of 
information analyses. 
To operationalise this step the regression results are used to produce 
bootstrapped estimates, this is achieved by incorporating the regressions that do 
predict and drive the mechanisms into the conceptual model and omitting those 
that do not contribute to the mechanism in the conceptual model, as proven by 
the regression results.  Where there are mediating relationships between 
components in the trial mechanism these should be included as nested equations 
where the output of one regression feeds into another.  
After the outputs of the bootstrapping exercise have been used to calculate 
point estimates the conceptual model driven analysis bootstrapped samples can 
be plotted on the cost-effectiveness plane to provide evidence of cost-
effectiveness.  If the conceptual model driven analysis has replicated the trial 
mechanism accurately, the spread of the samples should be smaller than the 
treatment arm-based analysis and may occupy fewer quadrants due to less 
uncertainty and fewer outliers. Any change in shape, placement or spread of 
plots between approaches will aid interpretation of the results, particularly in 
terms of how the trial mechanism has driven the components of the economic 
analysis, and how these components interact and the dynamics in them.  These 
bootstrapped samples can also be used to produce a CEAC, net monetary benefit 
measures and value of information estimates. The CEAC will provide estimations 
of the probability of the intervention being cost-effective at different 
willingness-to-pay thresholds.  The net monetary benefit provides another 
measure of cost-effectiveness which is not affected by the complexities of 
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negative ICERs.  The value of information measure places a value on eliminating 
uncertainty; if the results from a conceptual model driven analysis are less 
uncertain than the treatment arm-based analysis they can provide more certain 
information on the value of future research, as a whole or based on individual 
parameters. 
Finally, the results of the conceptual model driven analysis can be compared to 
the results of the treatment arm-based analysis to provide further information 
and interpretation of both sets of results. 
2.10.5 Discussion 
The new role for conceptual models has the potential to provide evidence to 
decision makers, in addition to the conventional treatment arm-based analysis, 
to help inform the adoption decision.  Associations are identified between 
components in the conceptual model, while regression techniques test the 
validity of these links and are used to produce bootstrapped samples.  These 
bootstrapped samples are then used to calculate summary measures, measures 
of uncertainty, and the summary measures from the conventional treatment 
arm-based analysis can be compared to the conceptual model driven analysis to 
add further interpretation. This new role for conceptual models provides a 
structured way of incorporating more information to inform the decision-making 
process, simultaneously considering the mechanism of the disease or system 
central to the clinical trial, and the dynamics of the key components of that 
mechanism relevant to the economic evaluation. Conducting clinical trials and 
obtaining the associated data is time consuming and expensive, this proposed 
further analysis of the trial data makes the best use of valuable evidence. 
Section 2.9 discussed the limitations inherent when conducting economic 
evaluations alongside clinical trials, the conceptual model approach just 
introduced is based solely on the evidence from one clinical trial so has some of 
these limitations of conducting an economic evaluation alongside a clinical trial. 
The new approach addresses a sub-set of the limitations in particular uncertain 
results.  The new approach also addresses the criticism of intervention focussed, 
outcomes-driven economic analysis. 
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This section would not be complete without a discussion about how this 
proposed new role for conceptual modelling fits into the ongoing debate about 
the benefits of a within trial analysis compared to a decision analytic model 
analysis (24). Many of the suggestions for minimising the limitations described in 
Section 2.9 are to use a decision analytic model, and it has been argued that to 
overcome the drawbacks of basing an economic evaluation solely on the data 
from a clinical trial, additional evidence synthesis and decision-modelling should 
be included (60).  There is a common belief that using clinical trial evidence or 
decision analytic models for economic evaluation are mutually exclusive (24), 
this is compounded by the ISPOR task force ‘Good research practices for cost-
effectiveness analysis alongside clinical trials’ (Ramsey et al.) guidance, and the 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
reporting guideline treating each approach separately (5, 90). However, treating 
these approaches as mutually exclusive is a false dichotomy as economic 
evaluations alongside clinical trials and decision analytic models synthesising 
evidence are not substitutes for each other, both are important approaches for 
informing decision makers (24). 
The proposed new role for conceptual models could arguably be described as 
bringing together these two approaches by going beyond the conventional 
treatment arm-based analysis of clinical trial data and investigating a causal (or 
associated) pathway based on the key economic components of the trial 
mechanism using patient level data, introducing a more nuanced understanding 
of the trial data.   Decision analytic models attempt to represent associations in 
the trial mechanism at an aggregate level using assumed mathematical 
relationships, considering the biological or clinical processes driving them and 
basing the model states on the well-known and understood natural history of 






This chapter explained the role of economic evaluation alongside clinical trials 
and presented the current guidance for conducting economic evaluations. 
Conventional economic evaluations alongside clinical trials often result in 
uncertain results, giving limited evidence to decision makers.  There is also 
criticism of the ‘black box’ approach of economic evaluations, which focusses on 
treatments and outcomes with no consideration of the mechanism driving the 
outcomes. However, despite these drawbacks there will continue to be demand 
for economic evaluations alongside clinical trials, the collection of clinical trial 
data is expensive and full use should be made of it to provide evidence to 
decision makers.  Therefore, there is scope for introducing a supplementary new 
approach for analysing the clinical trial data, to provide additional 
understanding to decision makers and make further use of the valuable clinical 
trial data. 
This chapter proposed such a supplementary new approach, a new role for 
conceptual models, beyond the conventional role of designing a decision analytic 
model structure.  This new role for conceptual models illustrates the expected 
trial mechanism resulting from the intervention and identifies the key elements 
of this mechanism driving the costs and outcomes of the economic evaluation. 
By simultaneously considering the conceptual model of the disease or system 
being analysed in the economic evaluation and the disaggregated impact of the 
components of the economic evaluation, a more nuanced analysis can be 
achieved; one that remains true to the key principle of estimation not 
hypothesis testing.  This new role for conceptual models provides a structured 
way of incorporating more evidence to inform the decision-making process.  The 
new role for conceptual models in economic evaluation is the third output and 
first objective of this thesis. 
The next chapter demonstrates the application of the current guidance for 
treatment arm-based analysis using two case studies. 
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economic evaluation guidance 
3.1   Chapter overview 
The previous chapter described the role of economic evaluations in providing 
decision makers with evidence for funding new healthcare technologies, it 
summarised the existing guidance for conducting treatment arm-based economic 
evaluations alongside clinical trials, highlighted the strengths and limitations of 
conducting economic evaluations alongside clinical trials and introduced the new 
role for conceptual models.   
The aim of this chapter is to illustrate the guidance for conducting standard 
economic evaluations alongside clinical trials described in Chapter 2, applying it 
to two case studies.  Both case studies are the economic evaluation component 
of NIHR funded clinical trials, conducted alongside a clinical trial. The first case 
study is introduced in Section 3.2, this case study is the Theophylline With 
Corticosteroids (TWICS) study; the second case study, introduced in Section 3.3, 
is the BeatIt study.  The layout of both case studies begin with the background 
and rationale of the clinical trial with a summary of the clinical outcome results, 
then the economic evaluation methods using the existing guidance are 
described, and finally the results of the economic evaluations are reported.  The 
chapter is summarised in Section 3.4. 
For both of these case studies my role was the analysis of the data constituting 
the economic evaluation. The design of the economic evaluation (in terms of 
resources and outcomes collected for analysis) was completed prior to my 
involvement with them. 
3.2 Case study #1 TWICS 
3.2.1 Background 
The TWICS study was a multicentred UK clinical trial and the aim of the trial was 
to determine the clinical and cost-effectiveness of adding a low dose of 
theophylline to usual care for people with chronic obstructive pulmonary disease 
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(COPD), compared to usual care plus a placebo. The protocol for the trial and 
full trial results are reported in detail in published articles (109-111). 
COPD is a lung disease and is associated with breathlessness on exertion, it can 
result in disability, absence from work, morbidity, early retirement, and 
premature death; the main cause of COPD is smoking, and most cases are 
diagnosed from the age of 50 onwards.  COPD is a progressive disease and 
patients are likely to deteriorate over time.  The burden from COPD in the UK is 
high; in 2014-2015 there were over 1 million diagnosed cases of COPD, this 
accounted for almost 2% of the population. In 2005 COPD accounted for 5% of 
global deaths and it is estimated that in 2030 COPD will be the third leading 
cause of death globally (112). In the UK COPD was recorded as the cause of 
approximately 30,000 deaths per year between 2008 and 2018 (113). The 
financial burden from COPD on the National Health Service (NHS) is about £1.9 
billion per year (114).  
A key feature of COPD are exacerbations, these are defined as a ‘sustained 
worsening of the patient's condition from the stable state and beyond normal 
day-to-day variations that is acute in onset and may warrant additional 
treatment in a patient with underlying COPD’ (115).  Symptoms of an 
exacerbation include breathlessness, coughing, and expelling mucus; this sudden 
worsening of a patient’s health is likely to result in a decrease in a patient’s 
quality of life.  Many exacerbations require treatment to manage them, this 
includes treatment with antibiotics and corticosteroids; less severe 
exacerbations can be managed at home or in the community, however more 
severe exacerbations require treatment in hospital, with associated higher costs 
of treatment.  Around 15% of COPD patients will experience an exacerbation 
annually, and of those hospitalised with an exacerbation 12% will die within a 
year of hospitalisation (116).  Exacerbations are linked to an increased decline in 
lung function, reduced physical activity, lower quality of life, an increased risk 
of some co-morbidities and increased mortality (115).  Therefore, the burden of 
patients with COPD on the NHS service is high. 
Treatment recommended for maintenance of COPD includes inhaled 
corticosteroids (ICS), combined with inhaled long-acting β2 agonists (LABA), 
however many patients still have exacerbations despite this treatment (117).  
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High doses of oral theophylline have also been used to treat COPD, but the high 
doses involved cause unpleasant side effects in patients resulting in treatment 
with other, better tolerated bronchodilators.  However, recent preclinical trials 
have indicated that oral theophylline at a low dose is beneficial in treating COPD 
in patients who are also treated with ICS; the low dose theophylline changes 
biological mechanisms in the patient allowing ICS to potentially reduce numbers 
of exacerbations more efficiently.  
TWICS was a randomised, pragmatic, double-blind, placebo trial comparing usual 
care plus low dose theophylline to usual care plus a placebo for patients with 
COPD.  The primary outcome of the trial was the number of moderate or severe 
exacerbations (requiring treatment/a change in management) during the 1-year 
trial follow-up period. The main inclusion criteria for participants included: 
people with a diagnosis of COPD; over 40 years old; currently treated with ICS, 
and with a history of two exacerbations needing treatment in the 12-month 
period prior to randomisation. Participants were randomised to either usual care 
plus low dose theophylline or usual care plus a placebo for 52 weeks.  The dose 
of theophylline was either 200mg or 400mg; the specific dose was determined by 
participants’ ideal body weight and smoking status.   
3.2.2 Clinical results 
Participants were recruited from 121 UK primary and secondary care sites 
between February 2014 and August 2016. 1,578 people were recruited and 
randomised to a treatment arm, 11 were excluded post-randomisation, leaving 
1,567 participants in total; 788 were randomised to the theophylline 
intervention arm and 779 were randomised to the placebo control arm.  Analysis 
of baseline characteristics found that participants in the two arms of the trial 
were evenly balanced for demographic and disease characteristics. 
Primary outcome data (number of exacerbations) was available for 1,536 
participants (Table 1): 772 in the theophylline arm and 764 in the placebo arm.  
633 (82.0%) participants in the theophylline arm and 609 (79.7%) participants in 
the placebo arm reported one or more exacerbations during the trial follow-up 
period. There was a total of 1,727 exacerbations reported by participants in the 
theophylline arm, a mean of 2.24 (standard deviation (SD) 1.99), and a total of 
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1,703 reported exacerbations in the placebo arm, a mean of 2.23 (SD 1.97).  
Although the mean number of exacerbations was slightly higher in the 
theophylline arm, statistically there was no difference between arms in the 
exacerbation rate.  The incidence rate ratio (IRR) was 0.99 (95% confidence 
interval (CI) 0.91 – 1.08); because the confidence interval crosses ‘1’ the IRR is 
not a statistically significant result and the trial concluded that there was no 
difference in treatment effect between treatment arms.  
106 (13.7%) participants in the theophylline arm and 130 (17.0%) participants in 
the placebo arm reported one or more exacerbations needing hospital treatment 
during the trial follow-up period. This amounted to a total of 134 hospital 
admissions in the theophylline arm and a total of 185 in the placebo arm; there 
were 51 more exacerbations resulting in a hospital stay in the placebo group 
compared to the theophylline group.  The mean number of exacerbations 
requiring hospital treatment was 0.17 (SD 0.49) in the theophylline arm and 0.24 
(SD 0.66) in the placebo arm, resulting in an adjusted IRR of 0.72, (95% CI 0.55 
to 0.94), this is a significant result suggesting that theophylline decreases the 
severity of exacerbations.  Further investigation of these results showed that 
most of these exacerbations were a result of more participants in the placebo 
arm reporting three or more exacerbations than in the theophylline arm. 39 
exacerbations needing hospital treatment were linked to 10 participants in the 
placebo group (who reported three or more exacerbations needing 
hospitalisation during the follow-up period), compared to three participants in 
the theophylline arm reporting 12 exacerbations needing hospital treatment.  
This additional investigation concluded that theophylline does not reduce the 
number of exacerbations needing hospitalisation (and therefore does not 
decrease the severity of exacerbations) compared a placebo, furthermore the 
trial was multicentred and it might be that some sites have different care 
pathways in terms of deciding what severity of exacerbation is treated in the 






Table 1: TWICS primary outcome (exacerbations) summary 
 











772 764  
Participants with at 
least one exacerbation 
633 609 
Total number of 
exacerbations 
1,727 1,703 Unadjusted 1.00 (0.92 to 
1.09) 
Mean number of 
exacerbations (SD) 
2.24 (1.99) 2.23 
(1.97) 
Adjusted 0.99 (0.91 to 
1.08) 
Exacerbations needing hospital treatment 
Participants included 
in analysis 
772 764  
Participants with at 
least one exacerbation 
106 130 
Total number of 
exacerbations 
134 185 Unadjusted 0.72 (0.55 to 
0.95) 
Mean number of 
exacerbations (SD) 
0.17 (0.49) 0.24 
(0.66) 
Adjusted 0.72 (0.55 to 
0.94) 
IRR – incidence rate ratio, SD – standard deviation 
In summary there was no statistically significant differences between arms in the 
total number of exacerbations, therefore, there was no difference in the 
treatment effect between arms on the rate of exacerbations.  
3.2.3 Economic evaluation methods 
The aim of the economic evaluation was to estimate the cost-effectiveness of 
adding theophylline to usual care in reducing exacerbations needing treatment, 
compared to usual care plus placebo.  The economic evaluation followed the 
existing guidance presented in Chapter 2 and the order in which the methods are 
presented below are: ‘Data identification and collection - Resource use’, ‘Data 
identification and collection - Health benefits’ and ‘Analysis’. 
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Data identification and collection - Resource use 
The first step was to ascertain relevant resource use for each of the 
participants. The guidance described in Chapter 2 sub-section 2.32.5.1 
recommends using the perspective of the economic evaluation to guide the 
identification of the type of resources used by participants.  This guidance also 
recommends considering the following categories to identify relevant resource 
use groups for inclusion in the economic evaluation; resources linked to the 
treatments and disease; resources likely to differ between arms, and resources 
linked to treatment side effects.  Based on these recommendations the following 
types of resource were collected in TWICS:   
Perspective – the perspective of the economic evaluation was the NICE 
recommended NHS and personal social services perspective (63); so only 
healthcare resource use that was paid for by the UK NHS (the healthcare payer) 
was included.   
Treatment – the intervention of the trial was low dose theophylline; resource 
use was collected for the participants in the intervention arm based on their 
assigned dose. The comparator was placebo so no resource was assigned to this. 
Disease – COPD is managed in this population with routine maintenance therapy; 
the resources used for this therapy were collected for all participants with input 
from clinicians to identify possible therapies.  
Between arms difference - the primary outcome of the trial was the number of 
exacerbations needing treatment reported by participants during the trial 
follow-up; resource use relating to the treatment, length of treatment and 
location of treatment (the location of the treatment was specified as ‘home’, 
‘care by services to prevent hospitalisation’ and ‘admitted to hospital’) of the 
exacerbations was collected. 
Side effects/disease – resource use that could potentially be linked to either 
COPD itself or the side effects of the intervention was also collected; this 
included resource use from inpatient stays, outpatient attendances, primary 
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care use, emergency hospital admissions (not related to COPD) and regular (non-
COPD maintenance) medication. 
Resource use collection 
Resource use was collected from each participant at three timepoints during the 
trial; baseline, six months after randomisation and 12 months after 
randomisation using a modified version of the Client Service Receipt Inventory 
(CSRI) (118), this is a research questionnaire used for retrospectively collecting 
health and social care related resource use from participants. The CSRI was 
included in the trial case report form and the timing of the resource use 
collection coincided with face-to-face assessments for the collection of clinical 
outcomes and safety data from trial participants, this was deemed frequent 
enough to minimise recall bias. 
At the baseline visit resource use categories collected were: COPD maintenance 
therapy; the number of exacerbations in the previous 12 months; the number of 
exacerbations resulting in hospitalisation in the previous 12 months, and 
medication. 
At the six and 12 month visits the resource use categories collected were: 
treatment for exacerbations; COPD maintenance therapy; other health service 
use (including inpatient stays, outpatient attendances, primary care use and 
non-COPD related emergency hospital admissions), and non-COPD maintenance 
medication, at each follow-up visit this resource use was retrospectively 
collected for the previous six months. The dose of the theophylline intervention 
for participants in the theophylline arm was collected in the trial database and 
the trial health economist was given access to this data. 
Unit costs 
Unit costs were obtained from different sources depending on the type of 
resource use category.  Medication costs for the intervention (theophylline) and 
COPD maintenance therapy were obtained from the British National Formulary 
(BNF) (119), exacerbation costs, inpatient stays, outpatient attendances, 
primary care costs and non-COPD emergency admissions were obtained from five 
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sources: NHS reference costs (120); Information Services Division (ISD) (121); 
Personal Social Services Research Unit (PSSRU) (122); BNF (119), and published 
literature (123, 124). Unit costs were all adjusted to 2016 prices using the UK 
Health Service Cost Index (122) and valued in pounds sterling (£).   
Data identification and collection - Health benefits 
The economic outcome used for measuring the health benefits experienced by 
participants in the trial was the preference-based QALY, this outcome was 
measured using the EQ-5D-3L questionnaire (74); a self-reported quality of life 
questionnaire, this outcome is the preferred measure of heath benefit described 
in the guidance in Chapter 2 sub-section 2.5.2.  The EQ-5D-3L questionnaire 
measures quality of life using five domains, these are: mobility; self-care; usual 
activities; pain/discomfort, and anxiety/depression. Participants choose from 
three levels of severity in each domain; for example in the mobility domain 
options include ‘I have no problems in walking about’, ‘I have some problems in 
walking about’ and ‘I am confined to bed’. Results from the questionnaire were 
valued using the UK value set (125), resulting in utility values of between -0.59 
and 1 where -0.59 represents a state worse than death, 0 represents death and 1 
represents full health. The quality of life utilities were combined with length of 
life (12 months follow-up or less if the participant died during the trial) to 
calculate QALYs using standard area under the curve methods.  The changes in 
the participant utilities between follow-up visits were assumed to be linear 
when calculating the QALYs. 
Designing the economic evaluation to reduce ‘noise’ 
At the design stage several decisions were made to limit the potential ‘noise’ in 
the results by limiting non-treatment resources likely to differ between arms and 
linked to the disease.  These included the perspective of the economic 
evaluation being restricted to the NHS and personal social services.  The main 
focus of resource use was healthcare directly relating to COPD: maintenance 
treatment and treatment of exacerbations. Other resource use that could 
potentially relate to COPD included: inpatient stays, outpatient visits and 
primary care use.  Two further resource use categories were collected, which 
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may not have been related to COPD: emergency hospital admissions not related 
to COPD and non-COPD medication. 
Analysis 
As recommended by the existing guidance for conducting economic evaluations, 
an analysis plan was produced, and an early summary was included in the 
published trial protocol (111).   
The analysis was based on the intention-to-treat population; participants’ results 
were analysed according to the treatment arm to which they were randomised.  
Where possible missing data was replaced based on plausible assumptions agreed 
with a clinical expert, where this was not possible missing data was replaced 
using the multiple imputation by chained equations method (84).  Three analyses 
were conducted: a complete case analysis; unadjusted multiple imputation, and 
adjusted multiple imputation using a generalised linear model (to address 
heterogeneity in the participants).  The data collected from participants who 
were lost to follow-up (censored) was included in the analysis, and the time that 
they had spent in the trial was used to adjust total costs and QALYs using 
regression techniques. 
The total costs and total QALYs were summed for each participant for both 
treatment arms, then divided by the number of participants in each treatment 
arm to give a mean cost or mean QALY per participant in each arm, the 
measures of variability for these means were standard deviation. The difference 
in mean costs and QALYs between treatment arms were calculated and 
presented with 95% confidence intervals for the measure of variability. The 
summary measure was the ICER, to assess cost-effectiveness this was compared 
to the current NICE willingness to pay threshold of £20,000 (55); if the ICER was 
below £20,000 the intervention would be deemed to be cost-effective.  
As well as including the 95% confidence intervals as described, recommendations 
in the guidance for representing uncertainty were followed by creating 
bootstrapped samples using non-parametric techniques; these were plotted onto 
a cost-effectiveness plane with a 95% confidence ellipse and were also used to 
produce a cost-effectiveness acceptability curve (2).  As previously mentioned, 
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uncertainty driven by the heterogeneity of participants was adjusted for using 
regression techniques based on the baseline participant characteristics as 
covariates.  For the costs these covariates were: medication count at baseline; 
EQ-5D-3L outcome at baseline; offset time (time spent in the trial); age; number 
of hospitalisations for exacerbations in the 12 months prior to randomisation; 
number of exacerbations in the 12 months prior to randomisation, and a cluster 
command was used for the trial site.  For QALYs the covariates were: baseline 
EQ-5D-3L data; medication count at baseline; offset time; age; sex; 
hospitalisation for exacerbations in the 12 months prior to randomisation; 
exacerbations in the 12 months prior to randomisation, and a cluster command 
was used for the trial site.  
3.2.4 Economic evaluation results 
The economic evaluation results are presented in full in the NIHR report (109). A 
summary of the results from this original treatment arm-based analysis are 
presented below, with additional results calculated specifically for this thesis 
(treatment and non-treatment cost point estimates, treatment and non-
treatment costs cost-effectiveness planes and value of information - EVPI). 
Economic resource use data was available for 1,470 participants: 743 in the 
theophylline arm and 727 in the placebo arm and quality of life data from the 
EQ-5D-3L questionnaire was available for 1,243 participants: 635 in the 
theophylline arm and 608 in the placebo arm. There was more missing data in 
the placebo arm compared to the theophylline arm; 4.8% v. 3.8% for resource 













Placebo     
(n=764) 
Total      
(n=1,536) 
Resource use 29 (3.8%) 37 (4.8%) 66 (4.3%) 
EQ-5D-3L at 
baseline/6 or 12 
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Baseline characteristic covariates included in the adjusted multiple imputations 
are presented in Table 3, the baseline variables were either significant 
predictors of costs or QALYs or both.  There were no significant differences 
between arms for the baseline resources. 
Table 3: TWICS baseline participant characteristics 
 Theophylline           
Mean (SD) 
Placebo                   
Mean (SD) 
Medication count at 
baseline * ^ 
4.65 (3.64) 4.41 (3.54) 
EQ-5D-3L outcome at 
baseline * ^ 
0.629 (0.280) 0.643 (0.279) 
Number of 
hospitalisations for 
exacerbations in the 12 
months prior to 
randomisation * ^ 
0.404 (0.840) 0.358 (0.918) 
Number of exacerbations 
in the 12 months prior to 
randomisation * ^ 
3.63 (2.22) 3.52 (2.08) 
Age * ^ 68.3 (8.2) 68.5 (8.6) 
Sex ^   
      Male 425/788 (53.9) 418/779 (53.7) 
      Female 363/788 (46.1) 361/779 (46.3) 




Results for the complete case and multiple imputed (unadjusted and adjusted) 
analyses, are reported in Table 4.  










Complete case analysis (unadjusted) 
Total costs £2,684 (£2,882) £3,136 (£4,851) -£452 -£771 to -£133 
Total QALYs 0.626 (0.259) 0.637 (0.263) -0.011 -0.040 to 0.018 
Unadjusted multiple imputation results 
Total costs  £2,702 (£110) £3,141 (£148) -£439  -£846 to -£32 
Total QALYs 0.617 (0.010) 0.621 (0.010) -0.004 -0.031 to 0.024 
Adjusted multiple imputation results 
Total costs £2,784 (£125) £3,006 (£167) -£222  -£472 to £27 
Total QALYs 0.621 (0.006) 0.616 (0.007) 0.005 -0.015 to 0.025 
SD – standard deviation, QALYs – quality adjusted life-years 
Complete case results for costs show that the theophylline arm was less costly 
than the placebo arm; £2,684 compared to £3,136, a statistically significant 
difference of £452 (95% CI £133 to £771). Complete case results for QALYs show 
that participants in the placebo arm reported higher QALYs than the participants 
in the theophylline arm; 0.637 compared to 0.626, a difference of 0.011 (95% CI 
-0.018 to 0.040).  The complete case results suggest that the ICER falls into the 
southwest quadrant where decision makers would need to assess what level of 
cost savings per loss in health benefit that they would be willing to accept in 
order to adopt the theophylline intervention, this is clearly illustrated by 
plotting the bootstrapped samples on a cost-effectiveness plane (Figure 4).  The 
cost-effectiveness plane includes a confidence ellipse to illustrate 95% 
confidence; we can be 95% confident that the true difference between costs and 




Figure 4: TWICS cost-effectiveness plane – original treatment arm-based analysis complete cases 
(unadjusted) 
 
The bootstrapped samples were also used to plot a CEAC, which showed that at 
the UK willingness-to-pay threshold of £20,000 there is a 75% chance of the 
theophylline arm being considered cost-effective (Figure 5).  
  
Figure 5: TWICS cost-effectiveness acceptability curve - original treatment arm-based analysis 
complete cases (unadjusted) 
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Once the missing data was replaced using multiple imputation the difference in 
costs decreased to £439; still higher in the placebo arm, however although this 
difference was still statistically significant the uncertainty around the cost 
difference was wider; 95% CI £32 to £846.  Imputed results for the difference in 
QALYs between arms mirror the complete case results, with higher QALYs 
reported in the placebo arm compared to the intervention arm; 0.621 compared 
to 0.617, a smaller difference of 0.004 (95% CI -0.024 to 0.031). The multiple 
imputation results also suggest that the ICER falls into the southwest quadrant 
where decision makers would need to assess what level of cost savings per loss in 
health benefit that they are willing to accept in order to accept the theophylline 
intervention. 
When the imputed results were adjusted for heterogeneity using baseline 
participant characteristics and offset time, costs remained higher in the placebo 
arm compared to the intervention arm, a smaller difference of £222 but this 
difference was no longer statistically significant, shown by the 95% confidence 
interval around the difference; -£27 to £472.  In this analysis the direction of the 
QALY results reversed; QALYs were marginally higher in the theophylline arm; 
0.621 compared to 0.616, a difference of 0.005, again this wasn’t a significant 
result shown by the 95% confidence interval of -0.015 to 0.025. This change in 
direction of QALY difference is likely, in part, due to a small imbalance of EQ-
5D-3L scores at baseline, however the difference in QALYs is not statistically 
significant in any of the analyses.  These multiple imputed adjusted results 
suggest that the ICER falls into the southeast quadrant where theophylline is 
considered to dominate placebo; it is less costly and produces more health 
benefit compared to the placebo arm, however it can be seen from Figure 6 how 
wide the spread of QALY differences are, and that they straddle the vertical axis 
of the cost-effectiveness plane.  An ICER was not calculated as planned due to 
the dominance in these results. 
Bootstrapped results taken from the multiple imputed and adjusted analysis and 
plotted on the cost-effectiveness plane show that the majority of the 
bootstrapped samples do fall into the southeast quadrant where the intervention 
would be considered cost-effective, however this is not a significant result, 
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which is indicated by the 95% confidence intervals reported in Table 4 crossing 
zero and the 95% ellipse crossing into all four quadrants (Figure 6).   
 
Figure 6: TWICS cost-effectiveness plane – original treatment arm-based analysis multiple 
imputation (adjusted) 
 
The bootstrapped samples were used to plot a CEAC, which suggests that the UK 
willingness to pay threshold of £20,000 there is a 90% chance of theophylline 
being cost-effective (Figure 7).  Although the results from the multiple imputed 
and adjusted analysis, for costs and QALYs, are statistically insignificant the 
probability of cost-effectiveness at £20,000 threshold is higher (90% compared to 
75%) than the complete case analysis which had statistically significant results 
for the difference in costs, this is driven by the cloud of bootstrapped samples 
moving from the southwest quadrant (where decision makers decide at what 
level the cost savings, or compensation for QALY lost is acceptable), towards the 





Figure 7: TWICS cost-effectiveness acceptability curve - original treatment arm-based analysis 
multiple imputation (adjusted) 
 
An exploratory analysis was carried out to further understand the higher number 
of exacerbations needing hospital treatment in the placebo arm compared to the 
theophylline arm (discussed in sub-section 3.2.2).  Mean total exacerbation costs 
were higher in the placebo arm compared to the theophylline arm, a difference 
of £447 (95% CI £186 to £709), a statistically significant result. Exacerbation 
costs were broken down into the location of the exacerbation treatment and 
treatment costs for the exacerbation.  Taking location of treatment costs first, 
these were higher in the placebo arm compared to the theophylline arm, a 
difference of £422 (95% CI £171 to £673), again a statistically significant result. 
When the location costs are broken down into the different locations 
(‘treatment at home’, ‘care by services to prevent hospitalisation’ and 
‘admitted to hospital’) only the costs of exacerbations treated in hospital 
showed statistical significance between arms; costs were higher in the placebo 
arm compared to the theophylline arm, a difference of £416 (95% CI £177 to 
£655). The treatment costs were higher in the placebo arm compared to the 
theophylline arm, a difference of £25 (95% CI £8 to £41). This difference was 




To further investigate exacerbation costs the mean cost of an exacerbation 
treated in hospital in each arm was calculated; the costs of exacerbations in the 
placebo arm were higher compared to the theophylline arm (£3,613 compared to 
£2,671), a difference of £941 (95% CI £140 to £1,743).  This difference was 
driven by the placebo arm recording the 10 most expensive exacerbations in the 
trial.  Interpreting this exploratory analysis, and because of the lack of 
treatment effect, the trial team believed that the difference in exacerbations 
requiring hospital treatment to be a chance finding. 
For the purposes of this thesis further analysis was carried out using complete 















As the comparator treatment was a placebo, this arm had no treatment costs, 
resulting in a highly statistically significant difference in treatment costs 
between arms of £22 (95% CI £22 to £22).  Bootstrapped samples from 
unadjusted complete cases are presented on a cost-effectiveness plane (Figure 
8), showing the difference in treatment costs and no difference in QALYs  
 











The difference in non-treatment costs between arms was £474 (95% CI £155 to 
£793), statistically higher in the placebo arm.  As discussed above exacerbations 
treated in hospital were statistically significantly higher in the placebo, and this 
result is driving the difference in non-treatment costs. Bootstrapped non-
treatment costs are presented in a cost-effectiveness plane in Figure 9, this 
shows that there is no difference in QALYs but the difference non-treatment 
costs between arms favours the theophylline arm. 
 










If the exacerbation costs are also removed from the non-treatment costs, 
leaving only the costs of COPD maintenance therapy, other health service use 
(including inpatient stays, outpatient visits, primary care use and non-COPD 
emergency hospital admissions) and non-COPD medication, the difference 
between arms is £26 (95%CI -£181 to £234), a non-statistically significant result 
with a wide confidence interval.  A cost-effectiveness plane including the 
difference in non-treatment, non-exacerbation costs and QALYs is presented in 
Figure 10, this clearly replicates a Scenario 9 where there is no difference 
between costs and QALYs. 
 
Figure 10: TWICS cost-effectiveness plane – original treatment arm-based analysis non-treatment, 
non-exacerbation costs only 
EVPI results estimate that the value of perfect information per participant is 
£41, therefore it is unlikely further research is worthwhile in terms of value for 
money as the cost of extra investigation is likely to be greater than this.  This 
result is driven by the difference in complete case total costs that shows that 
the total costs in the theophylline arm are statistically significantly lower than 
total costs in the placebo arm, however the additional analysis above shows that 
this is driven by a small number of participants in the placebo arm reporting 
exacerbations requiring hospital treatment, and when exacerbation costs are 
removed there is little difference between arms. 
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This additional analysis suggests that the difference in treatment costs is known 
and clear, however the difference in non-treatment costs, particularly when 
exacerbation costs are removed is not clear.  This highlights the fact that whilst 
treatment costs are often known and precise, non-treatment costs contain noise 
and are less easy to interpret. 
Whilst the total cost results suggest that theophylline dominates; is both 
cheaper and has higher QALYs than the placebo arm, the results should be 
interpreted with caution as the difference between arms for non-treatment, 
non-exacerbation costs is not statistically significant.  There is not a statistically 
significant difference in QALYs, a result echoed by the clinical effectiveness 
results: theophylline is not clinically effective in reducing exacerbations. 
3.3 Case study #2 BeatIt 
3.3.1 Background 
BeatIt was a multicentre UK based clinical trial which aimed to establish the 
effectiveness and cost-effectiveness of the BeatIt intervention compared to the 
StepUp intervention for adults with intellectual disabilities and a diagnosis of 
depression.  The trial protocol and full details of the trial results are reported in 
detail in published articles (126-128). 
Globally, depression is common; it affects around 300 million people (129) and 
places a huge burden on healthcare services in terms of costs of prescription and 
treatment, and on society with time off work.  In 2007 the estimated number of 
people with depression in England was 1.24 million, and costs were £1.7 billion 
for healthcare services and £5.8 billion in lost earnings, a total of £7.5 billion 
(130).  In 2017/18 the cost of antidepressants prescribed in Scotland was 
£44.8m, and over 900,000 patients were prescribed at least one antidepressant 
drug (131).  
Research suggests that depression is highly prevalent in adults with intellectual 
disabilities, with a point prevalence of 5% (132).  Depression is also more 
enduring in adults with intellectual disabilities compared with the general 
population; a cohort study found that in adults with intellectual disabilities 
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chronic depression was five times more common than in the adult general 
population (133). 
Psychological therapies for treating depression in the general population are 
well established, but for adults with intellectual disabilities techniques such as 
cognitive behavioural therapy (CBT), which are essentially talking therapies and 
rely on verbal communication, are less accessible (126).  While research into the 
use of CBT for adults with intellectual disabilities and depression has been 
encouraging (134), behavioural activation therapy, which is less reliant on verbal 
and cognitive skills, maybe more suited to this population. 
Behavioural activation therapy focuses on the link between mood and activity; it 
aims to increase participation in purposeful and motivating activities, thereby 
bringing the individual into contact with positive experiences and helping to lift 
their mood (135).   Research into members of the general population with a 
diagnosis of severe depression has shown that behavioural activation therapy is 
as effective as antidepressant medication and more effective than CBT (136, 
137), and the positive treatment effects have been shown to last as long as 
those for CBT (138).  Behavioural activation therapy is also recommended in 
NICE (2009) guidelines for the treatment of depression in the general population 
(139).   
There is little evidence on the effectiveness and cost-effectiveness of 
behavioural activation therapy in the population of adults with intellectual 
disabilities for treating depression; previous research is limited to a feasibility 
study undertaken prior to the clinical trial described here. The feasibility study 
evaluated the feasibility and acceptability of a behavioural activation therapy 
for treating adults with intellectual disabilities and symptoms of depression 
(140). A manual to guide the delivery of the behavioural activation therapy was 
developed and piloted for this population in the feasibility study. Twenty-three 
adults were recruited into the feasibility study, only two participants dropped 
out and a further two were lost to follow-up; the high completion rate indicated 
that the intervention was acceptable.  Results showed a significant reduction in 
self-reported depressive symptoms post-treatment, this reduction was 
maintained at 3-months follow-up suggesting that the behavioural activation 
92 
Chapter 3 
therapy intervention was feasible, and the authors concluded that a full 
randomised controlled trial was needed to establish effectiveness.  
This full trial was BeatIt; a multicentre, single-blind (participants and therapists 
were not blinded but the assessors of measures were), randomised controlled 
trial.  The aim of the trial was to determine the clinical effectiveness and cost-
effectiveness of BeatIt (behavioural activation therapy - intervention) compared 
to StepUp (guided self-help therapy - comparator) in reducing self-reported 
depressive symptoms in a population of adults with mild to moderate 
intellectual disabilities and a diagnosis of depression. Participants were 
recruited from sites in Scotland, England and Wales.  Key inclusion criteria for 
participants were mild to moderate learning disabilities; adults aged 18 years old 
or older; clinically significant depression; ability to give informed consent, and 
had a supporter (family member or carer) who was able to complete screening 
and baseline visits and accompany them to follow-up visits and therapy visits, 
plus provide a minimum of two hours support per week. 
Participants were randomised to either BeatIt or StepUp in a ratio 1:1. 
Therapists were trained to deliver one therapy only; BeatIt was delivered over 
12 sessions on a weekly to fortnightly basis, and StepUp was delivered over 8 
sessions also on a weekly to fortnightly basis.   
The main outcome measure was the Glasgow Depression Scale for Learning 
Disabilities (GDS-LD) score at 12-months post-randomisation (141). This is a self-
reported measure designed to assess depressive symptoms in this population, it 
has 20 questions with a choice of three answers: never, sometimes, always.  
Results range from a score of 0 to 40, with lower scores indicating fewer 
depressive symptoms. 
Participants and supporters were assessed separately at 4- and 12-months post-
randomisation during face-to-face assessments for the collection of data on 
resource use and outcomes, an additional data collection point at 8-months was 
included for the supporter only, via telephone.   
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3.3.2 Clinical results 
In total 161 participants were recruited and randomised to a treatment arm; 84 
to the BeatIt arm and 77 to the StepUp arm.  Six participants were lost to 
follow-up and 14 withdrew during the trial; this left a total of 141 participants 
who completed the trial (68 in the BeatIt arm and 73 in the StepUp arm).  The 
primary outcome was available for a total of 135 participants; 65 in the BeatIt 
arm and 70 in the StepUp arm. At the primary endpoint of 12-months there was 
no statistically significant difference in treatment effect between the arms; the 
mean GDS-LD score at 12-moths post-randomisation in BeatIt was 12.03 (SD 7.99) 
and in StepUp it was 12.43 (SD7.64), a difference of 0.40 (95% CI -2.26 to 3.06).  
However, a statistically significant reduction in the GDS-LD score was witnessed 
in both arms of the trial at both face-to-face follow-up points; 4- and 12- months 
post-randomisation. The reduction in GDS-LD scores for BeatIt and StepUp at the 
12-months follow-up was 4.20 (95% CI -6.0 to -2.40) and 4.46 (95% CI -6.21 to -
2.70) respectively, the difference between arms for this change was 0.26 (95% CI 
-2.18 to 2.70), a statistically insignificant result. 
A similar pattern is seen in measures of activity: The Index of Community 
Involvement (ICI) measures participation in social and community-based 
activities, and the Index of Participation in Domestic Life (IPDL) measures 
changes in participation in domestic tasks. Neither measure found a statistically 









A summary of clinical results is provided in Table 5. 
Table 5: BeatIt primary and secondary (activity) outcomes summary 




Mean (SD) n Mean (SD) n 
Glasgow Depression Scale for people with a Learning Disability (GDS-LD) 
Baseline 16.60 (7.91) n=84 16.90 (6.73) n=77  
Post intervention (4 
months) 




12.03 (7.99) n=65 12.43 (7.64) n=70 -0.40 (-3.06 to 
2.26) 
Change in mean scores from baseline (95% confidence interval) 
Post intervention (4 
months) 
-5.15 (-6.70 to -3.60) -4.40 (-5.89 to -
2.91) 




-4.20 (-6.0 to -2.40) -4.46 (-6.21 to -
2.70) 
0.26 (-2.18 to 
2.70) 
The Index of Participation in Domestic Life (IPDL) 
Baseline 19.07 (8.46) n=84 18.19 (9.03) n=77  
Post intervention (4 
months) 




16.47 (8.01) n=66 15.86 (7.97) n=69 0.61 (-2.11 to 
3.34) 
Change in mean scores from baseline (95% confidence interval) 
Post intervention (4 
months) 




-0.83 (-2.22 to 0.56) -1.58 (-2.94 to -
0.22) 
0.75 (-1.11 to 
2.61) 
SD – standard deviation 
In summary, there was no statistically significant difference between arms in 
GDS-LD scores at 12 months, however both arms had a statistically significant 
decrease in GDS-LD scores at 4- and 12-months suggesting that both therapies 
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were successful in reducing depressive symptoms in this population, but neither 
was more effective than the other.  
3.3.3 Economic evaluation methods 
The aim of the economic evaluation alongside the BeatIt trial was to estimate 
the cost-effectiveness of the BeatIt therapy compared to the StepUp therapy for 
reducing depressive symptoms in adults with mild to moderate intellectual 
disabilities and a diagnosis of depression.  The economic evaluation followed the 
existing guidance presented in Chapter 2, and the methods are presented below 
in the following order: ‘Data identification and collection - Resource use’, ‘Data 
identification and collection - Health benefits’ and ‘Analysis’. 
Data identification and collection - Resource use 
The first step in the economic evaluation was to identify resource use categories 
relevant to the participants and trial.  The guidance described in Chapter 2 
recommends considering: the perspective of the economic evaluation; resources 
linked to the treatments and disease being studied; resources likely to differ 
between arms, and resources linked to treatment side effects, when 
ascertaining what resource use categories to collect.  The resource use 
categories identified using these considerations are described below:  
Perspective – the perspective was the one set out in the NICE reference case 
(63); an NHS and social services perspective taking into account direct health 
service use paid for by the NHS and consumed by the participants. 
Treatment – the two treatments being compared were therapies delivered by a 
therapist, who had the support of a supervisor.  Resource uses identified and 
collected were: training of therapists for their allocated therapy; therapist time 
spent preparing for and delivering the therapy; the time and mileage spent 
travelling to the participants, and supervisor time.  The additional cost of the 





Resource use linked to depression and side effects of the therapies could 
potentially cover a wide range of categories, so healthcare resource use from 
hospital-based services, community-based services and medications (prescribed 
and over the counter) were collected. 
Between arms difference 
The aim of the BeatIt intervention was to increase activity levels in the 
participants randomised to this arm.  Daytime activities considered to be 
representative of types of activity encouraged by therapists were collected, 
examples include day centres, sheltered work, and drop-in centres. It was 
expected that the StepUp therapy would not increase activity levels, thereby 
resulting in a difference between arms in this resource use category. 
Resource use collection 
Therapist and supervisor resource use was collected on an ongoing basis 
throughout the trial using time sheets, these were completed by the therapists 
and supervisors for each participant.  Materials for the BeatIt and StepUp 
manuals, and materials used during therapy, were established based on expert 
opinion. 
Hospital-based, community-based, and daytime activity resource use was 
collected using an adapted CSRI form (118, 142).  The CSRI was completed at 
baseline, 4- and 12-months post-randomisation by both the participant and 
supporter, and at 8-months post-randomisation by the supporter alone.  At each 
resource use collection point the resources used for the previous 4-months (17 
weeks) were collected.  Medication use was collected on a separate medication 
inventory which was collected at the same time as the above.   





Unit costs for resource use categories came from several sources: treatment 
costs were taken from Personal Social Services Research Unit (PSSRU) (143) for 
therapist and supervisor time and from expert opinion for the materials for the 
therapies; daytime activity costs were taken from literature (142); hospital-
based resource use costs were sourced from NHS reference costs (144); 
community-based resource use costs were taken from PSSRU (143), and 
prescription costs were sourced from the BNF (119). All units costs were 
adjusted to 2015 prices using the Hospital and Community Health Services Index 
and reported in pounds sterling  (£) (143).   
Data identification and collection - Health benefits 
The economic outcome measuring health benefits was the preference-based 
QALY, measured using the EQ-5D-Y questionnaire (77); this outcome is the 
preferred measure of heath benefit suggested in the guidance reported in 
Chapter 2.  The EQ-5D-Y is a simplified youth version of the EQ-5D-3L 
questionnaire, it is aimed at children and adolescents aged 8 and above and the 
language used in it is simple and straightforward but not childlike, so this 
measure is suitable for adults with intellectual disabilities.   
Participant responses extracted from the EQ-5D-Y were valued using the UK 
adult value set; as yet Euroqol have not provided a UK child value set (145).  The 
resulting utility values were combined with length of life (12 months follow-up) 
to convert into QALYs using standard area under the curve methods.  Changes in 
utilities between follow-up visits were assumed to be linear when calculating 
QALYs. Participants completed the EQ-5D-Y questionnaire at baseline and the 4- 
and 12-month trial follow-up timepoints. 
Designing the economic evaluation to reduce ‘noise’ 
As depression could potentially affect many healthcare resources the resource 
collection included a wide range of healthcare resources. The perspective of the 
economic evaluation was restricted to the NHS and personal social services. 
Healthcare resource use covered hospital-based services, community-based 
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services and medications were collected. The treatment was hypothesised to 
increase activity so daytime resource use was collected as this could reasonably 
be expected to differ between arms. 
Analysis 
As recommended in the existing guidance for economic evaluations an analysis 
plan was developed, and an early summary of this was included in the published 
main trial protocol (128). 
The analysis was based on the intention-to-treat population, missing data was 
replaced using the multiple imputation using chained equation method, and 
results from both complete case and multiple imputation (unadjusted and 
adjusted) analyses were presented. Mean costs and QALYs in both arms were 
calculated by summing costs and QALYs for all participants in each arm to 
estimate total costs, and then dividing by the number of participants in each 
arm, these treatment arm specific means were presented with standard 
deviations to illustrate uncertainty. Differences between arms were estimated 
using the recommended generalised linear models, presented with 95% 
confidence intervals as a measure of uncertainty. The planned summary measure 
was the incremental cost per QALY ICER, presented with a 95% confidence 
interval, cost-effectiveness was assessed by comparing the ICER to the current 
NICE threshold of £20,000 (55).  
Uncertainty was further explored using non-parametric bootstrapping; 1,000 
samples were used, and results were presented on a cost-effectiveness plane 
and a cost-effectiveness acceptability curve.  The uncertainty resulting from 
heterogeneity was adjusted for by using a generalised linear model and including 
covariates. Covariates used in the cost model were baseline costs and therapist 
(both significant predictors of costs). Covariates in the QALY model were 
baseline EQ-5D-Y score and baseline GDS-LD score (both significant predictors of 
QALYs). Three sensitivity analyses were carried out to explore parameter 
uncertainty; one looking at the effects of some participants having a mix of 16- 
and 17-weeks resource use collected compared to only 17 weeks; and two 
exploring the training costs for therapists; one was the most efficient situation 
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when training therapists (the maximum possible number of therapists trained), 
and no training costs. 
3.3.4 Economic evaluation results 
The economic evaluation results are presented in full in the NIHR report(127), a 
summary of the results from the original treatment arm-based analysis is 
presented below, with additional analysis carried out specifically for this thesis 
comprising treatment and non-treatment costs, additional cost-effectiveness 
planes and EVPI results. 
The amount of missing data was less than 5% for all data categories, and one 
participant in the BeatIt arm had missing therapist data. Resource use data was 
available for 58 (85.3%) participants in the BeatIt arm and 68 (93.2%) in the 
StepUp arm. Quality of life data was available for 61 (89.7%) participants in the 
BeatIt arm and 68 (93.2%) in the StepUp arm. Missing data was highest in the 
BeatIt arm compared to the StepUp arm for both resources and quality of life 
data (Table 6). 
Table 6: BeatIt missing economic data 
Data BeatIt (n=68) StepUp (n=73) Total (n=141) 
Resource use 10 (14.7%) 5 (6.8%) 15 (10.6%) 









Baseline characteristics used in the generalised linear model for the adjusted 
multiple imputations are presented in Table 7. 
Table 7: BeatIt baseline characteristics 
Covariates in generalised 
linear model 
BeatIt                      
Mean (SD) 
StepUp                     
Mean (SD) 
Baseline costs * £11,980 (£13,686) £11,582 (£15,753) 
Baseline EQ-5D-Y score ^ 0.474 (0.438) 0.638 (0.374) 
Baseline GDS-LD score ^ 16.6 (7.91) 16.9 (6.73) 















Results for treatment arm specific total mean costs and QALYs, and differences 
between arms for complete cases, multiple imputation (unadjusted) and 
multiple imputation (adjusted) are presented in Table 8. 
Table 8: BeatIt original treatment arm-based economic evaluation results 
 BeatIt StepUp Difference 
 
Mean (SD) Mean (SD) Mean (SE) 
95% confidence 
interval 
Complete case analysis 











-0.063  -0.178 to 0.052 
Multiple imputation (unadjusted) 











-0.076  -0.185 to 0.033 














0.002 (0.043) -0.082 to 0.085 
 
SD – standard deviation, SE – standard error  
The complete case analysis shows that costs were lower in StepUp compared to 
BeatIt; £26,786 compared to £27,158, a difference of £371 (95% CI -£12,689 to 
£13,432), this difference was not statistically significant.  Complete case results 
for QALYs were higher in the StepUp arm compared to the BeatIt arm; 0.691 
compared to 0.628, a difference of 0.063 (95% CI -0.052 to 0.178), again a 
statistically insignificant difference. These results suggest that StepUp 
dominates BeatIt (less costly and more effective), but there is uncertainty in this 
result as the cost and QALY differences are not statistically significant.  These 
results suggest that the ICER would fall into the northwest quadrant of the cost-
effectiveness plane where decision makers would reject the BeatIt therapy. 
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As described in Chapter 2 it is good practice to replace missing data in a clinical 
trial; multiple imputation techniques were used to replace missing data.  
Unadjusted multiple imputation results confirmed the complete case results; 
StepUp dominates BeatIt, but these results are still uncertain as the 95% 
confidence interval crosses zero.  Again, the results suggest that the ICER would 
fall into the northwest quadrant of the cost-effectiveness plane where decision 
makers would reject the BeatIt therapy. 
After adjusting the multiple imputation results for heterogeneity uncertainty 
using baseline participant characteristics and allocated therapist as covariates, 
total costs for BeatIt were lower than for StepUp; £26,369 compared to £27,962, 
a difference of £1,593 (95% CI -£2,008 to £5,194).  Adjusted QALYs were higher 
in BeatIt than in StepUp; 0.657 compared to 0.655, a difference of 0.002 (95% CI 
-0.082 to 0.085). In this analysis the results have changed direction compared to 
the previous analyses, suggesting that BeatIt now dominates StepUp.  The 
imbalance at baseline in EQ-5D-Y scores is likely to have driven the reversal of 
total QALY results.  Total QALYs were higher in the StepUp arm for complete 
case and multiple imputation results, but higher in the BeatIt arm for multiple 
imputation adjusted results; baseline EQ-5D-Y was significantly higher in the 
StepUp arm compared to BeatIt. However, it is important to note that despite 
this change in direction of results, it is still uncertain as neither cost nor QALY 
differences are significant, with the 95% confidence crossing zero.  This result 
suggests that the ICER would fall into the southeast quadrant of the cost-
effectiveness plane where decision makers would accept the BeatIt therapy. 
Parameter uncertainty was explored in three sensitivity analyses (Table 9); total 
mean cost differences in all three scenarios favour StepUp mirroring the 
complete case and unadjusted multiple imputation results indicating that the 
























































SE – standard error 
 
The three main analyses (Table 8) show no statistical significant differences 
between treatment arms for mean total costs or QALYs.  Whilst there is no 
evidence of BeatIt being more cost-effective than StepUp, there is also no 
evidence that it is less cost-effective, this uncertainty is explored further below.   
The cost-effectiveness plane presented in Figure 11 illustrates the 1,000 
bootstrap samples from the complete case analysis, showing the mean 
difference in costs and QALYs between StepUp and BeatIt, the samples fall into 
all four quadrants of the cost-effectiveness plane reflecting the uncertainty in 
the results, and indicating that there is no evidence to show that one treatment 




Figure 11: BeatIt cost-effectiveness plane – original treatment arm-based analysis complete cases 
(unadjusted) 
These results are mirrored in the CEAC in Figure 12, illustrating that at the 
current NICE £20,000 threshold there is less than a 50% chance of BeatIt being 
cost-effective compared to StepUp. BeatIt is not likely to be cost-effective 
compared to StepUp at any threshold; at £120,000 the likelihood of BeatIt being 




Figure 12: BeatIt cost-effectiveness acceptability curve - original treatment arm-based analysis 
complete cases (unadjusted) 
 
For the purposes of this thesis additional analyses were conducted on the 
complete case unadjusted clinical trial data; treatment and non-treatment costs 
were separated out and the difference between arms estimated for these cost 
categories, the results were bootstrapped and samples were plotted on cost-
effectiveness planes, and EVPI was calculated. 
When looking at treatment costs only it is clear that the BeatIt intervention is 
more costly than the StepUp comparator, there is a difference between arms of 
£738 (95% CI £586 to £890), this is a statistically significant result; there is 
minimal uncertainty in the difference between arms for treatment costs.  This is 
illustrated by the cost-effectiveness plane in Figure 13.  It can also be seen that 
whilst BeatIt is more costly than StepUp to deliver, the difference between arms 
in QALYs is uncertain as the bootstrapped samples cross the vertical axis.  This 
uncertainty in the economic outcomes is reflected in the primary outcome of 



















When the non-treatment costs are assessed they are marginally higher in the 
StepUp arm compared to the BeatIt arm, a difference of £367 (95%CI -£12,684 to 
£13,418), however the wide confidence interval suggests that there is little 
certainty that non-treatment costs are higher in the StepUp arm.  This result is 
illustrated in the cost-effectiveness plane in Figure 14.   
 
Figure 14: BeatIt cost-effectiveness plane – original treatment arm-based analysis non-treatment 
costs only 
 
This additional analysis confirms that the treatment costs are known and 
certain, however non-treatment costs are uncertain, spreading widely either 
side of the horizontal axis on the cost-effectiveness plane. 
The EVPI estimate is £1,679 per person suggesting that further research may be 
worthwhile; additional research would be worthwhile if its cost is less than the 
population EVPI cost. This result is driven by the uncertainty in the results, as 
illustrated on the cost-effectiveness planes in this section; only the cost-
effectiveness plane for treatment costs shows a clear difference in costs. 
The results of the economic evaluation indicate that there was no difference in 
outcomes between arms, which was mirrored by the lack of difference between 
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arms in the primary outcome of change to GDS-LD in the trial (126). Although 
there was no significant difference in mean total costs between arms, this masks 
a statistically significant difference in treatment costs.   
3.4 Summary 
This chapter introduced the two case studies which will be used throughout this 
thesis.  In chapter 2 the limitations of using clinical trials to assess the cost-
effectiveness of a new technology were discussed, and the uncertainty in 
economic evaluation results as a consequence of these limitations was 
highlighted.  The purpose of the case studies in this chapter were to illustrate 
how the existing guidance for a standard treatment arm-based economic 
evaluation is applied in practice, and to demonstrate the uncertainty which can 
result from using trial data in an economic evaluation.  In these case studies the 
recommended methods for showing uncertainty were followed: 95% confidence 
intervals were presented; bootstrapped samples were used to populate cost-
effectiveness planes and cost-effectiveness acceptability curves; value of 
information was calculated; heterogeneity was adjusted for using baseline 
characteristics, and sensitivity analyses were conducted.  The case studies both 
show uncertainty around the ICER, and because of this uncertainty there is 
limited evidence for decision makers to base a decision on.   
Additional analysis conducted specifically for this thesis found that in both case 
studies the treatment costs were known and precise, however the other costs 
(except exacerbation costs in TWICS) were unclear and this uncertainty was 
masking the certain treatment costs. 
In the next chapter suggestions for developing a methodological framework are 
reported, these are then applied in Chapter 5 to develop a methodological 
framework for developing conceptual models.   
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framework development 
4.1  Chapter overview 
The aim of this chapter is to provide suggestions for developing a methodological 
framework, this is the first output of the thesis and partly fulfils the second 
objective. 
This thesis introduces a new role for conceptual models to provide additional 
understanding for decision makers to inform funding decisions. While guidance 
exists for developing conceptual models in the field of economic evaluation, this 
focusses on using conceptual models to guide the development of the structure 
of decision analytic models. New guidance is needed to develop conceptual 
models in the proposed new role and the chosen format of this guidance is a 
methodological framework. At the outset of this thesis there was no consensus 
on recommendations, or established methods, for developing a methodological 
framework (39), and due to this lack of guidance an extra work strand was 
added to the thesis; to compile practical suggestions for developing a 
methodological framework.   
The objectives of this chapter were to:  
1) identify existing methodological frameworks  
2) extract reported approaches used to develop the methodological 
frameworks  
3) collate and summarise the approaches into suggestions for developing 
methodological frameworks, and 
4) explore terminology used for methodological frameworks.  
A scoping review was used to achieve the objectives set out above, methods of 
the scoping review are described in Section 4.2, results of the scoping review are 
set out in Section 4.3, a discussion of the work in this chapter is included in 




4.2.1 Scoping review methodology 
A scoping review was chosen over a systematic review to provide the suggestions 
for developing methodological frameworks. Systematic reviews answer a clearly 
defined research question, and are typically used to inform current practice with 
robust and reliable estimations of treatment effects (146). Scoping reviews 
ascertain the extent of information in a given subject area, particularly when 
evidence on a topic has not previously been comprehensively reviewed, and in 
emerging areas (147). Whilst scoping reviews can be used to determine whether 
a full systematic review would be worthwhile, they can also be an exercise in 
their own right, as in this piece of work, where the purpose is to map the body 
of evidence on a topic and explore the extent of this evidence (148, 149).  
Scoping reviews identify the nature and range of the evidence, and summarise, 
using charts or maps, the research findings, providing a descriptive overview of 
emerging evidence (149, 150). Systematic reviews follow rigid inclusion and 
exclusion criteria decided a priori and critically appraise evidence identified 
(151). A scoping review includes a narrative review using an analytic framework 
or thematic review, without critical appraisal or synthesis (150).  Unlike 
systematic reviews, which synthesise evidence from studies, scoping reviews 
ascertain the extent of information on a given subject area (149).  The purpose 
of this chapter was not to answer a precise clinical research question, either by 
providing new evidence or refuting existing evidence; the purpose of this 
chapter was to map new and emerging evidence on methods used to develop 
methodological frameworks, from a wide range of sources, and to summarise 
this evidence.  
Guidance for conducting scoping reviews was first published by Arksey and 
O’Malley in 2005 (150).  This was updated by Levac et al. in 2010 (152), and 
again in 2014 by Colquhoun et al. who published clarification on definitions, 
methods and reporting (153). In 2015 Peters and colleagues at the Joanna Briggs 
Institute, published updated guidance on conducting scoping reviews (149).  In 
2016 Tricco et al. carried out a scoping review on the methodology and reporting 
of scoping reviews, comparing the methodology used in the scoping reviews to 
the guidance presented by the Joanna Briggs Institute in Peters et al. (147).  
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For my scoping review I followed guidance by Arksey and O’Malley, 
supplemented by the most recent guidance on conducting a scoping review in 
Levac et al. (152), Armstrong et al. (148), and  Peters et al. (149).  The 
remainder of this section reports a summary of this guidance and sub-sections 
4.2.2 through to 4.2.6, explain how this guidance is applied in my scoping 
review.  
Identifying the research question 
The first step is to identify the research question; the research question guides 
the search strategy and it should be broad enough to ensure a wide range of 
coverage (148).  The purpose and rationale of the scoping review should also be 
considered at this stage (150). 
Identifying relevant studies 
The search should be as broad and comprehensive as possible, including 
published and unpublished studies and reviews (150).  The strategy adopted by 
Arksey and O’Malley involved searching various sources: electronic databases, 
reference lists, hand-searching of key journals and existing networks, relevant 
organisations and conferences (150).  Levac et al. advise using the research 
question and purpose of the review to guide the scope of the search (152).  
Peters et al. divide this stage into three steps: a limited initial search to identify 
key text words and index terms to use in the search; a second comprehensive 
search using key words and index terms identified in the initial step, followed by 
searching the reference lists of record (149). 
Study selection 
Inclusion and exclusion criteria are developed on an ongoing basis, not prior to 
the search, based on increasing familiarity with the literature (150).  Levac et 
al. recommend that the study selection should be an iterative process including 
searching the literature, refining the search strategy and assessing articles for 
inclusion. Both Arksey and O’Malley and Levac et al. recommend using two 




Arksey and O’Malley describe this stage as ‘charting’ key items of information 
from the included studies (150). These key items should be entered onto ‘data 
charting forms’; Arksey and O’Malley used Excel software for developing their 
forms and suggest collecting both general and specific information from the 
study. Armstrong suggests using a spreadsheet or database to chart the data, 
and using the research question as a focus, this helps the researcher(s) in 
identifying commonalities, gaps and themes; the focus of the scoping review will 
determine what data is charted during this stage (148).  
Examples of the type of data to extract include: author/s, year of publication, 
location of study, intervention, comparator, duration of intervention, study 
population, aims of the study, methodology, outcome measures and important 
results. 
Levac et al. add that charting should be an iterative process where the 
researchers continually extract data and update the data charting form (152). 
Peters et al. also state that refinement of the charting forms may be needed and 
that the results should be presented as a map in a logical, diagrammatic, tabular 
and/or descriptive form, emphasising that the charted results chosen should 
align with and illustrate the aims and purposes of the review. 
Collating, summarising and reporting the results 
Peters et al. recommend a narrative description of the search process and 
identified records, plus a flowchart illustrating the process which depicts 
decisions on exclusion and inclusion and includes the final number of items of 
included. The narrative review should include a numerical analysis of the 
included records, including the extent, nature and distribution of records.  The 
numerical analysis can include tables and graphs.   
Levac et al. developed this stage further by suggesting three distinct steps: 
analysing the data, reporting results, and applying meaning to the results.  In 
analysing the data using thematic analysis, Levac et al. argue that this stage 
resembles qualitative data analytical techniques; researchers should think about 
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using qualitative analytical techniques and qualitative software to enable this 
process.  In the second stage, ‘reporting results’ the researchers should consider 
the best way to report the results, for example using themes, a framework or a 
table.  In the third stage the researchers should consider the implications of the 
results and apply meaning to the findings of the scoping review within the 
broader research, policy and practice context.  
Discussion 
A detailed discussion of the results and limitations of the sources, if relevant, 
should be included.  Results should be considered in the context of current 
literature, practice and policy. 
Conclusions and implications for research and practice 
Conclusions should match the review question/objective, starting with an overall 
conclusion based on the review results.  Recommendations for future research 
based on gaps identified in the review should be discussed, however, 
recommendations for future practice may not be able to be developed 
depending on the aim and focus of the review. 
The following sections describe the methods used in this present scoping review, 
based on the methods just explained. 
4.2.2 Identifying the research question 
The primary research question for this scoping review was ‘What reported 
approaches are being used to develop methodological frameworks?’  The working 
definition of a methodological framework for this scoping review was ‘a 
structured practical tool for guiding the user through a stepwise process, 
enabling/facilitating a standardised approach to the given task’.  As there is no 
formal terminology for a methodological framework (45) a secondary research 
question of ‘What terminology is used to define methodological frameworks?’ 
was included.  
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The purpose of the review was to identify reported approaches used to develop 
methodological frameworks to inform the development of my methodological 
framework for developing conceptual models later in the thesis. The rationale 
for conducting the review was that there is no formal guidance on developing 
methodological frameworks, nor any consensus on the terminology used for 
describing methodological frameworks. 
4.2.3 Identifying relevant studies  
The search strategy was developed with input from the College librarian, both 
for search terms and databases.   
Following Peters et al. guidance a simple initial search was conducted.  This 
initial search was conducted in Web of Science because this database covers a 
broad range of disciplines and topics, and it also allows the user to easily check 
citations of identified papers.  The initial search, using the broad terms of 
‘framework’ AND ‘develop*’, resulted in 11,120 potential records and the results 
of the initial search helped to inform the more comprehensive search. Index 
terms were scrutinised, this technique is particularly useful when there is no 
firm consensus or consistency on definitions and terms, as in this case. 
In Tricco’s review of scoping reviews, 93% of reviews searched more than one 
database, only 6% searched one database (147).  The comprehensive search 
followed Tricco’s research methods and Arksey and O’Malley’s methods 
described in sub-section 4.2.1, two databases were searched to identify peer-
reviewed publications, and the internet was searched to identify grey literature. 
Grey literature has been described as not being under the control of commercial 
publishers, and examples of grey literature include; government reports, 
PowerPoint presentations, best practise documents, newsletters and working 
papers (154).  The search took place in September 2018.     
After the initial database search returned 11,120 results, to ensure that a more 
manageable number of results were identified in the comprehensive database 
search, search terms were restricted to ‘methodological framework’ plus terms 
for development.  Details of search terms used are included in 0Appendix 2: 
Scoping review search terms (Chapter 4). The two databases searched were Web 
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of Science and Ovid Medline, and only titles rather than abstracts were searched 
to ensure that the search terms were the main focus of the article or paper.  
There is no gold standard for searching grey literature, however, research has 
shown that using internet search engines can identify up-to-date grey literature 
(155). I conducted an internet search which was guided by Godin’s methods; 
searching the first 10 pages (100 hits) of results, and bookmarking websites that 
looked relevant (156). Godin also targeted specific websites, but as this search 
was not restricted to specific disciplines, this more targeted aspect of Godin’s 
methodology was not used.   
The internet search was carried out using the ‘Google’ web browser, the search 
term used was ‘Methodological framework development’.  As methodological 
frameworks are often presented as a diagram I also conducted a separate search 
in Google Images; this replicated methods presented by Rivera et al. (39), and 
based on methods from Rivera et al. I screened the first 50 items.   
Following the three-step method recommended by Peters et al., the final stage 
was to search the references and citations of the methodological frameworks 
which met the inclusion criteria, for any additional relevant methodological 
frameworks.   
4.2.4 Study selection 
For the purposes of this search broad inclusion criteria were used, these 
included: a methodological framework which should be presented in the article 
and the approaches used in developing the methodological framework should be 
described; only English records were included, and only records published in the 
last ten years were included - from 2008 onwards.  Titles and abstracts were 
screened, then either discarded or kept and read in full, and the full texts that 
met the inclusion criteria were selected and included in the review results.   
4.2.5 Charting the data 
In line with the guidance described in sub-section 4.2.1, Excel was used to 
extract study characteristics, these were: author/s; title; date of publication; 
type of record (for example published journal/conference proceedings); 
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discipline; the country of origin of the study; reported approaches used in 
developing methodological framework; terminology used to describe the 
methodological framework, and any keywords used.   
To extract reported methodological approaches an iterative process was used, as 
recommended by Levac et al., for charting the data; initially basing the 
extracted the themes reported in Rivera et al. (39).  These original themes 
were: original source of the methodological framework; literature review; 
stakeholder involvement; incorporating stakeholder views, and piloting phase. 
These themes were added to and updated as approaches were extracted and I 
became more familiar with the methodological frameworks and the range of 
approaches taken.     
4.2.6 Collating, summarising and reporting the results 
The search results, including the inclusion/exclusion process, were illustrated in 
a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
diagram, and the characteristics of the studies identified and included in the 
results were presented narratively and graphically.  Reported approaches were 
examined in detail and presented descriptively with counts and percentages. 
Meaning was applied to the results by considering their implications and further 
categorising themes into phases and interpreting to make suggestions for 
developing methodological frameworks. Finally, terminology used for the 
methodological frameworks was described narratively, numerically and visually, 
and keywords used for the studies were summarised.   
4.2.7 Discussion and conclusions  
The results were summarised and compared to existing literature as far as was 
possible, strengths and limitations were discussed, and recommendations for 
future research were suggested. 
4.3 Results 
The results are presented in four sub-sections: the first reports the literature 
search results (sub-section 4.3.1), the second describes the study characteristics 
(sub-section 4.3.2), the third presents the suggestions for developing 
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methodological frameworks (sub-section 4.3.3), and the fourth describes the 
terminology used in the methodological frameworks (sub-section 4.3.4). 
4.3.1 Literature search  
The results of the search are presented in a PRISMA diagram in Figure 15.  In 
total 320 records were identified, 54 of these were duplicates, leaving 266 titles 
and abstracts to screen.  87 papers were excluded after reading titles and 
abstracts, and a further 149 were excluded after reading full texts; 30 papers 
were included in the final search results. 
 
Figure 15: PRISMA diagram, scoping review results for methodological frameworks (duplicated 





4.3.2 Study characteristics of included methodological 
frameworks 
Study characteristics are presented in full in Appendix 3: Results of scoping 
review – study characteristics (Chapter 4) and summarised in Figure 16.  Most 
studies were published in recent years; years of publication ranged from 2009 to 
2018, 12 were published between 2009 and 2013, and 18 were published 
between 2014 and 2018.  Most studies were journal articles (n=26), three were 
conference proceedings and one a book chapter.  The studies represent a wide 
range of subject areas; 20 fields were identified, the most frequent was ecology 
(n=6), then education and regional (n=4), next manufacturing (n=3), and 
healthcare, architecture and health economics (n=2).  The was one study each 
for agricultural systems, architecture, defence, forensic chemistry, geographic 
information system, organisation and qualitative research.  The papers 
originated from 14 countries; the country where most were published was the UK 
(n=8), then Greece, Germany, The Netherlands and the United States (US) (n=3) 
and finally Italy (n=2).  The remainder of the countries had one paper each.  
Most of the papers originated from Europe (80%), then America/Canada (13.3 %) 











GIS - geographical information system, UK – United Kingdom, US – United States 

























































































































































































































































4.3.3 Extracted reported approaches  
Following the iterative process of extracting and categorising reported 
approaches discussed in sub-section 4.2.6, eight reported approaches were 
extracted, results are presented in Table 10. 
Table 10: Methods reported as being used in methodological framework  




Based on existing methods 20 66.7 
Refined and validated 10 33.3 
Experience and expertise 9 30.0 
Literature review 8 26.7 
Data synthesis and amalgamation 7 23.3 
Data extraction 3 10.0 
Iteratively developed 2 6.7 
Lab work results 1 3.3 
 
The most frequently reported method was ‘based on existing methods’ (n=20, 
66.7%), this included the use of existing methods and guidelines as the 
foundations of the methodological framework being developed.  Existing 
methods and guidelines included previous methodological frameworks or 
guidance and published methodology.  Whilst some studies did not explain how 
the existing methods and guidelines formed the foundations of the 
methodological framework being developed, several did expand on this further: 
adapting the methods (31, 157), integrating methods (158, 159), building on the 
existing methods (37), based on the methodological framework, combining well 
established guidelines which comprised the same stages (34), and the 
methodological framework was the basic inspiration (36). Only one study 
reported how the existing methods were identified; Squires et al. used a 
literature review (22). 
Ten studies (33.3%) reported ‘refined and validated’ as an approach.  There 
were two aspects to this approach: refining the methodological framework and 
validating the methodological framework.  Specific approaches taken were: 
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piloting the methodological framework (160), trialling identified stages and using 
the results of the trial to further develop the methodological framework (161), 
using a case study to refine the methodological framework (162), using a case 
study or Delphi panel to evaluate and refine the methodological framework (22, 
42, 162), using a case study to validate to methodological framework (28, 33), 
and testing the methodological framework (32). Two studies did not report 
details of the case study (157, 163).  
Nine (30%) studies reported using ‘experience and expertise’ to develop the 
methodological framework.  This included experience at a personal (35), 
school/university (161) and country level (36).  Experience and expertise was 
collated during meetings (163), using consultations (37) and in collaboration 
(162).  Two studies did not specifically mention experience but used surveys and 
interviews (164), and focus groups for extracting expertise (22). 
Eight (26.7%) studies reported conducting a ‘literature review’. Two papers used 
purposeful sampling (38, 165), sources used for searches included databases, 
dissertations (30), library catalogues, contacting key authors, databases, 
websites and citations (42, 166).  Six studies included a literature review but did 
not report specific methods used (22, 28, 30, 42, 160, 162). 
Seven studies (23.3%) reported using ‘data synthesis and amalgamation’.  
Specific methods included: identifying phases (38), themes (22, 164) and 
dimensions (30), analysing and grouping or categorising themes, and thematic 
analysis (30, 38, 42, 165, 167).   
Three studies (10%) reported using ‘data extraction’ as an approach.  This 
included extracting data from interviews and focus groups using transcribing 
methods (22, 164), and extracting key information from published literature 
(38).  
‘Iteratively developed’ was reported in two studies (6.7%), one study had no 
further details on this (32), the other explained that the methodological 
framework evolved and developed as items were extracted, synthesised and 
revised.   
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The least frequently mentioned approach was ‘lab work results’; one study from 
the field of explosives reported this approach; the results of lab tests were used 
to inform the methodological framework (168). 
In applying meaning to, and considering the implications of, the results, a 
pattern emerged whilst reviewing the approaches and they were split into three 
categories.  The first category related to identifying evidence or data to inform 
and form the foundations of the proposed methodological framework.  This 
evidence came from: existing methods, literature reviews, lab results and 
experience/expertise.  The second category related to developing the proposed 
methodological framework, comprising: extracting data, and synthesising and 
amalgamating this data iteratively.  The third and final category was refining 
and validating the proposed methodological framework using: trialling the 
framework with pilot or case studies and or Delphi panels.  These categories are 
illustrated in Figure 17, and described below presenting suggestions for 
developing a methodological framework. 
Phase 1 – Identifying evidence to inform the methodological framework 
This phase describes two approaches for identifying evidence: identifying 
existing evidence and identifying new evidence. 
Existing frameworks or guidance can be identified using purposeful literature 
searches and evidence includes previous methodological frameworks, guidance 
or published methodology, and can inform the proposed methodological 
framework by adapting, integrating and building on the existing methods. 
New evidence comes from several sources: the experience and expertise of 
experts at a personal, organisational or country level; qualitative research 
(surveys, interviews and focus groups), and collaboration and consultation with 
interested experts.  If qualitative research is used it is preferable that experts in 
the field of the proposed methodological framework are used for this research 





Phase 2 – Developing the methodological framework 
In this phase the evidence identified in Phase 1 is analysed, adapted, combined 
and built upon to create the foundation of the proposed methodological 
framework.  Firstly, key information is extracted using appropriate methods: 
transcribing qualitative data; populating predesigned tables and entering 
quantitative evidence into piloted data extraction forms. Then the extracted 
data is analysed by synthesising, grouping or amalgamating it into categories, 
these categories then inform the proposed methodological framework.  This 
phase is iterative; the proposed methodological framework evolves after it is 
presented to key experts and study team members who will review it and revisit 
evidence from Phase 1 until a consensus is reached. 
Phase 3 – Evaluate and refine 
In this final stage the proposed methodological framework is evaluated and 
refined.  Evaluation techniques include case studies to pilot the methodological 
framework and Delphi panels.  If appropriate, the results from this evaluation 
can be used to refine the proposed methodological framework; updating it with 
changes identified during the evaluation and then presenting the revised 






Figure 17: Three categories of reported approaches for framework development  
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4.3.4 Terminology used for methodological frameworks 
Terminology used to describe the methodological frameworks included in the 
scoping review was extracted and the results are presented below. 
The studies included seven different terms to describe methodological 
frameworks, in both the titles and the main text of the studies: ‘methodological 
framework’; ‘framework’; ‘conceptual framework’; ‘sequential framework’; 
‘theoretical framework’; ‘governance framework’, and ‘problem-oriented 
framework’.   
Most studies (n=24, 80%) used the term ‘methodological framework’ in the title. 
Of the remaining six studies one included ‘methodological’ and ‘framework’ 
separately in the title, four included only ‘framework’ in the title and one used 













Within the main text of the study most studies used the seven identified terms 
interchangeably, this is illustrated in Figure 18. A combination of terms was used 
in most studies; 19 used a combination of ‘methodological framework’ and 
‘framework’, three used ‘framework’ only, two used a combination of 
‘conceptual framework’, ‘methodological framework’ and ‘framework’, one 
used ‘methodological framework’ only, the remaining five all used a 
combination of two or four terms to describe the methodological framework. 
 









Keywords extracted from the studies which are relevant to a methodological 
framework, are presented in Table 11. 15 (50%) studies had no keywords 
relevant to methodological frameworks, using only keywords relevant to the 
actual subject of the methodological framework.  Studies that included 
keywords relevant to methodological framework used; ‘methodology’ (4/30), 
‘methodological framework’ (3/30), ‘design methodology’ (2/30), ‘simulation 
methodology’ (1/30), ‘methods’ (1/30) and ‘guidance’ (1/30).  Ten studies 
included one relevant keyword, and one had two relevant keywords (‘methods’ 
and ‘guidance’).  
Table 11: Keywords relevant to methodological frameworks 
Keyword Number (percentage) (n=30) 
None 15 (50%) 
‘Methodology’ 4 (13.3%) 
No keywords 4 (13.3%) 
‘Methodological framework’ 3 (10.0%) 
‘Design methodology’ 2 (6.7%) 
‘Simulation methodology’ 1 (3.3%) 
‘Methods’ 1 (3.3%) 
‘Guidance’ 1 (3.3%) 
 
A PRISMA checklist is included in Appendix 4: PRISMA Scoping review checklist 
(Publication from Chapter 4). 
4.4 Discussion and conclusions 
4.4.1 Overview 
The scoping review reported in this chapter identified 30 methodological 
frameworks published in the last 10 years and reported the approaches that 
were used to develop them.  The studies covered 20 disciplines and originated 
from 14 countries; the reported approaches were extracted and grouped.  Eight 
reported approaches of development were identified and extracted from the 
frameworks, however, not all of the methodological frameworks identified in the 
scoping review reported the approaches used in developing them; 179 
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potentially relevant methodological frameworks were scrutinised in full and 37 
(20.7%) of these were rejected because the authors did not report the 
approaches used to develop them.  Studies which did report the approaches used 
for development were often not clear, however there was enough consensus in 
the common approaches to allow me to apply meaning to the results. The 
reported approaches form the basis of the suggestions for developing 
methodological frameworks presented in Figure 17. 
Of the studies which did report the approaches used to develop them the 
number of studies reporting one or more of the eight approaches ranged from 20 
(‘based on existing methods and guideline’) to one (‘lab work results’). The 
number of mentions of the remaining six approaches ranged from two to ten. 
Whilst ‘based on existing methods and guidelines’ and ‘literature review’ were 
presented separately in the results, it could be argued that these two 
approaches are closely linked: a literature review is carried out to identify 
previous methods and guidelines.  However, if a literature review is not carried 
out, it is entirely feasible that the framework will be based on previous methods 
that were not identified through a literature review.  
The number of terms used to describe methodological frameworks highlights the 
lack of clarity around terminology.  Most studies used a combination of 
‘methodological framework’ and ‘framework’, this is understandable when there 
are often word limits for journals and restricting the terminology to ‘framework’ 
can help to improve the flow of the discussion.  However, two studies used a 
combination of four terms to describe the methodological framework further 
illustrating lack of clarity between and within studies.  This confusion in 
terminology is likely to lead to difficulties in identifying methodological 
frameworks in a literature search as many methodological frameworks might not 
be identified.   
In addition to the lack of clarity in terminology, half of the identified studies did 
not include keywords relevant to methodological frameworks. This is likely to be 
the result of the subject of the methodological framework being the focus of the 
study rather than the actual methodological framework.  Again, this could lead 
to difficulties in identifying methodological frameworks in a literature search. 
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4.4.2 Comparison to existing evidence 
As there was no existing guidance for developing methodological frameworks it 
was not possible to interpret the results of this scoping review considering what 
is already known.  However, in the following paragraphs I compare the results to 
Rivera et al., this comparison is particularly useful as there was no duplication of 
studies between my scoping review and the Rivera et al. literature review. 
Rivera et al. reported that the methodological frameworks identified in their 
research varied in their development, but that there were some common 
approaches.  Only one paper (4%) did not report any approaches used in 
developing the methodological framework compared to 37 (20.7%) in my search. 
Rivera reported four key approaches reported: using a literature review, 
consulting with stakeholders using interviews or surveys etc, methods to 
incorporate stakeholder views (thematic analysis, refining and feedback) and 
piloting the methodological framework to refine or illustrate it.   
One approach identified by Rivera et al. that was not identified in my search 
was one used during the validation stage; comparing the methodological 
framework to existing literature to assess consistency.  Whilst this was not 
identified in the search or included in the results, I believe that comparing a 
version of the framework with existing literature in a discipline is a useful 
approach which would result in a methodological framework that has been 
evaluated and refined using tried and tested methods and will consequently be 
more robust. 
The results from my scoping review also identified approaches not identified by 
the Rivera et al. research, these were: refined and validated; data synthesis; 
data synthesis and amalgamation, and iteratively developed.  Overall, I was able 
to extract more details on ‘how to do’, rather than ‘what to do’.  
My scoping review has moved understanding forward by adding to the basic 
approaches extracted by Rivera et al., whose aim was to identify the impact of 
research and the approaches identified were extracted as part of reporting study 
characteristics.  The research is useful because whilst Rivera et al. reports 
approaches used to develop methodological frameworks there is no information 
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on how to apply these approaches; for example conducting a literature review 
but not reporting what to do with the information from the literature review, for 
example data extraction or synthesis. 
Finally, Rivera et al. concludes that the lack of guidance on developing 
methodological frameworks should be addressed to ensure that best practice 
methods can be used in the future.  This scoping review starts to address this 
lack of guidance in this area and provides a foundation for much needed future 
research to develop this area further; a systematic literature review with more 
resources should be carried out to identify more methodological frameworks, 
and guidance could be further developed by using expert feedback and piloting. 
Another recommendation for future research is to develop a standardised 
procedure for collecting qualitative data evidence in phase one of the 
suggestions.  
4.4.3 Strengths and limitations 
To the best of my knowledge this is the first research done with the aim of 
identifying approaches reported for developing a methodological framework.  
This research attempts to fill a gap where there is a need for guidance in 
developing methodological frameworks. 
The methodological frameworks identified are from many different contexts and 
countries, these demonstrate natural variation and give the suggested 
approaches a robust and generalisable nature.  This research also provides a 
contemporary overview of how methodological frameworks are being developed. 
Limitations of the scoping review mainly relate to the search strategy; 
restricting the search terms to titles, not abstracts ensured that the search 
terms were the main focus of any identified articles, however this may have 
excluded other relevant articles. Additionally, some frameworks may have 
missed in the search due to inconsistent terminology, in fact, none of the 
methodological frameworks identified by Rivera et al. were identified in this 
scoping review, this is because I used the search term ‘methodological 
framework’, not ‘framework’.   Rivera et al. was able to use ‘framework’ for a 
search term as their search was specifically for research impact papers which 
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would have reduced the number of potential hits compared to my broader 
search.  Some methodological frameworks will have been missed in the search 
due to restricting the search terms to ‘methodological framework’ because of 
pragmatism; if the term ‘framework’ had been used this is likely to have 
resulted in an impractical number of results.   
Limitations of internet searches include;  the search reports thousands of hits, 
when in reality far fewer are found; the transient nature of the internet, where 
documents may disappear over time; and the ‘personalised search feature’ 
element of an internet search making the search difficult to replicate, although 
Adams et al. concluded that replicating an internet search was feasible (155).   
Not all methodological frameworks identified reported approaches taken; out of 
179 potentially eligible methodological frameworks (met all criteria excluding 
including approaches), 37 (20.7%) were rejected because they did not report the 
approaches taken in developing the methodological framework, this limited the 
amount of data I could extract and include in the scoping review. Linked to this 
not all approaches were clearly reported, perhaps because of word count, aim of 
the paper, or traditionally how different disciplines report, so I needed to 
interpret them.  
Arksey and O’Malley and Levac et al. recommend using two researchers to 
independently review titles/abstracts and full articles, however as this was a 
piece of work for my PhD only one researcher was involved. 
Scoping reviews do not assess the quality of included evidence, therefore there 
is a risk that the frameworks included in this review were not of high quality.  
However scoping review methodology was the correct choice for this review; 
scoping reviews are recommended for identifying key characteristics related to a 
concept, which is useful when giving an overview of the evidence.  Furthermore, 
scoping reviews use rigorous and transparent methods ensuring that the results 
are trustworthy (146). 
Finally, the second objective in my thesis was to develop a methodological 
framework to guide the development of a conceptual model in economic 
evaluation, and it is possible that not all approaches identified and extracted in 
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this scoping review are suitable for developing a methodological framework 
specifically for developing a conceptual model.  
4.5 Summary 
This chapter used scoping review methods to produce suggestions for developing 
methodological frameworks, this is the first output of this thesis. The scoping 
review found that there was consistency and unspoken consensus on approaches 
used and a three-phase suggestion was produced to inform the development of a 
methodological framework.  Not only does the research from this chapter fill a 
previously identified gap, but it also feeds into the second objective of my thesis 
which is to develop a methodological framework for conceptual models in 
economic evaluation. Future research could update the results of this scoping 
review by using a systematic literature review to develop guidance, and evaluate 
this guidance using suitable methods to come to a consensus on the contents of 
the guidance. A standardised procedure for collecting qualitative data evidence 
in phase one should also be investigated.  I would also recommend the use of the 
term ‘methodological framework’ as a minimum in the titles of future 
methodological frameworks and as a keyword, this would enable future searches 
to identify all relevant evidence.   
The suggested approaches reported in this chapter feed into Chapter 5, where 
they are applied to develop a methodological framework for developing 
conceptual models.  
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conceptual models in economic evaluation 
5.1 Chapter overview 
The aim of this chapter is to apply the suggestions presented in Chapter 4 to 
develop a methodological framework.  The second objective of this thesis is to 
provide guidance for developing a conceptual model for the new role for 
conceptual models proposed in this thesis; while there is existing guidance on 
how to develop conceptual models for informing the structure of a decision 
analytic model in economic evaluation, there is no guidance on how to develop a 
conceptual model for other purposes. This chapter describes how the 
methodological framework was developed and presents the final version; this is 
the second output of the thesis.   
The layout of the chapter is as follows; three Sections, 5.2, 5.3, and 5.4 describe 
the methods used to develop the framework following the three phases of 
suggestions from Chapter 4.  To recap, in Phase 1 existing methodological 
frameworks for developing conceptual models are identified, in Phase 2 data is 
extracted from these methodological frameworks and amalgamated into a draft 
methodological framework, and in Phase 3 the draft methodological framework 
is evaluated and refined.  The result, in the form of the final methodological 
framework, is presented in Section 5.5, a discussion of the development of the 
methodological framework is included in Section 5.6, and Section 5.7 
summarises the chapter.   
5.2 Methods: Phase 1 - Identifying evidence to inform the 
methodological framework  
In this first phase evidence was identified to inform the methodological 
framework using a literature review. 
5.2.1 Literature search - methods 
The aim of the literature search was to identify existing methodological 
frameworks for developing conceptual models, searching outwith the field of 
economic evaluation, to inform the methodological framework.  
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From an initial search, it was apparent that conceptual modelling 
methodological frameworks were available in different disciplines and from 
different sources; not restricted to peer reviewed academic articles.  Therefore, 
I needed literature search methodology covering a broad range of different 
disciplines and sources, allowing me to identify a wide range of frameworks; 
scoping review methodology filled this requirement.  Scoping reviews are 
suitable for exploring an emerging area to ascertain the extent, nature and 
breadth of available evidence (147, 150). The purpose of a scoping review is to 
map the evidence in an area, with a range of designs and methods, giving a 
descriptive overview of the evidence without critical appraisal or synthesis 
(169).  Using a scoping review enabled me to identify frameworks from a wide 
range of disciplines, summarise the frameworks available in Phase 1 and to 
present the themes from these frameworks in Phase 2.  
5.2.2 Scoping review methodology 
As I have provided detailed information on scoping review methods in Chapter 4, 
in this chapter I present my methods without reference to published scoping 
review methods and guidance. 
1 - Identifying the research question 
My research question was ‘What reported steps are used to develop conceptual 
models in methodological frameworks, and is there enough commonality in these 
steps to combine them into a single methodological framework for developing 
conceptual models in economic evaluation?’     
2 - Identifying relevant studies  
Following scoping review guidance I conducted an initial search to gain an 
overview of the conceptual modelling methodological frameworks, then the 
results of the initial search were used to inform and guide the main literature 
search (149).    
The initial search comprised a general search using Web of Science and the 
Google search engine.  Search terms were kept simple; ‘conceptual model*’ and 
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‘framework’ OR ‘method’ in the Web of Science search and ‘steps for developing 
a conceptual model’ in the Google search. 
Published peer-reviewed and grey literature were found; grey literature included 
government guidelines and charity websites.   
Disciplines identified in the search included; operations research, database 
management, software design, ontology, ecology, engineering, space missions, 
healthcare and military/defence.  The methodological frameworks from 
database management, software design, ontology and space missions primarily 
focussed on the software used in the model at the conceptual model phase, 
rather than the representation of a decision problem, so at this stage seemed 
less likely to be suitable to inform the proposed framework.    
Alongside methodological frameworks, records with no stepwise methodological 
framework, only methodology and were also identified, these mainly described 
the iterative process of developing a conceptual model and keeping the 
conceptual model simple.  Whilst these points are not considered discrete steps, 
as they relate to more than one step in a conceptual model process, they are 
important in the development of a conceptual model. 
The results of this initial search informed the main literature search in the 
following ways: 
• Grey literature was searched in addition to published peer-reviewed 
literature. 
• Only methodological frameworks with discrete steps/stages were 
included; whilst methodology only is useful, the aim of this thesis was to 
present a stepwise methodological framework, therefore papers 
containing only methodology were excluded from the search. 
• All disciplines were included in the search ensuring that no relevant 
frameworks were omitted, however, special attention was given to any 
methodological frameworks identified from the fields of database 
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management, software design, ontology and space missions as these were 
unlikely to be suitable for inclusion. 
The search strategy was developed with input from the College librarian, both 
for search terms and databases.  The search terms were simple and not 
restrictive, and only titles were included rather than abstracts to ensure that 
the search terms were the main focus of the article or paper (search terms are 
included in Appendix 5: Scoping review search terms (Chapter 5)). 
The Web of Science database was purposefully searched to identify conceptual 
modelling methodological frameworks published in peer-reviewed academic 
articles.  The search took place in November 2016. An alert was set up for this 
search to identify relevant articles published after the search was carried out, I 
included the results of this alert in my search results up until October 2018.  A 
second search was undertaken in the Scopus database, Scopus is a larger 
database than Web of Science, and although there is overlap between the two 
databases it is considered good practice to search both databases.   
To ensure the search was as broad as possible in both database searches, there 
was no restriction on dates.  References and citations were examined to identify 
any further relevant methodological frameworks.  Where papers were not 
relevant (for example; not methodological frameworks but conceptual models of 
a specific subject), the methodology was scrutinised for any description of 
methodological frameworks used in the development of the specific conceptual 
model. 
Alongside these database searches, two grey literature searches were carried 
out to identify non-peer reviewed methodological frameworks. As mentioned 
previously, during the initial search it became apparent that there was a rich 
source of non-peer reviewed methodological frameworks that could add to this 
research and I did not want to exclude this potential source.  There is no gold 
standard for searching grey literature, however, research has found that using 




The two grey literature searches comprised an internet search and a search of 
the grey literature repository ‘OpenGrey’.  For the internet search, methods 
developed and presented by Godin for reviews of grey literature (156) were 
adopted.  The internet search was carried out using the ‘Google’ web browser, 
three search terms were used (‘conceptual model steps’, ‘conceptual model 
development’ and ‘conceptual model guide’).  OpenGrey is a grey literature 
repository with 700,000 pieces of grey literature produced in Europe. The types 
of grey literature include technical or research reports, doctoral dissertations, 
conference papers, official publications, and other types of grey literature.  The 
disciplines covered by OpenGrey include: science; technology; biomedical 
science; economics; social science, and humanities.  The OpenGrey search 
included two broad search terms (‘“conceptual model*” NEAR framework’ and 
‘“conceptual model*” NEAR methodology’). 
3 - Study selection 
The inclusion criteria were: 1) methodological frameworks with discrete steps 
only; 2) no restrictions on dates were included so that the search was as broad 
as possible; 3) only English records were included, and 4) I included all 
methodological frameworks whether or not they were intended for developing 
conceptual models that were planned to be used for further development to 
mathematical models.    
Duplicates were excluded, titles and abstracts were screened, and either 
discarded or kept and read in full.   
4 - Charting the data 
Excel was used to extract the following data from the included methodological 
frameworks: author/s; title; year; source and type of record (ie published 
article/government guidelines); discipline; rationale for developing the 
framework, and which search had identified the record. NVivo software was 
used to extract information on themes (NVivo qualitative data analysis software; 
QSR International Pty Ltd. Version 11, 2015).  Thematic analysis is recommended 
in scoping reviews (150) and this technique was used to extract data as there 
was no prior hypothesis to test; the themes needed to be extracted from the 
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frameworks in an inductive way to best summarise the evidence.  NVivo is 
compatible with thematic analysis (170); it is a data management tool useful for 
extracting themed data from a wide range of records.  NVivo is also useful for an 
iterative extraction process where themes are updated and developed as the 
literature is understood in more detail.  
5 - Collating, summarising and reporting the results 
The characteristics of the methodological frameworks were summarised 
narratively and in a table, and the rationales for developing the methodological 
framework were also presented, grouping the methodological frameworks into 
disciplines to highlight any commonalities within disciplines. 
The unit of analysis chosen for the thematic analysis was steps in the included 
methodological frameworks, these were coded and an iterative process was 
followed, as illustrated by the first four boxes in Jamieson’s diagram in Figure 
19, to allocate the units of analysis to the emerging themes (171). My rationale 
in choosing steps as a unit of analysis was that these are needed to answer the 
research question.  To avoid confusion with the stages in the proposed 
methodological framework these steps are called ‘themes’ in this chapter.  I 
went through three iterations of labelling emerging themes and allocating the 
units of analyses to these in a logical manner.  I present my results as both 
numerical and qualitative data. 
 
Figure 19: The process of qualitative data analysis from Jamieson (2016) (171) 
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5.2.3 Literature search - results 
Search results and selection of methodological frameworks 
Results of the search and selection are presented in Figure 20. 
 
Figure 20: PRISMA diagram of included methodological frameworks 
 
Records were identified from the Web of Science, Scopus, Google grey literature 
and Open Grey literature searches, and from searching the references and 
citations of included studies.  
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177 potential records were identified in the Web of Science search; articles, 
proceedings papers, meeting abstracts, book chapters, editorial materials, 
reviews and letters. A further 33 items were identified from the Web of Science 
alert.  253 potential records were identified in the Scopus search; articles, 
books, conference proceedings and reviews.  The Scopus search included 120 
items that had already been identified by Web of Science from a potential 253 
records, confirming that there is overlap between the two databases.   
The Google grey literature searches resulted in a total of approximately 
60,650,000 hits, Godin’s methodology was applied to reduce the number of 
potential records; 
• The ‘Conceptual model steps’ search resulted in approximately 
48,400,000 hits, I searched the first 10 pages, retrieving 99 potentially 
relevant records.  
• The ‘Conceptual model development’ search resulted in approximately 
7,780,000 hits, retrieving 99 potentially relevant records on the first 10 
pages.  
• The ‘Conceptual model guide’ search resulted in approximately 4,470,000 
hits, again retrieving 99 potentially relevant records on the first 10 pages. 
The OpenGrey literature search resulted in 81 potential records from the 
‘“conceptual model*” NEAR framework’ search and 10 from the ‘“conceptual 
model*” NEAR methodology’ search.  
In summary, 210 potential records were identified in the Web of Science search, 
253 from Scopus, 297 records were identified in the Google grey literature 
search and 91 from the OpenGrey literature search.  In total 851 potential 
records were identified from the literature search, and a further 8 from 
reviewing references and citations. 
Of the 859 potential records 129 were duplicates and discarded, after the titles 
and abstracts of the remaining records were scanned a further 663 records were 
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discarded. 67 records were screened in full for eligibility, 51 were excluded at 
this stage. 
In total 16 records (10 from the Web of Science search and 6 from the grey 
literature Google search) were identified as eligible to be included in the 
scoping review, these studies are reported in Appendix 6: Results of scoping 
review (Chapter 5). 
Methodological framework characteristics 
The included methodological frameworks came from the fields of ecology, 
engineering, operations research, healthcare, physics, manufacturing and 
construction. They dated from 2000 to 2017 and the types of records identified 
comprised: articles; conference proceedings; government guides; a charity 
guide, and a presentation, illustrating the broad origins of the methodological 
frameworks (Figure 21).  
 
Figure 21: Summary of framework characteristics 
 
In ecology the rationales for producing the methodological frameworks were 
either meeting statutory requirements, or the need for monitoring and risk 
assessments necessary in the discipline.  In engineering and operations research 
the rationales were mainly because of a lack of guidance, either in specific 
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methodologies such as discrete-event simulation, using soft systems 
methodology (SSM), or linking to engineering process.  In healthcare the 
rationales presented were mainly to increase the success of studies to inform 
change in healthcare. The rationale behind the physics methodological 
framework was to improve the quality and relevance of the simulation study, 
similarly in manufacturing the aim of the methodological framework was to use 
SSM to improve the simulation study.  The construction methodological 
framework rationale was that having a methodological framework to develop 
conceptual models reduces the burden of producing a conceptual model, which 
is believed to be a complex task, and having the conceptual model would 
increase the acceptance of discrete event simulation in the construction 
industry. 
In summary, reported rationales for developing the methodological frameworks 
can be split into three groups: first, to meet statutory requirements for risk 
assessments (15, 172) or to meet internal standards (14); second to produce 
guidance in areas where there is lack of methodology (18, 20, 21, 43, 173, 174), 
and third, to improve the conceptual modelling phase or quality of the 
conceptual model and therefore project outcomes or acceptance of modelling 
methods (12, 16, 175-177).  There were two papers with no rationale (19, 178) 
5.3 Methods: Phase 2 – Developing the methodological 
framework 
In the second phase the methodological frameworks identified in Phase 1 were 
analysed and built upon; key data was extracted from the identified evidence 
and amalgamated into common themes to inform and produce the draft 
methodological framework.  
5.3.1 Extraction of themes 
18 themes were identified from the 16 methodological frameworks.  Initially I 
extracted steps and allocated these to themes.  Allocating the steps to themes 
was an iterative process; as I read more papers and used NVivo to identify steps 
in the frameworks, it became clear that most methodological frameworks 
included similar themes, although sometimes different terminology in the steps 
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was used for the same theme. A summary of the different terminology allocated 
to each theme is included in Appendix 7: Terminology allocated to themes 
(Chapter 5).  
Themes identified in the included methodological frameworks are summarised 
with a count in Table 12, with the most frequently cited theme first. The 
descriptions of the steps and rationale for allocating the steps to each of the 
themes are summarised narratively.  These descriptions feed into the guidance 

















Table 12: Counts of themes in frameworks 
Summary of themes in frameworks (n = 16) Count (%) 















































































Whilst in most cases it was obvious which themes a step should be allocated to, 
where it was not clear I used the intended outcome of the step to guide the 
allocation. For example, ‘Understanding the problem’ overlaps with ‘System 
behaviour’, these steps have been allocated to separate themes based on the 
intended outcome or result of the step.  In ‘Understanding the problem’ the 
intention is for the modeller to get a good understanding of the problem 
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situation to lay the foundations of the conceptual model development and 
confirm that the modeller and stakeholders all have the same understanding 
from their different viewpoints. ‘System behaviour’ is how the entities within 
the system interact and the intention of this theme is to contribute to the 
development of the body of the conceptual model. 
Some methodological frameworks had more than one step in them that only 
related to one theme, in these cases the separate steps were amalgamated.  
Interpretation of the less clear, more discipline specific steps, was necessary to 
assign them to a relevant theme.  For example, the three ecology 
methodological frameworks; Brassington et al., Gross and Gentile et al. all have 
more than one step that relates to one theme, this is because ecology systems 
are complex with many components and stressors, so to develop an ecological 
conceptual model many elements need to be understood (15, 20, 172).  The 
Brassington framework has the following steps relating to the ‘model content’ 
theme; ‘defining the topography and surface water drainage’, ‘defining the 
geology’, ‘defining the aquifer framework and boundaries’, ‘defining 
groundwater flow directions’, ‘defining the aquifer relationships’ and ‘water 
balance’ (15).  Gentile has the following steps in the ‘stressors’ theme; 
‘Inventory resource use and other human activities’, ‘describe sources of natural 
and anthropogenic stressors’, ‘identify the primary and secondary stressors of 
concern’ and ‘describe stressor mechanisms and routes of exposure’ (172). 
Conversely, some methodological frameworks included more than one theme in 
a step, in these cases the steps were split into separate themes.  For example, 
in Brassington et al. the final step of ‘Description of model’ Brassington 
describes two themes; documenting the conceptual model and producing a 
diagram (15).  Robinson includes the themes ‘model scope’, ‘model content’, 
‘assumptions and simplification’ and ‘model detail’ in his step ‘defining the 







Objectives are linked to the project problem definition (44), examples include; 
identifying problems such as low productivity, long queues and bottlenecks, or 
checking the workings of new systems or modifications to old systems given (21). 
The objective should never be the development of the conceptual model (21, 
43).     
Rationales for including objectives in the methodological frameworks comprise; 
objectives are important in defining the ‘stressors, endpoints and management 
options’ relevant to the conceptual model and setting these objectives is 
essential because the conceptual model needs to relate to the research question 
(172).  Also, objectives are key; they drive the modelling process development 
and use of the conceptual model (43).   However, the relative importance of 
setting goals will vary depending on the audience (20).  Defining objectives also 
helps to manage stakeholders’ expectations of the model (12). 
Several methodological frameworks discussed two types of objectives; modelling 
and general objectives (12, 18, 43, 44).  Modelling objectives are specific to the 
conceptual model and project, for example limiting throughput times (43) and 
can be broken down into three components:  
1. Achievement: what the clients aim to achieve, such as increase 
throughput, reduce cost, improve understanding of the system, improve 
efficiency of resources. 
2. Performance: quantifying performance, such as increasing throughput by 
10% or reducing cost by £10,000. 
3. Constraints: constraints on the modeller, such as budget, design options. 
Modelling objectives may also change and develop, emphasising the iterative 
nature of conceptual modelling (43).   
General objectives are requirements of the conceptual model linked to the 
nature of the project, examples include run-time, development time of the 
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conceptual model, visualisation requirements or re-usability of the conceptual 
model, with ‘time-scale’ described as especially important (43).  These will 
likely be determined by the project.  General objectives add to the modelling 
objectives and include; visualisation, interaction, flexibility, reuse and project 
time frame (44).  
Model scope 
The scope defines the ‘extent’ of the project, an example being a 
manufacturing system where only certain parts of a process are included (21).  
Deciding on the conceptual model scope can be described as ‘bounding the 
decision problem’; choosing what is to be included in and excluded from the 
conceptual model (12), and what is outside the scope of the project (172). 
Model content 
There was only one description of conceptual model content; defining 
components of the conceptual model (15).  
System behaviour 
System behaviour relates to the components of the system, how these are linked 
(20), and the rules that control the conditional behaviour of the system (12).  An 
example is how endpoints are linked to physical characteristics and stressors; 
developing hypotheses for explaining how human influences in the South Florida 
ecosystems are responsible for the deterioration of the ecosystems (172).  
Understanding the problem 
This theme relates to understanding the subject matter (44), however no 
descriptions were reported in the methodological frameworks.  
Several methodological frameworks included a rationale; to develop a ‘sound’ 
conceptual model the system should be fully understood both as a whole and in 
individual sub-sections (13).  Furthermore, the more complete and clear a 
problem area is the easier it is to understand (176) and this stage is important 
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because it lays the foundation of the study (175). Robinson states that the need 
for a simulation model should always be ‘driven’ by attempting to improve the 
problem situation. Therefore, the starting point for developing a conceptual 
model should be understanding the problem situation, however, problems can 
occur when stakeholders hold different views of the problem situation.   
Model inputs 
Inputs are the information to be entered into the conceptual model (21), that 
can change in different scenarios (18).  For example, in the Furian et al. port 
problem case study, inputs denote the number of berths.  Furian et al. explain 
that in healthcare input factors may not represent single measures, but policies, 
the example given is dispatching orderlies in a hospital where different policies 
include; dispatch the closest orderly, dispatch the orderly who could get to the 
task first, or use an algorithm to dispatch orderlies.  Other examples of inputs 
are machines, work posts, reception areas, as well as individuals who work in 
these locations.  The project objectives will affect how these inputs are assessed 
(13). 
Conceptual model inputs (or experimental factors) can be either quantitative or 
qualitative (12).  For example, quantitative inputs include the number of staff or 
speed of service, whereas qualitative inputs include changes to rules or the 
structure of the model (43).  Overall, clients will have control over the inputs 
(for example staff numbers), however, it can be useful to vary the inputs with 
little control over them, which can help with understanding the system or help 
plan for future happenings.  
Documentation 
Documentation is a written description of the conceptual model (15), there are 
few descriptions or rationales of this theme. 
Model outputs 
Outputs are functions of ‘targeted performance measurements’, examples of 
which are; throughput, average time waiting and picker utilisations (21).  
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Outputs (or responses) can be either be numerical (for example means) or 
streamed data (for example time series) (18).  An example of outputs from the 
Furian et al. port case study is throughput times of tanker and container ships.  
An output is usually the output from the project system’s transformation 
process, for example a patient who needs treatment becomes a treated patient.  
The purpose of the output is to assess whether the objectives of the model are 
met, and if they are not met, why not (12, 13, 43). 
There are two categories of outputs.  The first type are linked to conceptual 
model objectives; performance measures. The second type are outputs helping 
to locate bottlenecks in the system, for example, flow time performance might 
be explained by waiting times (44).  
Diagram 
A diagram visually links the process and components (172). The rationales for 
including a diagram are; the process of visualising the conceptual model 
enhances the thought process of developing the conceptual model (16), it can be 
useful for validation and assessing relevance (44), and it can also be used as a 
communication tool (13). 
Assumptions and simplifications  
Assumptions and simplifications ‘define’ the conceptual model scope and detail 
(12). They ‘are a facet of limited knowledge or presumptions’ (21), a result of 
uncertainty about the real world situation (43), and the more assumptions made 
in developing the conceptual model the less detail is included in the conceptual 
model (21). ‘Simplifications are a facet of the desire to create simple models’ 
(21), and are made to make the conceptual model quicker to develop and use 
(43).   
Model detail 
The level of detail is the depth that the conceptual model goes into, this is 
subtle, for example ‘manufacturing process equipment’ might be included in the 
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model, but this may only be the total processing time of that equipment(21).  
Deciding on the conceptual model detail includes basic choices about whether a 
system is represented at a higher, more broader level, or whether the modeller 
drills down into sub-sections to include the level of detail required(176). 
Validation 
Validation is ‘determining that the theories and assumptions underlying the 
conceptual model are correct and that the model representation of the problem 
entity is ‘reasonable’ for the intended purpose of the model’ (13).  
The rationale for including this theme is that whilst the conceptual model may 
appear completely rational from the modeller’s point of view, the modeller 
should view the conceptual model as a communication tool to engage with 
stakeholders in the project and confirm and agree on understanding.  These 
stakeholders will have different perspectives of the research problem to the 
modeller and should test the conceptual model to ensure it is making sense. 
Gray et al. explain that this step is ‘informal but important’.  Validation ensures 
there are no errors in the conceptual model (179).   
Entities 
Entities are the core elements of a discrete event simulation; there are two 
types of entity; active and passive (12, 18).  Active entities comprise resources 
and consumers, and other entities that can change their role.  For example, in 
the tugboat case study these would be tugboats and tankers.  Passive entities 
are not related to the flow of a system, they are fixed, for example a harbour 
waiting area or berthing area (18). 
Entities are components that can be identified as a ‘pressure, state or response’ 
to aid model construction (178).  
Pace’s rationale for including this theme is that entities (and processes) are 
needed to achieve the project objectives and link to the detail and scope of the 




Stressors are human activities and natural stressors that affect the ecosystem 
(172), for example ‘excessive hunting and illegal timber extraction’ (14).  
Review, revise and refine  
The review, revise and refine theme is testing the conceptual model for its 
usefulness and suitability (16).  The rationale behind including this theme is that 
all conceptual models are an ‘incomplete abstraction of reality’ and that most 
will require revision to ‘accommodate new observations, information or changing 
goals’ (20).  Also, when the original conceptual model is first developed it will 
be based on the best-available knowledge, and as this knowledge is updated the 
conceptual model should be reviewed (178). 
Model structure  
The conceptual model structure is characterised by the entities and their 
aggregation (18). There are no examples or rationales for this stage. 
Team identification 
There were no descriptions of ‘team identification’.  The rationale given for 
including this stage is that choosing a project team results in a successful 
beginning to the project and a ‘seamless execution’ of the project (175).   
Use previous conceptual model 
There was no description of this theme.  The rationale given was that previous 
conceptual models can be applied or adapted to the research problem in hand 
(16).   
 
5.3.2 Ordering, categorising and amalgamating themes; 
developing the framework iteratively 
In this section the 18 extracted themes were grouped and amalgamated as the 
draft methodological framework was iteratively developed. First the number of 
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themes in each included methodological framework and the sequence of those 
themes were summarised, then the sequence of the themes was assessed for 
common patterns, this enabled the themes to be categorised into broad phases.  
Similar themes within each phase were amalgamated into stages, and the 
descriptions and approaches used in the identified methodological frameworks 
were summarised into ‘how to’ advice in the draft methodological framework. 
Care was needed when the existing guidance related to mathematical model 
development, which is not an element of my methodological framework.  
Ordering of themes 
The number of themes extracted from each of the included methodological 
frameworks varied from three to eleven (Figure 22). Seven was the most 
frequent number of themes extracted (n=4), and the least frequent was ten 
(n=0).  
 
Figure 22: Histogram of number of themes in included methodological frameworks 
 
Figure 23 sets out the sequence of the themes reported in each of the included 
methodological frameworks in the order that they were presented and includes 
the total number of themes identified.  Themes highlighted in yellow represent 
where two or more themes were identified in one step within the framework, 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Once the themes were ordered a general pattern emerged, and the themes were 
categorised as three phases (Figure 24).  The first phase was understanding the 
problem and setting the conceptual model objectives.  The second phase was 
the content of the model; what was included and excluded and at what level of 
detail, and how the components of the conceptual model are related to each 
other.  The third phase was validating the completed conceptual model and 
documenting it.  Full details and explanations of the ordering and sequence of 
themes in each phase is available in Appendix 8: Ordering and sequence of 





Figure 24: Initial sequence of stages and phases 
 
The next step in developing the methodological framework was to combine 
similar themes within each phase into discrete stages. To do this I looked at the 
sequence of themes within each phase and the descriptions of the themes to 
inform the amalgamation of similar themes into stages. The extracted themes, 
stages, and phases are presented in Figure 25.  
In Phase I ‘Context’, the ‘Understanding the problem’, ‘Use previous conceptual 
models’ and ‘Identify the team’ themes are combined into an initial stage of 
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‘Understanding the problem’.  The ‘Setting objectives’ theme is also included in 
this phase as a separate stage. 
In Phase II ‘Development’, I grouped all themes except the scope and detail 
themes into an umbrella ‘Determine model content’ stage, the determine the 
scope and detail themes were left as separate stages.  Assumptions and 
simplifications are an important aspect of developing the conceptual model (and 
are also used in understanding the problem), but I do not consider them to be a 
distinct stage, rather an concept that is crucial to the successful development of 
a conceptual model. 
In Phase III ‘Finalising’, I combined the diagram and document themes into one 
‘Diagram and documentation’ stage, and combined the ‘Validation’ theme with 
the ‘Review, revise and refine’ theme; validation is similar to reviewing and fits 









The stages were populated with descriptions from the themes extracted from 
the included methodological frameworks to produce the draft methodological 
framework, I also supplemented the descriptions with economic evaluation 
specific descriptions to tailor it to developing conceptual models in economic 
evaluations. The draft methodological framework is presented in Appendix 10: 
Draft methodological framework.   
 
5.3.3 Framework diagram 
In this section the steps for developing the diagram for my methodological 
framework are described.  
After reading the included methodological frameworks it was clear that 
including a diagram would be beneficial for my methodological framework; it 
would serve as a useful tool for the modeller, enabling them to see at a glance 
the stages involved in developing a conceptual model without being bogged 
down in the written detail.  Also, a diagram is a useful tool for showing the flow 
of the stages in the methodological framework and the links between those 
stages without the need for wordy explanations in addition to the written 
description of the methodological framework. 
To design a clear and understandable diagram I first looked at the included 
methodological frameworks to see if a diagram was included; eight 
methodological frameworks included a diagram (12, 15, 18, 19, 43, 175, 177, 
180), these diagrams are presented in Appendix 9: Methodological framework 
diagrams from identified studies and early drafts of diagram to include in final 
methodological framework (Chapter 5), along with early versions of my diagram. 
Whilst the Abdelmegid et al. diagram (Figure A9.70) showed the forward linear 
direction through the stages it read more like a list and had no indication of the 
iterative nature of a methodological framework (12).  The diagrams in the Tako 
et al. (175) and Furian et al. (18) methodological frameworks (Figure A9.71 & 
Figure A9.72Figure A9.71) were simple and easy to understand and follow, 
showing the flow through the process but again there was no indication of the 
important iterative nature of the methodological framework.  The layout of the 
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Robinson (43) and Pace et al. (176) diagrams (Figure A9.73 & Figure A9.74) was 
simple and clear, showing the flow of the process but also the iterative nature of 
the methodological framework, however my draft proposed methodological 
framework had more steps than these and I was concerned that using a similar 
diagram would look cluttered and busy and would be too difficult to understand 
at a glance. Brassington et al. (15) and Hesch (19) included diagrams (Figure 
A9.75 & Figure A9.76) that were complicated to follow, these were similar to 
flow charts and suitable for the complexity of the methodological frameworks, 
but not suitable for the draft proposed methodological framework.  Finally, the 
circular nature of the Pereira et al. (177) diagram (Figure A9.77) indicated the 
flow of the process, but also illustrated the iterative nature of the 
methodological framework.   
I wanted a diagram that was not simply a list, but which would be an easy to 
understand visual guide to the modeller, showing the order of the stages and 
phases, and also illustrating the iterative process of developing a conceptual 
model.  I felt it was extremely important to produce a diagram that succinctly 
and correctly summarised the proposed methodological framework as it would 
be the part of the methodological framework that would be the most memorable 
for many users. 
Based on the Robinson and Pace et al. diagrams I developed two drafts of linear 
diagrams, these showed the linear progression through the methodological 
framework but not the iterative nature (Figure A9.78 & Figure A9.79). 
I also looked at the wider literature to explore different types of diagram, firstly 
investigating ‘waterfall models’.  Waterfall models were introduced in 1970 by 
Winston W Royce and are primarily used for software development but can used 
for any step-by-step process (181).  They are also known as ‘linear-sequential 
life cycle models’ and ‘process models’.  This led me to explore process flow 
diagrams, these are often used in chemical and process engineering to illustrate 
the layout of major pieces of equipment to carry out a specific process (182). 
Having looked at examples of waterfall model diagrams I considered that a 
waterfall diagram with the general downward flow of stages or tasks, but with 
the ability to revisit previous stages iteratively, may illustrate my proposed 
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framework well.  However, on consultation with colleagues, it became clear that 
the iterative nature of the framework was not well communicated using a 
waterfall diagram (Figure A9.80).  I decided that a circular diagram would 
illustrate the framework at a high level of detail, similar to the Pereira et al. 
diagram, an early draft version of the circular diagram is included in the (Figure 
A9.81).  The final diagram is presented in the final methodological framework in 
Section 5.5, Figure 30. 
5.4 Methods: Phase 3 – Evaluate and refine 
In Phase 3 the draft methodological framework developed in Phase 2 was 
evaluated by comparing it to existing health economic evaluation conceptual 
modelling guidance and assessing any gaps (22, 23, 25, 26); refinements were 
made to produce the final methodological framework. Suggested approaches for 
evaluating the methodological framework from Chapter 4 did not include 
comparing the draft methodological framework to current guidance, however 
this method was reported by Rivera et al (39). 
5.4.1 Comparison to economic evaluation methodology 
In this section I compare my draft methodological framework to published 
guidance on developing conceptual models in the field of economic evaluation. 
This process helped me assess my draft methodological framework within the 
field of economic evaluation. I identified what was similar and what was 
different between the guidelines and my draft methodological framework.  I also 
assessed whether the differences warranted a change in my draft proposed 
framework, particularly to translate guidance extracted from methodological 
framework in fields other than economic evaluation into economic evaluation 
specific guidance in my methodological framework, but without including 
guidance related to decision analytic modelling. All of these guidelines were 
presented in Section 1.2. 





Squires et al. (22) comprises four discrete steps and advice and it is also 
described as a methodological framework by the author; the other guidance are 
presented as guidelines (23, 25, 26).  Tappenden’s guidance describes three 
broad steps, and the Roberts et al. guide and Chilcott research contains 
guidance rather than sequential steps.  These latter guidelines were harder to 
compare to my draft proposed framework as they do not comprise discrete 
steps.  
The four steps in the Squires framework are illustrated in Figure 26, they are: 1) 
‘Aligning the framework with the decision making process’; 2) ‘Identifying 
relevant stakeholder’; 3) ‘Understanding the problem’ and 4) ‘Developing and 
justifying the model structure’.  
The first step ‘Aligning the framework with the decision making process’ is not a 
step that was included in any of the methodological frameworks from the 
scoping review in Section 5.2.  The second step of ‘Identifying relevant 
stakeholders’ was included in two methodological frameworks from the scoping 
review, although it was implicit in many of the other methodological 
frameworks.  Whilst I do not include this step as a discrete stage in my draft 
methodological framework, I do include it in the first stage of my draft 
methodological framework: ‘Understanding the problem’.  The third step 
‘Understanding the problem’ is the first step in my draft methodological 
framework and was included in 50% of the methodological frameworks identified 
in the scoping review.   The Squires et al. final step of ‘Developing and justifying 
the model structure’ is analogous to my Phase 2 ‘Development of the conceptual 
model’.  Within the Squires et al. final step are several stages which I discuss in 




Figure 26: Squires framework diagram from Squires et al (2016) (22) 
 
Although Tappenden does not produce guidance with discrete steps (illustrated 
in Figure 27), he suggests starting the conceptual modelling process by 
developing a problem-oriented conceptual model; this helps the modeller to 
understand the decision problem and the system relating to that problem.  This 
is analogous to my first stage of ‘Understanding the problem’.  The second step 
in Tappenden’s advice is the development of a design-oriented model.  This type 
of conceptual model provides a platform to discuss and agree the structure of 




Figure 27: Hierarchy of models from Tappenden (2012) (23) 
 
This is mirrored in the Roberts et al. guidance in Figure 28; the paper is split into 
two components; conceptualising the problem and conceptualising the model.  
The authors state that understanding of the nature of the problem and the 
project objectives should be clear before developing a model. The rest of the 
guidance is set out as ‘best practices’, these will be compared to my guidance in 















Lastly, these stages are similar to the stages reported in the Chilcott paper 
(Figure 29): the first stage being ‘Understanding the decision problem’, and the 
second stage being ‘Conceptual modelling’ where the understanding from the 
first stage feeds into a decision analytic model.   
 
Figure 29: Model development process from Chilcott et al. (2010) (25)  
 
Best practise and guidance 
Next, the draft methodological framework was compared to the best practise 
and guidance included in the existing economic evaluation conceptual modelling 
guidance.  To do this I drilled down further into the guidance, breaking it down 
into component parts, these were not discrete steps followed in a linear or 
iterative way, but best practise, tips and guidance.  I have split the guidance 
into sections that follow the layout of the draft methodological framework. 
Before I present these comparisons, when reading through the existing guidance 
it became apparent that I needed to account for when a conceptual modelling 
process starts; does it begin with the research conception, or, in the case of a 
large trial or project where the economic evaluation is only one part, later in 
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the research process?  This is important because the point when the process 
starts dictates whether or not the conceptual modeller will decide on the 
research question, or whether it will have been decided at project conception, 
and the modeller ‘inherits’ the research question.  I have included determining 
the research question in Phase 1 in my draft methodological framework, but also 
made it clear that determining the research question is not always relevant.  I 
have included this in the final methodological framework in the ‘Understanding 
the problem’ stage. 
Phase 1 
Squires et al. suggests developing a conceptual model of the problem, bearing in 
mind causal links and current resource pathways.  Developing a conceptual 
model of the problem is implied in Tappenden with his suggestion of developing 
a problem-oriented conceptual model.  I haven’t specifically suggested this in 
my draft methodological framework, however, I do discuss the benefit of SSM 
techniques at this stage and creating a rich picture. I think that it would be very 
useful when understanding the problem and communicating this understanding 
with stakeholders to have a diagram to use as a communication tool and include 
this advice in the final methodological framework. Two of the papers identified 
in the scoping review, Gray and Robinson (16, 17), suggest using a conceptual 
model of the problem as a communication tool, indeed, even if the modeller 
does not consult with stakeholders to agree on their understanding of the 
problem, I still think setting out an understanding of the problem in a visual 
form would be beneficial. 
Squires et al. also recommend deciding on the research question and identifying 
sources of evidence in this phase.  I have discussed the research question in the 
section above. Using evidence to understand the problem is included in my draft 
methodological framework, however I do not suggest identifying the sources of 
this evidence, although it would be good practice to include this information in 
the document produced with the conceptual model. 
Squires et al. recommend examining existing health economics models, 
comparing structures, variables, results and identifying key variables that 
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influence the results; I include advice to examine previous conceptual models, 
but do not specify previous health economics models. 
Squires et al. recommend choosing interventions and comparators, whilst 
Roberts et al. state that the interventions should be clearly defined; I have 
assumed in my draft methodological framework that the intervention and 
comparators will have already been decided in the research question, and 
therefore will not need to be considered.  However, as discussed before, if the 
research question has not been decided, then choosing interventions and 
comparators is an important step in developing a conceptual model.  Roberts et 
al. also recommend identifying outcomes (which are linked to the research 
question), perspective (the outcome is consistent with the perspective), and 
population.  
Phase 2 
Squires et al. explain that the model boundary is different to the problem 
boundary, and that the following should be considered: population, subgroups, 
perspectives and outcomes.  Chilcott also recommends applying scope to the 
conceptual model.  Roberts et al. recommend that the scope and structure of 
the conceptual model should be consistent with and address the problem.  
Tappenden implies this stage by asking the modeller ‘is the breadth of the 
conceptual model complete?’  In my draft methodological framework my advice 
when deciding the scope is to ensure the research question is answered, I also 
recommend that the modeller considers the perspective and type of economic 
evaluation. 
Squires et al. and Chilcott recommend that the level of detail should be 
assessed, Squires et al. recommends assessing the impact of including more 
detail on results; the bigger the impact on the results, the more detail should be 
included.  
Tappenden recommends developing the structure of the problem-oriented 
conceptual model using clinical guidelines and health professionals, I 




Squires et al. recommends presenting a qualitative description of the conceptual 
model, in this guidance she doesn’t specifically mention a document, however, 
this is implied from the title of the guidance (‘Developing a qualitative 
description of the quantitative model’), and from the fact that she mentions 
documenting the conceptual model elsewhere in her guidance.  She adds that 
the conceptual model diagram is a communication tool.  Tappenden explains 
that the precise graphical approach taken in developing the diagram of the 
conceptual model is only important in that the diagram should be easily 
understood.  He adds that the diagram and accompanying text should use non-
technical language, and that key decisions should be clearly documented. 
Roberts et al. also recommend including a clear written statement of the 
decision problem, modelling problem and scope and ensuring that the policy 
context is clearly stated.  
Finally, Tappenden recommends including health professionals who were not 
involved in the development of the conceptual model to check their 
understanding of it and whether it is clear. Roberts et al. recommend consulting 
with experts and stakeholders to ensure that the model represents the disease 
process and addresses the decision problem. This advice is analogous to my 
‘Review, revise and refine’ stage in Phase 3. 
Roberts et al. also discuss the link between a simple model with the right level 
of complexity, I include this in my general advice section at the start of the 
framework. 
The existing economic evaluation conceptual modelling guidance also included 
guidance that was not relevant to my framework as it related solely to the 
development of a decision analytic model. This advice included:  
• Tappenden and Squires et al. explain that the conceptual model may need 
to be altered when developing the decision analytic model, as the process 
is iterative.   
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• Tappenden suggested assessing alternative model development choices to 
run through the model in order to assess each structure’s impact on the 
results.  Squires has a step in her framework to choose the model type, 
Roberts et al. add that several model types may be suitable; for simple 
problems (short time frame, or few outcomes), a decision tree may be 
appropriate; for problems involving a series of health states a transition 
state model would be appropriate, any interactions between individuals 
should be evaluated, resource constraints should be represented, and a 
combination of model types may be suitable for some problems.  
• Roberts et al. also recommend that the time horizon should be long 
enough to capture relevant differences in outcomes and that sensitivity 
analysis can be used to assess the impact of key uncertainties in the 
model structure. Finally, Roberts et al. explain that is it an explicit 













Summary of comparing published economic evaluation methodology with my 
draft methodological framework 
Table 13 summarises and compares which stages are in my draft methodological 
framework and are also included in the existing economic evaluation guidance.  
All of the stages in the draft methodological framework are included in two or 
more publications of the existing guidance.  The stages ‘Understanding the 
problem’ and ‘Determining the scope’ are included in my draft methodological 
framework and in all existing guidance. Therefore, five stages in the draft 
methodological framework are not in all of the publications of the existing 
guidance: ‘Setting objectives’, ‘Determine the detail’, ‘Determine the content’, 
‘Diagram and documentation’ and ‘Review, revise and refine’.  The 
methodological framework published by Squires et al. includes all but the 
‘Review, revise and refine’ stage in my draft methodological framework. 
Table 13: Summary of stages included in draft methodological framework and existing economic 











✓ ✓ ✓ ✓ ✓ 
Setting 
objectives 
✓ ✓ × ✓ × 
Determine 
scope 
✓ ✓ ✓ ✓ ✓ 
Determine 
detail 




















✓ × ✓ ✓ ✓ 
 
The main difference between the published economic evaluation guidance and 
my draft methodological framework was the purpose; the purpose of the 
published economic evaluation guidance was to recommend methods for the 
development of a conceptual model that aids the development and 
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implementation of a subsequent decision analytic model. Whereas the purpose 
of my draft methodological framework is to develop a conceptual model for the 
new role proposed in this thesis.   
The advice included in the existing economic evaluation guidance was more 
prescriptive and more focussed on economic evaluations and decision analytic 
models than the recommendations in my draft methodological framework.  I 
have taken some of this methodology and guidance and incorporated into my 
methodological framework to refine it.  Most of this additional guidance relates 
to the ‘Understanding the problem’ stage: patient representatives were added 
as suggested team members; developing a conceptual model of the bigger 
picture has been added; resource use has been emphasised; using clinical 
guidelines to gain understanding of the problem area and systems has been 
suggested, and questions to guide understanding the problem have been added. 
Additions in other stages of the methodological framework include: setting the 
scope to include components that are hypothesised to have an effect on the 
results; only including key assumptions in the document, and including specific 
aspects of understanding the problem (document stage). 
5.5 Results – Final methodological framework 
5.5.1  Introduction 
General advice 
This methodological framework is a guide to develop conceptual models for use 
in economic evaluations.  The methodological framework is not designed to be 
exhaustive or prescriptive, rather a guide to developing a conceptual model 
which should be applied to each study in a pragmatic way and tailored to each 
research problem.   Developing conceptual models is considered an ‘art rather 
than a science’ and each conceptual model will be different, dependant on the 
research problem and modeller. 
Because the research theme and question may be predefined (as is often the 
case in clinical trials), some aspects of the methodological framework may not 
be relevant to all circumstances. 
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How to use the methodological framework 
The methodological framework is based on two key concepts fundamental in 
developing all conceptual models: an iterative process and keeping the 
conceptual model simple. The modeller should iteratively revisit stages in the 
framework until the conceptual model is complete; each stage can be revisited 
at any time and from any stage. The conceptual model should be kept simple; it 
should contain enough detail to answer the research question, but not too much, 
otherwise it becomes unwieldy and contains unnecessary information.  Both 
concepts should be borne in mind by the modeller throughout the conceptual 
modelling process. 
The methodological framework is split into three phases; Context, Development 
and Finalising, within these phases are discrete stages making up the stepwise 
structure of the methodological framework, these are illustrated in Figure 30. 
The diagram depicts the methodological framework, in a clockwise direction 
(starting from ‘12 o’clock’), in three circles; the inner circle comprises the 
phases, the middle circle comprises the stages and the outermost circle presents 
an descriptive overview of each stage.  Each stage consists of a 
‘Recommendation’ and an ‘Explanation’; the Recommendation states an 
information request and rationale for each stage (except Stage 7), and the 
Explanation contains guidance for achieving the ‘Recommendation’. The output 
from the information request should be included in the conceptual model 
document. The modeller should work through the stages, revisiting previous 
stages iteratively when needed.  The outputs from this methodological 
framework are a conceptual model diagram and document depicting and 
explaining the conceptual model. Throughout the conceptual model 
development process the modeller will add information to the document, this is 





















5.5.2 Phase I - Context  
In this phase the modeller considers the context of the conceptual model, 
immersing themselves in the research problem, gaining an understanding of the 
problem system, assembling a project team, and setting the research question 
and objectives.  
Stage 1: Understanding the problem 
Recommendation 
The information request for this stage is a description of the research system, 
problem, project team and question.  The modeller should gain a good 
understanding of the bigger picture of the research problem, this involves 
looking at the wider systems and subject area in context to the research 
problem; without a sound understanding of the research problem it is not 
possible to develop an accurate conceptual model.  A diagram of the problem 
system is a useful communication tool at this stage to check understanding of 
the problem and to use during the development of the conceptual model. The 
project team should be identified during this stage if they have not been 
identified already and if the research question has not already been defined it 
should be determined during this stage.   
Explanation 
Gaining an understanding may require identifying patient pathways, patient 
behaviour or disease pathways and particular attention should be given to 
identifying possible categories of resource use.  Understanding can be taken 
from several sources: the literature, stakeholders, decision makers, experts, 
existing conceptual models, trial protocol (if relevant) and clinical guidelines.  
Questions useful to help the modeller understand the research problem are 
presented in Table 14.   
A specific element of soft systems methodology can be used in this stage to 
come to an understanding of the problem systems; developing a rich picture, 
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this is an informal, often hand drawn, diagram of the problem area, examples 
include the disease area or treatment pathway.  
The makeup of the project team will vary depending on the research problem 
and will typically comprise; the modeller, other health economists, clinicians 
with an expert knowledge of the disease area, patient representatives and study 
or trial team members (for example trial manager).  Whilst it is good practise for 
the project team to be involved at this stage, it may be practical to only include 
them at the later ‘Review, revise, refine’ stage.  However, if the project team 
are involved at this stage the project team and the modeller should come to a 
consensus on the research problem and question; the modeller can suggest 
alternative hypotheses to the project team at this stage to help reach an 
understanding of the research problem.  
The modeller will need to make assumptions when coming to an understanding 
of the problem; any key assumptions made in reaching this understanding should 
also be recorded in the conceptual modelling document.   
Table 14: Questions to help understanding the problem 
Questions to guide understanding the problem 
What is the problem? 
Why is it a problem? 
Who are the target population? 
What are the interventions and comparators to be included? 
What are the outcomes? 
What perspective will be taken? 
 
Stage 2: Setting objectives 
Recommendation 
The information request for this stage is a description of the objectives of the 
conceptual model; setting objectives is key in guiding the development of the 






There are two types of objectives to consider: modelling and project. 
The modelling objectives are closely linked to the research question and what 
the model should achieve, including the research problem outcomes. The 
outcomes may include hospital services and throughput, disease progression or 
patient behaviour.   
The project objectives relate to the resources available to the modeller; 
constraints on time and budget in the project, the modeller should ensure that 
the project objectives are realistic, and expectations are properly managed.    
The modeller should agree the objectives with the model team (if applicable) 
and record them in the conceptual model document. 
5.5.3 Phase 2 - Development  
In the second phase the modeller decides what to include and exclude in the 
model, which components best represent the research problem, the dynamics of 
these components and how they are linked.  During this phase the modeller 
should keep in mind the objectives set in Stage 2 and the project hypothesis, if 
there is one, to ensure the conceptual model is kept relevant. The development 
of the conceptual model will be an iterative process, with the modeller 
revisiting stages until it is complete. 
Stage 3: Determine the scope of the conceptual model 
Recommendation 
The information request for this stage is a description of the scope of the 
conceptual model. The scope bounds the research problem, limiting the 
conceptual model to the elements of the bigger picture needed to address the 





The modeller should see the ‘Understanding the problem’ stage as getting to 
know the ‘bigger picture’ of the problem; understanding the wider subject area 
that includes the research problem, whereas the ‘Determine the scope of the 
conceptual model’ stage is when the narrower scope of the conceptual model is 
considered.  The scope guides the development of the conceptual model, 
helping the modeller decide what should be included and excluded from the 
bigger picture to answer the research problem. 
When determining the scope, the modeller should consider the research 
question, project hypothesis (if there is one) and conceptual model objectives; 
only components important and relevant to these should be included.  The 
modeller should also consider which components may influence the results and 
include these, however, care should be taken not to make assumptions prior to 
the analysis.  If irrelevant components are included in the conceptual model it 
will become too complicated and unwieldy, creating ‘noise’, and making 
interpretation difficult.   
The modeller should consider resource use, the perspective taken for the costs 
and outcomes and the type of economic evaluation (cost-utility, cost-
effectiveness or cost-benefit), as all these considerations will determine the 
components to be included in the scope of the conceptual model.  
Each of the components identified as within the scope of the conceptual model 
should be assessed by evaluating the relevance of these components in 
answering the research question.   
The modeller and project team (if appropriate) should come to a consensus on 
the scope of the research problem and record this in the conceptual model 





Stage 4: Determine the detail of the conceptual model 
Recommendation 
The information request for this stage is a description of the detail of the 
conceptual model.  The detail determines how far the modeller will drill down 
into individual components of the conceptual model; depending on the 
objectives the detail may be high level, aggregated and simplified, or may 
include disaggregated levels of components.   
Explanation  
The modeller should determine the detail in relation to the research question, 
project hypothesis and conceptual model objectives.  The modeller should 
consider the components included in the conceptual model, including health 
events and resource use data needed to answer the research question and the 
detail needed to capture this.  For example, resource use may be amalgamated 
into one component or disaggregated into separate resource use categories such 
as treatment, resource directly related to disease area and other resource use. 
Like the ‘Determining the scope of the conceptual model’ stage above, the 
detail of each component should be assessed on their relevance in answering the 
research question. 
Stage 5: Determine the content of the conceptual model 
Recommendation 
The information request for this stage is a description of the trial mechanism, 
dynamics, and how the components in the conceptual model interact. This stage 
is arguably one of the most important and the most complicated in the 







The components within the scope of the conceptual model should be 
determined, along with how they interact or are linked to each other (system 
behaviour), these links can be causal or an association. Components are directly 
linked to the Scope and Detail stages and the decisions made in those stages will 
feed into this stage, they are also are closely linked to the research question and 
objectives. Components can either be passive (static) or active within the flow 
of the system, and can be classified into three groups; components which feed 
into the conceptual model (inputs), components in the body of the model 
illustrating the system behaviour, and components which are the product of the 
system behaviour (outputs). Model inputs are the components within the model 
which can be altered to represent different scenarios, examples include 
patients, health facilities and treatments.  Model outputs can be used to check 
that the objectives of the conceptual model have been reached, key model 
outputs are costs and health benefits; examples include an untreated patient 
becoming a treated patient, quality of life measures, clinical effects (such as 
strokes avoided or cancer cases detected), or patient behaviour such as increase 
in physical activity.  
The way in which the interventions alter, or are hypothesised to alter, the 
system behaviour should be established and included in the dynamics of the 
conceptual model.  The overall structure/layout of the model should be decided 
to best illustrate the trial process or system based on the research question and 
modelling objectives.  The model structure will be driven by the objectives and 
research problem, for example a simple patient pathway may be relevant, or 
disease progression.  When determining the model structure, the modeller 
should consider resource constraints and capturing relevant resource use 
categories and outcomes.  A conceptual model is a simplification of a real-world 
system, therefore assumptions and simplifications are important features of this 
stage; assumptions relate to limited knowledge of, or evidence of the research 
problem bigger picture.  The more assumptions made; the less detail included in 
the conceptual model.  Simplifications result from keeping the conceptual model 
straightforward and uncomplicated.   
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A description of the model content and assumptions and simplifications made to 
determine the model content, should be recorded in the conceptual model 
document, this section of the conceptual model document is key in explaining 
and describing the conceptual model, and particularly important for 
communicating with stakeholders. 
5.5.4 Phase 3 - Finalising 
In this phase of the methodological framework the conceptual model diagram 
and document are developed, then finalised with a ‘Review, revise, refine’ stage 
where the conceptual model is evaluated, and any new information is used to 
refine the existing conceptual model. 
  Stage 6: Diagram and documentation 
Recommendation 
The information request for this stage is the conceptual model diagram and an 
accompanying document containing background information on the research 
problem, and a description and explanation of the conceptual model.  The 
diagram should be a clear, accurate and relevant visual representation of the 
research problem, and as a communication tool should not leave the reader 
having to make assumptions.  The document, a non-jargon written description of 
the conceptual model, should help the reader to understand the model, and can 
be used as a communication tool, along with the diagram.   
Explanation 
The diagram should be clear and understandable, and it is likely that the 
modeller will need several iterations to develop it.  The diagram will show the 
components and how they interact and interconnect with each other, causally or 
otherwise.   If a rich picture has been used in the ‘Understanding the problem’ 
or ‘Determine the content of the model’ stages, it will be useful in developing 
the final conceptual model diagram. 
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The purpose of the document is to help the user to understand the model, it 
does not need to be extensive or overly comprehensive.  The document can act 
as a living document to the modeller and a short version focussing on the model 
content is helpful as a communication tool. Information recorded at each stage 
of the conceptual model development should be included in the document, this 
is summarised in Table 15, and key assumptions and simplifications made at each 
stage should be reported.   
The conceptual model diagram and document can be included in the Health 
















Table 15: Items included in the conceptual model document 
Conceptual modelling 
stage 
Output for diagram/document 
Understanding the 
problem 
Diagram of the problem system, with a 
written description of the research 
problem, problem system and the 
sources of evidence used in coming to 
this understanding 
Research question  
List key assumptions and simplifications 
made  
Setting objective Description of objective 
List key assumptions and simplifications 
made 
Determining the scope 
of the conceptual model 
Describe the scope of the conceptual 
model 
List key assumptions and simplifications 
made 
Determining the detail 
of the conceptual model 
Describe the detail of the conceptual 
model 
List key assumptions and simplifications 
made 
Determining the content 
of the conceptual model 
The model content (explanation of 
inputs/outputs, components and their 
relationships), and assumptions and 
simplifications made in developing the 
content of the conceptual model 
Diagram and 
documentation 
A diagram of the conceptual model, 
accompanied by a non-technical 
document 
Review, revise and 
refine 
Validation methods and update the 
diagram and document with any changes 
as a result of the validation 
 
Stage 7: Review, revise, refine 
Recommendations 
In this stage the conceptual model should be reviewed, seeking agreement and 
feedback on the conceptual model from the project team, this is an important 
step without which the conceptual model may not be accurate or useful.  Any 
suggested changes during this stage should be used to revise the model, 





The modeller and project team should check the conceptual model to ensure it 
accurately depicts and reflects the teams’ understanding of the research system 
and question, it is good practice to involve experts who were not involved in the 
development of the conceptual model in this stage. The conceptual model, and 
any assumptions and limitations made, should also be checked in terms of 
clinical accuracy, logic, presentation and ease of understanding.  Table 16 lists 
questions the modeller and project team can ask themselves during this stage to 
review the conceptual model. This is an iterative process where more than one 
version of the conceptual model is likely to be reviewed. 
Table 16: Validation questions for conceptual model 
Diagram: 
Is the diagram well defined, logical and transparent? 
Does the conceptual model reflect the research question and subject area 
system? 
Document: 
Is there a clear description of the research problem and question, including 
background information to help understand the problem? 
Is there a clear objective reported? 
Are the scope and detail considered relevant to the research question and 
objectives, and are they justified? 
Is there a clear and understandable explanation of the content of the 
conceptual model? 
Are the key assumptions and simplifications made explicit? 
Does the user need to make assumptions about the conceptual model to 
understand it? 
Are changes made to the conceptual model during the ‘Review, revise, refine’ 
stage recorded in the document? 
 
Any revisions made to the conceptual model after it is reviewed, should be 
reflected in the diagram and document. If new information comes to light after 
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the development of the conceptual model the conceptual model should be 
updated and refined if the new information is relevant. 
5.6 Discussion 
5.6.1 Overview 
From 859 potential records identified in the literature search, 16 frameworks 
were included in the scoping review results. These records were from seven 
different fields, and 18 themes were extracted from the records and used to 
inform the draft methodological framework. The sequence of the themes 
reported in the included frameworks was extracted to ascertain whether there 
were patterns or consistency in these sequences, by looking at this evidence it 
was established that the themes were split into three broad phases: 1) An initial 
phase where the modeller immersed themselves in evidence about the research 
problem, identifying the project team and setting objectives for the model and 
project; 2) a middle stage which considered the relevant components to include 
in order to answer the research question in the detail needed, and 3) the final 
stage included producing a diagram and document to represent the conceptual 
model, plus a stage to assess the conceptual model and revise it if necessary.  
I combined descriptions and recommendations from the stages identified in the 
included records in the development of the draft methodological framework.  I 
then added economic evaluation specific advice and compared the draft 
methodological framework with published guidance for developing conceptual 
models in economic evaluations. This comparison was difficult to undertake as 
some the existing guidance did not contain discrete stages, and some of the 
guidance was implied and only mentioned when discussing other aspects of the 
guidance. However, all stages included in my proposed framework were included 
in two or more of the existing guidance. Where gaps were identified refinements 
were made to the draft methodological framework if necessary, to produce the 
final methodological framework presented.   
Scoping review methodology was chosen for this literature review after 
considering and rejecting using a systematic review.  Systematic reviews are 
traditionally used to answer a specific question according to a rigid set of a 
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priori factors, they have narrow parameters, the quality of identified studies is 
assessed formally and there is detailed data extraction, with synthesised 
quantitative and qualitative data.  Whilst scoping reviews are often undertaken 
for ‘reconnaissance’ purposes to assess whether a full systematic review would 
be worthwhile, they can also be conducted as ‘exercises in and of themselves’ to 
summarise and present research results particularly where a research area is 
complex or has not been studied before and identify gaps in the research or 
recommend areas for future research (4).  Scoping reviews have a broader 
approach than systematic reviews, mapping literature and addressing broader 
research questions (4). The objective of a scoping review is to map key 
‘concepts that underpin a research area’ (5), assess the main types and sources 
of record available.  This requires a broad range of records, but not a great 
depth of analysis. Scoping reviews are designed to give an overview of the 
records in a research area, without assessing the quality of the records.  The 
objectives of a scoping review are a good match for the objectives of my 
literature review. The research question of the scoping review was ‘What 
reported steps are used to develop conceptual models in methodological 
frameworks, and is there enough commonality in these steps to combine them 
into a single methodological framework for developing conceptual models in 
economic evaluation?’  I found that although the included methodological 
frameworks came from different fields there were enough similarities in them 
that, when the themes (steps) were extracted, it was possible to combine them 
into a draft methodological framework.   
The overarching rationale of the identified frameworks was to fulfil an unmet 
need for a framework to guide the conceptual modeller in developing good 
quality and relevant conceptual models.  The rationale for this thesis is that 
there is a lack of guidance for developing conceptual models in the field of 
economic evaluation for the purpose of the proposed new role, this lack of 
guidance similar to the rationale reported in many of the included records.  
Despite the frameworks being heterogeneous in their origin and form; from 
seven diverse disciplines and five different types of publication, there was 
consistency in the steps included in them and I was able to allocate these steps 
to 18 different themes, with only one theme having one mention. Out of the 16 
186 
Chapter 5 
frameworks identified, six were identified in the Google search (two from the 
‘development’ search and four from the ‘steps’ search). This result suggests that 
whilst there is no gold standard for conducting an internet search in a literature 
review, it does produce relevant sources of evidence. 
Setting objectives was the most frequently reported theme, followed by scope, 
content, system behaviour, understanding the problem and inputs, all these 
themes were reported in 50% or more of the frameworks.  Amongst the least 
frequently mentioned themes were team identification, review, revise and 
refine, validation and diagram.  The lack of frequency of including a diagram as 
a step in a conceptual modelling framework was surprising as one of the top 
benefits mentioned for conceptual models is as a communication tool, and eight 
of the 16 identified methodological frameworks included a diagram. 
As far as I can ascertain, this is the first literature search completed for the 
purpose of identifying conceptual modelling frameworks in fields other than 
economic evaluation, with the aim of extracting data from those frameworks to 
inform a methodological framework for developing conceptual models in the 
field of economic evaluation.  Previously in Squires et al. , a literature search 
was completed to inform a conceptual model framework for public health 
economic evaluations, however this was limited to frameworks where the aim of 
the conceptual model was to develop a decision analytic model (22).  This 
search was also not restricted to stepwise methodological frameworks.  Squires 
et al. identified eight frameworks, two of which were included in my results 
above, the rest did not include a framework, only methodology. Furthermore, 
Squires et al. did not methodologically extract steps from a framework, they 
focussed on the methods discussed and amalgamated those. 
5.6.2 Strengths 
The strengths of my literature review were: I consulted with a qualitative 
researcher to identify suitable methodology for the purposes of the literature 
search; I followed scoping review methods; I applied methodological rigour even 
when there was scarce guidance for suitable methodology when conducting the 
internet engine literature search, and I consulted with a librarian over the 
search terms and sources to search.  I also followed the suggestions from 
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Chapter 4 to develop the methodological framework and evaluated it by 
comparing it to existing guidance. 
5.6.3 Limitations 
I needed a broad search for potential frameworks enabling me to identify them 
from different disciplines and from different sources. This involved using less 
established search techniques such as using an internet search engine. Whilst 
there is published methodology on this technique, it is not well established and 
there is little guidance on best practice and how to carry out and present these 
searches.   
I limited my search terms to ‘titles’, although this may have excluded some 
frameworks it was practical and by including four sources in my search I made 
the search as comprehensive as possible without it being unwieldy.   
A further limitation of the search was that specific terms for ‘logic model’ were 
not included, potentially decreasing the number of frameworks identified, and 
therefore the steps used in developing them.  Logic models are types of 
conceptual models, typically used in public health complex interventions, (183, 
184) and visually represent anticipated causal links between the intervention 
and outcomes.  They are recommended and encouraged for use in public health 
interventions (184, 185). Logic models are based on programme theory or theory 
of change, showing how the intervention works and in what population (183).  
Logic models can be simple or complex, with the simplest examples showing 
linear relationships between intervention, short-term, medium-term and long-
term outcomes (184). There is clear crossover between conceptual models and 
logic models, with logic models a specific type of conceptual model used in 
public health interventions.  Extracting the steps from the frameworks and 
amalgamating them into stages was an iterative process and interpretation was 
needed to decide on which stage was suitable for some steps that were 
ambiguous.  This made the research hard to reproduce as different researchers 
may have different interpretations.  However, there were not many ambiguous 
steps and I have been open about the names of the steps and where they were 




5.6.4 Further research 
The methodological framework needs further evaluation, which was outside the 
scope of this PhD, this could be a Delphi panel to come to a consensus on the 
content of the methodological framework, a focus group to discuss the 
methodological framework and suggest improvements and refinements, or with 
further case studies to validate it and suggest refinements. 
5.7 Summary 
This chapter used the suggestions for creating methodological frameworks 
described in Chapter 4 to develop a methodological framework for producing 
conceptual models in economic evaluation, fulfilling the second objective and 
producing the second output of the thesis. A scoping review identified 16 
existing methodological frameworks for developing conceptual models and the 
steps and approaches in these frameworks were extracted and synthesised to 
produce a draft methodological framework. The methodological frameworks 
identified in the scoping review were from seven different fields outwith 
economic evaluation, and although the purposes of the methodological 
frameworks differed 18 discrete themes were extracted with enough similar 
steps to produce the draft methodological framework.  This chapter 
demonstrates that it is possible to produce a methodological framework based 
on disciplines outwith economic evaluation.   
This draft methodological framework was compared to existing guidance for 
developing conceptual models in economic evaluation, the main difference was 
the purpose of the conceptual model, the comparison also highlighted gaps in 
the draft methodological framework which were filled when it was refined.   
The final methodological framework was presented and is the first to provide 
guidance for the development of conceptual models in economic evaluation that 
do not precede a decision analytic model.   
In the next chapter the methodological framework guidance is applied to the 
two case studies in this thesis, to develop conceptual models for use in the 
proposed new role.   
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framework to developing conceptual models 
6.1 Chapter overview 
In the previous chapter a methodological framework for developing conceptual 
models was introduced; the aim of this current chapter is to demonstrate the 
methodological framework by applying it to the thesis case studies, in 
illustrative examples, to develop two conceptual models, which are 
subsequently used to illustrate the new role in Chapter 7.  The demonstration of 
the methodological framework partly fulfils the second objective of the thesis. 
The layout of the chapter is as follows: Section 6.2 applies the methodological 
framework to the TWICS case study, Section 6.3 applies the methodological 
framework to the BeatIt case study, Section 6.4 discussion limitations and in 
Section 6.5 the chapter is summarised. 
6.2 Case study: application of the methodological 
framework - TWICS 
This section of the chapter describes applying the methodological framework to 
the TWICS case study which was introduced in Chapter 3. In sub-section 6.2.1 
the conceptual model development process is described, and the final iterations 
are presented.  The initial iterations of the conceptual model are presented in 
Appendix 11: Iterative development of TWICS case study conceptual model 
diagram (Chapter 6), and the output of diagram and documentation is presented 






6.2.1 Application of methodological framework 
This sub-section describes the development process step by step, presenting 
each stage separately, a reminder of the stages of the methodological 
framework the diagram is included in Figure 31. 
 
Figure 31: Methodological framework diagram 
 
Stage 1: Understand the problem  
The recommendation in this stage is to describe the relevant components of the 
decision problem, these include understanding the context of the research 
system and the problem.  Other aspects of this stage include developing a rich 
picture, determining the project team and defining the research question.   
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To understand the research problem the questions presented in Table 14 
(Chapter 5) were considered and answered in the conceptual modelling 
document.  Evidence was taken from the TWICS protocol (111), and published 
literature. 
The next step was to develop a rich picture of the disease area to help 
understand the disease area; a rich picture is an informal diagram of the 
problem area.  To do this I took my understanding of COPD from the questions 
above, and from existing diagrams depicting COPD and disease progression.  
Disease progression is illustrated by Hoogendoorn et al. in Figure 32 (186). 
 










A diagram by Borg et al. (Figure 33) illustrates that exacerbations can occur 
during any stage of the disease, that COPD is progressive, and the severity of 
COPD increases as the number of exacerbations increase (187).    
 
 
Figure 33: A computer simulation model of the natural history and economic impact of COPD from 
Borg et al. 2004 (187) 
 
The rich picture is presented in the conceptual model document in Figure 42. 
Finally, in this stage the research question for the conceptual model was defined 
and the team determined. 
Stage 2: Setting objectives 
The recommendation in this stage is to describe the objective of the conceptual 
model, this was closely linked to the research question.   
Stage 3 Determine scope of the conceptual model 
The recommendation in this stage is to describe the scope of the conceptual 
model.  In this stage I narrowed down the elements included in the rich picture 
relevant to the research question and objectives.  The trial mechanism did not 
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include any measure of disease severity so that was omitted; the inclusion and 
exclusion criteria of TWICS restricted participants to people with moderate or 
severe COPD and at a high risk of exacerbations requiring treatment, the aim of 
the trial was to assess the effect of theophylline on the number of exacerbations 
requiring treatment in this population.  The scope was also driven by the data 
available from TWICS. 
Stage 4 Determine the detail of the conceptual model 
The recommendation in this stage is to determine the level of detail of the 
conceptual model. This was driven by the objectives and available data from the 
TWICS clinical trial. 
 
Stage 5 Determine the content of the conceptual model 
The recommendation of this stage is to describe the trial mechanism and how 
the key components of the mechanism interact.   
The iterative nature of deciding components, system behaviour, structure and 
applying assumptions and simplifications was experienced in developing the 
conceptual model content and diagram and the initial interactions are described 
0, the conceptual models developed at each iterative stage are also included.  
The final conceptual models were based on the disaggregated cost-effectiveness 
template presented in Figure 3; first a full conceptual model was built up to 
comprise all components in the template, then the components not considered 
as important for the conceptual model driven analysis were dropped from this 
interim conceptual model to produce the final conceptual model.  Each step of 
the conceptual model content and diagram development is illustrated and 
explained in the following paragraphs, the final diagram and document is 
presented in the ‘Stage 6: Diagram and document’ section. 
Components included in the model comprise: Model input of treatment arm; 
model outputs are closely linked to the research question and hypothesis as 
suggested – treatment and non-treatment costs and quality of life as measured 
by QALYs. Exacerbations act as a mediator linking the inputs and outputs. 
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The first step was to develop a conceptual model of COPD, this simplified the 
disease and included key components of: symptoms, lung capacity, exercise 
capacity and exacerbations (Figure 34), a combination of these components 
predict survival.  The associations between these components are represented 
by arrows: COPD symptoms experienced by the patient with COPD predict lung 
and exercise capacity, and exacerbations, these three components in turn 
predict survival.  Lung capacity predicts survival and exacerbations, with a 
backward association of exacerbations predicting lung capacity (exacerbations 
worsen a patient’s lung capacity). Exercise capacity predicts survival and 
exacerbations. 
 








The next step was to include healthcare costs related to COPD (Figure 35), two 
categories of healthcare costs are added; costs associated directly to COPD that 
result from disease severity and COPD related health events, and costs 
associated with improved survival.  
 











Then health benefits in terms of health-related quality of life relating to COPD 
were added (Figure 36). The grey health-related quality of life utility panel 
represents the step in calculating QALYs where clinical events are measured 
using utilities. Clinical events are expected to result from the two elements of 
the disease area: symptoms, lung capacity, exercise capacity and exacerbations, 
and survival. The yellow ‘Health benefits’ panel represents utilities translated 
into QALYs.  
 











The next step is to layer in a generic treatment to include the treatment effects 
consistent with the disaggregated cost-effectiveness template (Figure 37). 
Layering in the generic treatment (and comparator) illustrates the incremental 
analysis of costs and health benefits; all cost and health benefit components are 
now incremental. In the ‘Disease Area’ panel a new red section is added with 
two components: the generic treatment itself and side effects resulting from the 
treatment.  These components are associated with costs and health benefits: 
potential costs are those associated with treatment side effects and those 
directly linked to treatment, and health benefits are the quality of life lost as a 
result of treatment side effects. 
 








Once generic treatment effects are included in the conceptual model the cost-
effectiveness can be illustrated (Figure 38).  This is depicted in the bottom row 
of the diagram where all cost components are summarised in ‘Net incremental 
costs’ and all health benefits are summarised in ‘Net incremental quality 
adjusted life-years’.  These summary components feed into the economic 
evaluation summary measure of cost per quality adjusted life-year (the ICER).  
This diagram in the conceptual model building process depicts a full economic 
evaluation.  The next step is to adapt it to TWICS, replacing the generic 
treatment with theophylline and taking out unnecessary elements that are not 
expected to effect or be relevant to theophylline and TWICS.  
 








The next step of applying TWICS to the COPD generic treatment conceptual 
model is depicted in Figure 39. This diagram is a copy of the COPD cost-
effectiveness conceptual model with components ‘crossed out’ that are not 
relevant to the treatment effect of theophylline.  The assumptions made in 
developing this step were not made with clinical input and are an illustrative 
example. First, treatment side effects were not expected to feature in TWICS as 
low dose theophylline has not shown the same side effects of high doses of 
theophylline. Removing treatment side effects from the conceptual model 
central disease area also led to removal of potential costs associated with 
treatment side effects and losses of health benefits associated with treatment 
side effects.  Disease severity was not measured in TWICS, nor included in the 
expectation of effects of theophylline on exacerbations, therefore ‘disease 
severity’ was removed from both costs and health benefits.  The TWICS clinical 
trial did not measure survival as an outcome and theophylline was not expected 
to directly affect survival, furthermore, survival was not expected to be a factor 
bearing in mind the one-year follow-up period, therefore survival was also 
removed from the COPD generic treatment conceptual model.  Removing 
survival from the conceptual model central disease area also led to removal of 
potential costs associated with improved survival and potential health benefits 
associated with improved survival. Finally, COPD symptoms and lung and 
exercise capacity were removed from the conceptual model.  These ‘Disease 
Area’ components were removed because the expected trial mechanism was 
that theophylline changes biological processes in the participant allowing 
inhaled corticosteroids to reduce numbers of exacerbations, it was not 
anticipated that theophylline would directly affect COPD symptoms, and lung 




Figure 39: COPD conceptual model building - applying theophylline 













Once the unnecessary components were removed from the COPD conceptual 
model the key components left were those expected to be important in the 
TWICS economic evaluation (Figure 40).  This conceptual model was a simplified 
illustration of the key components of the TWICS economic evaluation, the last 
step was to remove the conventional cost-effectiveness components of net 
incremental costs, net incremental quality adjusted life-years and cost per 
quality adjusted life-years necessary to conduct an economic evaluation, leaving 
the trial mechanism and key cost and health benefit components needed to 
conclude the development of the conceptual model and enable its application in 
a new role to conduct a conceptual model driven analysis.  A final conceptual 
model was developed from this diagram and is presented in sub-section 6.2.2.   
 
Figure 40: TWICS conceptual model building - economic evaluation 
 
Stage 6 Diagram and document 
The final TWICS conceptual model diagram and document are presented in sub-
section 6.2.2, the process of applying the methodological framework to the 
TWICS case study has been described above and further iterations of the 
conceptual model are included in Appendix 11: Iterative development of TWICS 




Stage 7 Review, revise and refine 
The earliest iterations of the conceptual model presented in Appendix 11: 
Iterative development of TWICS case study conceptual model diagram (Chapter 
6) were developed with input from the TWICS Chief Investigator and Senior 
Health Economist, Figure A11.94 was presented to TWICS investigators to get 
feedback on its accuracy, understandability and usefulness. This feedback was 
positive, with comments that it was useful and understandable.  Whilst 
presenting the conceptual model it was apparent that removing the lines from 
patient to data (quality of life and health resource use) and ‘treatment’ to 
‘health resource use’ did not correctly represent the links between patients and 
data, it made the conceptual model too simplified, these lines were added back 
in.  The description of ‘Data’ in the third column was changed back to 
‘Measures’ as this is a better description of the components in this column 













6.2.2 Final TWICS conceptual model 
This sub-section presents the final TWICS conceptual model and accompanying 
document. 
Diagram 
The final TWICS conceptual model diagram is a simplified representation of the 
TWICS trial mechanism and how it links the key components of the cost and 
health benefits (Figure 41).  
 




Chronic obstructive pulmonary disease (COPD) is a progressive lung disease 
associated with breathlessness on exertion, lung function, disability, absence 
from work, morbidity, early retirement, and premature death. The main cause 
of COPD is smoking and most cases are diagnosed from the age of 50 onwards.  
Exacerbations are a key feature of COPD; symptoms include breathlessness, 
coughing, and expelling mucus.  Annually around 15% of COPD patients 
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experience an exacerbation needing hospitalisation, and 12% of those COPD 
patients who are hospitalised will die within a year of hospitalisation (116).  
Exacerbations are linked with increased decline in lung function, reduced 
physical activity, lower quality of life and increased mortality (115). Mortality 
can also be predicted using the BODE index which includes Body-mass index, 
airflow Obstruction, Dyspnea (difficult or laboured breathing) and Exercise 
capacity (188). Patients are classified for treatment using a combination of 
symptom severity and exacerbation based on the Global initiative for chronic 
Obstructive Lung Disease (GOLD) assessment tool (189). 
It is predicted that in 2030 COPD will be the third leading cause of death 
globally, compared to the fifth leading cause of death in 2002 (112). The burden 
in the UK is high; in 2012 there were almost 1 million diagnosed cases of COPD, 
and COPD accounted for 5-6% of all deaths, financially COPD costs the NHS about 
£1 billion per year (111) and exacerbations account for 60% of the direct costs of 
COPD to the NHS (190). 
The effects of the exacerbations are: increased mortality, decreased lung 
function, decrease in quality of life, an increased risk of hospitalisation, 
accelerated lung function decline and an increase in symptoms related to COPD.  
Current COPD treatment includes inhaled corticosteroids, combined with inhaled 
long-acting β2 agonists, however patients still have exacerbations despite 
treatment (111).  Oral theophylline has also been used to reduce exacerbations, 
but the high doses involved cause unpleasant side effects which has led to 
treatment with other, better tolerated bronchodilators.  However, recent 
preclinical trials indicate that a low dose of oral theophylline is beneficial in 






A novel rich picture depicting the factors predicting a person’s severity of COPD 
and risk of death is presented in Figure 42.   
 
Figure 42: COPD rich picture 
 
The target population were adults aged 40 or above with a diagnosis of COPD 
and who are likely to exacerbate during the 12 months follow-up of the trial, as 
evidenced by two or more exacerbations in the year prior to recruitment into 
the trial.  Other inclusion criteria include; smoking history of at least 10 pack 
years and no exacerbations in the 4 weeks prior to recruitment. Full details on 
inclusion and exclusion criteria are published elsewhere (111). 
The intervention was usual care plus 200mg or 400mg (dose was dependant on 
ideal body weight and smoking status) theophylline for 52-weeks.  The 
comparator was usual care plus placebo.  
The primary outcome of TWICS was the number of exacerbations in the 52-week 
follow-up period of the clinical trial requiring treatment with antibiotics or oral 
corticosteroids. The health economic outcome was the quality adjusted life-
year, measured using the EQ-5D-3L questionnaire (74). The study type was a 
two-arm clinical trial. 
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The perspective taken in the economic evaluation was NHS direct healthcare 
costs and personal social services.   
The research question was ‘what are the trial mechanism and key economic 
components relevant to the TWICS economic evaluation?’ 
The conceptual modelling team comprised three people: a junior and a senior 
health economist and a medical consultant with expertise on COPD. 
Objectives 
The modelling objective was to simplify and represent the key components 
driving the economic evaluation of TWICS.  The conceptual model would be used 
as a communication tool, to test the logic of the associations represented in it, 
and to conduct an analysis based on these associations. 
Scope 
The scope was restricted to the key economic components of TWICS: treatment 
arm, treatment cost, exacerbations (as theophylline was expected to decrease 
the number of exacerbations experienced), non-treatment cost and quality of 
life.  The treatment and non-treatment costs were presented separately as the 
original economic evaluation showed that treatment costs were precise, whereas 
non-treatment costs were uncertain. 
Detail  
The detail of the model was at aggregate level for treatment, exacerbations, 
and quality adjusted life-years. Costs were disaggregated into treatment and 
non-treatment costs. 
Model contents 
The conceptual model is split into three sections: inputs (red); mediators 
(purple), and outcomes (blue).  Components in each section are represented by 
rectangles in the same colour.  Expected associations between components are 
represented by arrows; solid lines represent assumed associations, and dashed 
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lines represent possible associations.  Components with lines leaving from the 
right are explanatory variables; the component to which their arrow enters is 
predicted by them, for example treatment arm predicts treatment costs and 
exacerbations.  All components in the ‘inputs’ section are explanatory. 
Components with arrow heads entering on the left are dependant variables; they 
are predicted by the components from which the arrow originates.  For example, 
treatment costs are predicted by the treatment arm. All components in the 
‘outcomes’ section are dependent variables. A component can be both 
explanatory and dependent, mediating components are both explanatory and 
dependant; they have arrows entering and leaving.  For example, exacerbations 
are predicted by the treatment arm and also predict quality of life and non-
treatment costs.  
Assumed associations (solid lines) - Participants are randomised to one of two 
treatment arms: either theophylline or placebo.  The hypothesis of the clinical 
trial was that there would be less exacerbations needing treatment in the 
theophylline arm (association 2) due to chemical factors specific to theophylline. 
Exacerbations are expected to predict quality of life; participants experiencing 
lower numbers of exacerbations would report higher levels of quality of life 
(association 3), conversely participants experiencing higher numbers of 
exacerbations were expected to report lower levels of quality of life. Treatment 
costs are expected to be higher in the theophylline arm (association 1) due to 
zero costs for the placebo treatment. The number of exacerbations experienced 
are expected to predict non-treatment costs (association 4), most likely in the 
costs of treating exacerbations but also, if the severity of a participant’s COPD 
progresses, for non-exacerbation related healthcare costs.  
Possible associations (dashed line) – It is possible that the treatment arm the 
participant is randomised to can directly influence quality of life not mediated 
through exacerbations (association 3). There is a possibility that non-treatment 
costs (association 4) may be directly affected by the allocated treatment arm.  
These possible associations are equivalent to the outcomes-driven ‘black box’ 




Assumptions and simplifications 
The overarching simplification was to base the conceptual model on the 
disaggregated cost-effectiveness template using disaggregated key economic 
evaluation components, and that there would not be any key components 
identified outside of this template. 
The disease area initially included four key components: symptoms, lung and 
exercise capacity, and exacerbations (Figure 34), this was further reduced to 
only include exacerbations as the assumption was that theophylline affects a 
patient’s biological mechanism, which in turn decreases exacerbations. There 
was no expectation that theophylline would directly affect symptoms, lung and 
exercise capacity. 
It was assumed that there would be no treatment side effects as preclinical 
trials did not witness any side effects of using low dose theophylline.  It was also 
assumed that survival would not be an aspect of the trial mechanism, due to the 
short (12-months) follow-up period, also, survival was not an outcome of the 
clinical trial. 
The key components of costs were assumed to split into treatment and non-
treatment, it was not expected that further sub-division of costs would be 
useful.   
Finally, it was assumed that all clinical events and factors of COPD would be 
picked up by the EQ-5D-3L questionnaire to give a measure of health benefits. 
Whilst this may be a strong assumption based on the generic nature of the EQ-5D 
questionnaire, research has found that the EQ-5D measure is a reliable and 
responsive measure of health-related quality of life in people with COPD (191, 
192). Furthermore, this is an illustrative example to show how a chosen 
economic outcome measure from the trial data would feed into the conceptual 
model, not a formal conceptual model driven analysis.   
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6.3 Case study: application of the methodological 
framework - BeatIt case study 
This section of the chapter describes applying the methodological framework to 
the BeatIt case study which was presented earlier in Chapter 3 Section 3.3. In 
sub-section 6.3.1 the conceptual model development process is described and 
the final iterations are presented, the initial iterations of the conceptual model 
are presented in Appendix 12: Iterative development of BeatIt case study 
conceptual model diagram (Chapter 6), and the output of diagram and 
documentation is presented in sub-section 6.3.2.   
6.3.1 Application of methodological framework 
This sub-section describes the development process, presenting each stage 
separately. 
Stage 1: Understand the problem  
The recommendation in this stage is to describe the relevant components of the 
decision problem, these include understanding the context of the research 
system and the problem.  Other aspects of this stage include developing a rich 
picture, determining the project team and defining the research question.   
To gain an understanding of the research problem the questions in Table 14 were 
considered, and answers were included in the conceptual modelling document.  
Information and evidence was taken from the BeatIt protocol (128) and 
published literature. 
Developing a rich picture  
The next step was to develop a rich picture of the disease area, an informal 
diagram of the problem area.  To do this I took my understanding of depression 





Depression is characterised by an initial episode of depression during which 
symptoms worsen in severity, followed by complete remission and recovery, or 
periods of relapse and recurrence, this is illustrated well in the following figures 
(Figure 43 and Figure 44). 
 
Figure 43: Recurrent depression from Darcet et al. 2016 (193) 
 
 
Figure 44: Response, remission, recovery, relapse, and recurrence of depression during treatment 
stages from “Preventing recurrent depression: long-term treatment for major depressive 
disorder.” (194) 
 
The rich picture is presented in the conceptual model document in 6.3.2. 
Finally, in this stage the research question for the conceptual model was defined 





Stage 2: Setting objectives 
The recommendation in this stage is to describe the objective of the conceptual 
model, this was linked to the research question. 
Stage 3 Determine scope of the conceptual model 
The recommendation in this stage is to describe the scope of the conceptual 
model.  In this stage I narrowed down the elements included in the rich picture 
relevant to the objectives and research question.  The trial mechanism did not 
include severity of depression so that was omitted.  Activity was not included in 
the rich picture but was expected to be an effect of the BeatIt therapy so was 
included in the conceptual model diagram. 
Stage 4 Determine the detail of the conceptual model 
The recommendation in this stage is to determine the level of detail of the 
conceptual model.  
 
Stage 5 Determine the content of the conceptual model 
The recommendation of this stage is to describe the trial mechanism and how 
the key components of the mechanism interact.   
The format and iterations of the BeatIt conceptual models follow the format and 
iterations of the final TWICS conceptual models, using the disaggregated cost-
effectiveness template (Figure 3) then following the steps already presented in 






The first step was to develop a conceptual model of the disease area, this was a 
simplification of the disease.  For depression to be diagnosed in a patient a 
number of symptoms have to be experienced over a specific period of time, 
symptoms vary between people and are complex.  To simplify the disease area 
symptoms were represented as social, physical and psychological (Figure 45). 
 











The next step was to include healthcare costs, two categories of healthcare 
costs are added; costs associated directly to depression that result from disease 
severity and related health events, and costs associated with improved survival 
(Figure 46).  
 












Then health benefits in terms of health-related quality of life relating to 
depression were added (Figure 47). The grey health-related quality of life utility 
panel is the step in calculating QALYs where clinical characteristics are 
measured using utilities. The yellow ‘Health benefits’ panel represents utilities 
translated into QALYs.  
 












The next step is to layer in a generic treatment to include the treatment effects 
consistent with the disaggregated cost-effectiveness template (Figure 48). 
Layering in the generic treatment (and comparator) illustrates the incremental 
analysis of costs and health benefits; all cost and health benefit components are 
now incremental. In the ‘Disease Area’ panel a new red section is added with 
two components: the generic treatment itself and side effects resulting from the 
treatment.  These components are associated with costs and health benefits: 
potential costs are those associated with treatment side effects and those 
directly linked to treatment, and health benefits are the quality of life lost as a 
result of treatment side effects. 
 









Once generic treatment effects are included in the conceptual model the cost-
effectiveness can be illustrated (Figure 49).  This is depicted in the bottom row 
of the diagram where all cost components are summarised in ‘Net incremental 
costs’ and all health benefits are summarised in ‘Net incremental quality 
adjusted life-years’.  These summary components feed into the economic 
evaluation summary measure of cost per quality adjusted life-year (ICER).  This 
diagram in the conceptual model building process depicts a full economic 
evaluation.  The next step is to adapt the conceptual model to BeatIt, replacing 
the generic treatment with BeatIt and taking out unnecessary elements that are 
not expected to effect or be relevant to BeatIt.  
 









The next step of applying the BeatIt therapy to the depression generic treatment 
conceptual model is depicted in two diagrams (Figure 50 and Figure 51). The 
assumptions made in developing this step were not made with clinical input and 
are an illustrative example. The first diagram is a copy of the depression cost-
effectiveness conceptual model with components ‘crossed out’ that are not 
relevant to the treatment effect of the BeatIt therapy.  First, treatment side 
effects were not expected to feature in BeatIt. Removing treatment side effects 
from the conceptual model central disease area removes potential costs 
associated with treatment side effects and losses of health benefits associated 
with treatment side effects.  The BeatIt clinical trial did not expect survival to 
be affected by the therapy, only depressive symptoms, therefore survival was 
also removed from the depression generic treatment conceptual model.  
Removing survival from the conceptual model central disease area also led to 
removal of potential costs associated with improved survival and potential 
health benefits associated with improved survival. The severity of depression is 
not pertinent to the BeatIt clinical trial so the ‘disease severity’ aspects of costs 
and health benefits were removed. Finally, the separate social, physical and 
psychological components of depressive symptoms were removed as BeatIt 
measured depression as a whole as a primary outcome.   
  
Figure 50: BeatIt conceptual model building - applying BeatIt 




Once the unnecessary components were removed from the BeatIt conceptual 
model the key components left were those expected to be important in the 
economic evaluation (Figure 51).  This conceptual model was a simplified 
illustration of the key components of the BeatIt economic evaluation, the last 
step was to remove the conventional cost-effectiveness components of net 
incremental costs, net incremental QALYs and cost per quality adjusted life-
years necessary to conduct an economic evaluation, leaving the trial mechanism 
and key cost and health benefit components needed to conclude the 
development of the conceptual model and enable its application in a new role to 
conduct a conceptual model driven analysis.  As the BeatIt therapy is based on 
behaviour change a component to represent the expected increase in activity 
was added to the final conceptual model, this was not relevant to add to the 
conceptual model as it developed as it did not relate to treatment or disease 
area. This final conceptual model is presented in sub-section 6.3.2.   
 
Figure 51: BeatIt conceptual model building - economic evaluation 
 
Stage 6 Diagram and document 
The final BeatIt conceptual model diagram and document are presented in sub-
section 06.3.2, the process of applying the methodological framework to the 
BeatIt case study has been described above and further iterations of the 
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conceptual model are included in Appendix 12: Iterative development of BeatIt 
case study conceptual model diagram (Chapter 6). 
Stage 7 Review, revise and refine 
The earliest iterations of the conceptual model presented in Appendix 12: 
Iterative development of BeatIt case study conceptual model diagram (Chapter 
6) were developed with input from the BeatIt Chief Investigator and Senior 
Health Economist.  However, due to time constraints the final conceptual model 
was not seen by the Chief Investigator. 
6.3.2 Final BeatIt conceptual model 
This sub-section presents the final BeatIt conceptual model and accompanying 
document. 
Diagram 
The final BeatIt conceptual model diagram is a simplified representation of the 
BeatIt trial mechanism and how it links the key components of the cost and 
health benefits (Figure 52).  
 






Depression is a common mental health issue, an episode may be mild, moderate 
or severe. During a mild episode the person will not cease to function but may 
struggle to work and take part in normal social activities, during a severe 
episode most activities will be limited (195). Symptoms includes low mood most 
of the day nearly every day, taking less interest or pleasure in usual activities, 
insomnia, fatigue, worthlessness, and lack of concentration (196).  Depression is 
the leading cause of suicide, and suicide and suicide attempts are 10 times as 
high in people with psychiatric diseases compared to the general population 
(197).  
Depression is highly prevalent in adults with intellectual disabilities, with a point 
prevalence of 5% (132).  Evidence suggests that depression is five times more 
common in adults with intellectual disabilities compared with the general 
population (133). 
 
Depression affects around 300 million people globally (129). The burden of 
depression includes costs of prescription and treatments, and time off work.  In 
2007 1.24 million people in England were estimated to have depression, with 
healthcare costs of £1.7 billion and £5.8 billion in lost earnings (130).  In 
2017/18 over 900,000 patients were prescribed at least on antidepressant drug 
in Scotland, and the cost of antidepressants was £44.8 million (131). 
Psychological therapies for treating depression in the general population are 
well established. However, approaches like cognitive behavioural therapy (CBT) 
are essentially talking therapies and their reliance on verbal communication 
makes them less accessible for many adults with intellectual disabilities (126).  
While research concerning the use of CBT for adults with intellectual disabilities 
and depression has been encouraging (134), behavioural activation therapy 
which is less reliant on verbal and cognitive skills and maybe more suited to 




Behavioural activation focuses on the link between mood and activity. It aims to 
increase participation in purposeful and motivating activities, bringing the 
individual into contact with positive experiences and helping to lift their mood 
(135).   Research in the general population with severe depression has shown 
that behavioural activation is as effective as antidepressant medication and 
more effective than CBT (136, 137), with the positive treatment effects shown 
to last as long as those for CBT (138).  Behavioural activation is also 
recommended in the NICE (2009) guidelines for the treatment of depression in 
the general population (139).   
 
The target population were adults with mild to moderate intellectual 
disabilities, a diagnosis of depression, and a carer willing to accompany the 
participant to therapy visits and follow-up visits.  Full inclusion and exclusion 
criteria are published elsewhere (128). 
The intervention was a behavioural activation therapy (BeatIt) delivered over 12 
sessions.  The comparator was a guided self-help therapy (StepUp) delivered 
over eight weeks. Both treatments were delivered one-to-one with the 
participant’s supporter present. 
The primary outcome of BeatIt was depressive symptoms measured by the 
Glasgow Depression Scale for Learning Disabilities (GDS-LD) at the 12-month 
follow-up period (141). The economic outcome was the quality adjusted life-
year measured by the EQ-5D-Y questionnaire, this questionnaire is specifically 
designed aimed at children and adolescents using simplified language, making it 
suitable for adults with intellectual disabilities (77). 
The perspective taken was NHS and personal social services, personal costs and 





The rich picture shows the key symptoms of depression, the potentially 
repetitive circular nature of the illness, plus an indication that there are 
different severities of depression (Figure 53).  
 
Figure 53: Depression rich picture 
 
The research question for the conceptual model driven analysis was: ‘what are 
the key components in the BeatIt economic evaluation and how are they related 
the trial mechanism?’ 
The conceptual modelling team comprised three people: me, a senior health 
economist who was also PI on the BeatIt study and the Chief Investigator on the 
BeatIt study. 
Objectives 
The objective was to develop a conceptual model to depict the trial mechanism 
of BeatIt, linking the key components of the economic evaluation in terms of 
inputs and outputs; this could be used as a communication tool, to test the logic 
of the conceptual model and to conduct further analysis based on the 
conceptual model.   
 
                    
                    
           
        
                    
      
                       
           
              
        
               
       
     
               
                   
                 
       
            




The primary outcome of BeatIt was depressive symptoms so these were included 
along with the key economic components of treatment arm, treatment cost, 
non-treatment cost and quality of life.  Activity was also included as the 
expectation of the behavioural activation was that it would increase 
participation in activities, which in turn would decrease depressive symptoms.  
The treatment and non-treatment costs were kept separate as we knew from the 
original economic evaluation that treatment costs were precise, whereas non-
treatment costs were uncertain. 
Detail 
Treatment allocation, the quality of life measure taken from EQ-5D-Y 
questionnaire, depressive symptoms taken from the GDS-LD and levels of activity 
were all at an aggregate level. Costs were disaggregated into costs of treatment 
and non-treatment costs. 
Model contents 
The BeatIt conceptual model is split into three sections; inputs (red), mediators 
(purple) and outcomes (blue); components in each of these sections are 
represented by rectangles in the same colour.  Expected associations between 
components are represented by arrows; solid lines represent assumed 
associations, and dashed lines represent possible associations.  Components with 
lines leaving from the right are explanatory variables; the component to which 
their arrow enters is predicted by them, for example treatment arm predicts 
treatment costs and exacerbations.  All components in the ‘input’ section are 
explanatory. Components with arrow heads entering on the left are dependant 
variables; they are predicted by the components from which the arrow 
originates, for example treatment costs are predicted by the treatment arm. All 
components in the ‘outcome’ section are dependent variable. A component can 
be both explanatory and dependent, mediating components are both 
explanatory and dependant; they have arrows entering and leaving, for example 
exacerbations are predicted by the treatment arm and also predict quality of 
life and non-treatment costs.  
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Once the expected links and associations are defined and the dynamics of the 
mechanism represented, each dependant variable is allocated a number, this 
makes describing the conceptual model clearer and easier for the user to follow, 
as well as identifying regressions for the next stage of the new approach.  
Assumed associations (solid lines) - Participants were randomised to one of two 
treatment arms: BeatIt or StepUp. In the clinical trial the hypothesis was that 
the BeatIt therapy increased the level of activities in the participants in the 
BeatIt arm (association 1).  Levels of activity would affect symptoms of 
depression (association 2) with participants reporting higher levels of activity 
expected to report fewer depressive symptoms (association 2), conversely 
participants reporting lower levels of activity were expected to also report more 
depressive symptoms.  The level of depressive symptoms reported were 
expected to directly impact quality of life (association 4), with participants 
reporting fewer depressive symptoms expected to also report better quality of 
life and vice versa. Treatment costs were expected to be higher in the BeatIt 
arm (association 3) due to more sessions included in the BeatIt therapy 
compared to the StepUp therapy. Levels of activity were expected to affect the 
non-treatment costs (association 5), with higher reported levels of activity 
increasing non-treatment costs, and healthcare use relating to depression was 
expected to be associated with non-treatment costs (association 5).   
Possible associations (dashed lines) – It is possible that the treatment arm that 
participants are randomised to will directly affect the levels of depressive 
symptoms, for example through the therapy itself improving depressive 
symptoms, not mediated through activity (association 2). There is also the 
possibility that treatment arm will affect quality of life directly, (association 4), 
and that treatment arm will also affect non-treatment costs directly (association 
5), neither of these possible associations would be mediated through activity and 
depression, similar to a ‘black box’ evaluation. There is a possibility that levels 
of activity are directly associated with quality of life without being mediated 
through depression (association 4), for example through the ‘usual activities’ or 




Assumptions and simplifications 
Whilst depression may be more enduring in people with intellectual disabilities it 
was assumed that the characteristics of the disease would be the same in this 
population as in the general population when developing the rich picture and 
disease area in the conceptual model.  
Symptoms are amalgamated as it was not possible to extract specific symptoms 
which predicted others.  
It was assumed that the link between the BeatIt therapy and depression is 
mediated by activity only. 
It was assumed that no treatment side effects would be experienced so costs 
and benefits relating to side effects were removed.  Severity of depression was 
not included, this was not an inclusion factor or measured as an outcome; the 
disease severity was removed from costs and health benefits.  Survival was not 
an outcome in the BeatIt clinical trial, or expected as an effect of the BeatIt 
therapy; it was removed from costs and health benefits. 
Finally, it was assumed that quality of life measured by the EQ-5D-Y would pick 
up the effects of depression measured in the GDS-LD. 
6.4 Limitations 
These conceptual models were illustrative in nature, and whilst this highlighted 
the key attributes of development, it was potentially at the cost of omitting 
some details.  Due to time pressures, it was not possible to confirm the 
appropriateness of the conceptual models with the clinical trial team.  However, 
early iterations of the conceptual models did have input from the trial teams, 
these are included in 0Appendix 11: Iterative development of TWICS case study 
conceptual model diagram (Chapter 6) and Appendix 12: Iterative development 
of BeatIt case study conceptual model diagram (Chapter 6). Although there was 
input into their initial development, there was not any expert input for their 
refinement. Furthermore, it is realistic to assume that, had the conceptual 
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model been developed in a pilot or feasibility study compared to later in a 




This chapter has demonstrated the application of the methodological framework 
presented in Chapter 5 to the two thesis case studies.  For each case study a 
step-by-step description of the application the methodological framework to the 
case study was included, and the final version of the conceptual model 
presented. 
The next paragraphs describe lessons learnt whilst applying the methodological 
framework.  The methodological framework was largely a useful guide to 
developing the conceptual models. The questions in Table 14 acted as a 
checklist to ensure that all aspects of understanding the problem were 
considered and to systematically guide the gathering of information for 
understanding the problem. The explanations in Stage 5 were very useful, 
guiding the consideration and identification of components and associations for 
the content of the conceptual model.  This guidance helped give a clear 
understanding of what should be included in the conceptual model and how the 
components of the model are related. Identifying the conceptual model key 
components based on the disaggregated cost-effectiveness template was very 
useful, helping to focus on what is important in an economic evaluation; first a 
conceptual model of the disease or behaviour expected in the trial mechanism 
was developed, this formed the centre panel of the conceptual model, a generic 
treatment was then layered into this trial mechanism which includes 
components related to treatment including costs and the expected effect of 
treatment (side effects and mortality), to replicate the disaggregated cost-
effectiveness template; layering in the treatment allowed the conceptual model 
to depict the incremental costs and effects expected in a conventional economic 
evaluation. This gave a generic conceptual model for the trial mechanism.  Once 
this was developed the generic treatment was replaced with the specific 
treatments included in the clinical trial, then the modeller asks ‘what is relevant 
to the clinical trial?’ as not all components in this generic conceptual model will 
be relevant to individual trials, any components that are not relevant are 
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removed.  Another issue is ‘what is practical?’ although Roberts et al. guidance 
(26) recommends not considering data when developing a conceptual model, it is 
impractical to include components that cannot be represented by data, so once 
the generic treatment conceptual model was developed with all key components 
it was pragmatic to exclude components that are not possible to measure due to 
lack of data from the clinical trial. 
The iterative nature of developing a conceptual model was evident, particularly 
in TWICS as several iterations were developed.  There were also iterations 
developed in the ‘Review, revise and refine’ stage and the final three stages 
were closely linked.   
Finally, it would be useful to include the conceptual model diagram and 
document in the health economics plan for reference, for continuity when there 
are staff changes, and for communicating and agreeing understanding with the 
trial team.  
The next chapter uses the conceptual models developed in this chapter to 
demonstrate the new role using illustrative case studies; a conceptual model 
driven analysis.
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Chapter 7 Case studies to illustrate the new role 
for conceptual models  
7.1 Chapter overview 
The aim of this chapter is to demonstrate the new role for conceptual models 
using the two case studies introduced in Chapter 3, this fulfils the first objective 
of the thesis.  In demonstrating the new role, it can be evaluated and any 
strengths and limitations highlighted.  First a brief recap of the background and 
original results of the case studies from Chapter 3 is given, then the three 
aspects of the proposed novel approach are applied to each case study, these 
three aspects are: 1) the conceptual model for each case study is presented 
visually and described; 2) the regressions capturing the relationships identified 
in each case study are tested and results reported, 3) bootstrapped samples 
from these regression results are used to calculate point estimates, present cost-
effectiveness planes and cost-effectiveness acceptability curves, and estimate 
value of information figures, these results are then compared to the original 
treatment arm-based results.   
Both of the case studies are for illustrative purposes only, to demonstrate a 
potential method for implementing the conceptual model analysis.  The focus of 
the case studies was to introduce the concept of conceptual models in this role, 
not to rigidly recommend a predefined method. The method used in these 
illustrative case studies should not be assumed to be the most statistically 
rigorous suitable for the new role.  
The layout of the chapter is as follows: Section 7.2 refreshes the reader’s 
memory of the background to the TWICS case study; Section 7.3 describes the 
application of the novel approach to the TWICS case study; Section 7.4 
reintroduces the BeatIt case study; Section 7.5 describes the application of the 
novel approach to the BeatIt case study; Section 7.6 presents a discussion about 
the new role for conceptual models, and Section 7.7 summarises the chapter. 
Stata 16 (StataCorp. 2019. Stata Statistical Software: Release 16. College 




(To avoid unnecessary repetition in the BeatIt case study, there is more detail on 
the reasons for including each aspect of the novel approach presented in the 
TWICS case study.) 
7.2 Case study #1 TWICS 
7.2.1 Background of TWICS 
The TWICS clinical trial investigated the effectiveness and cost-effectiveness of 
adding low-dose theophylline as an adjunctive therapy to inhaled corticosteroids 
in patients with COPD and a history of frequent exacerbations, compared to 
placebo. The primary outcome was the number of moderate or severe 
exacerbations requiring treatment over the 12-month follow-up period for each 
participant. The population was adults with COPD who had a history of at least 2 
exacerbations (requiring treatment) in the previous 12 months and who were 
using inhaled corticosteroids as a maintenance treatment. 1,578 participants 
were randomised, 11 were excluded after randomisation, leaving 1,567 
participants: 788 in the theophylline arm and 779 in the placebo arm.   
The aim of the health economic evaluation was to evaluate the cost-
effectiveness of adding low-dose theophylline as an adjunctive therapy to 
inhaled corticosteroids, compared to a placebo, for reducing exacerbations in 
the trial population; cost-effectiveness was assessed using the incremental cost 
per QALY summary ICER measure. The categories of health economic resource 
use collected included treatment costs, exacerbation costs, COPD costs, 
emergency non-COPD hospital admissions and health service use not related to 
exacerbations. 
The main trial analysis found that there was no statistically significant 
difference in the number of exacerbations between arms; there was no 
treatment effect observed for theophylline. The economic evaluation complete 
case cost results (Table 17) found that the total costs were higher (statistically 
significant) in the placebo arm.  Further investigation found that this was due to 
higher exacerbation costs in the placebo arm, which was driven by more 
exacerbations in the placebo arm requiring hospital treatment; exacerbations 
treated in hospital are more costly than exacerbations treated in other 
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locations.  (This is explained in more detail in Chapter 3 sub-section 3.2.4).  
Treatment costs showed a statistically significant difference between arms, 
higher in the theophylline arm; £22 compared to no cost for placebo.  No other 
cost categories showed a difference between arms. QALYs were higher in the 
placebo arm compared to the theophylline arm, although this was not a 
statistically significant result. 
Table 17: TWICS health economic evaluation results 
 Theophylline Placebo Difference 
between arms 
(95% CI) 
Exacerbations (Mean) 2.24 2.23 Unadjusted IRR 
1.00 (0.92 to 
1.09) 
Complete case 
Treatment costs £22 £0 £22 (£22 to £22) 




£2,075 £2,101 -£26 (-£234 to 
£181) 
Total costs £2,684 £3,136  -£452 (-£771 to -
£133) 
Total QALYs 0.626 0.637 -0.011 (-0.040 to 
0.018 
Multiple imputation (unadjusted) 
Total costs  £2,702 £3,141 -£439 (-£846 to -
£32) 
Total QALYs  0.617 0.621 -0.004 (-0.031 to 
0.024) 
Multiple imputation (adjusted) 
Total costs  £2,784 £3,006 -£222 (-£472 to 
£27) 
Total QALYs  0.621 0.616 0.005 (-0.015 to 
0.025) 
 
CI – confidence interval, QALY – quality adjusted life-year 
When multiple imputation was used to compensate for missing data, without 
adjustment for baseline characteristics, the direction of the differences in total 
cost and total QALYs mirrored complete case results.  When multiple imputed 
total costs and QALYs were adjusted for baseline characteristics total costs were 
still higher in the placebo arm, but this was no longer statistically significant. 
The direction of the difference in QALY results swapped to being higher in the 
theophylline arm compared to placebo, however this difference remained a 
statistically insignificant result.  In summary, after using recommended methods 
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to conduct the economic evaluation and characterise uncertainty the results 
were still uncertain: the only thing that was known for certain was that the 
treatment cost was higher in the intervention arm, and that exacerbation costs 
were higher in the placebo arm as a result of more participants requiring 
hospital treatment for exacerbations in that arm compared to the theophylline 
arm, however the trial team concluded that this was not a result of any possible 
treatment effect. 
7.3 Applying the novel approach to the TWICS case 
study 
7.3.1 Conceptual model 
The first step in applying the novel approach to the TWICS data was to develop a 
conceptual model to illustrate the expected links and associations (direct and 
mediated) between the key components of the mechanism driving the TWICS 
trial, in relation to the health economic evaluation.  The conceptual model 
development is described in detail in Chapter 6 and the TWICS conceptual model 
for analysis is presented again here in Figure 54.  The main purpose for 
developing the conceptual model is to provide a framework on which to base the 
conceptual model driven analysis, it also provides a tool for communicating with 
the wider trial team to explain the economic evaluation process and why 
economic data collection is important, and to ask for feedback on the accuracy 




Figure 54: Final TWICS conceptual model  
 
The conceptual model is described in full in the previous chapter, briefly it is 
split into three sections: ‘Inputs’ which is the treatment arm a participant is 
randomised to; ‘Mediators’, there is one mediator which is number of 
exacerbations, and ‘Outcomes’ which are treatment and non-treatment costs, 
and quality of life measured in QALYs.  Each dependant variable has been given 
a number to identify a regression, this is to allow ease of description of the 
conceptual model and assumed and possible associations. 
The assumed associations in the conceptual model (solid lines) are that 
treatment arm predicts treatment costs (regression 1); it was known a priori that 
the intervention medication had a small cost, and that placebo has no cost.  
Regression 2 assumes that treatment arm affects the number of exacerbations 
experienced (this is based on the overarching trial hypothesis that theophylline 
may reduce the number of exacerbations a participant experiences).  Other 
assumed associations are that the number of exacerbations a participant 
experiences predicts quality of life (regression 3); it was expected that the 
number of exacerbations a participant experienced would be reflected in the 
quality of life reported (more exacerbations experienced would lead to lower 
reported quality of life).  The exacerbations could be considered a surrogate 
endpoint; where the effect of the treatment on QALYs is completely captured by 
the exacerbations, this effect would need to be validated by quantifying the 
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relationship between exacerbations and QALYs. The final assumed associations 
are that the number of exacerbations also predicts non-treatment costs 
(regression 4); exacerbations are a cost event themselves, plus if a participant 
experiences a deteriorating health status due to exacerbations they may face an 
increase their healthcare use. 
There are two possible associations in the conceptual model, both are predicted 
by the treatment arm; 1) quality of life (regression 3), and 2) non-treatment 
costs (regression 4).  These possible associations are equivalent to an 
intervention focussed evaluation, where there is no consideration of the process 
driving the results, only considering the treatment and outcomes. Possible 
drivers for these associations include treatment side effects (although these 
were not expected in TWICS.)   
Overall, the main assumptions in the conceptual model were that the 
intervention would lower the number of exacerbations experienced by 
participants in the intervention arm, conversely the participants in the placebo 
arm were expected to experience higher numbers of exacerbations. The number 
of exacerbations a participant experienced would drive the quality of life of that 
participant, it was also possible that treatment arm would directly affect quality 
of life without being mediated through the number of exacerbations.  It was 
assumed that the treatment arm would drive the level of treatment costs.  Non-
treatment costs were assumed to be driven by the number of exacerbations 
experienced, however it was also possible that non-treatment costs were driven 
by treatment arm too.  The possible associations replicated the ‘black box’ 
evaluation where treatment arm is regarded as being directly responsible for 
quality of life and non-treatment costs. 
7.3.2 Testing the accuracy of the conceptual model 
The next step in the novel approach is to test the accuracy of the conceptual 
model; once the conceptual model is finalised the accuracy of the predicted 
associations should be tested, this is done using regression techniques based on 
the numbered dependent variables in the conceptual model. Regression 
techniques were chosen for this as they estimate the relationships (or 
associations) between the independent variable and one of more predicted 
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variables; this identifies which predicted variables are impacted by the 
independent variable.  Testing the accuracy of the associations confirms the 
accuracy of the structure of the conceptual model and whether the assumptions 
made about associations and links are correct.  The following equations 
represent the regressions identified and presented in the conceptual model 
diagram: 
1. Treatment cost = constant + (beta1 * treatment arm) 
2. Exacerbations = constant + (beta2 * treatment arm) 
3. Quality of life = constant + (beta3 * exacerbations) + (beta4 * treatment 
arm) 
4. Non-treatment costs = constant + (beta5 * exacerbations) + (beta6 * 
treatment arm) 
 
Details of the variables in the TWICS clinical trial data used to represent the 
components in the regressions are presented in Table 18.  As there was a small 
amount of missing data in the trial dataset, for this demonstration missing cost 
and QALY data were replaced with a treatment arm specific mean, this produced 
a full dataset on which to base this demonstration. 
Table 18: Variables used in TWICS case study regressions 
Entity/variable Description 
Treatment arm Binary indicator of the treatment arm each participant 
was randomised to; theophylline or placebo  
Exacerbations Number of exacerbations reported by each participant 
(requiring treatment) over the follow-up period 
Treatment cost  Cost of theophylline treatment to participants in the 
theophylline arm (placebo was zero cost) 
Non-treatment 
costs 
Cost per participant of all non-treatment resources used 
during the follow-up period 
Quality of life Quality adjusted life-years accumulated over the follow-
up period, reported in EQ-5D-3L questionnaire 
 
The results from the equations defined in the conceptual model are presented in 
Table 19, with strong associations between independent and predicted variables 
highlighted in red and summarised below.   
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Equation 1) confirms that treatment costs only apply to the theophylline arm 
and are strongly associated with the intervention arm; £22 per participant 
annually. 
Equation 2) shows a trend towards 0.008 more exacerbations in the theophylline 
arm, a weak association, confirming the main clinical trial results; that 
theophylline does not affect the number of exacerbations needing treatment. 
Equation 3) demonstrates that treatment arm does not have a direct effect on 
quality of life, predicting 0.011 less QALYs in the theophylline arm, a weak 
association. However, regression results demonstrate that the number of 
exacerbations does have an effect on quality of life; each additional 
exacerbation results in a 0.022 reduction in QALYs, this is a strong association. 
Equation 4) shows that treatment arm does predict non-treatment costs; costs 
are £447 lower in the intervention arm (a strong association). Exacerbations 
have a direct effect on non-treatment costs; each additional exacerbation 
contributes an additional £529 to non-treatment costs, this is a strong 
association. 












£0 £22.0 (21.7 to 
22.3) 
2 Exacerbations Treatment 
arm 
2.23 0.008 -0.190 
to 0.206 
3 Quality of life Treatment 
arm 
0.687 -0.011 -0.034 
to 0.012 








£1,956 -£447 -853 to 
-103 
Exacerbations £529 434 to 
624 
 
CI – confidence interval 
In equation 4) it was known that the strong association between treatment arm 
and non-treatment costs was likely driven by a larger number of exacerbations 
requiring hospital treatment in the placebo arm, which are more costly to treat 
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than exacerbations treated in the primary care sector or at home.   A sensitivity 
analysis was conducted on equation 4) results to assess whether the treatment 
arm effect on non-treatment costs remained independently of the location of 
treatment for exacerbations (Table 20). Exacerbation costs were split into the 
costs of exacerbations treated in hospital and costs of exacerbations not treated 
in hospital, plus the additional costs of medication and oxygen required to 
manage the exacerbation were assessed separately. As expected, treatment arm 
was a strong predictor of the costs of exacerbations treated in hospital but not 
of non-hospital treated exacerbations, suggesting that theophylline reduces the 
number of exacerbations requiring hospitalisation, (further investigation in the 
original trial clinical effectiveness results concluded that this result was driven 
by a small number of participants in the placebo arm and not by any treatment 
effect; theophylline did not reduce the number of exacerbations treated in 
hospital).  Treatment arm was not a strong predictor of the cost medications and 
oxygen used to treat exacerbations. The same regression was run with non-
treatment, non-exacerbation costs.  The results confirmed that when removing 
treatment and exacerbation costs from total costs, treatment arm does not have 
any effect on the remaining costs, and furthermore, the number of 
exacerbations is a strong predictor of costs; each exacerbation predicted an 
increase of £193 (95% CI £137 to £249) in non-treatment, non-exacerbation 
costs.   
The results of this sensitivity analysis showed that the difference between arms 
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CI – confidence interval 
To explore this further the mean cost of an exacerbation treated in hospital in 
the placebo arm was calculated, £3,613, compared to £2,671 in the theophylline 
arm, a difference of £941 (95% CI £140 to £1,743).  This difference was driven by 
longer lengths of stay in the placebo arm compared to the theophylline arm; 
overall the distribution of length of stay was similar in both arms, however there 
were 10 participants in the placebo arm with lengths of stay greater than 40 
days (and therefore high exacerbation costs), two of these had a length of stay 
of over 100 days.  This compares to no participants in the theophylline arm with 
a length of stay greater than 40 days.  This can be seen in Figure 55 which 
illustrates that the majority of stays in both arms were below 40 days. 
Furthermore, when these 10 participants (with longer lengths of stay) are 
omitted from data in equation 4, treatment arm is no longer a strong predictor 




Figure 55:TWICS length of stay - hospital treated exacerbations (all length of stays) 
This step of performing regressions in the novel approach tested the accuracy of 
the conceptual model.  The regressions confirmed that there were two predictor 
components in the TWICS conceptual model: treatment arm and number of 
exacerbations.  Treatment arm was strongly associated with treatment cost and 
non-treatment costs.  However, the association between treatment arm and 
non-treatment costs resulted from a small number of participants in the placebo 
arm requiring hospital treatment for exacerbations, and treatment arm was not 
associated with other resource categories included in non-treatment costs. 
Clinicians in the TWICS trial did not believe there was any plausible biological 
mechanism linking theophylline to a reduction in exacerbations needing hospital 
treatment (109). The sensitivity analysis presented in this section showed that 
treatment arm was only strongly associated with the costs of exacerbations 
treated in hospital, not the costs of exacerbations treated elsewhere, which was  
driving the regression results of the non-treatment costs.  The number of 
exacerbations were strongly associated with quality of life and non-treatment 
costs; these were both assumed associations.   
In conclusion the assumed associations in the conceptual model were accurate, 
except treatment arm predicting number of exacerbations.  Furthermore, the 
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regression results confirmed that the possible association of treatment arm 
predicting quality of life was not strong, but that treatment arm predicted non-
treatment costs directly, this goes some way to confirm that the trial 
assumption of no treatment side effects from theophylline, and confirms the 
original treatment arm-based analysis results of no difference between arms for 
QALYs, the only difference was treatment and non-treatment costs.  The 
regression results also validate the inclusion of exacerbations as a mediator in 
the conceptual model as they predict both quality of life and non-treatment 
costs.  The results from this step in the novel approach could be used to inform a 
future trial; the number of exacerbations affect quality of life when measured 
using the EQ-5D-3L, and if a future intervention was expected to affect the 
severity of exacerbations the economic evaluation should look at the location of 
treatment for different severity of exacerbations. 
7.3.3 Final analysis results  
The final step in the new approach is to use the conceptual model as a 
framework to further analyse trial data, in this step the results from the 
regressions (testing the accuracy of the conceptual model) are used to inform 
similar summary measures and measures of uncertainty to the original treatment 
arm-based analysis.  The aim of this final analysis is to apply the trial mechanism 
driving the economic evaluation in the conceptual model to the trial data, to 
give a more detailed understanding of the trial than the treatment arm-based 
analysis.  The results of this final analysis are compared to the results of the 
original analysis; this comparison is important as it provides the additional 
interpretation and understanding of the economic evaluation results based on 
the expected causal mechanism in the clinical trial; presenting the final analysis 
results on their own would not provide this additional understanding. 
This final analysis is operationalised by applying the results of the above 
regressions in sub-section 7.3.2 and taking forward regressions with strong 
predictors to inform bootstrapped samples using the TWICS trial data. Where 
there are mediating relationships, the output of one regression should feed into 
another.  The regressions included in the TWICS case study were: 
1. Treatment costs were predicted by treatment arm 
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2. Exacerbations were predicted by treatment arm 
3. Quality of life was predicted by exacerbations 
4. Non-treatment costs were predicted by exacerbations 
Regression 1 is used to predict treatment costs, regression 2 is used to predict 
exacerbations. The exacerbations predicted in regression 2 are used to predict 
quality of life in regression 3 and non-treatment costs in regression 4.  
Treatment and non-treatment costs were summed to create a new variable for 
total costs and the difference in total costs and QALYs was calculated. 
Treatment costs, non-treatment costs, total costs and total QALYs are included 
in bootstrapping syntax to replicate 1,000 iterations.  Annotated Stata syntax is 
included in Appendix 13: Stata syntax for TWICS and BeatIt conceptual model 
analysis case studies.  The resulting bootstrap dataset is then used to calculate 
mean cost and QALY differences and produce cost-effectiveness planes and a 
cost-effectiveness acceptability curve. The purpose of producing cost-
effectiveness planes and cost-effectiveness acceptability curves is to graphically 
represent uncertainty in the conceptual model driven analysis. 
Bootstrapping techniques have been chosen as they do not make assumptions 
about distributions and estimate a large sample size treating the study sample as 
a population and allowing the presentation of confidence intervals, uncertainty 
using cost-effectiveness planes and cost-effectiveness acceptability curves; the 
larger the sample size the more confidence can be placed on the summary 
statistic.  In this analysis the association between treatment arm and non-
treatment costs was removed despite it being strong, this decision was made 
based on the clinical assumption that theophylline does not reduce the number 
of exacerbations requiring hospitalisation.  This may lead to bias in the final 
TWICS conceptual model analysis results, potentially creating bias away from 
theophylline; if this association had been left in the conceptual model results, 
they may have favoured theophylline as being cost saving. More generally, if 
associations are removed from conceptual models, as they have been in this case 
study, there is a potential for the conceptual model analysis to produce 
misleading results if the association stands. In this illustrative example the 
clinician’s opinion that this was a chance finding was taken at face value when 
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developing the conceptual model, however the additional post-hoc analysis 
undertaken in this thesis suggests a different model, where exacerbation costs 
are separate from the remaining non-treatment costs.  In this different 
conceptual model, and contra to clinical opinion, the association between 
treatment arm and the cost of exacerbations remains, but the link between 
treatment arm and remaining non-treatment costs is removed. However, without 
a prior hypothesis that theophylline reduces exacerbations requiring 
hospitalisation, justification of post-hoc findings would be problematic, 
particularly if these go against clinical opinion and notions of implausibility from 
clinicians who designed the trial.  Finally, future clinical trials in this field 
should consider the potential for this finding to reoccur, possibly reassessing 
current evidence about the link.   
Please note that although treatment arm was not a strong predictor of number 
of exacerbations this regression is included to operationalise the bootstrapped 
samples.  This approach is discussed in sub-section7.6.3. 
Figure 56 presents the cost-effectiveness plane using all regressions in the 
conceptual model bootstrap samples.  This is similar to the treatment arm-based 
complete case cost-effectiveness plane (Figure 4) where the majority of the 
bootstrapped samples fall into the southwest quadrant; decision makers would 
need to decide what level of cost saving per loss in health benefit they would be 
willing to accept.  However, the confidence ellipse crosses into the northwest, 
southwest and southeast quadrants illustrating the uncertainty in the samples.  
This cost-effectiveness plane is included to show the results of including all 
associations in the conceptual model regardless of their accuracy. 
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Figure 56: TWICS cost-effectiveness plane – conceptual model driven analysis (including all 
regressions in the conceptual model) 
 
Although in this case study each component was predicted by only one other 
component, the annotated syntax in Appendix 13: Stata syntax for TWICS and 
BeatIt conceptual model analysis case studies includes syntax to produce Figure 
56 where all equations were included, this gives guidance to the reader to 
operationalise a conceptual model which has more than one predictor for one or 
more equations. 
Figure 57 presents the conceptual model driven analysis incorporating the 
regression results: in equation 1) treatment costs are predicted by treatment 
arm, in equation 2) the number of exacerbations is predicted by treatment arm, 
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in equation 3) QALYs are predicted by the number of exacerbations and in 
equation 4) non-treatment costs are predicted by the number of exacerbations.  
The cost-effectiveness plane shows that, compared to the cost-effectiveness 
plane with all associations, the plots are more concentrated, covering a smaller 
area, they also cross the axis close to the origin, however the ellipse still crosses 
into three quadrants.  The shape of the plot clearly shows that as incremental 
QALYs decrease the incremental costs increase, this is driven by the 
exacerbations included in the analysis; as the number of exacerbations 
experienced by a participant increases so do the costs for treating those 
exacerbations, and a higher number of exacerbations also leads to a decrease in 
quality of life.  By removing the association between treatment arm and non-
treatment costs I have mimicked using an average cost for exacerbations, which 
removes the noise of the more expensive hospitalised exacerbations in the 
placebo arm. Removing treatment arm from predicting quality of life also 
removes the noise of this regression, leaving a less uncertain prediction of 
quality of life from exacerbations. To present this cost-effectiveness plane in 










Figure 58: TWICS cost-effectiveness plane – conceptual model driven analysis (with strongly 













Next bootstrapped samples should be used to produce a cost-effectiveness 
acceptability curve, presented in Figure 59, this shows that at a willingness-to-
pay threshold of £20,000 the theophylline arm has a 41.3% chance of being cost-
effective. 
 
Figure 59: TWICS cost-effectiveness acceptability curve - conceptual model driven analysis 
 
The last step in this final analysis in the novel approach is to use the 
bootstrapped samples to calculate point estimates, summary measures (for 
example ICER and net monetary benefit), and value of information estimates, 
and to compare these to the original treatment arm-based analysis results.  The 
crucial aspect of this last step is the comparison of these conceptual model 
driven analysis results (including the cost-effectiveness planes and cost-
effectiveness acceptability curves presented above) to the original treatment 
arm-based analysis results. The aim of this comparison is to provide additional 
insight and more detailed understanding of the original treatment arm-based 




Point estimates and 95% confidence intervals for cost and QALY differences and 
incremental net monetary benefits, ICERs and measures of value of information 
are presented in Table 21 for the treatment arm-based and conceptual model 
driven analyses.  Measures included are taken from bootstrapped results for both 
the treatment arm-based analysis and conceptual model driven analysis to allow 
direct comparison between the results for both approaches.  Measures to 
characterise uncertainty around the ICERs are not included as they are ratios 
and there are statistical complexities attached to calculating uncertainties 
around ratios particularly when the bootstrapped samples fall into all quadrants 
of the cost-effectiveness plane as it is not possible to identify which quadrant 
the positive and negative ICERs fall into, however, uncertainty was presented in 
the cost-effectiveness planes using a confidence ellipse which characterises 
uncertainty around the ICER clearly, with none of the pitfalls just described. 
Table 21: TWICS results from both analyses 
 Treatment arm-based 
analysis  
Mean (95% CI) 
Conceptual model 
driven analysis 
Mean (95% CI) 
Cost differences -£458 (-£863 to -£86) £22 (-£85 to £131)  
QALY differences -0.011 (-0.034 to 0.012) -0.00004 (-0.005 to 
0.004) 
ICER  £48,186  -£18,869 
Incremental NMB £244 (-£370 to £894) -£23 (-£217 to £168) 
EVPI £41 £29 
EVPPI – QALYs £19 £9 
EVPPI - Costs £8 £12 





treatment costs  
 £12 
 
CI - confidence interval, EVPI - expected value of perfect information, EVPPI - expected value of 
perfect parameter information, ICER - incremental cost-effectiveness ratio, NMB - net monetary 
benefit, QALY - quality adjusted life-year 
 
In the treatment arm-based analysis the theophylline arm is less costly and less 
effective than the placebo arm; the decision maker would need to decide what 
level of compensation (or cost saving) is acceptable for each QALY lost. In the 
conceptual model driven analysis the theophylline arm is more costly and less 
effective than the placebo arm, putting the ICER estimate in the northwest 
quadrant of the cost-effectiveness plane where theophylline would be 
considered to be dominated, however the 95% confidence intervals for cost and 
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QALY differences cross zero so there is some uncertainty as to the exact value of 
these differences.  This comparison suggests that theophylline is not cost-
effective and should not be adopted.  The 95% confidence interval decreases 
more than three times for cost differences and five times for QALY difference in 
the conceptual model driven analysis compared to the treatment arm-based 
analysis.  
The less uncertain results from the conceptual model driven analysis are clearly 
illustrated in Figure 60; a comparison of cost-effectiveness planes for both 
analyses.  In the treatment arm-based analysis cost-effectiveness plane (top) 
most of the bootstrapped samples are in the southwest quadrant where the 
decision maker should consider their willingness-to-accept a reduction in health 
benefits.  In the conceptual model driven analysis cost-effectiveness plane 
(bottom) most samples fall into the northwest quadrant where theophylline is 
considered dominated and should be rejected.   However, a significant number 
of samples fall into the southeast quadrant where theophylline is considered 
dominant and would be adopted, this inconclusive result is driven by the number 
of exacerbations a participant experiences and should be interpreted with 
caution due to the uncertainty.  Despite uncertain results in both analyses it is 
clear that the conceptual model driven analysis results in less uncertain 




Figure 60: BeatIt cost-effectiveness planes - comparison of treatment arm-based and conceptual 
model driven analyses 
 
The cost-effectiveness acceptability curves from both analyses are presented in 
Figure 61 for comparison. The treatment arm-based analysis curve (top) shows 
that at a willingness-to-pay threshold of £20,000 the theophylline arm has a 75% 
chance of being cost-effective compared to placebo, however in the conceptual 
model driven analysis the chance of being cost-effective compared to placebo is 
41%.  The treatment arm-based analysis cost-effectiveness acceptability curve 
shows that at a low willingness-to pay threshold theophylline has a high 
probability of being cost-effective compared to placebo, but that this probability 
decreases as the threshold increases.  In the conceptual model driven analysis 
theophylline has a probability of less than 40% of being cost-effective compared 
to placebo, this increases slightly as the threshold increases but remains 
constant beyond a threshold of £40,000.  This result confirms the results from 
the cost-effectiveness planes; in the treatment arm-based analysis the decision 
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maker would need to access their willingness-to-accept, and in the conceptual 
model driven analysis theophylline is not cost-effective at any level of 
willingness-to-pay threshold. 
 
Figure 61: TWICS cost-effectiveness acceptability curves – comparison of treatment arm-based 
and conceptual model driven analyses  
 
The incremental net monetary benefit is positive in the treatment arm-based 
analysis, indicating that the theophylline intervention should be accepted, 
although the 95% confidence interval around this measure crosses zero so the 
results are uncertain.  In the conceptual model driven analysis, the incremental 
net monetary benefit is negative, indicating that the theophylline intervention 
should be rejected, again the 95% confidence interval around the incremental 
net monetary benefit crosses zero.  However, the 95% confidence interval is 
three times narrower in the conceptual model driven analysis compared to the 
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treatment arm-based analysis, suggesting the summary measure is less uncertain 
in the conceptual model driven analysis.  The net monetary benefit results from 
both approaches are plotted in a histogram to illustrate the variation of the 
results in each approach in Figure 62.  Again, these histograms demonstrate the 
narrower spread of results from the conceptual model approach compared to the 
treatment-arm based results and the movement of the point estimate closer to 
zero.  These results mirror the interpretations above; at some levels of 
willingness-to-pay decision makers would accept theophylline looking at the 
treatment arm-based analysis results, whereas there is no evidence in the 
conceptual model driven analysis results that theophylline is cost-effective.   
 
Figure 62: TWICS - histogram of net incremental monetary benefit results showing the distribution 
of the results from both approaches 
 
Value of information results per person are also included in Table 21 to explore 
the value of eliminating sampling uncertainty; what can be gained if there was 
no uncertainty. These value of information results show that the expected value 
of perfect information is higher in the treatment-arm based approach compared 
to the conceptual model driven approach, £41 compared to £29; there is 
potentially more value in conducting further research into the treatment arm-
based analysis compared to the conceptual model driven analysis, however both 
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EVPIs are low and it is debatable whether either would convince decision makers 
to commission further research. The reduced EVPI estimate is a result of the 
additional structure in the conceptual model driven analysis providing a more 
detailed understanding. Results of EVPPI for total costs are £8 in the treatment 
arm-based analysis and £12 in the conceptual model driven analysis, for total 
QALYs the results are £19 in the treatment arm-based analysis and £9 in the 
conceptual model driven analysis.  These estimates indicate that there is more 
decision uncertainty linked to QALYs than to costs, and therefore potentially 
more to be gained by removing uncertainty in QALYs in the treatment arm-based 
analysis and total costs in the conceptual model driven analysis.  To further 
investigate these results the EVPPI for treatment and non-treatment costs was 
estimated; this showed that there was more decision uncertainty in non-
treatment costs compared to treatment costs (£12 v £0); this result confirms 
that treatment costs are precise are known, but the accuracy of the non-
treatment cost estimate could be improved.   
 
7.3.4 TWICS summary 
In the original treatment arm-based analysis the complete case and multiple 
imputed unadjusted costs and QALYs were higher in the placebo arm compared 
to the theophylline arm, the difference in costs was statistically significant, but 
not for the difference in QALYs.  In the multiple imputed adjusted results the 
costs were still higher in the placebo arm compared to the theophylline arm but 
the results were no longer statistically significant.  The direction of the QALY 
results changed in the multiple imputed adjusted results with more QALYs 
reported in the theophylline arm, this was not a statistically significant result.  
Overall, although there was a trend for higher costs in the placebo arm this 
result was uncertain, and there was a lot of uncertainty in the QALY results. In 
the conceptual model driven analysis costs were marginally higher in the 
theophylline arm and QALYs were barely higher in the placebo arm, with the 95% 
confidence crossing zero for both differences. 
The conceptual model driven analysis found that the treatment arm predicts 
treatment costs and non-treatment costs but does not predict exacerbations.  A 
sensitivity analysis found that the effect of treatment on non-treatment costs 
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only held true for the costs of treating exacerbations requiring a stay in hospital.  
The treatment arm does not predict the costs of exacerbations requiring 
treatment at home or in a community setting, nor non-exacerbation costs. This 
sensitivity analysis illustrated that unexpected results can be analysed further. 
The removal of this equation (treatment arm predicting exacerbations) was 
based on clinical opinion, with further analysis described above showing that this 
strong prediction was driven by the costs of exacerbations requiring 
hospitalisation, however it is important to keep in mind that by excluding this 
regression, bias may have resulted in the final conceptual model analysis, a 
limitation of this case study.  The conceptual model driven analysis also found 
that exacerbations predict quality of life and non-treatment costs, including 
non-treatment non-exacerbation costs.  The assumed associations in the 
conceptual model gave an accurate representation of the trial mechanism 
except for the treatment arm predicting exacerbations, whereas none of the 
possible associations were strong and were removed from the final analysis. 
As neither of the possible associations depicted in the conceptual model were 
strong it could be argued that this confirms: 1) the trial assumption of no 
treatment side effects from theophylline, and 2) the original treatment arm-
based analysis results of only treatment costs showing a difference between 
arms.  The original trial results found no treatment effect on the number of 
exacerbations, the conceptual model driven analysis confirmed this but also 
found that exacerbations do influence quality of life and non-treatment, non-
exacerbation costs; validating the inclusion of exacerbations as a mediator in the 
conceptual model as they predict both quality of life and non-treatment costs.  
The results from this aspect of the novel approach could be used to inform a 
future trial design. 
The incremental net monetary benefit favoured TWICS in the treatment arm-
based analysis but not for the conceptual model driven analysis, suggesting that 
despite the uncertainty in the treatment arm-based results decision makers 
might adopt the theophylline intervention, however the net monetary benefit 
summary measure is calculated using complete case bootstrap results, and may 
overestimate the difference in costs between arms. EVPPI for the treatment 
arm-based analysis suggests that there is potentially more value in further 
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research into QALYs compared to costs resulting from this comparison of 
treatments, due to more decision uncertainty in QALYs.  However, in the 
conceptual model driven analysis, there is less value in further research into 
QALYs compared to costs. 
Overall, the conceptual model driven analysis concluded that theophylline would 
not be a cost-effective intervention; it does not reduce the number of 
exacerbations experienced or result in cost savings.  
7.4 Case study #2 BeatIt 
7.4.1 Background of BeatIt 
The BeatIt trial compared a behavioural activation therapy (BeatIt) with a 
guided self-help therapy (StepUp) in a cohort of adults with an intellectual 
disability and a diagnosis of depression, evaluating improvements in depressive 
symptoms. The primary outcome was a change in measure of depressive 
symptoms using the GDS-LD score at 12 months follow-up.  The economic 
outcome was the quality adjusted life-year measure using the EQ-5D-Y 
questionnaire. In total 161 participants were randomised with 141 providing data 
at the primary endpoint of 12 months (68 BeatIt and 73 StepUp).   
The aim of the health economic evaluation was to evaluate the cost-
effectiveness of BeatIt compared to StepUp, measured by an incremental cost 
per quality adjusted life-year ICER. Resource use and outcome measures were 
collected at baseline, 4 and 12 months with an additional collection of resource 
use data at 8 months reported by carers.  The analysis was conducted using the 
intention-to-treat population from an NHS and social services perspective.   
A summary of the trial-arm based analysis results is presented in Table 22.  
Briefly, main trial results at 4 and 12-month follow-ups demonstrated no 
statistical difference between arms in the GDS-LD score, however, there was a 
statistically significant improvement in GDS-LD scores over the follow-up period 
in both BeatIt and StepUp arms, suggesting that both therapies were successful 
in reducing depressive symptoms in this population.  The economic evaluation 
results showed a statistically significant difference at baseline for health utilities 
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between treatment arms; but for 4, 8 and 12-months follow-up there were no 
statistically significant differences after adjusting for baseline health utilities.  
Similar to the primary outcome there was a statistically significant improvement 
in health utility scores in both arms suggesting that both therapies were 
successful in improving quality of life, however there was a trend for higher 
QALYs in the StepUp arm (0.691 compared to 0.628, a difference of 0.063 (5% CI 
-0.052 to 0.178). The treatment cost was higher in the BeatIt arm, a statistically 
significant difference between arms, however there was no statistically 
significant difference between arms in non-treatment costs or total costs.  There 
was a trend for higher total costs in the BeatIt arm (£27,158 compared to 
£26,786), this was driven by treatment costs. Bootstrapped plots on the cost-
effectiveness plane showed no difference in costs nor effects between arms.  
When missing data was replaced using multiple imputation, results mirrored the 
complete case results, however when these multiple imputation results were 
adjusted for baseline characteristics the direction of the previous results 
reversed; total costs were higher in the StepUp arm and QALYs were marginally 
higher in the BeatIt arm.  In summary, after applying recommended methods in 
conducting the original treatment arm-based economic evaluation, the results of 
the economic evaluation were uncertain and gave little evidence for decision 
makers to base a decision on. The treatment costs were certain, they were 
higher in the intervention arm, however there was no statistically significant 
difference between arms for total costs or total QALYs despite using multiple 
imputation and adjusting for baseline characteristics.  It was also clear that both 
treatments improved depressive symptoms but the mechanism of how this 







Table 22: Results from BeatIt trial-arm based analysis at 12 months follow-up (complete case) 
 BeatIt StepUp Difference 
between arms 
(95% CI) 
GDS-LD score 12.43 12.03 0.40 (-2.26 to 
2.70) 
Treatment costs £1,788 £1,050 £738 (£586 to £890 
Non-treatment costs £25,370 £25,736 -£367 (-£13,418 to 
£12,684) 
Total costs £27,158 £26,786 £371 (-£12,689 to 
£13,432) 
Total QALYs 0.628 0.691 -0.063 (-0.178 to 
0.052) 
Multiple imputation (unadjusted) 
Total costs £27,223 £26,021 £1,201 (-£11,299 
to £13,702) 
Total QALYs 0.617 0.693 -0.076 (-0.185 to 
0.033) 
Multiple imputation (adjusted) 
Total costs £26,369 £27,962 -£1,593 (-£5,194 to 
£2,008) 
Total QALYs 0.657 0.655 0.002 (-0.082 to 
0.085) 
 
7.5 Applying the novel approach to the BeatIt case study 
7.5.1 Conceptual model 
The first step in the novel approach is to develop a conceptual model illustrating 
the links between the inputs and outputs of the economic evaluation, mediated 
through the trial mechanism, the development of the conceptual model was 
described in detail in Chapter 6 and the final BeatIt conceptual model is 




Figure 63: Final BeatIt conceptual model 
 
As the conceptual model is described in full in the previous chapter it will only 
be briefly described here. The conceptual model is split into three sections: 
‘Inputs’ which is the treatment arm; ‘Mediators’ which are activity and 
depression, and outcomes which are treatment and non-treatment costs, and 
quality of life.  Each dependant variable has been allocated an identifying 
number, this enables a clear description of the conceptual model and the 
associations included in it.  
Assumed associations include the treatment arm predicting treatment costs 
(regression 3) and activity levels (regression 1).  The latter assumption is based 
on the hypothesis of the trial; the BeatIt therapy increases engagement with 
activities.  It was also assumed that levels of activity would predict symptoms of 
depression (regression 2), with participants reporting higher levels of activity 
expected to report fewer depressive symptoms and vice versa.  The level of 
depressive symptoms reported were assumed to predict quality of life 
(regression 4), with participants reporting fewer depressive symptoms expected 
to also report better quality of life and vice versa. Levels of reported depression 
could be considered a surrogate endpoint for QALYs if effects of the treatment 
on QALYs is completely captured by levels of depression with no other possible 
links to QALYs. Finally, it was assumed that activity levels and depressive 
symptoms would predict non-treatment costs (regression 5); higher reported 
levels of activity would increase non-treatment costs, and more reported 
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depressive symptoms were expected to lead to higher healthcare use and 
therefore higher non-treatment costs.   
Possible associations included the treatment arm predicting levels of depressive 
symptoms, without being mediated through activity levels (regression 2), and 
treatment arm predicting quality of life and non-treatment costs, not being 
mediated through activity and depression (regressions 4 and 5). There is also a 
possibility that levels of activity are directly associated with quality of life 
without being mediated through depression (regression 4), for example through 
the ‘usual activities’ or ‘mobility’ domains of the EQ-5D-Y questionnaire.  
Overall, the main assumptions in the conceptual model were that the BeatIt 
therapy would increase the levels of activity of participants in the intervention 
arm, which would in turn reduce depressive symptoms.  The reduction in 
depressive symptoms and increase in activities were predicted to improve 
quality of life in these participants.  The StepUp therapy was predicted to 
reduce depressive symptoms, but not mediated through a change in activity 
levels. There was a possibility that quality of life would be directly affected by 
treatment arm, not mediated through depression (and activity possibly).  It was 
expected that treatment arm would directly predict treatment costs, and could 
possibly affect non-treatment costs, although it was assumed that non-
treatment costs would be mediated through activity (and depression).  The 
direct links between treatment arm and outcomes represents the ‘black box’ 







7.5.2 Testing the accuracy of the conceptual model 
The next step was to test the accuracy of the structure of conceptual model; to 
do this the associations presented in the conceptual model are tested using the 
numbered dependant variables in the conceptual model to represent 
regressions.  The suitability of regression in this purpose is described in the 
TWICS case study.  The following equations represent the regressions identified 
and presented in the conceptual model diagram (Figure 63), attached to each 
dependent variable: 
1. Activity = constant + (beta1 * treatment arm) 
2. Depression = constant + (beta2 * treatment arm) + (beta3 * activity) 
3. Treatment cost = constant + (beta4 * treatment arm) 
4. Quality of life = constant + (beta5 * treatment arm) + (beta6 * activity) + 
(beta7 * depression) 
5. Non-treatment cost = constant + (beta8 * treatment arm) + (beta9 * 
activity) + (beta10 * depression) 
 
The details of the clinical trial variables used to represent the components 
included in the conceptual model are presented in Table 23.  To allow for full 
use of the data in the trial dataset missing cost and QALY data was replaced with 
a treatment arm specific mean. 
Table 23: Variables used in the regressions 
Entity/variable Description 
Treatment arm Binary indicator of whether the treatment arm represents 
StepUp or BeatIt 
Activity Total reported activity over the 12 months follow-up 
Depression GDS-LD scores at 12 months follow-up. A high score 
indicates more depressive symptoms (more severe 
depression) than a low score 
Quality of life Quality adjusted life-years accumulated over the follow-
up period collected using the EQ-5D-Y 
Treatment cost The cost of the therapy each participant received 




Results from the equations defined in the conceptual model are reported in 
Table 24, with strong associations highlighted in red, and summarised below.  
Equation 1) demonstrates a small trend towards higher reported levels of 
activity over the 12 months of the trial in the BeatIt arm, however this is not a 
strong association. 
Equation 2) demonstrated that higher reported activity levels are associated 
with lower reported levels of depressive symptoms after 12 months (0.003 for 
each 1-point decrease in depressive symptoms), this is a small but strong 
association. The BeatIt treatment arm is associated with lower reported 
depressive symptoms; however, this is not a strong association.   
Equation 3) shows that, as expected, BeatIt is associated with higher treatment 
costs of £738, a strong association. 
Equation 4) demonstrates that lower reported depressive symptoms are 
associated with higher reported quality of life, this is a small but strong 
association of 0.017 QALYs.  Higher reported levels of activity are associated 
with lower reported quality of life; this is a small trend and not a strong 
association.  BeatIt is associated with a small reduction in quality of life, this is 
not a strong association of 0.101 QALYs. 
Equation 5) shows that an improvement in reported depressive symptoms is 
associated with higher non-treatment costs, however this is not a strong 
association. Higher reported levels of activity are associated with higher non-
treatment costs of £19, a small but strong association. BeatIt is associated with a 
£3,756 reduction in non-treatment costs, however this is a weak association. 
In summary, the regressions established the relationships in the trial mechanism 
and found that participants with higher levels of activity also reported lower 
levels of depressive symptoms, treatment costs were higher in the BeatIt arm 
compared to the StepUp arm, participants reporting lower levels of depressive 
symptoms also reported higher quality of life, and finally, higher reported levels 
of activity resulted in higher non-treatment costs.   
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1 Activity Treatment 
arm 
495 96.5 -131 to 324 










£1,050 £738 £608 to 
£868 
4 Quality of 
life 
Depression 0.952 -0.017 -0.025 to -
0.009 









Depression £25,367 -£435 -£1,496 to 
£625 




-£3,756 -£18,581 to 
£11,069 
CI – confidence interval 
 
7.5.3 Final analysis results  
The final step in the new approach is to use the confirmed conceptual model as 
a framework to further analyse trial data. In this step the results from the 
regressions above are used to inform estimates of similar summary measures and 
measures of uncertainty to the original treatment arm-based analysis.  The aim 
of this final analysis is to apply the trial mechanism driving the economic 
evaluation to the trial data, the results of this final analysis are compared to the 
results of the original treatment arm-based analysis.  This comparison is 
important as it provides additional interpretation and understanding of the 
economic evaluation results based on the expected causal mechanism in the 
clinical trial, compared to the traditional ‘black box’ evaluation; presenting the 
final analysis results on their own would not provide this additional 
understanding. 
The final analysis is operationalised by applying the results of the regressions in 
sub-section 7.5.2, taking forward the regressions with strong predictors to 
262 
Chapter 7 
inform bootstrapped samples using the BeatIt trial data. The following 
regressions included in the BeatIt case study were: 
1. Activity was predicted by treatment arm 
2. Depressive symptoms were predicted by activity levels 
3. Treatment costs were predicted by treatment arm 
4. Quality of life was predicted by depressive symptoms 
5. Non-treatment costs were predicted by activity levels 
In regression 1 treatment arm is used to predict activity, the output from this 
regression is used to predict depression (equation 2) and non-treatment costs 
(equation 5).  The output of equation 2 (depression) is used to predict quality of 
life in equation 4.  Treatment costs are predicted by treatment arm in equation 
3. Treatment and non-treatment costs were summed to produce total costs and 
the difference in total costs and total QALYs were used to inform the bootstrap 
syntax. 1,000 iterations were run and these bootstrap samples were used to 
calculate mean cost and QALY differences and to produce cost-effectiveness 
planes and cost-effectiveness acceptability curves. The aim of including these 
figures is to provide graphical representations of uncertainty. 
Please note that although treatment arm did not strongly predict levels of 
activity it has been included to operationalise the bootstraps.   
Figure 64 presents the cost-effectiveness plane when all associations depicted in 
the conceptual model are included in the bootstrapped samples. The conceptual 
model driven cost-effectiveness plane shows that costs are higher in the BeatIt 
arm compared to the StepUp arm, and QALYs are also higher in the BeatIt arm.  
Whilst the majority of the bootstrapped samples fall into the northeast 
quadrant, where BeatIt would be considered cost-effective if the ICER is below 
the willingness-to-pay threshold of £20,000, there is uncertainty in this result as 
the confidence ellipse crosses into all four quadrants of the cost-effectiveness 
plane.  This is similar to the cost-effectiveness plane presented for the original 
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treatment arm-based analysis (Figure 11) where the confidence ellipse crosses 
into all four quadrants, but the samples in the original cost-effectiveness plane 
show more uncertainty in the difference between arms for costs and QALYs with 
samples more evenly spread in all four quadrants.  The aim of including this 
cost-effectiveness plane is to replicate the full conceptual model regardless of 
the associations’ accuracy.  
 
Figure 64: BeatIt cost-effectiveness plane – conceptual model driven analysis (including all 
regressions in the conceptual model) 
 
Although in this case study, as in the TWICS case study, each component was 
predicted by only one other component, the annotated syntax in Appendix 13: 
Stata syntax for TWICS and BeatIt conceptual model analysis case studies 
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includes syntax to produce Figure 64 where all equations were included, this 
enables to the reader to understand how to operationalise a conceptual model 
which has more than one predictor for one or more equations. 
Figure 65 presents the conceptual model driven analysis informed by the results 
from the regressions, this analysis includes the following associations: in 
equation 1) the treatment arm predicts levels of activity, in equation 2) levels of 
activity predict depressive symptoms, in equation 3) the treatment arm predicts 
treatment costs, in equation 4) depressive symptoms predict QALYs, and in 
equation 5) levels of activity predict non-treatment costs.  Compared to the 
cost-effectiveness plane presented above with all associations (Figure 64), the 
plots in this cost-effectiveness plane are concentrated around the origin and 
cover a smaller area than previously, however the ellipse still crosses into all 
four quadrants. The shape of the bootstrap samples show that as incremental 
costs increase so do incremental QALYs, however the incremental QALYs remain 
close to the vertical axis.  QALYs are predicted by depression, which is predicted 
by activity, and the regression results show that higher levels of activity led to 














Next the bootstrapped samples should be used to produce a cost-effectiveness 
acceptability curve, presented in Figure 66, this shows that at a willingness-to-
pay threshold of £20,000 the BeatIt arm has a 12.1% chance of being cost-
effective. 
 
Figure 66: BeatIt cost-effectiveness acceptability curve - conceptual model driven analysis 
 
The last step in this final analysis is to use the bootstrapped samples to calculate 
point estimates, summary measures (for example ICER and net monetary 
benefit), and value of information estimates, and compared to the original 
treatment arm-based analysis results. The comparison of these conceptual 
model driven analysis results (including the cost-effectiveness planes and cost-
effectiveness acceptability curves presented above) to the original treatment 
arm-based analysis results is a crucial aspect of the final analysis; the aim of this 
comparison is to provide additional insight and understanding to the original 





The differences in costs and QALYs and incremental net monetary benefits, with 
95% confidence intervals, and ICERs and value of information estimates are 
presented in Table 25 for both the treatment arm-based and conceptual model 
driven analyses.  The measures included are derived from bootstrapped results 
for both analyses to allow a direct comparison between the results for both 
approaches.  Measures to characterise uncertainty around the ICERs are not 
included as they are ratios and there are statistical complexities attached to 
calculating uncertainties around ratios.   
Table 25: BeatIt results from both analyses 
 Treatment arm-based 
analysis  
Mean (95% CI) 
Conceptual model 
driven analysis 
Mean (95% CI) 
Cost differences £444 (-£10,911 to 
£11,876) 
£2,621 (-£1,965 to 
£7,758) 
QALY differences -0.064 (-0.168 to 0.037) 0.004 (-0.007 to 0.019) 
ICER  -£105,823 £496,160 
Incremental net 
monetary benefit 
-£1,729 (-£13,495 to 
£10,241) 
-£2,533 (-£7,558 to 
£1,892) 
EVPI £1,679 £148 
EVPPI - QALYs £21 £0 
EVPPI – Total costs £1,570 £171 
EVPPI – Treatment costs  £0 
EVPPI – Non-treatment 
costs  
 £168 
CI - confidence interval, EVP - expected value of perfect information, EVPPI - expected value of 
perfect parameter information, ICER - incremental cost-effectiveness ratio, QALY - quality adjusted 
life-year 
 
In the treatment arm-based analysis the BeatIt is more expensive and less 
effective than the StepUp arm, in this scenario the decision makers should 
reject BeatIt.  In the conceptual model driven analysis BeatIt is more expensive 
and more effective than StepUp, in this scenario decision makers should adopt 
BeatIt if the ICER is below £20,000, however the ICER is much larger than 
£20,000; it is £496,160.  The 95% confidence interval for the difference in costs 
and QALYs in both analyses crosses zero, indicating uncertainty in both of the 
results.  The difference in costs is larger in the conceptual model driven analysis 
but the 95% confidence interval is narrower by a factor of nearly two, illustrating 
that uncertainty in the point estimate has decreased despite BeatIt being more 
costly than StepUp.  The difference in QALYs between arms is smaller in the 
conceptual model driven analysis compared to the treatment arm-based analysis 
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and the 95% CI is narrower by a factor of almost eight, again confirming that 
uncertainty in the point estimate has decreased.   
The less uncertain results from the conceptual model driven analysis are clearly 
illustrated in Figure 67, where the cost-effectiveness planes for both approaches 
are compared.  The spread of bootstrapped samples is wider in the treatment 
arm-based analysis (top) and they are relatively evenly spread in all four 
quadrants of the cost-effectiveness plane, the confidence ellipse is also crossing 
into all four quadrants confirming the uncertainty in these results.  In the 
conceptual model driven analysis (bottom) the samples are more focussed 
around the origin.  In this analysis the costs show a broader spread north of the 
horizontal axis and less spread south of the horizontal axis. There are more 
bootstrapped samples in the northeast quadrant compared to the southwest 
quadrant, showing a stronger trend towards BeatIt being more expensive and 
more effective than StepUp.  The costs and QALYs have a narrower spread in the 
conceptual model driven analysis compared to the treatment arm-based analysis 
indicating less uncertainty in the difference, however the 95% confidence 
interval for differences still crosses zero in the conceptual model driven 
analysis.  Furthermore, despite a narrower spread of samples the confidence 





Figure 67: Cost-effectiveness planes - comparison of treatment arm-based and conceptual model 
driven analyses 
 
The cost-effectiveness acceptability curves from both analyses are presented in 
Figure 68 for comparison. The treatment arm-based analysis curve (top) shows 
that at a willingness-to-pay threshold of £20,000 the BeatIt therapy has less than 
a 50% chance of being cost-effective compared to the StepUp therapy, however 
in the conceptual model driven analysis (bottom) the chance of BeatIt being 
cost-effective compared to StepUp is approximately 12%.  The treatment arm-
based analysis cost-effectiveness curve shows that the probability of BeatIt 
being cost-effective compared to StepUp is fairly constant at all willingness-to-
pay thresholds; there is little chance of BeatIt being cost-effective.  In the 
conceptual model driven analysis there is also an almost constant probability of 
BeatIt being cost-effective compared to StepUp, this is lower than the 
probability in the treatment arm-based analysis.  This result confirms the 
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interpretation of the cost-effectiveness planes, there is little chance of BeatIt 
being cost-effective in the treatment arm-based analysis, this is confirmed in 
the conceptual model driven analysis with less chance of BeatIt being cost-
effective. 
 
Figure 68: BeatIt cost-effectiveness acceptability curves - comparison of treatment arm-based and 
conceptual model driven analyses 
 
The incremental net monetary benefit measure is particularly helpful for 
interpreting results when bootstraps fall into more than one quadrant of the 
cost-effectiveness plane, as in this situation.  The incremental net monetary 
benefit for both analyses is negative, indicating that decision makers should not 
adopt the BeatIt intervention in either analyses. The negative incremental net 
monetary benefit from the conceptual model driven analysis is greater than the 
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net monetary benefit resulting from the treatment arm-based analysis indicating 
that this approach less cost-effective. The uncertainty (95% CI) around the net 
monetary benefit measures is over two times bigger in the treatment arm-based 
analysis, again showing that the conceptual model driven analysis results has less 
uncertainty around the results, but these results still confirm that BeatIt is not 
cost-effective.  The incremental net monetary benefit results from both 
approaches are plotted in a histogram to visually illustrate the variation of the 
results in each approach in Figure 69.  This demonstrates the narrower spread of 
results from the conceptual model approach compared to the trial-arm based 
results and the lower incremental net monetary benefit point estimate, 
confirming the previous results that BeatIt would be considered less cost-
effective in the conceptual model driven analysis compared to the treatment 
arm-based analysis.   
 
 
Figure 69: BeatIt - histogram of net incremental monetary benefit results showing the distribution of 
the results from both approaches 
 
Value of information results per person are also included in Table 25 to explore 
the value of eliminating sampling uncertainty and having perfect information.   
These results show that there is more value to be gained by doing more research 
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in the treatment arm-based analysis compared to the conceptual model driven 
analysis (£1,679 v £148), the lower EVPI estimate for the conceptual model 
driven analysis suggests that this analysis provides a more detailed 
understanding than the treatment arm-based analysis as a result of the 
additional structure in the conceptual model.  EVPPI results indicate there is 
more decision uncertainty in total costs, and potential value in further research 
on total costs in both analyses compared to further research on QALYs.  In the 
treatment arm-based analysis the value of more research per person is £21 for 
QALYs and £1,570 for total costs.  In the conceptual model driven analysis, the 
value of more research per person is £0 for QALYs and £171 for total costs.  
These results confirm that there is more decision uncertainty in the treatment 
arm-based analysis.  When the EVPPI for total costs is broken down into 
treatment and non-treatment costs in the conceptual model driven analysis, the 
results show that there is no value to be gained by reducing the uncertainty in 
treatment costs (EVPPI results are £0); this result is expected as treatment costs 
are known and precise, there is no decision uncertainty.  For non-treatment 
costs the EVPPI is £168 indicating a level of decision uncertainty, and that the 
value of further research into these costs is greater than further research into 
treatment costs. 
7.5.4 BeatIt summary 
In the original economic evaluation, the treatment arm-based results for the 
complete case analysis reported higher costs and lower QALYs for the BeatIt arm 
compared to the StepUp arm, however there was uncertainty in these results as 
bootstrapped samples fell into all four quadrants, as did the confidence ellipse. 
These treatment arm-based results were confirmed in the multiple imputed 
unadjusted results; however, the multiple imputed adjusted results are reversed 
with lower costs and higher QALYs in the BeatIt arm compared to the StepUp 
arm.  These results showed there was uncertainty in the economic evaluation, 
the only certain element was that treatment costs were greater in the BeatIt 
arm compared to the StepUp arm.  In the conceptual model driven analysis costs 
and QALYs were higher in the BeatIt arm compared to the StepUp arm, these 
results were also uncertain with the confidence ellipse crossing all four 
quadrants of the cost-effectiveness plane, however the 95% confidence interval 
was narrower in this analysis compared to the original treatment arm-based 
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analysis, showing the greater precision of the conceptual model driven analysis 
results. 
The conceptual model driven approach demonstrated that the treatment arm 
predicted treatment costs, but not depression, activity nor non-treatment costs. 
Levels of activity predicted non-treatment costs and depression but not quality 
of life, and depressive symptoms predicted quality of life but not non-treatment 
costs.  In the original treatment arm-based analysis the quality of life (in terms 
of QALYs) improved in both arms, the conceptual model driven analysis can give 
a more detailed understanding of the mechanism driving this; it showed that 
there was no difference in activity levels between arms, but that there was a 
link between activity and depression, and depression and quality of life 
demonstrating that both therapies affected depressive symptoms and quality of 
life.  This result validated including the link between activities, depressive 
symptoms and quality of life in the conceptual model. 
None of the possible associations were found to be strong and they were all 
omitted from the conceptual model final analysis. One assumed association was 
omitted in the final analysis: depressive symptoms predicting non-treatment 
costs, this may be a result of the increase in activity costs linked to increased 
activity levels masking this association.  The conceptual model driven analysis 
confirmed the original treatment arm-based analysis findings that treatment arm 
only predicted treatment cost, not depressive symptoms nor quality of life.  
Additionally, it found that the BeatIt intervention did not alter activity levels 
significantly differently compared to the StepUp comparator. These findings 
could feed into future trials with knowledge that the GDS-LD is linked to the EQ-
5D-Y outputs and that activity levels predict depressive symptoms.  However, it 
should be borne in mind that the sample in this trial was small and that any 
conclusions reached should be treated with caution. 
The incremental net monetary benefit showed that neither analysis considered 
BeatIt to be cost-effective.  Value of information results showed that additional 
research was valued higher in the treatment arm-based analysis compared to the 
conceptual model driven analysis, and that the less uncertain estimates in the 
latter analysis indicated that there would be no value to be gained by further 
research into treatment costs and QALYs. 
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Overall, the conceptual model driven analysis demonstrated that BeatIt is not a 
cost-effective therapy compared to StepUp.   
7.6 Discussion of new role for conceptual models 
7.6.1 Overview 
The purpose of the new role for conceptual models is to provide decision makers 
with additional insight into the results of conventional treatment arm-based 
analyses, going beyond an intervention focussed, outcomes-driven analysis to 
provide understanding of the trial mechanism driving the economic evaluation 
results. 
This new role involves developing a conceptual model to represent the trial 
mechanism linking inputs to economic outputs via expected associations.  The 
approach comprises three aspects: 1) develop a conceptual model which can be 
used as a communication tool to explain the economic evaluation to the clinical 
trial team, and confirm assumptions made and the clinical integrity of the 
conceptual model: 2) regressions are performed to confirm or otherwise the 
accuracy of the mechanism in the conceptual model, this provides additional 
understanding to the treatment arm-based results, and 3) provides a framework 
on which to carry out further analysis to assess point estimates and produce 
cost-effectiveness planes, cost-effectiveness acceptability curves, net monetary 
benefit, and value of information estimates.  These outputs are compared to the 
original treatment arm-based results to provide a more nuanced understanding 
of the treatment arm-based results. 
The case studies were used to evaluate the new role and establish whether it 
achieved its purpose of providing additional insight and understanding. 
In both case studies the results from confirming the accuracy of the conceptual 
model provided additional understanding of the treatment arm-based results, for 
example the TWICS case study confirmed the validity of including exacerbations 
as a mediator as the number of exacerbations was found to predict quality of 
life and non-treatment costs.  In BeatIt the results confirmed that levels of 
activity predicted depressive symptoms, which in turn predicted quality of life.  
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Neither case study showed that the treatment arm directly predicted quality of 
life or non-treatment costs, this illustrates the value of this new role when most 
economic evaluations are conducted based solely on the difference in economic 
outcomes between arms.  The results from understanding the trial mechanism 
could inform the design of future trials in terms of resource use categories 
collected and evidence of associations in trial mechanisms. 
Applying the case study did not reverse or significantly change the original trial 
results but did provide a more less uncertain estimate of cost-effectiveness, 
witnessed by narrower variances in uncertainty measured by 95% confidence 
intervals and presented on the cost-effectiveness planes with confidence 
ellipses. Both case study cost-effectiveness acceptability curves showed a lower 
probability of the intervention being cost-effective, and overall, the conceptual 
model driven analyses reported lower EVPI estimates than the original treatment 
arm-based analyses suggesting less value to be gained by future research based 
on the conceptual model driven results, it could be argued that the additional 
structure of the conceptual model driven analysis has added value without the 
need for future research.    
Despite the similarity in results between the two analyses in the case studies 
there may be a times where the treatment arm-based analysis produces 
conflicting results to the conceptual model driven analysis, in this scenario the 
new role will not help interpret the original results but will add confusion.  
These conflicting results may result from an inaccurate conceptual model, in 
which case the accuracy of the conceptual model should be checked, however if 
the conflicting results are genuine then this should be presented in a transparent 
way. 
The regressions in the case studies were kept deliberately straightforward as 
their purpose was to illustrate the new concept. Ordinary least squares 
regressions were chosen as they are simple to interpret, easy to understand, are 
unbiased, and have less assumptions than other regression techniques.  Whilst I 
acknowledge that cost and count data is often skewed and other regression 
techniques are better suited to account for this skewedness, the focus of the 
case studies was to illustrate the new conceptual model driven analysis approach 
without the distraction of statistical model selection.  For this same reason 
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covariates were not included in the regressions, nor multiple imputation in the 
dataset (except a straightforward replacement of missing data with treatment 
arm specific means). 
To prevent bias in the conceptual model it should be developed prior to 
receiving the clinical trial data, if the clinical trial results produce unexpected 
outcomes sensitivity analyses can be carried out. For example, I used the TWICS 
conceptual model to further analyse the clinical trial data when results showed 
that there were more participants reporting exacerbations requiring hospital 
treatment in the placebo arm. However, there will be a point when additional 
sensitivity analysis turns into a data fishing exercise; the analysts perform many 
unplanned sensitivity analyses with the aim of discovering a significant finding 
from the data.  Which leads to the question; ‘when do you stop this analysis?’  
The conceptual model sets out a priori the expected associations in the 
economic evaluation, the first level of analysis confirms the accuracy of the 
conceptual models, sensitivity analysis (such as in TWICS) comprises the second 
level of analysis, I would argue that two levels are enough to gain sufficient 
understanding of the trial data in this new approach and stops the analysis 
becomes a data fishing exercise. 
Finally, it is important to be clear about the key assumptions made in developing 
the conceptual model, as discussed in the methodological framework in Chapter 
5, so the results can be interpreted correctly. 
I believe that the new role achieved its purpose; it has the potential to provide 
additional insight and more detailed information for decision makers, 
particularly when the original treatment arm-based economic analysis is 
uncertain, however the new role should not be seen as limited only in providing 
further insight into uncertain results.  The conceptual model driven analysis 
should be seen as a supplement to the treatment arm-based analysis, adding 
value to it.  
Strengths and limitations of this novel approach were highlighted in applying it 




This is a new role for conceptual models in the field of economic evaluation, 
aside informing the structure of a decision analytic model; it provides a novel 
approach in analysing valuable clinical trial data, going beyond the conventional 
treatment arm-based analysis where the focus is on the difference in costs and 
health benefits between treatment arms as measured by the ICER, with no 
regard to what is driving the costs and health benefits.  The new role also 
considers the trial mechanism driving the results, providing understanding into 
what is driving the results. It could be argued that this new role brings together 
elements of treatment arm-based economic evaluation and a decision model 
based economic evaluation by considering the underlying processes driving the 
trial mechanism. 
The conceptual model driven analysis addresses a sub-set of limitations that 
result from conducting economic evaluations alongside clinical trials, these 
include insufficient sample size, suboptimal collection of economic data and 
protocol-driven costs.  However, as mentioned earlier, this new role is not 
limited to uncertain clinical trial results. 
Conducting clinical trials and collecting data for analysis is expensive, time 
consuming and uses human resources in terms of the trial team and participants, 
by using the data for additional analysis these valuable resources are further 
utilised. 
In sub-section 2.5.1 approaches that should be used to reduce the burden of 
resource use collection were discussed, one of these was limiting the resource 
use categories to those directly affected by the disease or intervention.  
Developing these conceptual models can help communicate the rationale behind 
omitting some resource use costs whilst including others.  
The case studies showed that more detailed understanding provided by the 
conceptual model driven analysis could inform the design of future clinical 
trials, both in terms of identifying resource use categories and in terms of giving 




The methods described in the case studies are illustrative only and should not be 
interpreted as the most robust and valid method to conduct conceptual model 
analyses. The method was chosen because it is easy to understand and simple to 
apply in this role. 
Due to the nature of conceptual models the results are based on a simplification 
of the trial mechanism, as such identified mediators may be overstated. As the 
approach uses the clinical trial data there may be mediators that are not 
measured (unobserved), thereby overemphasising the mediators included in the 
conceptual model, this may produce spurious results due to underlying 
mechanisms not being identified and tested.  This approach may work better in 
a clinical trial with a straightforward mechanism, more complex mechanisms 
may include mediators which are not collected in the clinical trial data leading 
to issues with unmeasured components.  
When identifying the regressions to include in the bootstrapped analysis the 
regression results showing strong associations should be included, however 
sometimes only one component is predicting another (for example in the TWICS 
case study treatment arm linked to exacerbations, and in the BeatIt case study 
treatment arm linked to activities); if the regression does not show a strong 
association between these components the regression still needs to be included 
to facilitate the full conceptual model driven analysis. This is likely to be the 
case in many conceptual models developed for this new role as the first 
component will nearly always be the treatment arm and this is likely to only 
feed into one main component in the trial mechanism, which in turn may drive 
the rest of the trial mechanism. 
It could also be argued that reliance on statistical significance when interpreting 
the regression results is counterintuitive when many economic evaluations are 
underpowered due to an insufficient sample size for economic analysis. Due to 
potential lack of power, there is a possibility that one or more pathways in the 
conceptual models were rejected when they should have been included. 
However, the purpose of the regressions is not to conduct a conventional 
statistical hypothesis test, but as a filter to confirm the logical hypothesis of the 
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conceptual models. To provide additional evidence to decision makers, I believe 
this potential trade-off is acceptable. 
By following clinical opinion there was a potential for bias in the final 
conceptual model analysis results for TWICS, caused by omitting the link 
between treatment arm and non-treatment costs in the conceptual model.  The 
conceptual model found that treatment was a strong predictor of non-treatment 
costs, however this link was omitted in the final conceptual model analysis. 
There was no a priori hypothesis that theophylline would have an effect on the 
severity of exacerbations and therefore the suitable setting for treatment (home 
or hospital), which is why a link between treatment arm and type of 
exacerbation cost was not illustrated in the proposed conceptual model (Figure 
54). However, when the accuracy of the conceptual model was tested there was 
strong link between treatment arm and non-treatment costs. Further sensitivity 
analysis found that this link was driven by the cost of exacerbations treated in 
hospital – there were more participants with hospitalised exacerbations in the 
placebo arm than the theophylline arm, and 10 of these participants had lengths 
of stay greater than 40 days.  Clinicians from the TWICS trial put this down to a 
chance finding; there was no plausible biological mechanism for this, and as the 
trial was multi-site there may be differing criteria for admitting participants to 
hospital for treatment compared to treating at home in different sites. Because 
of this information the link between treatment arm and non-treatment costs was 
omitted from the final conceptual model analysis. However, this 
assumption/omission may have resulted in the final conceptual model analysis 
results not fully reflecting the trial mechanism and being biased, limiting the 
usefulness of the resulting analysis in the case study. This also highlights a 
potential limitation of the proposed new role for conceptual models; when 
testing the conceptual model accuracy results in a conflict between regression 
results and clinician input.  In this situation the modeller would need to decide 
whether to omit links based on clinical opinion, with resulting potential bias to 
the final results.   
There are limitations in the case studies due to simplifying the new approach to 
suit an illustrative case study; complete case data has been used without any 
multiple imputation (only a naive method of replacing missing data with 
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treatment arm specific means).  Furthermore, no adjustments for imbalances 
were performed, this was to keep the case studies simple, for example BeatIt 
had an imbalance in quality of life at baseline and omitting this adjustment in 
the conceptual model driven case study may have affected the results, but I did 
not want to introduce the complexity of choosing statistical methods when 
demonstrating the new role.  
Whilst the regression method, based on p-values, chosen to illustrate the new 
role in the case studies was straightforward, it was not intended to be a 
prescriptive method, there are alternative methods that could be used in this 
role, and these should be explored in future work. These methods relate to 
causal inference and include structural equation models (SEM), path analysis and 
directed acyclic graphs (DAGs).  SEM entails numerous linear equations being 
used to identify causal relationships in observed and unobserved variables(198). 
Path analysis is similar to SEM, but does not consider unobserved variables, it 
was developed by Sewall Wright to test whether data is consistent with a 
hypothesised model (106). The path analysis method is based on hypothesised 
nested causal relationships in a system which are represented by linear 
regressions. Data is assessed to identify any effects on one variable being caused 
by another, testing the hypotheses in the model(199). This format is similar to 
DAGs, these are mathematical models which represent causal relationships. 
When developing DAGs and identifying possible causal relationships there are 
constraints on how they are developed, adding to the complexity of this 
method(108). The main difference between path analysis and DAGs is that in 
path analysis the models predetermine linear causal effects, whereas in DAGs 
the models may be linear or non-linear (108). The regression method chosen for 
these case studies shows correlation – a linear relationship between two 
variables, whereas causal inference tests hypothesised links.  A step away from 
the causality methods described above is stepwise variable selection, this 
method is model driven and does not include any logic imposed on the model, 
focussing solely on which predictors have the biggest effect on dependent 
variables(199). 
I assessed the appropriateness of using SEM but rejected it as it added an 
additional layer of complexity to include and consider unobserved variables. A 
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fundamental concept in this new role is that data from the clinical trial is 
analysed further by conceptual models, if the data is not available because it is 
unobserved this would change the focus of the concept. I also applied path 
analysis methods to the case study data but found model specification was 
difficult to achieve. The language/terminology, software and assumptions 
inherent in SEM, path analysis and DAGs were also a barrier for their use as an 
illustrative method for the case studies, adding extra complexity to the case 
studies, the purpose of which is to illustrate the new role, not to set prescriptive 
methods for the new role.    
Moving away from causality hypothesis testing and the p-value some have 
championed using effect size and uncertainty (95% confidence intervals) as a 
means to measure effects(200). However, for the purpose of the new role 
decisions would still need to be made on which links in the conceptual model to 
reject or accept, meaning an acceptable method of interpreting effect size and 
uncertainty would need to be considered. Another alternative to establishing 
causality would be to impose a minimum clinically important level as a ‘cut-off’ 
for acceptance/rejection, however, again this would need to be considered and 
data is unlikely to be available for all clinical outcomes.  
In summary, in this proposed new role for conceptual models, they are used to 
illustrate causal links, similar to DAGs, however the relationships are tested 
using different methods of analysis.  Future research should identify differences 
and overlaps between the methods used in the illustrative examples and SEM (or 
other methods); however it is unlikely that additional statistically significant 
results would be found.  Furthermore, neither SEM, path analysis nor DAGs are 
routinely used in economic evaluation and by illustrating the new role for 
conceptual models using regressions I am not proposing that they are replaced, 
it may be proven in future work that they are the most valid statistical method, 
however, as they are not routinely used in economic evaluation, regressions are 
a simple and widely understood concept to use for illustration purposes.  
Variables from the trial data used to represent the components in the 
conceptual model may not be suitable for that purpose, depending on the 
variables collected and the purpose of collecting them.  For example, utilities 
are driven by how a person feels and their capabilities, this may not always 
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relate directly to the disease and changes in the disease, therefore using health 
utilities can be a blunt instrument in terms of evaluating the expected trial 
mechanism.  
It was not possible to compute the EVPPI for components within the trial 
mechanism, only the outputs of costs and QALYs, this was because of how the 
bootstrapping was operationalised, further work needs to be done to identify a 
suitable mathematical method to extract this data. Furthermore, whilst EVPI 
was estimated EVSI and ENBS were not, this limits the conclusions on whether 
future research is worthwhile. 
7.7 Summary 
This chapter demonstrated the proposed new role for conceptual models to add 
further insight and understanding into the clinical trial data, this is the third 
output in this thesis and fulfils the first objective.  The case studies were used 
to evaluate the new role for conceptual models, and highlight the strengths and 
limitations experienced in applying the new role to the case studies. 
The case studies demonstrated that using this conceptual model driven analysis 
produces additional insight into the valuable clinical trial data, evaluating and 
confirming which key components of the conceptual model are driving the trial 
mechanism in relation to the economic evaluation and comparing the original 
conventional treatment arm-based analysis to the new conceptual model driven 
analysis.  
The inclusion of the case studies was intended to illustrate the concept of the 
new role for conceptual model and not be an exhaustive presentation of the 
methods of analysis, therefore the results of the conceptual model driven 
analysis should be interpreted with caution in terms of understanding the TWICS 
and BeatIt analyses. 
Further research to develop this new approach could include using more case 
studies to evaluate the new role, in particular in different disease areas, care 
pathways and in clinical trials reporting certain results.  The conceptual model 
and variables from the clinical trial data could be tested further using path 
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analysis, and possibly structural equation modelling if latent variables are 
relevant to the particular trial mechanism.  Plus, methods could be investigated 
to provide complete EVPPI results. 
The next chapter is the final chapter of the thesis and presents a discussion and 










Chapter 8 Discussion and conclusions  
8.1 Chapter overview 
The aim of this chapter is to discuss the work in the thesis and to provide a 
conclusion, answering the research question ‘how can conceptual modelling 
enhance health economic evaluation?’ 
The aim of this thesis was to expand the role of conceptual modelling in health 
economic evaluation.  The two objectives of the thesis were to propose and 
demonstrate a new role for conceptual models in health economic evaluations, 
and to propose and demonstrate a methodological framework for developing 
conceptual models in this new role.  
Currently the role of conceptual models in economic evaluation is restricted to a 
pre-cursor for a decision analytic or mathematical model; these models are 
routinely used to extract and amalgamate evidence from different sources to 
estimate cost-effectiveness.  This thesis introduces a new role for conceptual 
models in economic evaluation; to provide decision makers with additional 
understanding and insight into clinical trial data.  Clinical trials are expensive to 
run and the data collected in them should be explored fully, currently there is 
robust guidance for carrying out economic evaluations using clinical trial data, 
however, inherent problems with sample size and conflicting objectives for 
clinical and cost-effectiveness analyses often lead to uncertain results in 
economic evaluations alongside clinical trials.  A standard treatment arm-based 
analysis also overlooks important aspects of the trial mechanism relating to costs 
and quality of life focussing solely on the ICER and not considering what is 
driving it, in an outcomes driven ‘black box’ evaluations.  These drawbacks 
provide scope for a new approach to analyse valuable clinical trial data, and 
thereby giving additional understanding to decision makers. 
The contributions of this thesis are summarised by chapter in Section 8.2, the 
strengths and limitations of the thesis are then discussed in Section 8.3, 
implications for policy and practice are presented in Section 8.4, 
recommendations for further work are suggested in Section 8.5, and finally, 
conclusions are made in Section 8.6.  
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8.2 Overview of chapters 
8.2.1 Chapter 2 – The role and practices of economic evaluation 
alongside clinical trials 
This chapter considered the role and purpose of economic evaluations; budgets 
for allocating healthcare services are limited and decision makers need to 
decide which new and existing health technologies to fund, based on safety, 
efficacy, effectiveness and cost-effectiveness evidence, the gold standard 
vehicle for basing these decisions on are clinical trials.  Clinical trials follow a 
pre-determined protocol for determining sample size, recruiting participants, 
delivering the health technology and establishing the effectiveness of the 
technology (the treatment effect).  Established guidance exists for conducting 
economic evaluations alongside clinical trials, however there are drawbacks for 
using clinical trial data for this purpose, these stem from differences in the main 
objectives and audiences of the clinical effectiveness analysis of a clinical trial 
and the economic analysis of a clinical trial.  Drawbacks resulting from the 
differences in objectives include lack of generalisability, shortened time 
horizon, limited comparators and lack of power for economic outcomes.  The 
main consequence of these drawbacks is uncertainty.  Guidance exists on how to 
express and describe uncertainty in economic evaluations; however decision 
makers are often left with limited evidence on which to base a decision.  There 
is also criticism of the ‘black box’ nature of economic evaluations, with the 
analysis driven by treatment arms with no consideration of the mechanisms and 
associations linking the treatments to the outcomes. This chapter highlighted 
that although there is well established guidance for conducting economic 
evaluations alongside clinical trials several potential drawbacks in this field 
remain.  A new role for conceptual models could provide additional information 
to decision makers, adding understanding of the trial mechanism process and 
giving an interpretation of the economic evaluation components that goes 
beyond the conventional focus on the ICER. An overview of this new role was 
introduced, then a description of the methods in the new role was given: 1) the 
key economic components of the economic evaluation are identified, helped by 
a template based on the Weinstein and Stason equations, the trial mechanism is 
identified and simplified, and the links and associations between the key 
economic components and trial mechanism are depicted in a conceptual model 
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diagram; 2) the conceptual model diagram is tested for accuracy using 
regression techniques, this provides information on components and associations 
in the conceptual model giving further understanding of the key drivers of the 
trial mechanism driving economic evaluation results, 3) the confirmed 
conceptual model is then used as a framework to conduct an additional analysis 
on the valuable trial data, the results of this additional analysis are compared to 
the original treatment arm-based analysis results giving further insight and 
understanding.   This chapter provided the reader with an understanding of the 
role of economic evaluation, guidance used to perform economic evaluations, 
drawbacks of conducting economic evaluation, and an introduction to a new role 
for conceptual models that attempts to address the drawbacks and provide 
further understanding. 
8.2.2 Chapter 3 – Case studies: an illustration of current 
economic evaluation guidance 
Chapter 3 introduced the two case studies used for illustration purposes in this 
thesis.  Both cases studies were NIHR funded clinical trials: 1) TWICS 
investigated the clinical and cost-effectiveness of including theophylline 
alongside usual care compared to usual care only in patient with COPD to reduce 
the number of exacerbations needing treatment, and 2) BeatIt investigated the 
clinical and cost-effectiveness of a behavioural activation therapy (BeatIt) 
compared to self-help therapy (StepUp) for adults with intellectual disabilities 
and depression, to reduce depressive symptoms.  In both case studies the 
established methods for conducting economic evaluations alongside clinical trials 
described in Chapter 2 were applied and the results of a conventional treatment 
arm-based analysis were presented.  Both economic evaluations showed 
uncertain results, and the uncertainty in the results was illustrated using 
recommended approaches.  By presenting these case studies the scene was set 
for introducing the proposed novel approach, based on representing the 
anticipated causality in the trial mechanism (10) using conceptual models. This 
chapter demonstrated the application of the guidance presented in Chapter 2 
and the uncertainty experienced in many economic evaluations. 
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8.2.3 Chapter 4 – Scoping review of methodological framework 
development 
The second objective of this thesis was to provide guidance for developing 
conceptual models for the new role in economic evaluation.  Methodological 
frameworks provide a step-wise structured guide for a process, suitable for this 
objective. However, at the outset of the thesis research there was no guidance 
on how to develop methodological frameworks, so a new work strand was added 
to this second objective; to map the existing approaches taken in developing 
methodological frameworks and amalgamate and summarise these approaches 
into suggestions for developing methodological frameworks.  A scoping review 
identified 30 methodological frameworks which reported the approaches taken 
in developing the included methodological frameworks.  The approaches taken 
were extracted and synthesised into phases to make suggestions for developing 
methodological frameworks.  Chapter 4 demonstrated that there are enough 
similarities in current reported approaches to developing methodological 
frameworks to group and produce suggestions based on the approaches. This 
chapter was the first output of the thesis, and partly fulfilled the second 
objective. 
8.2.4 Chapter 5 – A methodological framework for conceptual 
models in economic evaluation 
In this chapter the suggestions for developing a methodological framework from 
Chapter 4 were used to develop a draft methodological framework for designing 
conceptual models.  The existing guidance for developing conceptual models in 
economic evaluations focusses on using the conceptual model to design the 
structure of a decision analytic model, however the aim of this thesis was to 
explore using conceptual models for guiding trial data analysis, so new guidance 
was needed. A scoping review identified 16 existing methodological frameworks 
for developing conceptual models, 18 steps for the process were extracted, 
these were grouped into phases and amalgamated into stages within the phases. 
Although the identified methodological frameworks were from seven fields there 
were enough similarities to create a draft methodological framework, this was 
then evaluated by comparing it to existing guidance for developing conceptual 
models in economic evaluation.  The draft methodological frameworks was 
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amended for any gaps or issues highlighted by the evaluation exercise to produce 
a final methodological framework.  This chapter demonstrated that it was 
possible to produce a methodological framework for developing conceptual 
models based on reported approaches for development in fields other than 
economic evaluation; there were similarities in all fields.  Also, by applying 
economic evaluation specific concepts the methodological framework was 
similar to established conceptual model development guidance.  This chapter 
formed the second output from the thesis and fulfilled the second objective. 
8.2.5 Chapter 6 – Applying the methodological framework to 
developing conceptual models 
This chapter applied the methodological framework to the thesis case studies to 
develop conceptual models to use in the new role.  In applying the 
methodological framework each stage of the methodological framework was 
described, and the iterations of each conceptual model were presented with a 
description of how each conceptual model was developed.  The template based 
on the Weinstein and Stason was used to identify the key economic components, 
these were combined with the trial mechanism to produce the final conceptual 
models. This chapter demonstrated that following the stages in the 
methodological framework enables the user to develop a conceptual model, the 
stages and guidance in the methodological framework were helpful and clear, 
and several iterations of the diagram were needed before the final conceptual 
models were developed. 
8.2.6 Chapter 7 – Case studies to illustrate the new role for 
conceptual models  
In this chapter the two case studies used throughout this thesis demonstrated 
the new role for conceptual models. The conceptual model driven analysis 
delves into the trial data to further understand the trial mechanism beyond a 
conventional treatment arm-based analysis.  The logic of the conceptual models 
was assessed using regression techniques, this aspect of the new role provided 
additional understanding in terms of what was driving the economic results, 
giving insight into the current trial and potentially informing the design of future 
trials.  The results from the regressions fed into the conceptual model driven 
analysis, results from the analyses showed less uncertainty in the conceptual 
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model driven analyses compared to the treatment arm-based analysis, overall 
the conclusions of the original treatment arm-based analysis results did not 
change but additional understanding was provided.   The conceptual model 
highlighted the key mechanisms within the clinical trial generating costs and 
health benefits.  Decision makers can use the results of the conceptual model 
driven analysis to better understand clinical trial results and consider the value 
of future research and how it might incorporate evidence identified in the 
conceptual model driven analysis.  This chapter demonstrated the new concept 
and illustrated how it could be applied in practice, highlighting its strengths and 
limitations.  This fresh approach for using conceptual models in economic 
evaluation is the final output in the thesis and fulfils the first objective. 
8.3 Strengths and limitations of this research 
This section discusses the strengths and limitations of the research, taking one 
output at a time: 1) the first major methodological piece of work was the 
scoping review of current reported approaches for developing methodological 
frameworks; 2) the second major methodological piece of work was presenting a 
methodological framework for developing conceptual models, and 3) the last 
output was introducing the new role for conceptual models in economic 
evaluations. 
Strengths 
Starting with the first major methodological piece of work, this research 
identified a gap in the evidence; at the outset of this thesis there was no 
guidance available for developing methodological frameworks.  This piece of 
novel work addressed this gap by identifying current reported approaches for 
developing methodological frameworks and grouping and amalgamating them 
into similar themes to produce suggestions for developing methodological 
frameworks.  Evidence in the scoping review was taken from different fields 
which naturally leads to a variation in approaches, despite this there were 
enough similarities in the reported approaches to provide suggestions, and the 
natural variations resulted in robust and generalisable suggestions. Furthermore, 
this scoping review identified a lack of consistency in terminology used to 
describe methodological frameworks and made suggestions for the use of 
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consistent terminology to aid identification of methodological framework in 
literature searches in the future.  This piece of work has been published in a 
peer-reviewed journal.   
The second major methodological component of this thesis, the development of 
the methodological framework, was developed using robust suggestions from the 
scoping review above.  The methodological framework for developing conceptual 
models is the first in the field of economic evaluation that is not for the purpose 
of developing the structure of a decision analytic model.  The evidence for 
informing the development of the methodological framework came from outwith 
economic evaluation; it was based on evidence from several fields and for 
several purposes, there was enough homogenous themes to group into stages and 
produce a robust methodological framework.  The additional step in developing 
the methodological framework of comparing the draft version to existing 
conceptual modelling guidance in economic evaluation added an evaluation, 
however the purpose of my methodological framework and the existing guidance 
differs. The final methodological framework was successfully applied to the two 
case studies for demonstration. 
The final contribution of the thesis was the new role of the conceptual model, 
introducing a fresh approach. A strength of this contribution was to provide 
additional information and evidence to decision makers from valuable clinical 
trial data, there is also potential for the results from the conceptual model 
driven analysis to inform future clinical trials.  The additional evidence provided 
by the new role comprises three strands: 1) a communication tool to illustrate 
(and receive agreement of the associations linking the trial mechanism and 
economic evaluation components) with interested parties, and explain the 
rationale behind economic evaluation decisions, for example omitting or 
including specific resource use categories; 2) confirmation of the underlying trial 
mechanism presented in the conceptual model using regression techniques, 
providing understanding of the trial mechanism driving the economic evaluation 
results, and 3) additional analysis based on the confirmed trial mechanism, when 
this is compared to the original treatment arm-based analysis additional 
understanding is provided. Often the only certain results from the treatment 
arm-based analysis are the known and precise treatment costs, the conceptual 
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model acts as a filter to remove noise from the original results and adding value 
as a supplementary analysis. Another method of reducing this noise is to limit to 
the breadth of the economic data collection at the planning stage of the 
economic evaluation, by focussing on resources and outcomes likely to be 
affected by the treatment, this also has the benefit of lessening the burden on 
participants.  However, it is important not to make too many assumptions at this 
early stage to allow potential genuine differences between arms to be identified 
in the data.  Using a conceptual model at this earlier stage can help focus data 
collection on resources likely to be affected, whereas the later conceptual 
model analysis can help filter out potential noise in the data. This conceptual 
model driven analysis has the potential to address a sub-set of limitations that 
result from conducting economic evaluations alongside clinical trials; insufficient 
sample size, suboptimal collection of economic data and protocol-driven costs. 
The additional information goes beyond the conventional treatment arm-based 
analysis, where the analyst focusses on the end product of the ICER without 
considering the trial mechanism, to consider the underlying mechanism driving 
the clinical trial and economic evaluation.   
Limitations 
Starting with the scoping review of reported approaches in methodological 
frameworks, whilst a scoping review was the correct method for a first step in 
identifying current reported approaches in an area with scarce evidence, the 
resulting suggestions produced can only be described as suggestions, not 
recommendations to inform practice, for this a full systematic review would be 
needed with external validation. A full systematic outwith the scope of this 
thesis due to time and resource constraints.  However, the scoping review has 
been published in a peer reviewed journal and the interest in the paper shows 
there is an appetite for this information. The search terms of the scoping review 
were restricted to make the search manageable and pragmatic for the timescale 
of the thesis, these may have led to the exclusion of some relevant 
methodological frameworks.  The lack of consistent terminology may also have 
led to the exclusion of relevant evidence. Whilst published guidance for grey 
literature searches was followed there are limitations in searching the internet, 
these are the transient nature of the internet and the personalised nature of 
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internet searches making replication difficult.  A fifth of all identified 
methodological frameworks were rejected because they did not report the 
methods used in their development, or approaches were not clear, limiting the 
amount of evidence I could include in the suggestions. Finally, as the purposes of 
the methodological frameworks were varied and none were for developing 
conceptual models, it is possible that the suggestions extracted were not all 
suitable for methodological frameworks for developing conceptual models. 
For the second output of the methodological framework, similar to the scoping 
review above, the search terms were limited to make the search pragmatic, 
therefore some evidence may have been missed, plus the internet search will 
have been subject to the same limitations as described above.  Particularly 
evident were the exclusion of logic models, which are very similar to the 
purpose of conceptual models proposed in this thesis. Both can be used a priori 
to identify suitable outcome measures, provide transparency (184), and are 
visual representations of expected outcomes of an intervention in the system 
they depict. Extracting the themes and amalgamating them into stages was 
iterative and based partially on personal opinion making the methodological 
framework subject to personal interpretation. The methodological framework 
was applied to the two case studies as an illustration, however the case studies 
do not represent the full breadth of circumstances and possibilities of all 
economic evaluations, so it is possible that the methodological framework may 
not be suited to all economic evaluation situations.  Due to time constraints, it 
was not possible to externally validate the methodological framework, which 
may have enhanced it.   
Limitations of the new role for conceptual models include no opportunity to 
present the results of the conceptual model driven analyses case studies to the 
relevant clinical trial teams.  Had this been possible there would be three 
possible benefits: 1) more complete understanding of the economic evaluation 
results for the clinical trial team, 2) feedback from the clinical trial teams might 
have enhanced interpretation of the conceptual model driven analyses for 
further refinement of the proposed application, and 3) their feedback might 
have fed back into the methodological framework. The nature of conceptual 
models is a simplification of a real-life system or process, therefore it is possible 
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that some important mediators may be missed, and/or identified mediators 
overstated.  Data for some components may not be available from the clinical 
trial data, therefore limiting the analysis. The purpose of this third output of the 
thesis was to propose a new role for conceptual models, part of this 
demonstration were examples of possible analyses, as these are illustrative only 
they have been kept simple so may not stand up to mathematical rigour. The 
purpose of these case studies is not to rigidly prescribe methods or definitive 
guidance, but to introduce the concept of conceptual model analysis, highlight 
key issues and stimulate debate and conversation around applying the new role 
for conceptual models.  The methods used in the case studies were kept simple 
in order to illustrate the new role clearly. The TWICS case study highlighted a 
limitation of the new role; there is potential for conflict between the results 
when testing the accuracy of the conceptual model and clinical 
opinion/biological plausibility, and potential biases when assessing the effects of 
interventions on economic outcomes if clinical opinion is followed.  
8.4 Policy and practice implications and 
recommendations 
When existing guidance is applied to an economic evaluation, the focus is on the 
ICER for estimating the cost-effectiveness in clinical trials.  However, this thesis 
has shown that looking at the underlying process driving the trial mechanism can 
provide additional evidence and interpretation to decision makers when funding 
decisions are made; this additional analysis considers where the costs and QALYs 
were generated along the trial mechanism pathway. 
The new role for conceptual models has implications at several stages of the 
HTA process, these are discussed below and then recommendations are made. 
When a funding bid is released, funders should encourage applications to build in 
time for conceptual model development, this should allow sufficient time for the 
development of a conceptual model, sharing it with the wider clinical trial team, 
and conducting a planned conceptual model driven analysis.  
If the conceptual model is developed early on it has the potential to input into 
the trial design by confirming key components including mediators and 
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covariates, this can inform the collection of variables important to the economic 
evaluation. A well-developed conceptual model, which has had input from the 
clinical trial team, could prevent unnecessary data collection and enable a less 
burdensome reporting for participants. 
In its conventional role as a communication tool the conceptual model can be 
used to help understanding of the economic evaluation with the wider clinical 
trial team throughout the HTA process, and to emphasise the importance of 
economic data collection and minimising missing data. 
Results from the conceptual model driven analysis will help interpretation of the 
treatment arm-based results and provide confirmation of the trial mechanism 
important to the economic evaluation.  The conceptual model provides a 
framework for discussions of cost-effectiveness results, which in turn can inform 
future research, either from testing the accuracy of the conceptual model or 
from the final analysis. 
If a body of conceptual models are developed and stored in a public repository, 
these could provide better information about important and relevant economic 
outcomes in different disease areas, providing evidence to developers of future 
trials. 
Based on the research in this thesis the following recommendations are made: 
1. The suggested approaches presented in this thesis should be followed to 
develop methodological frameworks, for transparency and consistency. 
2. When publishing a methodological framework, the authors should use the 
term ‘methodological framework’ in the title and keywords to aid future 
literature searches.  
3. The methodological framework included in this thesis should be used 
when developing a conceptual model for the new role; it provides 
detailed stages to follow a standardised approach based on existing 
methodological frameworks.  
295 
Chapter 8 
4. A conceptual model should be developed early on in the trial to reduce 
bias, input from the trial team and other relevant parties is encouraged as 
it improves the accuracy of the conceptual model.   
5. The conceptual model should be used as a communication tool throughout 
the clinical trial, this helps with understanding of the economic 
evaluation, highlighting the key drivers of costs and health benefits. 
6. There is potential to use a conceptual model driven analysis of the clinical 
trial data to provide additional information to decision makers as a 
supplement to the conventional treatment arm-based analysis, as 
illustrated in the case studies in this thesis.  However, given the potential 
limitations of the regression method used in the case studies (as discussed 
previously), further work on alternative methods is needed before the 
new role for conceptual models can be recommended for routine use.  
8.5 Future work 
8.5.1 Methodological framework  
The suggestions in Chapter 4 for developing methodological frameworks were 
extracted from a scoping review, this was the first step in developing guidance. 
To produce more robust recommendations the terminology extracted in the 
scoping review should be used to develop and conduct a full systematic review.  
This should be followed by validation of the recommendations with a group of 
experts to produce best practise guidance. 
Particular attention should be given to develop a standardised procedure for 
collecting qualitative data in phase one, this would add consistency and 
transparency to the evidence gathering. 
8.5.2 Evaluating and validating the methodological framework for 
developing conceptual models  
Within the scope of this thesis the methodological framework for developing 
conceptual models was evaluated by comparing it to existing guidance for 
developing conceptual models.  Further work needs to be done to validate the 
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methodological framework; it should be scrutinised by experts and consensus on 
the contents of the methodological should be reached using suitable methods, 
for example a Delphi panel or focus groups.  The methodological framework 
should also be evaluated by users in additional case studies. 
8.5.3 New role evaluation 
This thesis introduced a new role for conceptual models in economic evaluation 
and demonstrated it with two case studies.  This new role should be evaluated 
and developed further: it should be evaluated by applying the new role to more 
case studies in a variety of disease areas, research problems and levels of 
certainty in the treatment arm-based results, this will highlight any potential 
weaknesses of the new role or situations when the role is not suitable.  Further 
development should assess more sophisticated mathematical methods of analysis 
such as path analysis and DAGs to confirm the model structure and structural 
equation modelling if a latent variable is expected to drive the conceptual 
model.  
Future work should also assess the value of qualitative research to inform the 
conceptual model, understand the trial mechanism and interpret results; in 
developing the case studies and in my experience of conducting economic 
evaluations, qualitative research carried out as part of the clinical trial has been 
crucial for informing the economic evaluation, particularly in understanding trial 
mechanisms, services provided, and participant behaviour.  The role of realist 
evaluations should be considered and explored in this assessment of qualitative 
research. 
8.6 Conclusions 
The research question posed in this thesis was ‘How can conceptual modelling 
enhance health economic evaluation?’  This thesis found that it is possible to use 
conceptual modelling to enhance economic evaluations using the proposed new 
role.  The thesis showed that conducting an analysis, guided by a conceptual 
model, does provide additional understanding and further interpretation to 
conventional economic evaluation, and has the potential to inform future 
clinical trial designs.  Overall, the thesis concluded that performing the 
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supplementary conceptual model driven analysis is worth doing and should be 
routinely conducted.    
The two objectives of the thesis were to: 
• Propose and demonstrate a new role for conceptual models in health 
economic evaluations.  
• Propose and demonstrate a methodological framework for developing 
conceptual models in this new role. 
The first objective was fulfilled by developing and presenting the new role and 
demonstrating it with two case studies.  The new role has three components: 1) 
developing a conceptual model depicting key components in the economic 
evaluation, with associations linking the key components to illustrate the trial 
mechanism driving the results, this can be used as a communication tool; 2) 
testing the associations in the conceptual model for accuracy to provide 
additional insight into what is driving the economic evaluation results, and 3) 
conducting an additional analysis based on the strong associations in the 
conceptual model, using the conceptual model as a framework, the results of 
which are compared to the original treatment arm-based evaluation to provide 
further insight.   
The second objective was fulfilled in two parts: 1) using scoping review 
methodology to identify approaches used in developing methodological 
frameworks and provide suggestions based on these approaches, and 2) applying 
these suggestions to develop a methodological framework for developing 
conceptual models; a scoping review identified methods used for developing 
conceptual models outwith economic evaluation, and these methods were 
grouped into stages to develop a methodological framework. The methodological 
framework was demonstrated with two case studies; conceptual models were 
developed using the methodological framework, these conceptual models were 
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trivalent inactivated 
influenza vaccination in 
2010/11 to 2015/16: the 
SIVE II record linkage study 
No 
      
Medina-Lara A, et 
al. (207) 
Cancer diagnostic tools to 






     




rehabilitation for patients 
at risk of poor outcomes 
after knee arthroplasty: 
CORKA RCT 







Yes, 95% CI 




of costs and 
differences 




Batchelor JM, et 
al. (209) 
Home-based narrowband 
UVB, topical corticosteroid 
or combination for children 
and adults with vitiligo: HI-
Light Vitiligo three-arm 
RCT 
Yes Within trial 
(3 arm) 
No No, 95%CI 
difference in 




























offset by cost 
savings in other 
cost categories 
discussed 
Taylor AH, et al. 
(210) 
Adding web-based 
behavioural support to 
exercise referral schemes 
for inactive adults with 
chronic health conditions: 
the e-coachER RCT 















Crawford F, et al. 
(211) 
Risk assessments and 
structured care 
interventions for 
prevention of foot 
ulceration in diabetes: 
development and 
validation of a prognostic 
model 
Yes DAM 
     
Pickard R, et al. 
(212) 
Open urethroplasty versus 
endoscopic urethrotomy 
for recurrent urethral 
stricture in men: the OPEN 
RCT 







costs does not 
cross 0 and 
urethrotomy is 
dominant 
None No No 
Clarkson JE, et al. 
(213) 
Risk-based, 6-monthly and 
24-monthly dental check-
ups for adults: the 
INTERVAL three-arm RCT 









Yes, 95% CI 
crosses 0 in all 
analyses 


















offset by cost 





Abel KM, et al. 
(214) 
An intervention to improve 
the quality of life in 
children of parents with 
serious mental illness: the 
Young SMILES feasibility 
RCT 
No 
      
Appleton RE, et al. 
(215) 
Levetiracetam as an 
alternative to phenytoin 
for second-line emergency 
treatment of children with 
convulsive status 
epilepticus: the EcLiPSE 
RCT 
No 
      
Gilbert R, et al. 
(216) 
Antimicrobial-impregnated 
central venous catheters 
for preventing neonatal 
bloodstream infection: the 
PREVAIL RCT 
Yes Cost study 
and DAM 
     
Stephenson J, et 
al. (217) 
An interactive website to 
aid young women's choice 
of contraception: 
feasibility and efficacy RCT 
No 


















offset by cost 
savings in other 
cost categories 
discussed 
Duffy S, et al. 
(218) 
Annual mammographic 
screening to reduce breast 
cancer mortality in women 
from age 40 years: long-
term follow-up of the UK 
Age RCT 
No 
      
Rodgers H, et al. 
(219) 
Robot-assisted training 
compared with an 
enhanced upper limb 
therapy programme and 
with usual care for upper 
limb functional limitation 
after stroke: the RATULS 
three-group RCT 





Yes for one 
comparison. No, 
95% CI does not 
cross 0 with 
usual care and 
robot, but yes 
uncertain 
between usual 







reverses trend   
Yes Yes 




with current approaches in 
primary care for children 
aged 5 years and under: a 
method comparison study 
No 
      
Dias J, et al. (221) Surgical fixation compared 
with cast immobilisation 
for adults with a bicortical 
fracture of the scaphoid 
waist: the SWIFFT RCT 
Yes Within trial 
and DAM 
No No, 95% CI does 






















offset by cost 
savings in other 
cost categories 
discussed 





people with chronic liver 
disease needing an elective 






     
Bray N, et al. (223) Powered mobility 
interventions for very 
young children with 
mobility limitations to aid 




Yes Cost analysis 
only 
     
Foster NE, et al. 
(224) 
Stratified versus usual care 
for the management of 
primary care patients with 
sciatica: the SCOPiC RCT 

































offset by cost 
savings in other 
cost categories 
discussed 
Walton M, et al. 
(225) 
Selective internal radiation 
therapies for unresectable 









     
Gilson R, et al. 
(226) 
Imiquimod versus 
podophyllotoxin, with and 
without human 
papillomavirus vaccine, for 
anogenital warts: the 
HIPvac factorial RCT 





No, 95% CI does 
not cross 0 
Results section 
some discussion 
on most costly 
category 
Yes No 
Leaviss J, et al. 
(227) 
Behavioural modification 
interventions for medically 
unexplained symptoms in 
primary care: systematic 




     
Baker P, et al. 
(228) 
Occupational advice to 
help people return to work 
following lower limb 
arthroplasty: the OPAL 
intervention mapping study 
No 


















offset by cost 
savings in other 
cost categories 
discussed 
Crawford MJ, et al. 
(229) 
Switching antipsychotic 
medication to reduce 
sexual dysfunction in 




     
Melton H, et al. 
(230) 
Interventions for adults 
with a history of complex 




      
Lewis AL, et al. 
(231) 
Urodynamics tests for the 
diagnosis and management 
of bladder outlet 
obstruction in men: the 
UPSTREAM non-inferiority 
RCT 
Yes Within trial, 
using 3 
perspectives 
No Hard to tell as 




No No No 
Worthington J, et 
al. (232) 
Thulium laser transurethral 
vaporesection versus 
transurethral resection of 
the prostate for benign 
prostatic obstruction: the 
UNBLOCS RCT 
Yes Within trial 
with 2 
perspectives 
No Hard to tell as 
no incremental 
costs for CEA, 






on what was 
driving the costs 
Yes No 
Earl H, et al. (233) Six versus 12 months' 
adjuvant trastuzumab in 
patients with HER2-
positive early breast 
cancer: the PERSEPHONE 
non-inferiority RCT 
Yes Within trial 
and DAM 
Yes No, 95% CI does 
not cross 0 




















offset by cost 
savings in other 
cost categories 
discussed 
Corbett M, et al. 
(234) 
Point-of-care creatinine 
tests to assess kidney 
function for outpatients 
requiring contrast-
enhanced CT imaging: 
systematic reviews and 
economic evaluation 
Yes DAM 
     
Costa ML, et al. 
(235) 
Negative-pressure wound 
therapy compared with 
standard dressings 
following surgical 
treatment of major trauma 
to the lower limb: the 
WHiST RCT 




No, 95% CI does 
not cross 0 for 
base-case 
analysis  
No No No 
Hamdy FC, et al. 
(236) 
Active monitoring, radical 
prostatectomy and radical 
radiotherapy in PSA-
detected clinically 
localised prostate cancer: 
the ProtecT three-arm RCT 
Yes Within trial, 
three arm 
comparison 
No No for RT v AM 
comparison and 
yes for RP v RT 
comparison 
In Results section 
discussion of 
resource use and 
distribution of 
costs over time 
No No 
Jones AP, et al. 
(237) 
Different corticosteroid 
induction regimens in 
children and young people 
with juvenile idiopathic 
arthritis: the SIRJIA mixed-
methods feasibility study 
No 


















offset by cost 
savings in other 
cost categories 
discussed 
Rodgers M, et al. 
(238) 
Interventions based on 
early intensive applied 
behaviour analysis for 
autistic children: a 
systematic review and 
cost-effectiveness analysis 
Yes DAM 
     
Hernández Alava 
M, et al. (239) 
Mapping clinical outcomes 
to generic preference-
based outcome measures: 
development and 
comparison of methods 
No 
      
Coomarasamy A, et 
al. (240) 
Progesterone to prevent 
miscarriage in women with 
early pregnancy bleeding: 
the PRISM RCT 




Yes, 95% CI 
crosses 0 
Key driver only Yes No 





to reduce distress in 
relatives of people with 
psychosis or bipolar 
disorder: the REACT RCT 




Yes, 95% CI 
crosses 0 
Discussion in 


























offset by cost 
savings in other 
cost categories 
discussed 
Fraser H, et al. 
(242) 
Rapid antigen detection 
and molecular tests for 
group A streptococcal 
infections for acute sore 
throat: systematic reviews 
and economic evaluation 
Yes DAM 
     
Hounsome J, et al. 
(243) 
Prophylactic removal of 
impacted mandibular third 
molars: a systematic 





     
Davis S, et al. (244) Denosumab, raloxifene, 
romosozumab and 
teriparatide to prevent 
osteoporotic fragility 
fractures: a systematic 





     




management of type 1 and 
type 2 diabetes: a 
systematic review 
Yes DAM 


















offset by cost 
savings in other 
cost categories 
discussed 
Witham MD, et al. 
(246) 
Sodium bicarbonate to 
improve physical function 
in patients over 60 years 
with advanced chronic 
kidney disease: the BiCARB 
RCT 




Mix of certain 
and uncertain 
results 
None No No 
Bhatnagar R, et al. 
(247) 
Thoracoscopy and talc 
poudrage compared with 
intercostal drainage and 
talc slurry infusion to 
manage malignant pleural 
effusion: the TAPPS RCT 







Yes, 95% CI 
crosses 0 
None No No 
Poolman M, et al. 
(248) 
Carer administration of as-
needed subcutaneous 
medication for 
breakthrough symptoms in 
people dying at home: the 
CARiAD feasibility RCT 
No 
      
Shaw L, et al. (249) An extended stroke 
rehabilitation service for 
people who have had a 
stroke: the EXTRAS RCT 

































offset by cost 
savings in other 
cost categories 
discussed 
cost saving may 
accrue to 
service/organisati
on not paying for 
the intervention - 
disincentive/barri
er to adopting 
cost-effective 
intervention 
Tume LN, et al. 
(250) 
Routine gastric residual 
volume measurement to 
guide enteral feeding in 
mechanically ventilated 
infants and children: the 
GASTRIC feasibility study 
No 
      
Dennis M, et al. 
(251) 
Fluoxetine to improve 
functional outcomes in 
patients after acute 
stroke: the FOCUS RCT 




Yes, 95% CI 
crosses 0 


















offset by cost 
savings in other 
cost categories 
discussed 
Davidson B, et al. 
(252) 
Liver resection surgery 
compared with thermal 
ablation in high surgical 
risk patients with 
colorectal liver 
metastases: the LAVA 
international RCT 
No 
      
Beard DJ, et al. 
(253) 
Total versus partial knee 
replacement in patients 
with medial compartment 
knee osteoarthritis: the 
TOPKAT RCT 
Yes Within trial Yes, 
total 
costs 
No, 95% CI does 
not cross 0 
Results discusses 




health-care costs  
Yes No 
Palmer R, et al. 
(254) 
Computerised speech and 
language therapy or 
attention control added to 
usual care for people with 
long-term post-stroke 
aphasia: the Big CACTUS 
three-arm RCT 
Yes Within trial 
and DAM 
 
No, 95% CI does 
not cross 0 
Discussion of 
total costs in 




Dorling J, et al. 
(255) 
Two speeds of increasing 
milk feeds for very 
preterm or very low-
birthweight infants: the 
SIFT RCT 
Yes Within trial Yes, 
total 
costs 
Yes, 95% CI does 
cross 0 


















offset by cost 
savings in other 
cost categories 
discussed 






to prevent shunt infection: 
the BASICS three-arm RCT 
Yes Within trial, 
three arm 
comparison 








could be justifies 
by associated 
cost savings of 
further surgery 
and hospital care. 
Also talks about 
CMA results if 
they had been 
appropriate 
Yes Yes 
Surr CA, et al. 
(257) 
Dementia Care Mapping to 
reduce agitation in care 
home residents with 
dementia: the EPIC cluster 
RCT 
Yes Within trial  Yes, 
total 
costs 
No, 95% CI does 
not cross 0 
One treatment 
more costly due 
to one cost 
category with 6 
participants with 























offset by cost 
savings in other 
cost categories 
discussed 
Francis NA, et al. 
(258) 
C-reactive protein point-
of-care testing for safely 
reducing antibiotics for 
acute exacerbations of 
chronic obstructive 
pulmonary disease: the 
PACE RCT 
Yes Within trial  Yes, 
total 
costs 
No, 95% CI does 




higher costs and 








in one specific 
cost category for 
intervention arm, 




Day C, et al. (259) An intervention for parents 
with severe personality 
difficulties whose children 
have mental health 
problems: a feasibility RCT 
No 
      
Hemming C, et al. 
(66) 
Surgical interventions for 
uterine prolapse and for 
vault prolapse: the two 
VUE RCTs 





No, 95% CI does 























offset by cost 





Snowden C, et al. 
(260) 
Preoperative behavioural 
intervention to reduce 
drinking before elective 
orthopaedic surgery: the 
PRE-OP BIRDS feasibility 
RCT 
No 
      
Stevenson M, et al. 
(261) 
Interventions to reduce the 
risk of surgically 
transmitted Creutzfeldt 
Jakob disease: a cost-
effective modelling review 
Yes DAM 
     
Rake C, et al. (262) High-dose oral vitamin D 
supplementation and 
mortality in people aged 
65 84 years: the VIDAL 
cluster feasibility RCT of 
open versus double-blind 
individual randomisation 
No 


















offset by cost 
savings in other 
cost categories 
discussed 
Davies NM, et al. 
(263) 
Varenicline versus nicotine 
replacement therapy for 
long-term smoking 
cessation: an observational 
study using the Clinical 
Practice Research Datalink 
No 
      
Costa ML, et al. 
(264) 
Plaster cast versus 
functional bracing for 
Achilles tendon rupture: 
the UKSTAR RCT 








arm, and other 
costs lower in 






























offset by cost 
savings in other 
cost categories 
discussed 
Riley P, et al. (265) Oral splints for patients 
with temporomandibular 
disorders or bruxism: a 
systematic review and 
economic evaluation 
Yes DAM 
     
Froggatt K, et al. 
(266) 
A group intervention to 
improve quality of life for 
people with advanced 
dementia living in care 
homes: the Namaste 
feasibility cluster RCT 





     
Edwards SJ, et al. 
(267) 
Implantable cardiac 
monitors to detect atrial 
fibrillation after 
cryptogenic stroke: a 





     
Lincoln NB, et al. 
(268) 
Group cognitive 
rehabilitation to reduce 
the psychological impact of 
multiple sclerosis on 
quality of life: the CRAMMS 
RCT 
Yes Within trial  Yes, 
total 
costs 































offset by cost 
savings in other 
cost categories 
discussed 
Duarte R, et al 
(269) 
Lead-I ECG for detecting 
atrial fibrillation in 
patients with an irregular 
pulse using single time 
point testing: a systematic 





     
Fleeman N, et al. 
(270) 
Lenvatinib and sorafenib 
for differentiated thyroid 
cancer after radioactive 
iodine: a systematic review 




     
Maguire A, et al. 
(271) 
Best-practice prevention 
alone or with conventional 
or biological caries 
management for 3- to 7-
year-olds: the FiCTION 
three-arm RCT 










Appendix 2: Scoping review search terms (Chapter 4) 
OVID Medline search - September 2018 
1. "develop*".m_titl. 
2. methodological framework.m_titl. 
3. "design*".m_titl. 
4. "creat*".m_titl. 
5. 1 or 3 or 4 
6. 2 and 5 
Web of Science search - September 2018 
#1 TITLE: (methodological framework)  
DocType=All document types; Language=All languages 
#2 TITLE: (develop*) OR TITLE: (creat*) OR TITLE: (design*) OR TITLE: (writ*)  
DocType=All document types; Language=All languages; 






Appendix 3: Results of scoping review – study characteristics (Chapter 4) 
Author(s) Title Year of 
publication 






Tzetzisa, D (35) 
A methodological framework for the 
inclusion of modern additive 
manufacturing into the production 
portfolio of a focused factory 
2015 Journal article Manufacturing Greece 
Anagnostou, A; 
Taylor, S (34) 
A distributed simulation methodological 
framework for OR/MS applications 
2017 Journal article Simulation 
modelling  
UK 
Battini, D.; Faccio, 
M.; Persona, A.; 
Sgarbossa, F  (33) 
New methodological framework to 
improve productivity and ergonomics in 
assembly system design 
2011 Journal article Manufacturing Italy 
Brondizio, E; Vogt, 
N; Mansur, A; 
Anthony, E; Costa, 
S; Hetrick, S (272) 
A conceptual framework for analysing 
deltas as coupled social-ecological 
systems: an example from the Amazon 
River Delta 
2016 Journal article Ecology US 
Chesson, L; Howa, 
J; Lott, M; 
Ehleringer, J  (168) 
Development of a methodological 
framework for applying isotope ratio 
mass spectrometry to explosive 
components 
2016 Journal article Forensic 
chemistry 
US 
Dean, E; Taylor, M; 
Francis H; Lisboa, P; 
Appleton, D; Jones, 
M  (163) 
A methodological framework for 
Geographic Information Systems 
development 
2017 Journal article GIS UK 
George, H.; Bosc, P. 
M.; Even, M. A.; 
Belieres, J. F.; 
Bessou, C.  (31) 
WAW proposed methodological 
framework to monitor agricultural 
structural transformations and their 








Adamowski, J  (32) 
A methodological framework to support 
the initiation, design and 
institutionalization of participatory 





Author(s) Title Year of 
publication 
Type of record Subject area Source 
origin 
modeling processes in water resources 
management 
Ianni, M; de Leon, M  
(273) 
Applying Energy Performance-Based 
Design in Early Design Stages A 
methodological framework for integrating 





Kallio, H; Pietila, A; 
Johnson, M; 
Kangasniemi, M  (38) 
Systematic methodological review: 
developing a framework for a qualitative 
semi-structured interview guide 
2016 Journal article Qualitative 
research 
Finland 
Kumar, A; Singh, A; 
Deng, Y; He, X; 
Kumar, P; Bansal, R  
(274) 
A novel methodological framework for 
the design of sustainable rural microgrid 
for developing nations 
2018 Journal article Electricity 





Vietor, T  (167) 
A new methodological framework for 
design for additive manufacturing 
2016 Journal article Manufacturing Germany 
Lee, J; Jang, S  (30) A methodological framework for 
instructional design model development: 
critical dimensions and synthesized 
procedures 
2014 Journal article Education Korea 
Linek, S; Schwarz, 
D; Bopp, M; Albert, 
D  (157) 
When playing meets learning: 
methodological framework for designing 
educational games 




Cecilia, R  (161) 
Designing technology-mediated tasks for 
language teaching: A methodological 
framework 
2017 Journal article Education Portugal 
Nicod, E; Kanavos, P  
(165) 
Developing an evidence-based 
methodological framework to 
systematically compare HTA coverage 
decisions: A mixed methods study 
2016 Journal article Healthcare UK 
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Holtz, G; Kastens, 
B; Knieper, C  (37) 
Analyzing complex water governance 
regimes: the Management and Transition 
Framework 
2010 Journal article Ecology Germany 
Panagiotopoulou, M; 
Stratigea, A  (275) 
 
A participatory methodological 
framework for paving alternative local 
tourist development paths-the case of 
Sterea Ellada Region 
2014 Journal article Tourism Greece 
Procházka, J: 
Melichar, J  (36) 
Methodological framework for operational 
risk assessment 
2017 Journal article Defence Czech 
Republic 
Reed, M; Kenter, J; 
Bonn, A; Broad, K; 
Burt, T; Fazey, I; 
Fraser, E; Hubacek, 
K; Nainggolan, D; 
Quinn, C; Stringer, 
L; Ravera, F  (28) 
Participatory scenario development for 
environmental management: A 
methodological framework illustrated 
with experience from the UK uplands 
2013 Journal article Ecology UK 
Reidsma, P; Konig, 
H; Feng, S; 
Bezlepkina, I; 
Keulen, H. van; 
Ittersum, M van; 
Brouwer, F  (29) 
A methodological framework for 
sustainability impact assessment of land 
use policies in developing countries: re-







Author(s) Title Year of 
publication 
Type of record Subject area Source 
origin 
Rijke, J; Brown, R; 
Zevenbergen, C; 
Ashley, R; Farrelly, 
M; Morison, P; van 
Herk, S (276) 
Fit-for-purpose governance: A framework 
to make adaptive governance operational 
2012 Journal article Ecology The 
Netherlands 
Rodgers, M; Thomas, 
S; Harden, M; 
Parker, G; Street, A; 
Eastwood, A   (42) 
Developing a methodological framework 
for organisational case studies: a rapid 
review and consensus development 
process 
2016 Journal article Organisation UK 
Schmitt, J; 
Apfelbacher, C; 
Spuls, P; Thomas, K; 
Simpson, E; Furue, 
M; Chalmers, J; 
Williams, H  (277) 
The Harmonizing Outcome Measures for 
Eczema (HOME) roadmap: A 
methodological framework to develop 
core sets of outcome measurements in 
dermatology 
2015 Journal article Healthcare Germany 
Stratigea A; 
Papadopoulou, C-A  
(158) 
Foresight analysis at the regional level - A 
participatory methodological framework 
2013 Journal article Regional studies Greece 
Stremke, S; Van 
Kann, F; Koh, J  
(162) 
Integrated visions (Part I): Methodological 
framework for long-term regional design 
2012 Journal article Regional design The 
Netherlands 
Squires, H; Chilcott, 
J; Akehurst, R; Burr, 
J; Kelly, M  (22) 
A framework for developing the structure 
of public health economic models 
 





Author(s) Title Year of 
publication 
Type of record Subject area Source 
origin 
Sun, Y; Strobel, J  
(164) 
Elementary Engineering Education (EEE) 
adoption and expertise development 
framework: An inductive and deductive 
study 
2013 Journal article Education US 
Tappenden, P; 
Chilcott, J; 
Brennan, A; Squires, 
H; Stevenson, M  
(160) 
 
Whole disease modeling to Inform 
resource allocation decisions in cancer: A 
methodological framework 
 
2012 Journal article Health 
economics 
UK 
Tondel, K; Niederer, 
S; Land, S; Smith, N   
(159) 
 
Insight into model mechanisms through 
automatic parameter fitting: a new 
methodological framework for model 
development 
 
2014 Journal article Biology models UK 
NB: Where the country of employment varies between authors, the country of employment of the lead author, at the time of publication is used. 
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Appendix 4: PRISMA Scoping review checklist 
(Publication from Chapter 4) 
 
Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping 
Reviews (PRISMA-ScR) Checklist 
SECTION ITEM PRISMA-ScR CHECKLIST ITEM 
REPORTED 
ON PAGE # 
TITLE 





Provide a structured summary that includes (as 
applicable): background, objectives, eligibility criteria, 
sources of evidence, charting methods, results, and 





Describe the rationale for the review in the context of 
what is already known. Explain why the review 




Provide an explicit statement of the questions and 
objectives being addressed with reference to their key 
elements (e.g., population or participants, concepts, 
and context) or other relevant key elements used to 






Indicate whether a review protocol exists; state if and 
where it can be accessed (e.g., a Web address); and 
if available, provide registration information, including 





Specify characteristics of the sources of evidence 
used as eligibility criteria (e.g., years considered, 






Describe all information sources in the search (e.g., 
databases with dates of coverage and contact with 
authors to identify additional sources), as well as the 
date the most recent search was executed. 
Page 6 
Search 8 
Present the full electronic search strategy for at least 
1 database, including any limits used, such that it 







State the process for selecting sources of evidence 






Describe the methods of charting data from the 
included sources of evidence (e.g., calibrated forms or 
forms that have been tested by the team before their 
use, and whether data charting was done 
independently or in duplicate) and any processes for 
obtaining and confirming data from investigators. 
Page 6/7 
Data items 11 
List and define all variables for which data were 









If done, provide a rationale for conducting a critical 
appraisal of included sources of evidence; describe 
the methods used and how this information was used 







Synthesis of results 13 
Describe the methods of handling and summarizing 
the data that were charted. 
Page 7 
RESULTS 
Selection of sources 
of evidence 
14 
Give numbers of sources of evidence screened, 
assessed for eligibility, and included in the review, 
with reasons for exclusions at each stage, ideally 
using a flow diagram. 
Page 8 
Characteristics of 
sources of evidence 
15 
For each source of evidence, present characteristics 
for which data were charted and provide the 
citations. 




within sources of 
evidence 
16 
If done, present data on critical appraisal of included 
sources of evidence (see item 12). 
N/A 
Results of individual 
sources of evidence 
17 
For each included source of evidence, present the 
relevant data that were charted that relate to the 
review questions and objectives. 
Pages 8-12  
Synthesis of results 18 
Summarize and/or present the charting results as 






Summarize the main results (including an overview 
of concepts, themes, and types of evidence 
available), link to the review questions and 








Provide a general interpretation of the results with 
respect to the review questions and objectives, as 




Describe sources of funding for the included 
sources of evidence, as well as sources of funding 
for the scoping review. Describe the role of the 
funders of the scoping review. 
Page 17 
JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and 
Meta-Analyses extension for Scoping Reviews. 
* Where sources of evidence (see second footnote) are compiled from, such as bibliographic 
databases, social media platforms, and Web sites. 
† A more inclusive/heterogeneous term used to account for the different types of evidence or data 
sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may 
be eligible in a scoping review as opposed to only studies. This is not to be confused with information 
sources (see first footnote). 
‡ The frameworks by Arksey and O’Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 
5) refer to the process of data extraction in a scoping review as data charting. 
§ The process of systematically examining research evidence to assess its validity, results, and 
relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of 
bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge 
the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or 
qualitative research, expert opinion, and policy document). 
 
 
From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for 
Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. ;169:467–473. doi: 
10.7326/M18-0850 
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Appendix 5: Scoping review search terms (Chapter 5)  
Web of Science - November 2016 (with alert to October 2018) 
TITLE: Conceptual model* NEAR framework 
OR 
TITLE: Conceptual model* NEAR method 
OR 
TITLE: Conceptual model* NEAR guide* 
Scopus - November 2016 (with alert to October 2018) 
(TITLE “conceptual model*” W/5 “framework”) 
OR 
(TITLE “conceptual model*” W/5 “method”) 
 OR  
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Poshdar, M (12) 
Towards a conceptual modeling 
framework for construction 
simulation 
2017 Winter Simulation 
Conference 
Proceedings paper 2017 WoS Construction 
Brassington, FC; 
Younger, PL (15) 
A proposed framework for 
hydrogeological conceptual 
modelling 
Water And Environment 
Journal 
Article 2010 WoS Ecology 
(groundwater) 
Chwif, L; Banks, J; de 
Moura, JP; Santini, 
B(21) 
A framework for specifying a 
discrete-event simulation 
conceptual model 
Journal Of Simulation Article 2013 WoS Operations 
research 
Furian, N; O'Sullivan, 
M; Walker, C; Vossner, 
S; Neubacher, D (18) 
A conceptual modeling 
framework for discrete event 
simulation using hierarchical 
control structures 
Simulation Modelling 
Practice And Theory 
Article 2015 WoS Engineering  
Gentile, JH; Harwell, 
MA; Cropper, W; 
Harwell, CC; 
DeAngelis, D; Davis, S; 




Ecological conceptual models: a 
framework and case study on 
ecosystem management for 
South Florida sustainability 
Science Of The Total 
Environment 
Article 2001 WoS Ecology  





Gray, K; Sockolow P 
(16) 
Conceptual models in health 
informatics research: A 
literature review and 
suggestions for development 
JMIR informatics Article 2016 Google CM 
steps 
Healthcare 
Gross, J (20)  Developing conceptual models 
for monitoring programs 
NPS Website NPS inventory and 
monitoring 
program 






Friend, JD (13) 
Using a soft systems 
methodology framework to 
guide the conceptual modeling 
process in discrete event 
simulation 
2012 Winter Simulation 
Conference  
Proceedings Paper 2012 WoS Industrial 
engineering 
NSW website (178) Building a conceptual model NSW website Office of 
environment and 
heritage  
2011 Google CM 
steps 
Ecology 
Pace, D (176) Ideas about simulation 
conceptual model development 
John Hopkins Applied 
Physics Laboratory 
Technical Digest 





Miranda, RD; Friend, 
JD (179) 
Integrating soft systems 
methodology to aid simulation 
conceptual modeling 
International Transactions 
In Operational Research 
Article 2015 WoS Manufacturing 
Robinson, S (43) Conceptual modelling for 
simulation Part II: a framework 
for conceptual modelling 
Journal Of The Operational 
Research Society 
Article 2008 WoS Operations 
research 





Tako, AA; Kotiadis, K; 
Vasilakis, C (175) 
A participative modelling 
framework for developing 
conceptual models in 
healthcare simulation studies 
Proceedings Of The 2010 
Winter Simulation 
Conference 
Proceedings Paper 2010 WoS Healthcare 
van der Zee, DJ (44) An integrated conceptual 
modeling framework for 
simulation linking simulation - 
modeling to the systems 
engineering process 
2012 Winter Simulation 
Conference  
Proceedings Paper 2012 WoS Engineering 
Hesch, W (19) Conceptual model development 




element flow simulator) 




Morgan, A (WWF) (14)   Basic guidance for cross-
cutting: Conceptual models 















Appendix 7: Terminology allocated to themes (Chapter 5) 
Theme Author’s name for theme Included framework 
Objectives ‘Defining the model objectives’ Abdelmegid (12) 
‘Defining the objectives’ Brassington (15) 
‘Defining the OCIR (objectives, complexity, input/outputs and runs)’ Chwif (21) 
‘Define objectives’ Hesch (19) 
‘Identification of modelling and general objectives’ Furian (18) 
‘Define the environmental goals and objectives’ Gentile (172) 
‘Clearly state the goals of the conceptual models’ Gross (20) 
‘Developing simulation project objectives through SSM’ Montevechi (13) 
‘Clearly state goals for developing the model’ NSW (178) 
‘Objectives and system definition’ Pereira (177) 
‘Determining the modelling and general project objectives’ Robinson (43) 
‘Study objectives’ Tako (175) 
‘Determine objectives – modelling objectives/general project objectives’                 
 
Van der Zee (174) 
Model scope ‘Designing conceptual model: Individual model behaviour’ Abdelmegid (12) 
‘Defining the OCIR (objectives, complexity, input/outputs and runs)’ Chwif (21) 
‘Model content (scope, level of detail)’ Furian (18) 
‘Delineate the spatial, temporal and ecological scales and boundaries’ Gentile (172) 
‘Identify bounds of the system of interest’ Gross (20) 





Theme Author’s name for theme Included framework 
‘Address relationships among simulation relationships’ Pace (176) 
‘Determining the model content (scope and level of details), identifying any assumptions and 
simplifications’ 
Robinson (43) 
‘Determine model contents, scope and level of detail’ Van der Zee (174) 
‘Scope and vision’ WWF (14) 
Model content ‘Defining the topography and surface water drainage’, ‘defining the geology’, ‘defining the aquifer 
framework and boundaries’, defining groundwater flow directions’, ‘defining the aquifer 
relationships’ and ‘water balance’ 
Brassington (15) 
‘Build conceptual model’ Hesch (19) 
‘Allow the conceptual model to influence the research design’ Gray (16) 
‘Developing model inputs, outputs and content through SSM’ Montevechi (13) 
‘Develop simulation elements’ Pace (176) 
‘Construction of the conceptual model’ Pereira (177) 
‘Determining the model content’ Robinson (43) 
‘Model content’ Tako (175) 
System behaviour ‘Designing conceptual model: Model control’ Abdelmegid (12) 
Model control Furian (18) 
‘Develop risk hypotheses and stress-effects causal pathways’ Gentile (172) 
‘Identify key model components, subsystems, and interactions’, develop control models of key 
systems and subsystems’, and ‘articulate key questions or alternative approaches’ 
Gross (20) 
‘Identify relationships between components of the model’ NSW (178) 
‘Identify entities and processes for representation’ Pace (176) 





Theme Author’s name for theme Included framework 
‘Targets’ WWF (14) 
Understanding the 
problem 
‘Problem formulation’ Abdelmegid (12) 
‘Understanding of the problem situation’ Furian (18) 
‘Acknowledge the conceptual models of contributing domains’ Gray (16) 
‘Developing system understanding through SSM’ Montevechi (13) 
‘Collect authoritative simulation context information’ Pace (176) 
‘Understand the problem situation’ Robinson (43) 
‘Initiate study’ Tako (175) 
‘Understanding the problem and candidate solutions’ Van der Zee (174) 
Model inputs ‘Determining the conceptual model inputs and outputs’ Abdelmegid (12) 
‘Defining the OCIR (objectives, complexity, input/outputs and runs)’ Chwif (21) 
‘Collect data’ Hesch (19) 
‘Defining input factors’ Furian (18) 
‘Developing model inputs, outputs and content through SSM’ Montevechi (13) 
‘Identify the model inputs (experimental factors)’ Robinson (43) 
‘Inputs and outputs’ Tako (175) 
‘Identifying the model inputs’ Van der Zee (174) 
Model outputs ‘Determining the conceptual model inputs and outputs’ Abdelmegid (12) 
‘Defining the OCIR (objectives, complexity, input/outputs and runs)’ Chwif (21) 





Theme Author’s name for theme Included framework 
‘Developing model inputs, outputs and content through SSM’ Montevechi (13) 
‘Identifying the model outputs (responses)’ Robinson (43) 
‘Inputs and outputs’ Tako (175) 
‘Identify the model outputs’ Van der Zee (174) 
Documentation ‘Describing the conceptual model’ Brassington (15) 
‘Revision timetable and adjustments’ Chwif (21) 
‘Explicating a conceptual model verbally and graphically’ Gray (16) 
‘Documentation’ NSW (178) 
‘Documentation of the conceptual model’ Pereira (177) 
‘Determine model contents: scope and level of detail’ Van der Zee (174) 
Assumptions and 
simplifications 
‘Designing conceptual model: Individual model behaviour’ Abdelmegid (12) 
‘Process description, including model assumptions’ Chwif (21) 
‘Documentation’ NSW (178) 
‘Determining the model content (scope and level of detail), identifying any assumptions and 
simplifications’ 
Robinson (43) 
‘Assumptions and simplifications’ Tako (175) 
‘Determine model contents, scope and level of detail’ Van der Zee (174) 
Model detail ‘Designing conceptual model: Individual model behaviour’ Abdelmegid (12) 
‘Defining the OCIR (objectives, complexity, input/outputs and runs)’ Chwif (21) 
‘Model individual behaviour’ Furian (18) 





Theme Author’s name for theme Included framework 
‘Determining the model content (scope and level of detail), identifying any assumptions and 
simplifications’ 
Robinson (43) 
‘Determine model detail (attributes) for all components included’ Van der Zee (174) 
Diagram ‘Describing the conceptual model’ Brassington (15) 
‘Develop graphical conceptual model’ Gentile (172) 
‘Explicating a conceptual model verbally and graphically’ Gray (16) 
‘Transform the SSM models into a visual abstraction’ Montevechi (13) 
‘Determine model contents: scope and level of detail’ Van der Zee (174) 
Entities ‘Designing conceptual model: Model structure’ Abdelmegid (12) 
‘Model structure’ Furian (18) 
‘Identify ecological receptors and at-risk components’ Gentile (172) 
‘Identify key components of the model and pressures’ NSW (178) 
‘Identify entities and processes for representation’ Pace (176) 
Validation ‘Suitable?’ Hesch (19) 
‘Seek critical feedback on the conceptual model from multiple perspectives’ Gray (16) 
‘Conceptual model validation through SSM’ Montevechi (13) 
‘Validation of the conceptual model’ Pereira (177) 
Stressors ‘Inventory resource use and other human activities’, ‘describe sources of natural and 
anthropogenic stressors’, ‘identify the primary and secondary stressors of concern’ and ‘describe 
stressor mechanisms and routes of exposure’ 
Gentile (172) 
‘Identify natural and anthropogenic stressors’ and ‘describe relationships of stressors, ecological 
factors, and responses’ 
Gross (20) 





Theme Author’s name for theme Included framework 
Review and refine ‘Revisit the conceptual model in light of the research findings’ WWF (14) 
‘Review, revise, refine models’ Gross (20) 
‘Review and refine the model’ NSW (178) 
Model structure ‘Designing conceptual model: Model structure’ Abdelmegid (12) 
‘Model structure’ Furian (18) 
Team 
identification 
‘DES study initiation’ Abdelmegid (12) 
‘Initiate study’ Tako (175) 
Use previous 
conceptual model 
‘Review conceptual models already used in health informatics’ Gray (16) 
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Appendix 8: Ordering and sequence of themes in each 
phase (Chapter 5)  
Below, the order of the themes included within each phase is explained, and the 
theme descriptions (if reported) are summarised with advice from the 
methodological framework.  
Phase 1 – Getting familiar with the research problem and setting the 
objectives of the model  
This first phase mainly includes getting to know the problem situation and 
setting the objectives of the conceptual model.  It comprises four stages; 
• Understanding the problem 
• Use previous conceptual model 
• Identify the team 
• Setting objectives 
Understanding the problem 
‘Understanding the problem’ is the first stage in this phase of the draft 
methodological framework.  ‘Understanding the problem’ is nearly always the 
first stage when it is included in any of the methodological frameworks.  
Understanding the problem is key to developing a conceptual model; without a 
good and detailed understanding of the problem it would be impossible to 
develop an accurate conceptual model (173).  And the more complete and clear 
a problem area is the easier it is to understand (176). 
Seven of the eight frameworks that include this stage mention stakeholders (not 
Montevechi), either coming to an agreement with them on the understanding of 
the research problem or using the stakeholders to explain the problem (12, 16, 
18, 43, 44, 175, 176). Furian and Robinson also suggest that the modeller 





stakeholders(18, 43).  Abdelmegid comments that limitations in knowledge at 
this stage will result in assumptions being made (12). 
Furian states that the outcome of this stage is an informal description of the 
problem, including assumptions used in reaching an understanding of the 
problem(18). Robinson advises that assumptions made in coming to an 
understanding of the problem situation are recorded(43).  Gray and Robinson 
both recommend using conceptual models of the problem situation as a tool to 
describe the problem (16, 43). 
Four methodological frameworks recommend using soft systems methodology to 
gain an understanding of the problem situation (12, 18, 43, 173), in particular 
the Purposeful Activity Model.  Robinson also suggests the use of cognitive 
mapping and causal loop diagrams to help understanding the problem. 
Use previous conceptual model 
This stage was only included in one methodological framework; Gray, it was 
included as a second stage in the framework (16).  Gray suggests identifying 
previous conceptual models that could be adapted for use in the current 
project.  I have included it in this phase however, it may be good practice to 
review previous conceptual models during Phase 2 too, in relation to the model 
structure and content. 
Identify the team 
This stage was included in two methodological frameworks, Tako and 
Abdelmegid (12, 175).  Tako placed this stage with the ‘Understanding the 
problem’ stage in the initial section of the framework, and Abdelmegid placed it 
at the initiation of the study.  
The majority of included methodological frameworks mentioned working with 
stakeholders in various stages, and it seemed to be taken as read that the 
modeller would not work alone in developing the conceptual model. Tako 
suggests a maximum of 12 people on the project team, comprising modellers and 





should include decision makers who ought to be the key stakeholders.  Tako also 
recommends appointing a ‘project champion’ who would oversee the conceptual 
model.  Abdelmegid suggests meeting with the problem owner to collect 
information on the system and understand it, and a stakeholder list should be 
developed. 
Setting objectives 
The final stage in this phase is ‘Setting objectives’. This stage has the highest 
number of mentions in the methodological frameworks; 13 frameworks included 
this stage.  This stage is the second one in this phase because out of the 13 
methodological frameworks which included ‘Setting objectives’ as a stage, seven 
had it as a first stage, and five as a second stage after ‘Understanding the 
problem’.  Therefore, it is included early on in the draft methodological 
framework to mirror its position in the included frameworks and because of its 
importance in guiding the development of the conceptual model, as discussed 
below.   
Brassington states that objectives should be agreed and set in writing early on 
with clients (15).  Gentile reiterates this saying that this stage is essential and 
objectives are important in defining model content and endpoints (172). 
Robinson confirms this; objectives are key and drive the modelling process (43).  
Brassington suggests that objectives should focus on key questions needing to be 
answered (15). Chwif advises that objectives are often linked to performance 
measures (21) and van der Zee states that objectives are linked to the project 
problem (44).  Gross maintains that different goals require different model 
structures and level of detail (20).  
Abdelmegid, Furian and Robinson split objectives between general objectives 
and modelling objectives (12, 18, 43). General objectives include wider project 
objectives such as time frame and visualisation, and should be kept in mind 
when deciding on complexity of the model.  Modelling objectives are what it is 
hoped the model will achieve, such as increasing throughput or reducing cost 





modelling and general objectives should be agreed with the client so that 
expectations can be managed.  
Montevechi, Pereira and Tako all suggest the use of soft systems methodology to 
set the objectives; explaining that the five steps in developing a Performance 
Measurement Model will generate the objectives (13, 175, 177).  
Phase 2 – Model content; what is included and excluded  
This middle phase includes 10 stages identified from the included 
methodological frameworks; model scope, model detail, model outputs, model 
inputs, model content, entities, system behaviour, stressors, model structure 
and assumptions and simplifications.  These are discussed one-by-one below, in 
the order in which they should be considered in the draft methodological 
framework.   
Model scope 
Ten methodological frameworks include ‘Model Scope’ as a stage. Five included 
‘Scope’ as the first or second stage in the framework, the remaining five 
methodological frameworks position ‘Model scope’ in the second half of the 
framework.   
Once the problem situation is understood and goals or objectives for the 
conceptual model set, the scope of the model should be considered.  The scope 
will guide the development of the conceptual model. It is this stage that the 
modeller decides what is included and excluded from the bigger picture of the 
problem situation to answer the research question.   
Many of the methodological frameworks that include the ‘Model scope’ stage 
give definitions of scope; Chwif; the extent of the project, for example 
restricting it to only certain parts of a manufacturing process (21).  Furian; 
which entities will be included in the model (18). Gentile; ‘bounding the 
decision problem’, what is included, excluded and outside the scope of the 
conceptual model (172). Gross; bounds of system and what components should 





defining the scope as deciding which entities, activities, queues and resources 
are included in the conceptual model (43, 178).  In summary the scope of the 
conceptual model is what is included and excluded.  
Abdelmegid, Gross and Robinson recommend that the modeller and the project 
team decide the scope of the project and document this (12, 20, 43). 
Robinson and van der Zee consider similar methods for this stage (43, 174); 
1. Identify the conceptual model boundary 
2. Identify all the components in the real system lying within that boundary 
3. Assess whether to include or exclude the components identified. Each 
component should be assessed for importance in ‘validity, credibility, 
utility and feasibility’ of the model in this step.  
I think the ‘relevance’ of the components to the research question is an 
important factor here too. 
Model detail 
Once the breadth of the conceptual model is decided in the ‘Model scope’ stage 
above, the depth of the conceptual model should be considered.  This is the 
depth or detail the conceptual model goes into. Six frameworks include this 
stage, two frameworks position it in the first half of the framework, the 
remaining four in the second half of the framework. It is always included as a 
step within the framework that includes two or more stages, so these positions 
are open to interpretation.  
Descriptions of ‘Model detail’ include; Chwif; the depth of the model is subtle 
(21). Pace; whether the system is represented at a higher/broader or drilled 
down to greater detail (176). Furian explains that looking at the detail of the 






Robinson suggests that the modeller and project team should decide on the 
detail and then document the level of detail for each component in the 
conceptual model (43).  The level of detail should be determined for each 
component depending on its effect on the validity, credibility, utility and 
feasibility of the conceptual model.  Again, as in ‘Model scope’ above, I think 
that the relevance of the level of detail to the research question is important in 
this stage.  
Model content 
Eight methodological frameworks include ‘Model content’. Three have ‘Model 
content’ as a stage in the first half of the framework (13, 15, 177), the 
remaining five frameworks position it in the second half of the framework. 
I include ‘Model content’ as an umbrella ‘catch all’ stage that includes all the 
components and their relationships within the conceptual model. Stages that 
related to the content of the conceptual model but were not clearly linked to a 
particular stage were included in this stage, along with specific ‘Model content’ 
stages.  
The methodological frameworks which included less specific details were: 
Brassington - ecology based steps relating to components and their relationships 
were included in this stage (15); Hesch - ‘build conceptual model’ (19); Gray - 
‘allow the model to influence the research  design’ (16); Montevechi’s step 
includes inputs, outputs and activities (13); Pace includes entities and process 
(176); and Pereira’s step is ‘construction of the conceptual model’ (177). 
Robinson and Tako are more specific and label the step ‘determining model 
content’ and ‘model content’ respectively (43, 175). 
Montevechi and Tako recommend the use of soft systems methodology to 
determine the contents of the model (13, 175). Tako also recommends using a 
patient flow diagram to establish contents, however, depending on the research 






Model outputs  
Seven methodological frameworks include ‘Model outputs’. Four frameworks 
position the ‘Model output’ stage in the first half and the remaining three place 
it in the second half of the framework.   
Furian describes model outputs as responses which can be numerical (means) or 
streamed data (time series).  Montevechi defines model outputs as the output 
from the model’s system transformation process (patient to treated patient).  
Abdelmegid, Furian, Montevechi,  Robinson, Tako and van der Zee all state that 
model outputs are linked to objectives; they are used to evaluate whether the 
objectives of the model have been met, and if the objectives have not been 
met, why not.  Tako suggests that once objectives are set, the next stage should 
be determining the inputs and outputs.  
Abdelmegid, Furian, Robinson and van der Zee all recommend considering how 
the outputs should be presented (tables or graphs).   
Both Montevechi and Tako suggest identifying inputs and outputs using soft 
systems methodology, in particular Performance Measurement Model. 
Model inputs 
Eight methodological frameworks included ‘Model inputs’ as a stage, the 
majority (five) placed this stage in the middle of the framework.  Model inputs 
are also called experimental factors.  They are the components of the model 
that can be altered to represent different scenarios.  
Some frameworks included descriptions and examples of Model inputs; Furian 
and Robinson state that inputs are also known as experimental factors; they can 
change in different scenarios and should a range around them should be 
included. Furian adds that in healthcare inputs examples may include policies 
such as best way to dispatch orderlies. Montevechi gives examples of Model 
inputs; workstations, machines and individuals, continuing that objectives affect 





either qualitative or quantitative and their ranges should be determined. 
Robinson goes on to say that the modeller should vary inputs the client has little 
control over, adding that identifying inputs is an iterative process.  
Three methodological frameworks suggest methods for identifying conceptual 
model inputs; Tako suggests that stakeholders should be consulted on how much 
the inputs can vary, Robinson states that identification is driven by objectives, 
Tako and Montevechi suggest the use of SSM. Tako specifically advises the use of 
a PMM, Montevechi suggests using CATWOE mnemonic components ‘customers’ 
and ‘actors’, these are individuals who will use resources such as workstations 
and equipment; from this inputs are identified.  
Whilst I feel it is important to identify which components are inputs at this 
stage, I would argue that it is not appropriate to be deciding numerical values 
and ranges, this would relate to a mathematical model, not a conceptual model.  
Taking into account the descriptions of inputs above I would argue that inputs 
for the purposes of my methodological inputs relate to components at the start 
of the system or process, such as treatment or patient.   
Model entities 
Five frameworks include the stage of ‘Entities’, all but one (NWS) come in the 
second half of the framework.   
Abdelmegid describes entities as core components of the model structure. Furian 
describes two types of entities; active and passive. Active can change their role 
and passive are fixed and not related to the flow of a system. NSW also describes 
different entities; they can be ‘pressure, state or response’.  Pace suggests 
identifying entities needed to achieve the objectives. For the purpose of the 









Eight methodological frameworks included a system behaviour stage, mainly in 
the middle of the framework. 
The system behaviour is how the components of the system are linked, or relate, 
to each other.  Furian reports that the components included in this stage are 
control units (combined entities), events and activities.  Abdelmegid comments 
that ‘control units represent different levels of decision making within the 
system’ (‘determining the set of rules and their relations’).  Gentile links end-
points to physical characteristics and stressors in their system behaviour stage. 
Gross recommends identifying components of the system and how they are 
linked, this can be done by breaking systems down into habitats for the ecology 
discipline.  NSW and Pace both reflect Gross’ recommendation of identifying 
relationships between components of the model.  Gross adds that questioning 
the system and suggesting alternative hypotheses can help develop an 
understanding of the system behaviour.   
Tako suggests using SSM methodology, specifically the CATWOE and root 
definition, to define system behaviour.  However, it could be argued that this is 
methodology that would aid in the ‘Understanding the problem’ stage as well as 
the ‘System behaviour’ stage, applying it to understand the bigger or rich 
picture. 
Model stressors 
The three methodological frameworks containing ‘Stressors’ position this stage 
in the first half, the second half and right in the middle of the framework. 
All the methodological frameworks including this stage were from the ecology 
discipline.  Stressors are specific to ecology and are the threats to, or 
constraints on, the ecosystem.  They are mainly related to human activity, 
(pollution, timber extraction and hunting), but can also be natural (fires or 
storms).  Gross advises that only the stressors relating to the project are 






Two methodological frameworks include ‘Model structure’ as a stage, and it is 
placed half way through both of these frameworks. Furian states that this stage 
is closely linked to the Entity stage because the Model structure is characterised 
by the entities and their aggregation.  Abdlemegid states that designing the 
model structure begins with defining the entities.  For the purpose of my 
proposed framework I will use the description of ‘Model layout’ for this stage. 
Assumptions and simplifications 
Five methodological frameworks have ‘Assumptions and simplifications’ as a 
stage and all of these are in the second half of the framework.   
Whilst I do not consider this to be a separate discrete step in the framework it is 
important.  It can be applied to ‘Understanding the problem’ if when 
understanding assumptions and simplifications are used to gain an understanding 
of the problem.  However, assumptions and simplification are mostly applied to 
the model contents so I will include it in this stage of the proposed framework.  
At each stage of considering the model content the modeller will make 
assumptions about the contents and how the components interact.  The 
modeller will also need to make simplifications to make the conceptual models 
understandable and not overcomplicated.  
Chwif and Robinson explain that assumptions relate to a limited knowledge or 
uncertainty of the problem situation/real world, and simplifications result from 
keeping the model simple and easy to use. Chwif adds that the more 
assumptions made, the less detail included in the conceptual model. Robinson 
explains that when identifying scope and detail of the conceptual model 
assumptions and simplifications will be made. Adding that assumptions and 
simplifications are referenced by components and detail omitted from the 
model, Abdelmegid adds that the assumptions and simplifications define the 
scope and detail of the model. Robinsons suggests that the impact of 
assumptions and simplifications should be assessed in agreement with the 





determined regarding scope and detail, and the effect on outputs should be 
considered. Chwif recommends that assumptions are recorded. 
Phase 3 – Documentation and validation 
This final section includes documenting and validating the conceptual model 




• Review, revise, refine 
Diagram 
Five methodological frameworks include a ‘Diagram’ stage, all but one of these 
have it as the last stage of the framework. 
Brassington advises including a diagram with the documentation. Gentile 
explains the diagram visually links the process and components. Gray states that 
the diagram acts as a check for the modeller; the detail in the diagram should 
match the detail in the conceptual model, the modeller should ask themselves 
‘does the diagram leave the user making assumptions?’ Montevechi explains 
there is no formal way of producing visual representation of conceptual model, 
and adds that the diagram should be used as a communication tool and can take 
the form of a chart, image or diagram, and that using SSM can help the 
development of the diagram. Van der Zee comments that visualisation is useful 









Six methodological frameworks included ‘Documentation’ as a stage, five of 
these had this stage in the second half, of these, four had it as the last stage (or 
in a step that was the last stage).   
The first stage in this phase is to produce a diagram of the conceptual model, 
this is closely linked to producing a document of the conceptual model, they 
should be presented together.  The document should include explanations, 
assumptions, simplifications and a description of the model, this is closely linked 
to the diagram stage above.  
Brassington recommends that once the conceptual model is agreed by 
stakeholders it should be documented as a written description. Chwif suggests 
the document should include any conceptual model revisions. Gray advises 
documenting the conceptual model diagram, including justification of the choice 
of illustration. NSW proposes the document should record sources of evidence, 
key questions, assumptions and limitations. Van der Zee suggests to document 
the conceptual model and to justify scope and detail. 
In my draft methodological framework I will combine the diagram and document 
stages as they are so closely linked. 
Validation 
Four methodological frameworks include ‘Validation’, all of them position this 
stage in the second half of the framework.  Two of these methodological 
frameworks have ‘Validation’ as the final stage.   
FEFLOW suggests that if the conceptual model is not suitable the modeller 
should revisit earlier stages, rebuild the conceptual model and revisit this stage. 
Gray suggests that the modeller uses the conceptual model as a communication 
tool in this stage and get feedback from the stakeholders. It is likely that the 
stakeholders will have a different perspective of the problem than the modeller 
and should sense check the conceptual model.  Gray adds that this stage is 





used to refine and strengthen the supporting arguments for the conceptual 
model.  Gray goes on to say that this stage is important to confirm whether the 
conceptual is robust and will stand up to scrutiny from experts. Montevechi 
suggests this stage should be done in parallel with other stages whilst developing 
the conceptual model.  Montevechi adds that this stage is used to test the 
theories and assumptions underlying the conceptual model, that it is suitable for 
its intended purpose, and that if SSM methods were used to develop the 
conceptual model the documented methods will act as a validation method.  
Pereira advises that if the model is not validated the modeller should revisit the 
development of the conceptual model.  Pereira suggests that validation is done 
in conjunction with experts.  
Review, revise, refine 
Three methodological frameworks include this stage, two include it as the last 
stage and the other second to last.  
Gray suggests revisiting the conceptual model when the results from the project 
are available, assessing whether these results support the original conceptual 
model and if any modifications are needed.  Gross believes that conceptual 
models are an ‘incomplete abstraction of reality’ and will need revisions as new 
evidence is available and goals alter.  The conceptual model should be reviewed 
periodically to ensure it reflects current knowledge. NSW suggests revising the 
original conceptual model; it was based on the best knowledge at the time of 




Appendix 9: Methodological framework diagrams from 
identified studies and early drafts of diagram to 
include in final methodological framework (Chapter 5) 
 














Figure A9.72: Furian et al. methodological framework diagram (18) 
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Appendix 10: Draft methodological framework (Chapter 5) 
 
Figure A10.82: Draft methodological framework diagram 
 
General advice 
This proposed framework is a generic guide to developing conceptual models for 
use in economic evaluations.  It should be applied to each research project in a 
pragmatic way and tailored to each situation. 
The framework is based on two key concepts. These two key concepts are 
fundamental in developing all conceptual models: the iterative process and 





the framework until the conceptual model is completed.  The conceptual model 
should be kept simple; it should contain enough detail to answer the research 
question, but not too much that would make it unwieldy, containing unnecessary 
detail.  Both of these elements should be borne in mind by the modeller 
throughout the conceptual modelling process. 
This conceptual modelling framework is intended for when the main/key 
purpose is to develop a conceptual model; for guiding the analysis, 
interpretation and presentation of results. 
Because the research theme and question may be predefined (as is often the 
case in clinical trials), some aspects of the proposed framework may not be 
relevant to all circumstances. 
The framework is split into three phases: Getting the picture, Development of 
the conceptual model and Wrapping up.  Within these phases are discrete 
stages, making up the steps of the framework.  The outputs of this framework 
are a diagram and document depicting and explaining the conceptual model 
(Figure A10.82). 
Throughout the conceptual model development process the modeller will add 
information to a document, this will be described in more detail in Stage 6 
‘Diagram and documentation’.  
Phase 1 - Getting the picture  
In this phase the modeller immerses themselves in the research problem, gaining 
an understanding of the problem and research question, and setting objectives.  
Stage number 1: Understanding the problem 
Recommendation 
The modeller should gain a good understanding of the bigger picture of the 
research problem.   This involves looking at the wider systems and subject area 





defined it should be determined during this stage.  Without a sound 
understanding of the research problem, it is not possible to develop an accurate 
conceptual model.  The problem may require identifying patient pathways, 
patient behaviour or disease pathways.  The project team should also be 
identified during this stage if they have not been identified already. 
Explanation 
Understanding can come from literature, stakeholders, decision makers, experts, 
existing conceptual models, trial protocol (if relevant) and clinical guidelines.  
Questions useful to help in understanding the problem are presented in Table 
A10.26.  These questions are split into two sections; understanding the problem 
and understanding the systems within the problem area.   
Specific elements of soft systems methodology can be used in this stage to come 
to an understanding of the problem systems.  These elements of soft systems 
methodology involve developing a rich picture (an informal, often hand drawn 
diagram of the problem area) and using the CATWOE mnemonic to understand 
important aspects of the problem system.  The CATWOE mnemonic is a checklist 
used to identify the purpose and key elements of a system. The rich picture and 
CATWOE mnemonic are used to produce a description of the system. 
The makeup of the project team will vary depending on the research question.  
The project team will typically comprise; the modeller, other health economists, 
clinicians with an expert knowledge of the disease area, patient representatives 
and study or trial team members (i.e. trial manager).  Whilst it is good practice 
for the project team to be involved at this stage, it may be practical to only 
include them at the later ‘Review, revise, refine’ stage.  If the project team are 
involved at this stage the project team and the modeller should come to a 
consensus on the understanding of the research problem; the modeller can 
suggest alternative hypotheses to the project team at this stage to help reach an 
understanding of the research problem.  
A structured description of the research problem and system (including activities 
within the system) should be developed to include in the conceptual model 





understanding of the problem; any key assumptions made in reaching this 
understanding should also be recorded in the conceptual modelling document.   
Table A10.26: Questions to help understanding the problem 
Questions to guide understanding the problem 
What is the problem? 
Why is it a problem? 
Who are the target population? 
What are the treatments to be included? 
What are the outcomes? 
What is the policy context? 
Questions to guide understanding the problem systems 
Who benefits in the system? (ie patients) 
Who carries out the activities in the system?  (ie clinicians) 
What is the purpose of the system?  
How does the system fit into the bigger picture? 
Who has formal power over the system? 
What constraints are there on the system? 
 
Stage number 2: Setting objectives 
Recommendation 
The objectives of the conceptual model should be set in this stage.  Setting 
objectives is key in guiding the development of the conceptual model and 
defining the model outputs and content.  
Explanations 
The objectives will be closely linked to the research question(s) and what the 
model should achieve. The objectives will be related to outcomes, including 
hospital services and throughput, disease progression or patient behaviour.  The 
modeller should ask themselves; what are the project performance measures or 
outcomes?  Can these performance measures or outcomes be broken down 





The modeller should also bear in mind the constraints on time and budget of the 
project; making sure the objectives are realistic and expectations are managed.    
The modeller should agree the objectives with the model team (if applicable) 
and record them in the conceptual model document. 
Phase 2 - Development of the conceptual model 
In the second phase the modeller decides what to include and exclude in the 
model, which components best represent the research problem, and how these 
components are linked.  During this phase the modeller should keep in mind the 
objectives set in Stage 2 and the project hypothesis if there is one, to ensure the 
conceptual model is relevant to the research question. The development of the 
conceptual model will be an iterative process, with the modeller revisiting 
stages until it is complete. 
Stage number 3: Determine the scope of the conceptual model 
Recommendation 
In the first stage of this phase the modeller determines the scope of the 
conceptual model.  The scope bounds the research problem, restricting the 
conceptual model to only the elements of the bigger picture needed to address 
the research question.   
The modeller should see the ‘Understanding the problem’ stage as getting to 
know the ‘bigger picture’ of the problem; understanding the wider subject area 
that includes the research problem.  The modeller then decides on the narrower 
scope of the conceptual model in the ‘Determine the scope of the conceptual 
model’ stage.  This guides the development of the model, helping the modeller 
decide what should be included and excluded from the bigger picture to answer 
the research problem. The relationship between the bigger picture and the 













Figure A10.83: Bigger picture v. research question 
 
Explanation 
When determining the scope the modeller should concentrate on the research 
questions, project hypothesis (if there is one) and conceptual model objectives.  
Only components important and relevant to the research question, hypothesis 
and objectives are included.  If components that are not relevant to the 
research question etc are included in the conceptual model it will become too 
complicated and unwieldy, creating ‘noise’ and making interpretation difficult.  
If there is a trial protocol available this can also help determine the scope of the 
conceptual model. 
The modeller should consider resource use, the perspective taken for the costs 
and outcomes and the type of economic evaluation (i.e. cost-utility, cost-
effectiveness or cost-benefit), as these considerations will determine 
components to be included in the scope of the conceptual model.  
Each of the components identified as within the scope of the model should be 
assessed by evaluating the relevance of these components to answering the 
research question.  The modeller should bear in mind that the purpose of 
economic evaluations is the comparison of health technologies and should 








The modeller and project team (if appropriate) should come to a consensus on 
the scope of the research problem and record this in the conceptual model 
document.   
Stage number 4: Determine the detail of the conceptual model 
Recommendation 
Once the scope of the conceptual model has been determined the depth of the 
conceptual model should also be considered.  The depth determines how far the 
modeller will drill down into individual elements of the conceptual model.  
Depending on the objectives the detail may be high level and simplified or could 
involve precise details of all or some of the components.   
Explanation  
The modeller should determine the detail in relation to the research question, 
project hypothesis and conceptual model objectives.  The modeller should bear 
in mind resource use data needed to answer the research question and the detail 
needed to capture this.  The modeller should take care to only include detail 
relevant in testing the hypothesis and comparing the health technologies. 
Similar to ‘Determining the scope of the conceptual model’ above, the detail of 
each component should be assessed on their relevance and validity in answering 
the research question. 
The decided detail of the conceptual model should be reported in the 
conceptual model document. 
Stage number 5: Determine the content of the conceptual model 
Recommendation 
The final stage in this phase is deciding on the content of the model.  There are 
several elements that the modeller should consider in this stage. These are 





Model outputs are important aspects of this stage.  Outputs can be used to 
check that the objectives of the conceptual model have been reached. Model 
inputs should also be considered if appropriate, they are components within the 
model that can be altered to represent different scenarios.   
The components within the scope of the conceptual model should be 
considered, along with how they interact or are linked to each other (system 
behaviour). Components can either be passive (static) or active within the flow 
of the system. Stressors are the interventions; they alter or are hypothesised to 
alter the flow of the system.  The overall structure/layout of the model should 
be considered.  Assumptions and simplifications will be used in most of the 
stages in model development and are also relevant to understanding the 
research problem, scope and detail.   Assumptions relate to limited knowledge 
or evidence of the research problem bigger picture.  The more assumptions 
made, the less detail included in the conceptual model.  Simplifications result 
from keeping the conceptual model straightforward and uncomplicated.   
Explanation 
Model outputs will be closely linked to the research question and hypothesis.  
Key outputs are costs and effects; examples include a patient becoming a 
treated patient, quality of life measures, clinical effects (such as strokes 
avoided or cancer cases detected) or patient behaviour such as increase in 
physical activity. Examples of Model inputs include health resources and 
patients. The Model structure will be driven by the objectives and research 
problem.  For example a simple patient pathway may be used, or disease 
progression, however the structure of any planned mathematical model would 
not be relevant here.  When determining the model structure the modeller 
should consider resource constraints and capturing resource use.   
As in the ‘Understanding the problem’ stage the modeller can use soft systems 
methodology to define the root definition of the problem system within the 
scope of the conceptual model. Again, suitable methods to do this include 
drawing a rich picture and using the CATWOE mnemonic to develop a description 





activities in the system? What is the purpose of the system? Who has formal 
power over the system? What constraints are there on the system?  
In determining the content of the model the modeller should be constantly 
reminding themselves of the objectives of the project, research question and 
hypothesis, if applicable. 
Model content, and assumptions and simplifications made in determining the 
model content, should be recorded in the conceptual model document. 
Phase 3 - Wrapping up 
The final phase of the framework includes diagram, documentation, and review, 
revise, refine.  The conceptual model is presented in a visual form and 
documented.   The conceptual model is then validated and, if necessary, 
revisions are made. 
Stage number 6: Diagram and documentation 
Recommendation 
A visual representation of the conceptual model should be presented.  This 
should link the components and processes in a clear way. The diagram used 
should be clear, accurate and relevant to the research problem.  As a 
communication tool the diagram should not leave the user having to make 
assumptions.  For the modeller carrying out the economic evaluation the 
conceptual model will guide the analysis, interpretation and presentation of the 
research project. 
The document, a non-jargon written description of the conceptual model, should 
help the reader understand the model, and should be used as a communication 








The diagram should be clear and understandable; it is likely that the modeller 
will need several iterations to develop the diagram.   
The purpose of the document is to help the user to understand the model, it 
does not need to be extensive or overly comprehensive. 
Information recorded at each stage of the conceptual model development 
included in the document will consist of;  
• evidence used in understanding the bigger picture,  
• an explanation of the research problem, including funder, population, 
outcomes and interventions, 
• conceptual model objectives, 
• descriptions of the scope and detail of the conceptual model,  
• the key section of the document should be a description of the conceptual 
model, describing the components included, the relations between them, 
and the general ‘flow’ of the conceptual model 
• assumptions and simplifications made in the development of the 
conceptual model; only key assumptions should be recorded, unimportant 
assumptions and simplifications should be omitted    
• finally, methods of validation and any revisions should be documented  
A summary of the diagram and document can be included in the Health 







Stage number 7: Review, revise, refine 
Recommendations 
The final stage of the framework is ‘Review, revise and refine’.  In this stage the 
conceptual model should be validated and, if appropriate, the modeller should 
seek agreement and feedback on the conceptual model from the project team.  
The project team should be shown the conceptual model diagram and document 
to check they reflect the team’s understanding of the research question and the 
research system. The conceptual model should also be checked in terms of logic, 
presentation and ease of understanding. This is an important step, without 
which the conceptual model may not be accurate or useful.  Any suggested 
changes during this stage should be used to refine the model, strengthening it 
and making it robust and suitable for its intended purpose. 
Explanations 
If changes are made to the conceptual model the diagram and documentation 
should be updated in this stage. If new information comes to light after the 
development of the conceptual model the conceptual model should be updated 
if relevant. 
The modeller and project team should check the conceptual model to ensure it 
accurately depicts the research area and question.  Table A10.27 lists questions 
the modeller and project team can ask themselves during this stage to review 










Table A10.27: Validation questions 
Diagram: 
- Is the diagram well defined, logical and transparent? 
- Does the conceptual model reflect the research question and subject 
area system? 
Document: 
- Is there a clear description of the research question, including 
background information to help understand the problem? 
- Are there clear objectives reported? 
- Are the scope and detail considered relevant to the research question 
and justified? 
- Is there a clear and understandable description of the content of the 
conceptual model? 
- Are the key assumptions and simplifications made explicit? 
- Does the user need to make assumptions about the conceptual model to 
understand it? 
- Does the conceptual model include all the components needed to 
complete an economic evaluation, accurately representing resource 
use, outcomes and perspective? 
- Are changes made to the conceptual model during the ‘Review, revise, 
refine’ stage recorded in the document? 
372 
Appendix 11: Iterative development of TWICS case study 
conceptual model diagram (Chapter 6) 
The first rich picture developed illustrated both the increasing disease severity 
and progressive nature of COPD and the effects of exacerbations (Figure 
A11.84). 
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The first version of the conceptual model is presented in Figure A11.85.  I 
decided to concentrate on the conceptual model depicting the intervention arm 
incorporating the theophylline intervention initially.  Working from the left-hand 
side of the conceptual model to the right-hand side of the model starting with 
the COPD patient, the patient is anticipated to experience serious adverse 
events resulting from co-mobilities, COPD related resource use and 
exacerbations.  The intervention (theophylline) is anticipated to affect the 
number of exacerbations the patient experiences during the trial, and serious 
adverse events are unknown as a result of the intervention.  Exacerbations are 
one of the outcomes used in the economic analysis, and therefore is depicted by 
a beige oval with two outlines and linked by an ‘analysis’ line to the ‘cost per 
exacerbation avoided’.  The third column from the left consisting of all blue 
‘entity’ ovals represent measures that feed into the economic evaluation 
analysis, such as quality of life and mortality data.  The fourth column of beige 
‘output’ ovals depict the two main elements of an economic evaluation; namely 
costs and effects, in this case the effects are quality adjusted life-years.  The 
final column containing the green rectangles illustrates the analysis measures 
that were used to report the cost-effectiveness results, for example an 
incremental cost-effectiveness ratio of cost per quality adjusted life-year 
















A ‘comparator’ version of version 1 was then developed as depicted in Figure 
A11.86.  The columns in this diagram are more clearly defined and are 
categorised into: ‘disease area’, ‘changes in health’, ‘results of changes in 
health’, ‘summary of results’ and ‘estimation’.   Serious adverse events have 
been removed as it was not considered a good representation of the economic 
evaluation.  Instead in the ‘Changes in health’ column the entities are ‘non-
exacerbation COPD complications’, ‘non-COPD related changes in health’ and 
the original output of ‘exacerbations’.  In this diagram ‘comparator’ routes are 
added in black; it was considered after reviewing version 1 ‘intervention’ that 
there would be more links from the COPD patient to entities in the conceptual 
model, not necessarily mitigated through the ‘changes in health’ events, such 
as: quality of life and mortality.   For example, a patient will use COPD related 
non-exacerbation health resources (maintenance therapy) whether they 
experience a health event or not and they will have a quality of life 
level/measure too.  The red lines between the ‘changes in health’ column and 
‘results of changes in health’ indicate that health events in the former column 
will result in the use of health services resources, change in quality of life 
measure and potentially length of life.  As in the previous conceptual model 
these feed into the outcome measures which, in turn, feed into the analysis 
























Version 2 of the ‘intervention’ TWICS conceptual model builds on the 
‘comparator’ version 1 adding in the intervention Figure A11.87.  The 
anticipated consequences of the treatment effect the number of exacerbations, 
and unknown effects on ‘non-exacerbation COPD complications’ and ‘non-COPD 








































The ‘comparator’ version of version 2 amalgamates the 3 health resource use 
entities into one to make the conceptual model simpler and easier to interpret 
(Figure A11.88).  
 









Version 3 ‘intervention’ is similar to version 2 ‘comparator’ but with the 


































Version 3 ‘comparator’ TWICS conceptual model (Figure A11.90) has the same 
layout and components, with a small change in descriptions: the ‘columns’ have 
changed from ‘changes in health’, results of changes in health’, ‘summary of 
results’ and ‘estimation’ to ‘events’, ‘measures’, and ‘summary of results’.  
These latter descriptions/labels were considered to be clearer and a better 
explanation of the components in the columns labelled.  Some labels in the 
legend were also updated: ‘entity’ to ‘component’, ‘outputs’ to ‘output’, 
‘estimation’ to ‘summary of results’ and the blue ‘estimation’ arrow to 


































Version 4 ‘intervention’ of the conceptual model utilises the changes to 

































At this stage in the development of the conceptual model it was presented to 
and discussed with the lead clinician in the TWICS trial.  Changes made as a 
result of this consultation are explained next.  To be more accurate about the 
description of the patient or participant the description should be changed to 
‘High risk COPD patient’ from simply ‘COPD patient’. (All participants are 
classified as GOLD stages C&D, as they have all had at least 2 exacerbations in 
year prior to recruitment).  Instead of splitting the COPD related health events 
into exacerbations and non-exacerbations, the clinician advised splitting COPD 
related events into ‘causal complications’ (including exacerbations, pneumonia 
and collapsed lung) and ‘associated complications’ (such as CVD, depression, 
osteoporosis; these are lifestyle factors of COPD patients, side effects of 
medication or linked to COPD – depression - rather than a direct causal link - 
comorbidities linked to lifestyle).  This adds an extra layer to divide the direct 
causal COPD events into exacerbations and non-exacerbations (pneumonia and 
collapsed lung), this makes more clinical sense than having COPD related 
complication and exacerbations separately in the first column. 
The ‘causal complications’ description was split into exacerbations and ‘COPD 
causal non-exacerbations’ (pneumonia and collapsed lung). Then another 
component was included for events not linked to COPD events such as cancers 
(not lung cancers), falls, etc.  We also took out the direct link between patient 
and mortality because mortality will always occur as a result of an event, 
whether it is COPD related or not. 
To make the conceptual model clearer the ‘events’ column was renamed 
‘patient-related events’.  
Side effects of treatment may increase health resource use (primary care visits 
for example) and treatment side-effects may also be the cause of pulling out of 
study, so may find the patients who pull out of study in the intervention arm 
have higher health resource use prior to dropping out – side effects may cause 
the patient to stop and re-start taking the intervention more than once. Increase 
use of ICS is linked to increase in pneumonia. 
After making the changes suggested by the clinician the legend was moved 





arrows were made narrower as they were so wide that they were dominating the 
model.   
All these changes were made in version 5 ‘comparator’ (Figure A11.92).  
Version 5 ‘intervention’ uses different colours for each column to make it easier 
to see that each column relates to different aspects of the economic evaluation 
(Figure A11.93).  The ‘measures’ description the third column has been changed 
to ‘data’ to make it clearer what the component relate to in this column.  It also 
incorporates a bracket to cut out the arrows from the ‘patient-related events’ 



























V5 part 4 takes out direct links between patient and resource use and EQ-5D, 
whilst there is still a link between resource use and EQ-5D directly from the 
patient that does not have to be mediated through a patient-related event, the 
addition of the bracket to the right of this column represents that all previous 
components are able to link to the three relevant components in the ‘data’ 













V5 part 4 was presented to TWICS investigators as part of the ‘Review, revise, 
refine’ stage.  Whilst presenting the conceptual model it was apparent that 
removing the lines from patient to data (quality of life and health resource use) 
and ‘intervention’ to ‘health resource use’ did not correctly represent the links 
between patients and data, it made the conceptual model too simplified, these 
lines were added back in.  The description of ‘Data’ in the third column was 
changed back to ‘Measures’ as this is a better description of the components in 
this column.  Therefore, the conceptual model reverted to V5. This was the last 
version in this sequence, after this the conceptual model was based on the 
disaggregated cost-effectiveness template. 
Figure A11.95 is an early version of a generic conceptual model based on the 
disaggregated cost-effectiveness template; it has three panels relating to costs, 











Figure A11.95: Early generic conceptual model – disaggregated cost-effectiveness template 
 
Figure A11.96 is an early version of a COPD disease conceptual model based on 
the disaggregated cost-effectiveness template. 
 




Appendix 12: Iterative development of BeatIt case study 
conceptual model diagram (Chapter 6) 
This appendix includes early drafts of diagrams that feed into the final rich 
picture and conceptual model of the BeatIt case study. 
The first diagram is an early rich picture of depression that depicts the 
characteristics of depression, showing that a patient with depression may 
achieve remission, however they may also experience a recurrence of depression 
Figure A12.97. 
 






















The next figure is an early conceptual model showing the BeatIt therapy and its 
expected effect on activity (Figure A12.98), and then adding in the economic 
data and finally the analysis summary measure of incremental cost-effectiveness 
ratio (Figure A12.99). 
 
 
Figure A12.98: BeatIt v1 
 
 







The last figure shows an early draft of the conceptual model with StepUp 




Figure A12.100: StepUp v1 
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Appendix 13: Stata syntax for TWICS and BeatIt 









*** This Do file includes the TWICS conceptual model analysis  
*** presented in Chapter 7 of PhD thesis 
************************************************************** 
 
*** First upload dataset 
use "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 6 
TWICS\Further TWICS analysis novel approach\Analysis included in thesis\twics dataset for novel 
approach 030821.dta", clear 
 
** This dataset includes the ITT population (n=1536) 
** Missing data is replaced with treatment arm specific mean to enable use of a 
** full dataset in the case study without complications.  
** NB THE CASE STUDY IS FOR ILLUSTRATIVE PURPOSES ONLY 
 
************************************************** 
*** Variables in dataset (n=15) 
************************************************** 
** totalex - total number of exacerbations 
** exac_tc - total cost of exacerbations 
** exloc_tc - total cost of exacerbation treatment realting to location (home, service and 
hospital) 
** extrt_tc - total cost of treating exacerbation (non location) 
** exhome_tc - total cost of treating excerbations at home 
** exserv_tc - total cost of treating excerbations with care by services to prevent hospitalisation  
** exhosp_tc - total cost of treating excerbations in hospital 
** treatmentno - treatment allocation (0 placebo, 1 theophylline) 
** qaly_tot - total QALYs over trial period 
** noofexacerbationstreatment - reported number of exac at baseline needing treatment for 
previous 12 months 
** noofexacerbationshospital - reported number of exac at baseline needing hospital treatment in 
previous 12 months 
** twics_tc - total TWICS costs 
** nonintnonexac_tc - total costs excluding treatment and exac costs 
** non_int_tc - total costs less treatment costs 









** Regression 1) Does treatment arm predict treatment cost? 
*********************************************************** 







** Regression 2) Does treatment arm predict no. of exacerbations? 
***************************************************************** 
reg totalex treatmentno 
 
*********************************************************************************************  
** Regression 3) Do number of exacerbations predict QALYs, and possible association with trt? 
********************************************************************************************* 
reg qaly_tot totalex treatmentno 
 
****************************************************************************************** 
** Regression 4) Does number of exacerbations predict non-treatment costs, and possible 
association with trt? 
****************************************************************************************** 








** Treatment does predict non-treatment costs 
** We think this is due to exacerbation costs for hospitalised exacerbations 
** Split the exacerbation costs into location - hospital v non-hospital to explore the affect of 
treatment on exacerbation costs 
 
** generate a variable for non-hospital treatment costs 
gen ex_nonhosp_tc = exhome_tc + exserv_tc  
 
** Does treatment predict exacerbation costs - hospital and non-hospital? 
** Plus does treatment predict the costs of treating exacerbations? 
reg exac_tc treatmentno 
reg exhosp_tc treatmentno 
reg ex_nonhosp_tc treatmentno 
reg extrt_tc treatmentno 
 
** Only costs of exacerbations treated in hospital are predicted by treatment  
** Try this with number of exacerbations included 
reg exac_tc totalex treatmentno 
reg exhosp_tc totalex treatmentno 
reg ex_nonhosp_tc totalex treatmentno 
reg extrt_tc totalex treatmentno 
 
** Look at non-treatment, non-exacerbation costs 










** Cost-effectiveness plane 1 - trial-arm based - THIS IS FOR CHECKING PURPOSES ONLY 
** Syntax to compute difference in costs and effects based on treatment arm only - 
** should be similar to the CE plane included in chapter 3 (slight difference  
** as CE plane in chapter 3 uses complete case data and this one uses dataset with 









** define program and variables  
gen temp=. 
capture program drop booticer  
program define booticer, rclass 
tempvar cost0 cost1 qaly0 qaly1 
 
** replicate original treatment arm based analysis by only using treatment arm in regression 
replace temp=treatmentno 





sum `cost0', meanonly 
local mcost0=r(mean) 
sum `cost1', meanonly 
local mcost1=r(mean) 
 
replace temp = treatmentno 










return scalar cost1 = `mcost1' 
return scalar cost0 = `mcost0' 
return scalar costDiff=`mcost1' - `mcost0' 
return scalar qaly1 = `mqaly1' 
return scalar qaly0 = `mqaly0' 
return scalar qalyDiff = `mqaly1' - `mqaly0' 
end 
** END OF PROGRAM 'booticer' 
 
*Bootstrap the difference in costs and effects & save the output file 
bootstrap  cost1=r(cost1) cost0=r(cost0) costDiff=r(costDiff) /// 
   qaly1=r(qaly1) qaly0=r(qaly0) qalyDiff=r(qalyDiff) /// 
   icer=(r(costDiff)/r(qalyDiff)), /// 
   reps(1000) saving(bstwicsphd_ceplane1_thesis.dta, replace) 
seed(12345):booticer 
 
*Summarize the differences in costs and effects 
use bstwicsphd_ceplane1_thesis.dta, replace 
label var costDiff "Incremental cost" 
label var qalyDiff "Incremental QALY" 
log using icer_qaly, replace 
sum costDiff qalyDiff icer 
matrix list e(b) 
quietly mean costDiff 
matrix b = e(b) 
local Cost = b[1,1] 
quietly mean qalyDiff 
matrix b=e(b) 
local qaly = b[1,1] 
display "ICER: " `Cost'/`qaly' 
 
*plot the cost/effects on the cost-effectiveness plane 
twoway (scatter costDiff qalyDiff, msize(tiny)), yline(0) xline(0) /// 





graph save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 6 
TWICS\Further TWICS analysis novel approach\Analysis included in 
thesis\twics_ceplane1_thesis.gph", replace 
 
*** exporting .dta file to excel  
export excel using "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old 




save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 6 






** CONCEPTUAL MODEL 2 (Figure 55) 
** Conceptual model based analysis with all hypothesised equations 
** Syntax to compute difference in costs and effects based on full conceptual  




** Import same data as above 
use "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 6 
TWICS\Further TWICS analysis novel approach\Analysis included in thesis\twics dataset for novel 
approach 030821.dta", clear 
 
** Generate two temporary variables for predictor variables 
gen temp=. 
gen exac_temp=. 
** Delete the program if it already exists 
capture program drop cm_ceplane  
** Create program 
program define cm_ceplane, rclass 
** Define variables for program 
tempvar cost0t cost1t cost0nt cost1nt exac0 exac1 qaly0 qaly1 
 
************************************************************************** 
*** Equation #1 these are treatment costs only (predictor - treatment arm) 
************************************************************************** 
** Take a copy of treatment indicator 
replace temp=treatmentno 
** Conceptual model regression 
regress int_tc temp 
** Run as if everyone is in placebo arm and store prediction in new variable  
replace temp=0 
predict `cost0t' 
** Run as if everyone is in theophylline arm and store prediction in new variable  
replace temp=1 
predict `cost1t' 
** Calculate the mean for the bootstrap run for both arms 
sum `cost0t', meanonly 
local mcost0t=r(mean) 




*** Equation #2 exacerbations (predictor - treatment arm) 
********************************************************* 
** Take a copy of treatment indicator 





** Conceptual model regression 
regress totalex temp  
** Run as if everyone is in placebo arm and store prediction in new variable  
replace temp=0 
predict `exac0' 





*** Equation #3 QALYs (predictors - treatment arm and number of exacerbations) 
****************************************************************************** 
** Take a copy of treatment indicator 
replace temp = treatmentno 
** Take a copy of exacerbations variable  
replace exac_temp = totalex 
** Conceptual model regression 
regress qaly_tot exac_temp temp 
** Run as if everyone is in placebo arm and store prediction in new variable  
replace temp=0 
** Run with predicted exacerbations from equation #2 
replace exac_temp = `exac0' 
predict `qaly0' 
** Run as if everyone is in theophylline arm and store prediction in new variable 
replace temp=1 
** Run with predicted exacerbations from equation #2 
replace exac_temp = `exac1' 
predict `qaly1' 







*** Equation #4 these are non-treatment costs only (predictors treatment arm 
** and number exacerbations) 
**************************************************************************** 
** Take a copy of treatment indicator 
replace temp=treatmentno 
** Take a copy of exacerbations variable  
replace exac_temp = totalex 
** Conceptual model regression 
regress nonint_tc exac_temp temp 
** Run as if everyone is in placebo arm and store prediction in new variable  
replace temp=0 
** Run with predicted exacerbations from equation #2 
replace exac_temp = `exac0' 
predict `cost0nt' 
** Run as if everyone is in theophylline arm and store prediction in new variable 
replace temp=1 
** Run with predicted exacerbations from equation #2 
replace exac_temp = `exac1' 
predict `cost1nt' 
** Calculate the mean for the bootstrap run for both arms 
sum `cost0nt', meanonly 
local mcost0nt=r(mean) 
sum `cost1nt', meanonly 
local mcost1nt=r(mean) 
 
** Instruction to return the predictions and to combine treatment and non-treatment costs into 
one total cost. Also to calculate cost and QALY differences 





return scalar cost0 = `mcost0t' + `mcost0nt' 
return scalar cost1t = `mcost1t' 
return scalar cost0t = `mcost0t' 
return scalar cost1nt = `mcost1nt' 
return scalar cost0nt = `mcost0nt' 
 
return scalar costDiff= (`mcost1t' - `mcost0t')+(`mcost1nt' - `mcost0nt') 
return scalar qaly1 = `mqaly1' 
return scalar qaly0 = `mqaly0' 
return scalar qalyDiff = `mqaly1' - `mqaly0' 
end 
 
*** END OF PROGRAM 'cm_ceplane' 
 
**** Bootstrap the difference in costs and effects  & save the output file 
bootstrap  cost1=r(cost1) cost0=r(cost0) costDiff=r(costDiff) ///  
   cost1t=r(cost1t) cost0t=r(cost0t) /// 
   cost1nt=r(cost1nt) cost0nt=r(cost0nt) /// 
   qaly1=r(qaly1) qaly0=r(qaly0) qalyDiff=r(qalyDiff) /// 
   icer=(r(costDiff)/r(qalyDiff)), /// 
   reps(1000) saving(bstwicsphd_ceplane2_thesis, replace) 
seed(12345):cm_ceplane 
 
** Summarise the differences in costs and QALYs 
label var costDiff "Incremental cost" 
label var qalyDiff "Incremental QALY" 
sum costDiff qalyDiff icer 
quietly mean costDiff 
matrix b = e(b) 
local Cost = b[1,1] 
quietly mean qalyDiff 
matrix b=e(b) 
local qaly = b[1,1] 
display "ICER: " `Cost'/`qaly' 
 
*** Use difference in cost and effects to produce cost-effectiveness plane 
ellip costDiff qalyDiff , c(f) level(95) plot(scatter costDiff qalyDiff, xlabel(-0.08(0.02)0.04) 
ylabel(-1500(500)500) xline(0) yline(0) msize(tiny) mcolor(teal) xtitle("Difference in QALYs") 
ytitle("Difference in costs (£)") title("Cost-effectiveness plane") subtitle("Conceptual model 
driven analysis (all regressions)") legend(label(1 "95% confidence ellipse") label(2 "Bootstrap 
samples"))) 
graph save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 6 
TWICS\Further TWICS analysis novel approach\Analysis included in 
thesis\twics_ceplane2v2_thesis.gph", replace 
 
*** Export .dta file to excel  
export excel using "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old 




save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 6 
TWICS\Further TWICS analysis novel approach\Analysis included in 





** CONCEPTUAL MODEL 3 (Figure 56 & 57) 
** Using strongly associated predictors identified in regressions 
** Syntax to compute difference in costs and effects based on conceptual  








* Import same data as above 
use "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 6 
TWICS\Further TWICS analysis novel approach\Analysis included in thesis\twics dataset for novel 
approach 030821.dta", clear 
 
** Generate two temporary variables for predictor variables 
gen temp=. 
gen exac_temp=. 
** Delete the program if it already exists 
capture program drop cm_ceplane  
** Create program 
program define cm_ceplane, rclass 
** Define variables for program 
tempvar cost0t cost1t cost0nt cost1nt exac0 exac1 qaly0 qaly1 
 
******************************************************************************** 
*** Equation #1 these are treatment costs only (predicted by treatment arm only) 
******************************************************************************** 
** Take a copy of treatment indicator 
replace temp=treatmentno 
** Conceptual model regression 
regress int_tc temp 
** Run as if everyone is in placebo arm and store prediction in new variable  
replace temp=0 
predict `cost0t' 
** Run as if everyone is in theophylline arm and store prediction in new variable  
replace temp=1 
predict `cost1t' 
** Calculate the mean treatment cost for the bootstrap run for both arms 
sum `cost0t', meanonly 
local mcost0t=r(mean) 




*** Equation #2 exacerbations (predicted by treatment arm only) 
*************************************************************** 
** Take a copy of treatment indicator 
replace temp = treatmentno 
** Conceptual model regression 
regress totalex temp  
** Run as if everyone is in placebo arm and store prediction in new variable  
replace temp=0 
predict `exac0' 





*** Equation #3 QALYs (predicted by number of exacerbations only) 
***************************************************************** 
** Take a copy of exacerbations variable  
replace exac_temp = totalex 
** Conceptual model regression 
regress qaly_tot exac_temp  
** Run as if everyone is in placebo arm and store prediction in new variable  
replace temp=0 
** Run with predicted exacerbations from equation #2 
replace exac_temp = `exac0' 
predict `qaly0' 






** Run with predicted exacerbations from equation #2 
replace exac_temp = `exac1' 
predict `qaly1' 







*** Equation #4 Non-treatment costs (predicted by number of exacerbations only) 
**********************************************************************************************  
** Take a copy of exacerbations variable  
replace exac_temp = totalex 
** Conceptual model regression 
regress nonint_tc exac_temp  
** Run as if everyone is in placebo arm and store prediction in new variable  
replace temp=0 
** Run with predicted exacerbations from equation #2 
replace exac_temp = `exac0' 
predict `cost0nt' 
** Run as if everyone is in theophylline arm and store prediction in new variable 
replace temp=1 
** Run with predicted exacerbations from equation #2 
replace exac_temp = `exac1' 
predict `cost1nt' 
** Calculate the mean non-treatment costs for the bootstrap run for both arms 
sum `cost0nt', meanonly 
local mcost0nt=r(mean) 
sum `cost1nt', meanonly 
local mcost1nt=r(mean) 
 
** Instruction to return the predictions and to combine treatment and non-treatment costs into 
one total cost. Also to calculate cost and QALY differences 
return scalar cost1 = `mcost1t' + `mcost1nt' 
return scalar cost0 = `mcost0t' + `mcost0nt' 
return scalar cost1t = `mcost1t' 
return scalar cost0t = `mcost0t' 
return scalar cost1nt = `mcost1nt' 
return scalar cost0nt = `mcost0nt' 
 
return scalar costDiff= (`mcost1t' - `mcost0t')+(`mcost1nt' - `mcost0nt') 
return scalar qaly1 = `mqaly1' 
return scalar qaly0 = `mqaly0' 
return scalar qalyDiff = `mqaly1' - `mqaly0' 
end 
 
*Bootstrap the difference in costs and effects & save the output file 
bootstrap  cost1=r(cost1) cost0=r(cost0) costDiff=r(costDiff) ///  
   cost1t=r(cost1t) cost0t=r(cost0t) /// 
   cost1nt=r(cost1nt) cost0nt=r(cost0nt) /// 
   qaly1=r(qaly1) qaly0=r(qaly0) qalyDiff=r(qalyDiff) /// 
   icer=(r(costDiff)/r(qalyDiff)), /// 
   reps(1000) saving(bstwicsphd_ceplane3_thesis, replace) 
seed(12345):cm_ceplane 
 
** Summarize the differences in costs and QALYs 
use bstwicsphd_ceplane3_thesis.dta, clear 
label var costDiff "Incremental cost" 
label var qalyDiff "Incremental QALY" 
sum costDiff qalyDiff icer 





matrix b = e(b) 
local Cost = b[1,1] 
quietly mean qalyDiff 
matrix b=e(b) 
local qaly = b[1,1] 
display "ICER: " `Cost'/`qaly' 
 
*** Use difference in costs and effects to produce cost-effectiveness plane 
ellip costDiff qalyDiff , c(f) level(95) plot(scatter costDiff qalyDiff, xlabel(-0.08(0.02)0.04) 
ylabel(-1500(500)500) xline(0) yline(0) msize(tiny) mcolor(teal) xtitle("Difference in QALYs") 
ytitle("Difference in costs (£)") title("Cost-effectiveness plane") subtitle("Conceptual model 
driven analysis (strongly associated predictors)") legend(label(1 "95% confidence ellipse") label(2 
"Bootstrap samples"))) 
graph save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 6 
TWICS\Further TWICS analysis novel approach\Analysis included in 
thesis\twics_ceplane3v2_thesis.gph", replace 
 
*** Plot the cost/qalys on the cost-effectiveness plane with alternative large axis 
ellip costDiff qalyDiff , c(f) level(95) plot(scatter costDiff qalyDiff, xlabel(-0.02(0.01)0.02) 
ylabel(-200(100)300) xline(0) yline(0) msize(tiny) mcolor(teal) xtitle("Difference in QALYs") 
ytitle("Difference in costs (£)") title("Cost-effectiveness plane") subtitle("Conceptual model 
driven analysis (strongly associated predictors)") legend(label(1 "95% confidence ellipse") label(2 
"Bootstrap samples")))  
graph save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 6 




**** Calculate net monetary benefit 
***************************************** 
 
gen nmb1 = (qaly1 * 20000) - cost1 
gen nmb0 = (qaly0 * 20000) - cost0 
gen incnmb = (qalyDiff * 20000) - costDiff 
 
********************************************* 
**** Calculate point estimates for Chapter 7 
********************************************* 
tabstat costDiff, stat(mean n) 
tabstat qalyDiff, stat(mean n) 
tabstat icer, stat(mean n) 
tabstat incnmb, stat(mean n) 
 
*** Export .dta file to excel  
export excel using "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old 




save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 6 
TWICS\Further TWICS analysis novel approach\Analysis included in 
thesis\twicsceplane3_thesis.dta", replace  
 
*** Work is done externally on CEAC imports in Excel sheet which is saved 
*** as 'bootstrap_twics_ceplane3_workings_thesis.xls' 
   
*** CEAC 
import excel "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 
6 TWICS\Further TWICS analysis novel approach\Analysis included in 






twoway (line Probabilitycosteffective Willingnesstopaythreshold, lcolor(teal) 
xlabel(0(20000)120000) ylabel(0(0.2)1.0)title("Cost-effectiveness acceptability curve") 
subtitle("Conceptual model driven analysis (strongly associated predictors)")) 
graph save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 6 
TWICS\Further TWICS analysis novel approach\Analysis included in 
thesis\phdtwics_cm_ceac_thesis.gph", replace   
   
 
****************** 









**** BEATIT ANALYSIS FOR CONCEPTUAL MODEL APPROACH  





*** This Do file includes the BeatIt conceptual model analysis  
*** presented in Chapter 7 of the PhD thesis 
******************************************************************* 
 
*** Upload dataset 
use "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 5 
BeatIt\Further BI analysis\Included in thesis\bi_maindataset_for_cmanalysis_thesis.dta", replace 
 
*** This dataset contains the ITT population (n=141) 
*** It takes the BeatIt complete case trial data and replaces missing data with treatment arm 
specific mean to enable the use of a full dataset in the case study without complications 
*** NB THE CASE STUDY IS FOR ILLUSTRATIVE PURPOSES ONLY 
 
********************************************** 
**** Variables in the dataset (n=7) 
********************************************** 
 
** trt - treatment arm: StepUp (0) and BeatIt (1) 
** activity_total - reported activity 
** gds_v3 - GDS-LD scores at 12 months follow up.  NB A high GDS-LD score indicates more 
depressive symptoms than a low score ie a lower score indicates improvement in depression. 
** qaly_totCC - QALYs for follow-up period 
** int_tc - treatment cost  
** beatit_tc - total costs  













** Regression 1) Is activity predicted by treatment arm? 
********************************************************** 
reg activity_total trt 
 
*********************************************************************************************  
** Regression 2) Is depression predicted by treatment arm and is there a possible association with 
activity? 
*********************************************************************************************  
reg gds_v3 activity_total trt  
 
*************************************************************** 
** Regression 3) Is treatment cost predicted by treatment arm? 
*************************************************************** 
reg int_tc trt  
 
******************************************************************************************** 
** Regression 4) Is quality of life predicted by depression, and possible associations with activity 
and treatment arm? 
********************************************************************************************  
reg qaly_totCC gds_v3 activity_total trt 
 
************************************************************************************* 
** 5) Is non-treatment cost predicted by depression and/or activity, with possible associations 
with treatment arm? 
************************************************************************************* 











*** Cost-effectiveness plane 1 - replicate original cost-effectiveness plane from trial-arm based 
analysis.  THIS IS FOR CHECKING PURPOSES ONLY 
*** Syntax to compute the difference in costs and effects between treatment arms, should be 
similar to the cost-effectiveness plane in Chapter 3 - slight difference due to different datasets - 




** Generate a temporary variable for predictor variable 
gen temp=. 
*** Program to implement set of equations 
capture program drop booticer  
program define booticer, rclass 
tempvar cost0 cost1 qaly0 qaly1 
 
** Replicate original treatment arm analysis  
replace temp=trt 











sum `cost1', meanonly 
local mcost1=r(mean) 
 
replace temp = trt 










return scalar cost1 = `mcost1' 
return scalar cost0 = `mcost0' 
return scalar costDiff=`mcost1' - `mcost0' 
return scalar qaly1 = `mqaly1' 
return scalar qaly0 = `mqaly0' 
return scalar qalyDiff = `mqaly1' - `mqaly0' 
end 
 
*** END OF PROGRAM 'booticer' 
 
*Bootstrap the difference in costs and effects & save the output file  
bootstrap  cost1=r(cost1) cost0=r(cost0) costDiff=r(costDiff) /// 
   qaly1=r(qaly1) qaly0=r(qaly0) qalyDiff=r(qalyDiff) /// 
   icer=(r(costDiff)/r(qalyDiff)), /// 
   reps(1000) saving(icer_bootsrep_BI, replace) seed(12345):booticer 
   
    
** Summarize the differences in costs and effects 
use icer_bootsrep_BI.dta, clear 
label var costDiff "Incremental cost" 
label var qalyDiff "Incremental QALY" 
sum costDiff qalyDiff icer 
matrix list e(b) 
quietly mean costDiff 
matrix b = e(b) 
local Cost = b[1,1] 
quietly mean qalyDiff 
matrix b=e(b) 
local qaly = b[1,1] 
display "ICER: " `Cost'/`qaly' 
 
** Plot the cost/effects on the cost-effectiveness plane 
twoway (scatter costDiff qalyDiff, msize(tiny)), yline(0) xline(0) /// 
 xlabel(-0.4(0.1)0.2) ylabel(-20000(10000)20000) 
graph save "Graph" "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old 
layout\Chapter 5 BeatIt\Further BI analysis\Included in thesis\ceplane_step1_thesis.gph" 
, replace 
 
*** Export .dta file to excel  
export excel using "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old 
layout\Chapter 5 BeatIt\Further BI analysis\Included in thesis\ceplane_step1_thesis.xls", replace 
 
** Save dataset 
save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 5 









*** Conceptual model analysis with all hypothesised equations 
*** Syntax to compute difference in costs and effects based on full conceptual model (including 




*** Upload same dataset as above 
use "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 5 
BeatIt\Further BI analysis\Included in thesis\bi_maindataset_for_cmanalysis_thesis.dta", replace 
 
** Generate three temporary variables for predictor variables 
gen temp=. 
gen act_temp = . 
gen dep_temp = . 
** Delete the program if it already exists 
capture program drop booticer  
** Create program 
program define booticer, rclass 
** Define variables for program 
tempvar cost0t cost1t cost0nt cost1nt act0 act1 dep0 dep1 qaly0 qaly1 
 
****************************************************** 
*** Equation #1 Treatment arm only predicting activity 
****************************************************** 
** Take a copy of treatment indicator 
replace temp = trt 
** Conceptual model regression 
regress activity_total temp  
** Run as if everyone is in Step-up arm and store prediction in new variable  
replace temp=0 
predict `act0' 





*** Equation #2 Activity and treatment arm predicting depression 
**************************************************************** 
** Take a copy of predictors 
replace temp = trt 
replace act_temp = activity_total 
** Conceptual model regression 
regress gds_v3 act_temp temp 
** Run as if everyone is in Step-up arm and store prediction in new variable  
replace temp=0 
** Run with predicted activity from equation #1 
replace act_temp = `act0' 
predict `dep0' 
** Run as if everyone is in BeatIt arm and store prediction in new variable 
replace temp=1 
** Run with predicted activity from equation #1 




*** Equation #3 Treatment arm predicting treatment costs 
******************************************************** 
** Take a copy of the treatment indicator 
replace temp=trt 
** Conceptual model regression 
regress int_tc temp 







** Run as if everyone is in BeatIt arm and store prediction in new variable  
replace temp=1 
predict `cost1t' 
** Calculate the mean treatment cost for the bootstrap in each arm 
sum `cost0t', meanonly 
local mcost0t=r(mean) 




*** Equation #4 QALYs predicted by treatment arm, depression and activity 
************************************************************************* 
** Take a copy of predictor variables  
replace temp = trt 
replace act_temp = activity_total 
replace dep_temp = gds_v3 
** Conceptual model regression 
regress qaly_totCC dep_temp act_temp trt 
** Run as if everyone is in the Step-up arm and store prediction in new variable 
replace temp=0 
** Run with predicted depression from equation #2 
replace dep_temp = `dep0' 
** Run with predicted activity from equation #1 
replace act_temp = `act0' 
predict `qaly0' 
** Run as if everyone is in the BeatIt arm and store prediction in new variable 
replace temp=1 
** Run with predicted depression from equation #2 
replace dep_temp = `dep1' 
** Run with predicted activity from equation #1 
replace act_temp = `act1' 
predict `qaly1' 







*** Equation #5 non-treatment costs predicted by treatment arm, activity and depression 
******************************************************************************************  
*** Take a copy of predictor variables 
replace temp=trt 
replace act_temp = activity_total 
replace dep_temp = gds_v3 
** Conceptual model regression 
regress beatit_tc_nonint dep_temp act_temp trt 
** Run as if everyone is in the Step-up arm and store prediction in new variable 
replace temp=0 
** Run with predicted depression from equation #2 
replace dep_temp = `dep0' 
** Run with predicted activity from equation #1 
replace act_temp = `act0' 
predict `cost0nt' 
** Run as if everyone is in the BeatIt arm and store prediction in new variable 
replace temp=1 
** Run with predicted depression from equation #2 
replace dep_temp = `dep1' 
** Run with predicted activity from equation #1 
replace act_temp = `act1' 
predict `cost1nt' 





sum `cost0nt', meanonly 
local mcost0nt=r(mean) 
sum `cost1nt', meanonly 
local mcost1nt=r(mean) 
 
** Instruction to return the predictions and to combine treatment and non-treatment costs into 
one total cost. Also to calculate cost and QALY differences 
return scalar cost1 = (`mcost1t' + `mcost1nt') 
return scalar cost0 = (`mcost0t' + `mcost0nt') 
return scalar cost1t = `mcost1t' 
return scalar cost0t = `mcost0t' 
return scalar cost1nt = `mcost1nt' 
return scalar cost0nt = `mcost0nt' 
return scalar costDiff = (`mcost1t' - `mcost0t') + (`mcost1nt' - `mcost0nt') 
return scalar qaly1 = `mqaly1' 
return scalar qaly0 = `mqaly0' 
return scalar qalyDiff = `mqaly1' - `mqaly0' 
end 
 
*** END OF PROGRAM 'booticer' 
   
** Bootstrap the difference in costs and effects & save the output file 
bootstrap  cost1=r(cost1) cost0=r(cost0) costDiff=r(costDiff) ///  
   cost1t=r(cost1t) cost0t=r(cost0t) /// 
   cost1nt=r(cost1nt) cost0nt=r(cost0nt) /// 
   qaly1=r(qaly1) qaly0=r(qaly0) qalyDiff=r(qalyDiff) /// 
   icer=(r(costDiff)/r(qalyDiff)), /// 
   reps(1000) saving(icer_bootsrep_BI2_thesis, replace) 
seed(12345):booticer    
    
** Summarize the differences in costs and effects 
use icer_bootsrep_BI2_thesis.dta, clear 
label var costDiff "Incremental cost" 
label var qalyDiff "Incremental QALY" 
sum costDiff qalyDiff icer 
matrix list e(b) 
quietly mean costDiff 
matrix b = e(b) 
local Cost = b[1,1] 
quietly mean qalyDiff 
matrix b=e(b) 
local qaly = b[1,1] 
display "ICER: " `Cost'/`qaly' 
 
*** Plot cost-effectiveness plane 
ellip costDiff qalyDiff , c(f) level(95) plot(scatter costDiff qalyDiff, xlabel(-0.2(0.1)0.2) ylabel(-
10000(10000)20000) xline(0) yline(0) msize(tiny) mcolor(teal) xtitle("Difference in QALYs") 
ytitle("Difference in costs (£)") title("Cost-effectiveness plane") subtitle("Conceptual model 
driven analysis (all regressions)") legend(label(1 "95% confidence ellipse") label(2 "Bootstrap 
samples"))) 
graph save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 5 
BeatIt\Further BI analysis\Included in thesis\bi_ceplane2v3_thesis.gph", replace 
 
*** Export .dta file to excel  
export excel using "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old 
layout\Chapter 5 BeatIt\Further BI analysis\Included in thesis\ceplane_step2v3_thesis.xls", 
replace 
 
** Save dataset 
save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 5 









*** CONCEPTUAL MODEL 3 (Figure 64)  
*** Using strongly associated predictors identified in regressions 
*** Syntax to compute difference in costs and effects based on conceptual model identified after 
regressions to test accuracy 
*************************************************************************************** 
*************************************************************************************** 
*** Upload same dataset as above 
use "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 5 
BeatIt\Further BI analysis\Included in thesis\bi_maindataset_for_cmanalysis_thesis.dta", replace 
 
** Generate temporary variables for predictor variables 
gen temp=. 
gen act_temp = . 
gen dep_temp = . 
** Delete program if it already exists 
capture program drop booticer  
** Create program 
program define booticer, rclass 
** Define variables for program 
tempvar cost0t cost1t cost0nt cost1nt act0 act1 dep0 dep1 qaly0 qaly1 
 
************************************************** 
** Equation #1 activity predicted by treatment arm 
************************************************** 
** Take a copy of treatment indicator 
replace temp = trt 
** Conceptual model regression 
regress activity_total temp  
** Run as if everyone is in Step-up arm and store prediction in new variable  
replace temp=0 
predict `act0' 





** Equation #2 depression predicted by activity 
*********************************************** 
** Take a copy of activity indicator 
replace act_temp = activity_total 
** Conceptual model regression 
regress gds_v3 act_temp  
** Run as if everyone is in Step-up arm and store prediction in new variable  
** Using activity predicted in equation #1 
replace act_temp = `act0' 
predict `dep0' 
** Run as if everyone is in BeatIt arm and store prediction in new variable 
** Using activity predicted in equation #1 




** Equation #3 treatment costs predicted by treatment arm 
********************************************************* 
** Take a copy of treatment indicator 
replace temp=trt 
** Conceptual model regression 
regress int_tc temp 







** Run as if everyone is in BeatIt arm and store prediction in new variable 
replace temp=1 
predict `cost1t' 
** Calculate the mean treatment cost for both arms for bootstrapping exercise 
sum `cost0t', meanonly 
local mcost0t=r(mean) 




** Equation #4 QALYs predicted by depression 
******************************************** 
** Take a copy of depression indicator 
replace dep_temp = gds_v3 
** Conceptual model regression 
regress qaly_totCC dep_temp  
** Run as if everyone is in Step-up arm and store prediction in new variable 
** Using depression predicted in equation #2 
replace dep_temp = `dep0' 
predict `qaly0' 
** Run as if everyone is in BeatIt arm and store prediction in new variable 
** Using depression predicted in equation #2 
replace dep_temp = `dep1' 
predict `qaly1' 







** Equation #5 non-treatment costs predicted by activity 
*********************************************************** 
** Take a copy of activity indicator 
replace act_temp = activity_total 
** Conceptual model regression 
regress beatit_tc_nonint act_temp  
** Run as if everyone is in Step-up arm and store prediction in new variable  
** Using activity predicted in equation #1 
replace act_temp = `act0' 
predict `cost0nt' 
** Run as if everyone is in BeatIt arm and store prediction in new variable 
** Using activity predicted in equation #1 
replace act_temp = `act1' 
predict `cost1nt' 
** Calculate mean non-treatment costs for both arms for bootstrapping exercise 
sum `cost0nt', meanonly 
local mcost0nt=r(mean) 
sum `cost1nt', meanonly 
local mcost1nt=r(mean) 
 
** Instructions to combine treatment and non-treatment costs into total costs and to calculate 
differences in costs and QALYs 
return scalar cost1 = (`mcost1t' + `mcost1nt') 
return scalar cost0 = (`mcost0t' + `mcost0nt') 
return scalar cost1t = `mcost1t' 
return scalar cost0t = `mcost0t' 
return scalar cost1nt = `mcost1nt' 
return scalar cost0nt = `mcost0nt' 
return scalar costDiff = (`mcost1t' - `mcost0t') + (`mcost1nt' - `mcost0nt') 
return scalar qaly1 = `mqaly1' 
return scalar qaly0 = `mqaly0' 







** END OF PROGRAM 'booticer'  
    
*Bootstrap the difference in costs and effects & save the output file 
bootstrap  cost1=r(cost1) cost0=r(cost0) costDiff=r(costDiff) ///  
   cost1t=r(cost1t) cost0t=r(cost0t) /// 
   cost1nt=r(cost1nt) cost0nt=r(cost0nt) /// 
   qaly1=r(qaly1) qaly0=r(qaly0) qalyDiff=r(qalyDiff) /// 
   icer=(r(costDiff)/r(qalyDiff)), /// 
   reps(1000) saving(icer_bootsrep_BI3_thesis, replace) 
seed(12345):booticer    
    
*summarize the differences in costs and effects 
use icer_bootsrep_BI3_thesis.dta, clear 
label var costDiff "Incremental cost" 
label var qalyDiff "Incremental QALY" 
sum costDiff qalyDiff icer 
matrix list e(b) 
quietly mean costDiff 
matrix b = e(b) 
local Cost = b[1,1] 
quietly mean qalyDiff 
matrix b=e(b) 
local qaly = b[1,1] 
display "ICER: " `Cost'/`qaly' 
 
*** Plot cost-effectiveness plane 
ellip costDiff qalyDiff , c(f) level(95) plot(scatter costDiff qalyDiff, xlabel(-0.2(0.1)0.2) ylabel(-
10000(10000)20000) xline(0) yline(0) msize(tiny) mcolor(teal) xtitle("Difference in QALYs") 
ytitle("Difference in costs (£)") title("Cost-effectiveness plane") subtitle("Conceptual model 
driven analysis (strongly associated predictors)") legend(label(1 "95% confidence ellipse") label(2 
"Bootstrap samples"))) 
graph save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 5 
BeatIt\Further BI analysis\Included in thesis\bi_ceplane3v2_thesis.gph", replace 
 
***************************************** 
**** Calculate net monetary benefit 
***************************************** 
gen nmb1 = (qaly1 * 20000) - cost1 
gen nmb0 = (qaly0 * 20000) - cost0 
gen incnmb = (qalyDiff * 20000) - costDiff 
 
********************************************* 
**** Calculate point estimates for Chapter 7 
********************************************* 
tabstat costDiff, stat(mean n) 
tabstat qalyDiff, stat(mean n) 
tabstat icer, stat(mean n) 
tabstat incnmb, stat(mean n) 
 
*** Export .dta file to excel 
export excel using "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old 
layout\Chapter 5 BeatIt\Further BI analysis\Included in thesis\ceplane_step3v2thesis.xls", replace 
 
** Save dataset 
save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 5 
BeatIt\Further BI analysis\Included in thesis\ceplane_step3v2_thesis.dta", replace 
 
*** To produce the cost-effectiveness acceptability curve the above output is worked on to 
produce data points for CEAC 






*** Load data for CEAC 
import excel "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 
5 BeatIt\Further BI analysis\Included in thesis\ceplane_step3v2thesis_ceacworking.xls", 
sheet("stata data") firstrow clear 
 
twoway (line Probabilitycosteffective Willingnesstopaythreshold, lcolor(teal) 
xlabel(0(20000)120000) ylabel(0(0.2)1.0)title("Cost-effectiveness acceptability curve") 
subtitle("Conceptual model driven analysis (strongly associated predictors)")) 
graph save "C:\Users\nmm13h\OneDrive - University of Glasgow\PhD\Writing\Old layout\Chapter 5 
BeatIt\Further BI analysis\Included in thesis\phdbi_cm_ceac_thesis.gph", replace 
 
******************* 
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